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Osteoporosis affects the osteo-articular system. However, there are hormonal, 
kidney related, gastrointestinal and neuromuscular factors among other, that can be 
involved in the etiopathogenesis of the disease. In the other hand, for osteoporosis 
prevention there are many lifestyle conditions that are very important, as dietary 
habits, physical activity, drugs and caffeine intake, smoking, associated diseases, etc. 
Based on the above, treatment and prevention of osteoporosis have to be addressed in 
a multidisciplinary and integral approach. The knowledge about bone metabolism and 
the related disorders represents an extensive field that is currently increasing through 
many investigations conducted in the world. The purpose of this book is to show 
several reviews and original investigations related with osteoporosis.
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In the last decades the world has faced several epidemic health problems; among them are
osteoporosis, osteoarthritis, diabetes mellitus, obesity and cardiovascular diseases. All these
diseases share characteristics as their multifactorial and polygenic origin and the extensive
involvement of the environment in their etiology strongly associated with the actual lifestyle
(bad dietary habits, sedentary life and eating disorders, among others). At present, the
above mentioned diseases do not exclusively affect elderly people and are currently afflict‐
ing young adults and even children, obligating us to intensify our efforts to prevent them.
The progressive loss of bone mineral density and bone microarchitecture deterioration in
osteoporosis, promote the occurrence of fractures which can develop complications and dis‐
abilities and imply high costs to the healthcare services. There is no doubt that the efforts
should focus on prevention and on strengthening of programs directed toward protecting
and improving the bone health to induce bone mass gain in early stages of life and to limit
the potential risks related with the onset of the disease. Actually a great number of investi‐
gations throughout the world continuously contribute with information about functioning
of bone tissue and the physiopathology of osteoporosis which enable researchers to explore
new therapeutic possibilities in bone resorption disorders.
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1. Introduction
Bone is a dynamic tissue in constant change; maintenance of bone mass throughout life relies
on the bone remodeling process, which continually replaces old and damaged bone with new
bone. This remodeling is necessary to maintain the structural integrity of the skeleton and
allows the maintenance of bone volume, the repair of tissue damage and homeostasis of
calcium and phosphorous metabolism. This process allows the renewal of 5% of cortical bone
and trabecular 20% in a year, and although the cortical portion makes up most of the bone
(75%), the metabolic activity is ten times greater in the trabecular since the relationship between
surface and volume is greater in this, which is achieved by an annual renewal of 5-10% of bone
volume and although this remodeling takes place throughout life, your balance is positive only
during the first three decades. The skeleton is particularly dependent on mechanical informa‐
tion to guide the resident cell population towards adaptation, maintenance and repair; a wide
range of cell types depend on mechanically induced signals to enable appropriate physiolog‐
ical responses. The bone remodeling has two main phases: a resorption phase, consisting of
the removal of old bone by osteoclasts, and a later phase of formation of new bone by osteo‐
blasts that replaces the tissue previously resorbed. While osteoclasts are derived from hema‐
topoietic precursor cells and degrade the bone matrix, osteoblasts originate from mesenchymal
stem cells, they deposit a collagenous bone matrix and orchestrate its mineralization. While
the interaction of bone cells with their mechanical environment is complex, an understanding
of mechanical regulation of bone signaling is crucial to understanding bone physiology, the
etiology of bone diseases such as osteoporosis, and to the development of interventions to
improve bone strength. The clinical importance of bone formation has stimulated a lot of
research aimed at understanding its mechanism. Much knowledge has been gained in the
recent years, especially in relation with the signaling pathways controlling osteoblast differ‐
entiation. The purpose of this chapter is to review current knowledge on biochemical and
© 2013 Parra-Torres et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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physiological mechanisms of remodeling bone, with particular attention to the role in the cell
involved, the process, regulation signals into the control and pathophysiology of bone
remodeling (diseases).
2. Cells involved in bone remodeling
Two bone cell lineages have been identified: cells of the osteoblast lineage (osteoblasts,
osteocytes and bone-lining cells) and bone resorbing cells (osteoclasts) that together with their
precursor cells and associated cells (e.g. endothelial cells, nerve cells) are organized in
specialized units called bone multi cellular units (BMU). The main function of the BMU is to
mediate a bone ‘‘rejuvenation” mechanism called ‘‘bone remodeling”. Bone remodeling
maintains the integrity of the skeleton by removing old bone of high mineral density and high
prevalence of fatigue micro-fractures through repetitive cycles of bone resorption and bone
formation [1]. This is a direct and crucial interaction that has been well established in vivo.
Once osteoblasts and osteoclasts are fully differentiated, there is a less direct relationship [2].
Despite the know close physiological interactions of the two main cellular systems in bone,
there are effectively separate and distinct origins of osteoblast (hematopoietic cell origin) and
stromal/osteoblast linages from the developing fetus onward in mammalian development;
circulating osteogenic precursor cells are blood-borne cells that express a variety of osteoblastic
markers and are able to form bone in vivo. Strong evidence suggests that cells are derived from
bone marrow and are of hematopoietic origin [3].
2.1. Osteoblast
Osteoblasts derive from mesenchymal precursor cells, which also originate, chondrocytes
(cartilage), adipocytes (bone marrow stroma), fibroblasts (periosteum), and adventitial
reticular cells (bone marrow stroma). Although the claim that bone marrow stromal cell can
also give raise chondrocytes, myoblasts, adipocytes and tendon cells, depending on the
transcription factors that regulate the pathway [4]. There are four stages that have been
identified in osteoblast differentiation: the preosteoblast, osteoblast, osteocyte and bone-lining
cell that histologically these cells stain positively for alkaline phosphatase, however, only
mature osteoblasts have the ability to produce mineralized tissue [5], and can be identified by
their cuboidal morphology and strong alkaline phosphatase positivity. The master gene that
encodes for a protein involved in the osteogenic differentiation process from mesenchymal
precursors is the nuclear transcriptional factor Runx-2 (Runt related transcription factor 2,
cbfa-1) (Figure 1) [6].
The osteoblast resides along the bone surface at sites of active bone formation. They secrete
type 1 collagen, the basic building block of bone; non-collagenous proteins including osteo‐
calcin and alkaline phosphatase, which is essential for mineral deposition [7]. The principal
function of the osteoblast is bone formation and these occur via two distinct mechanisms: the
intramembranous ossification (flat bones of the skull and most of the clavicle) and the endo‐
chondral ossification, which produces most bones, involves the transformation of mesenchyme
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into a cartilage model that resembles the shape of the bone [8]. They are also responsible for
the mineralization, although the exact mechanism by which mineralization occurs remains
unclear [9]. Mature osteoblasts have one of three fates: they undergo apoptosis, differentiate
further into osteocytes or become quiescent lining cells. Approximately 50 to 70% of osteoblasts
undergo apoptosis [10].
2.2. Osteocyte
Osteocytes are non-proliferative, terminally differentiated cells of the osteoblast lineage, how
osteoblasts transform into osteocytes is dependent on the mode of ossification (Figure 1). They
reside both in the mineralized bone matrix and in newly formed osteoid, locked inside small
lacuna spaces in the hard substance of bone are smaller than osteoblasts and have lost many
of their cytoplasmic organelles [11-13]. They compose over 90–95% of all bone cells in the adult
skeleton and are thought to respond to mechanical strain to send signals of resorption or
formation, due to their distribution throughout the bone matrix and extensive interconnec‐
tivity, osteocytes are thought to be one if not the major bone cell type responsible for sensing
mechanical strain and orchestrating signals of resorption and formation. Evidence suggests
that the primary function of the osteocyte relates to the determination and maintenance of
bone structure. Osteocytes are mechanosensors capable of transducing musculoskeletal
derived mechanical input into biological output [14], the osteocyte appears to be capable of
Figure 1. Osteoblasts derive from Mesenchymal Stem Cells. Osteoclasts derive from by the fusion of mononuclear pro‐
genitors of the monocyte/macrophage family, and Osteocytes are non-proliferative differentiated cells of the osteo‐
blast lineage.
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relating the intensity of strain signals and the distribution of the strain throughout the whole
bone into signals to regulate [15]. Microdamage in the bone matrix has been shown to initiate
bone remodeling, the osteocytes located near these sites undergo apoptosis correlated with
increased bone remodeling due to enhanced RANKL production and an increase in osteoclast
formation [16], and the osteocytes may be the major source of RANKL during bone remodeling
[17-19]. For some time it has been estimated that the average life of this cell would be 25 years.
The percentage of dead osteocytes increases with age senescence, being from 1% to 75% rise
in the eighth decade [20,21].
2.3. Osteoclast
Osteoclasts, which are the only cells capable of resorbing bone, are multinucleated giant cells
formed from by the fusion of mononuclear progenitors of the monocyte/macrophage family
in a process termed osteoclastogenesis (Figure 1) [22], they are located on endosteal surfaces
within the Haversian system and on the periosteal surface beneath the periosteum, in the bone
has only two to three per μm3 [23]. Osteoclasts are terminally differentiated myeloid cells that
are uniquely adapted to remove mineralized bone matrix. These cells have distinct morpho‐
logical and phenotypic characteristics that are routinely used to identify them, including
multinuclearity and expression of tartrate-resistant acid phosphatase and the calcitonin
receptor. Osteoclast differentiation is supported by cells of the osteoblast lineage that express
membrane-bound receptor activator (RANK) of RANKL (NF-kB ligand) and macrophage-
colony stimulating factor (M-CSF) [22]; this process is also regulated by a secreted decoy
receptor of RANKL, osteoprotegerin (OPG), which functions as a paracrine inhibitor of
osteoclast formation [24]. The balance between OPG and RANKL regulates bone resorption
and formation and one imbalance of the RANKL/OPG system have been implicated in the
pathogenesis of various primary and secondary bone malignancies [25]. In the motile state the
osteoclast migrate from the bone marrow to their resorptive site and in the resorptive phase
they exert their bone resorbing function, in each state the osteoclast display morphological
differences [26], the motile osteoclasts are flattened, non-polarised cells and they are charac‐
terised by the presence of membrane protrusions (lamellipodia), and podosome. Upon
reaching the resorptive site, osteoclasts become polarised through cytoskeletal reorganization,
results in the formation of a ruffled border, sealing zone, functional secretory domain and
basolateral membrane. The sealing zone is an osteoclast specific structure, which separates the
acidic resorptive environment from the rest of the cell, forming an organelle free area [27].
2.4. Bone-lining cells
The bone lining cells constitute a subpopulation of the osteoblast family. Bone lining cells were
characterized by their long, slender, and flattened appearance; and their association with the
bone surface at sites where a thin no mineralized collagen layer was present [28]. Although
not being osteoblasts in the sense that they produce an osteoid layer, belong to the same lineage
as osteoblasts for the following reasons: they are alkaline phosphatase positive, respond to
PTH, and are associated with the bone surface. The bone lining cells contained a low level of
labeled osteocalcin, and they have electron-dense vacuoles containing crossbanded collagen
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fibrils in the cytoplasm [28]. It has been proposed that bone lining cells play a role in bone
remodeling by preventing the inappropriate interaction of osteoclast precursors with the bone
surface. It is thought that the signals that initiate osteoclast formation may stimulate the bone
lining cells to prepare for bone resorption, through the actions of collagenase which digests a
thin layer of non-mineralized bone, revealing the mineralized matrix underneath [29,30]. The
bone lining cells migrate to form a canopy over the remodeling area, particularly at sites
adjacent to osteoclasts, creating a microenvironment (in phagocytosis of collagen at the bone
surface) for the coupling required during bone remodeling. It has been proposed that the bone
lining cells are responsible for the cell to cell interactions between RANKL and RANK receptor
on osteoclast precursors [31].
3. Bone remodeling: The process
The normal bone remodeling is a process that couples bone resorption and bone formation, it
occurs in discrete locations and involves a group of different kinds of cells and takes 2 to 5
years for an area on the bone surface to complete one bone remodeling cycle [32]. The bone
tissue is morphologically and physiologically separated from the marrow by bone lining cell;
the process of cancellous bone remodeling occurs on the surface of trabeculae at the boundary
between bone and marrow. In normal bone length of the remodeling is about 200 days, with
the majority of that time (approx. 150 days) devoted to bone formation [33]. The bone remod‐
eling takes place in the BMU and the skeleton contains millions which comprises the next:
osteoclasts that resorbing the bone, the osteoblasts that replacing the bone, the osteocytes
within the bone matrix, the bone lining cells that covering the bone surface and the capillary
blood supply. All BMU are in different stages, and the life span of individual cells in a BMU
is much shorter than that of a BMU [31,35,36]. Mechanical stress in the bone can be sensed by
osteocytes that can signal giving to lining cells to form a new BMU at cortical or cancellous
surfaces and estimates that the duration is 2-8 months [12]. The bone remodeling follows
coordination of distinct and sequential phases of this process, (Figure 2):
Activation Phase- The first stage of bone remodeling involves detection of an initiating remod‐
eling signal, the activation is a continuing process that occurs at the cutting edge of the BMU,
and this signal can take several forms as a direct mechanical strain on the bone that results in
structural damage or hormone (e.g. estrogen or PTH) action on bone cells in response to more
systemic changes in homeostasis [32]. Conceivably, osteocyte apoptosis and possible release
of osteotropic growth factors and cytokines could be attractants for blood vessels, which would
then subsequently initiate the formation of a resorptive of the bone remodeling compartment
which are a prerequisite for osteogenesis, including bone development, fracture healing, and
cortical bone remodeling that support recruitment of osteoblast progenitors to bone remod‐
eling sites, thus highlight a link between activation of bone remodeling on the cancellous bone
surfaces and activation of neighbouring bone marrow events [12,34,36,37]. The mechanical
environment to which bone cells are exposed is a dynamic milieu of biophysical stimuli that
includes strain, stress, shear, pressure, fluid flow, streaming potentials and acceleration. While
ultimately it may not be possible to separate specific effects of each of these factors, it is clear
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relating the intensity of strain signals and the distribution of the strain throughout the whole
bone into signals to regulate [15]. Microdamage in the bone matrix has been shown to initiate
bone remodeling, the osteocytes located near these sites undergo apoptosis correlated with
increased bone remodeling due to enhanced RANKL production and an increase in osteoclast
formation [16], and the osteocytes may be the major source of RANKL during bone remodeling
[17-19]. For some time it has been estimated that the average life of this cell would be 25 years.
The percentage of dead osteocytes increases with age senescence, being from 1% to 75% rise
in the eighth decade [20,21].
2.3. Osteoclast
Osteoclasts, which are the only cells capable of resorbing bone, are multinucleated giant cells
formed from by the fusion of mononuclear progenitors of the monocyte/macrophage family
in a process termed osteoclastogenesis (Figure 1) [22], they are located on endosteal surfaces
within the Haversian system and on the periosteal surface beneath the periosteum, in the bone
has only two to three per μm3 [23]. Osteoclasts are terminally differentiated myeloid cells that
are uniquely adapted to remove mineralized bone matrix. These cells have distinct morpho‐
logical and phenotypic characteristics that are routinely used to identify them, including
multinuclearity and expression of tartrate-resistant acid phosphatase and the calcitonin
receptor. Osteoclast differentiation is supported by cells of the osteoblast lineage that express
membrane-bound receptor activator (RANK) of RANKL (NF-kB ligand) and macrophage-
colony stimulating factor (M-CSF) [22]; this process is also regulated by a secreted decoy
receptor of RANKL, osteoprotegerin (OPG), which functions as a paracrine inhibitor of
osteoclast formation [24]. The balance between OPG and RANKL regulates bone resorption
and formation and one imbalance of the RANKL/OPG system have been implicated in the
pathogenesis of various primary and secondary bone malignancies [25]. In the motile state the
osteoclast migrate from the bone marrow to their resorptive site and in the resorptive phase
they exert their bone resorbing function, in each state the osteoclast display morphological
differences [26], the motile osteoclasts are flattened, non-polarised cells and they are charac‐
terised by the presence of membrane protrusions (lamellipodia), and podosome. Upon
reaching the resorptive site, osteoclasts become polarised through cytoskeletal reorganization,
results in the formation of a ruffled border, sealing zone, functional secretory domain and
basolateral membrane. The sealing zone is an osteoclast specific structure, which separates the
acidic resorptive environment from the rest of the cell, forming an organelle free area [27].
2.4. Bone-lining cells
The bone lining cells constitute a subpopulation of the osteoblast family. Bone lining cells were
characterized by their long, slender, and flattened appearance; and their association with the
bone surface at sites where a thin no mineralized collagen layer was present [28]. Although
not being osteoblasts in the sense that they produce an osteoid layer, belong to the same lineage
as osteoblasts for the following reasons: they are alkaline phosphatase positive, respond to
PTH, and are associated with the bone surface. The bone lining cells contained a low level of
labeled osteocalcin, and they have electron-dense vacuoles containing crossbanded collagen
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fibrils in the cytoplasm [28]. It has been proposed that bone lining cells play a role in bone
remodeling by preventing the inappropriate interaction of osteoclast precursors with the bone
surface. It is thought that the signals that initiate osteoclast formation may stimulate the bone
lining cells to prepare for bone resorption, through the actions of collagenase which digests a
thin layer of non-mineralized bone, revealing the mineralized matrix underneath [29,30]. The
bone lining cells migrate to form a canopy over the remodeling area, particularly at sites
adjacent to osteoclasts, creating a microenvironment (in phagocytosis of collagen at the bone
surface) for the coupling required during bone remodeling. It has been proposed that the bone
lining cells are responsible for the cell to cell interactions between RANKL and RANK receptor
on osteoclast precursors [31].
3. Bone remodeling: The process
The normal bone remodeling is a process that couples bone resorption and bone formation, it
occurs in discrete locations and involves a group of different kinds of cells and takes 2 to 5
years for an area on the bone surface to complete one bone remodeling cycle [32]. The bone
tissue is morphologically and physiologically separated from the marrow by bone lining cell;
the process of cancellous bone remodeling occurs on the surface of trabeculae at the boundary
between bone and marrow. In normal bone length of the remodeling is about 200 days, with
the majority of that time (approx. 150 days) devoted to bone formation [33]. The bone remod‐
eling takes place in the BMU and the skeleton contains millions which comprises the next:
osteoclasts that resorbing the bone, the osteoblasts that replacing the bone, the osteocytes
within the bone matrix, the bone lining cells that covering the bone surface and the capillary
blood supply. All BMU are in different stages, and the life span of individual cells in a BMU
is much shorter than that of a BMU [31,35,36]. Mechanical stress in the bone can be sensed by
osteocytes that can signal giving to lining cells to form a new BMU at cortical or cancellous
surfaces and estimates that the duration is 2-8 months [12]. The bone remodeling follows
coordination of distinct and sequential phases of this process, (Figure 2):
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eling signal, the activation is a continuing process that occurs at the cutting edge of the BMU,
and this signal can take several forms as a direct mechanical strain on the bone that results in
structural damage or hormone (e.g. estrogen or PTH) action on bone cells in response to more
systemic changes in homeostasis [32]. Conceivably, osteocyte apoptosis and possible release
of osteotropic growth factors and cytokines could be attractants for blood vessels, which would
then subsequently initiate the formation of a resorptive of the bone remodeling compartment
which are a prerequisite for osteogenesis, including bone development, fracture healing, and
cortical bone remodeling that support recruitment of osteoblast progenitors to bone remod‐
eling sites, thus highlight a link between activation of bone remodeling on the cancellous bone
surfaces and activation of neighbouring bone marrow events [12,34,36,37]. The mechanical
environment to which bone cells are exposed is a dynamic milieu of biophysical stimuli that
includes strain, stress, shear, pressure, fluid flow, streaming potentials and acceleration. While
ultimately it may not be possible to separate specific effects of each of these factors, it is clear
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that several of these parameters independently have the ability to regulate cellular responses
and influence remodeling events within bone. Furthermore, components of these specific
factors (such as magnitude, frequency, and strain rate) also affect the cellular response [38].
Figure 2. Schematic presentation of trabecular and cortical bone remodeling by BMU. In trabecular, the osteoclast
create Howship´s lacunas that are refilled by osteoblast, and in the cortical bone, the osteoclast erode bone tissue and
are followed by osteoblast that refill the gap with new bone.
The osteocyte, which is uniquely situated in cortical bone to sense mechanical strain and load
generated factors (e.g., fluid flow, streaming and pressure) through a connected network of
sister cells contributes to the perception of and response to loading and unloading [12], this
canalicular network responds to unloading, or a decrease in mechanical signals, with upre‐
gulation of the proteins sclerostin and RANKL that control bone remodeling at multiple levels.
The long osteocytic processes are able to pass information between cells separated by hard
tissue [16,19]. Osteoblast linage cells and bone marrow stromal cells (BMSCs) are thought to
be the major cell types that express RANKL in support of osteoclastogenesis [39,40]; however
the actual major source of RANKL in vivo is the osteocyte [12].
Resorption Phase-  In this  phase,  the formation and activity of  osteoclasts is  controlled by
cells of the osteoblast lineage that recruit osteoclast precursors to the remodeling site with
the expression of the master osteoclastogenesis cytokines, CSF-1, RANKL, and OPG, is also
modulated in response to PTH [32,45,46].  Remodeling is  initiated by osteoclastic resorp‐
tion, which erodes a resorption lacuna, they attach to the bone surface, sealing a resorb‐
ing compartment that they acidify by secreting H+ ions, facilitating dissolution of the bone
mineral and thereby exposing the organic matrix to proteolytic enzymes that degrade it,
during resorption the bone matrix and bone mineral is digested. Some fragments can be
used as biochemical markers for overall bone resorption [43]. The depth of which varies
between 60-40 μm in young and older individuals, and the resorption period has a median
duration of  30–40 days [45].  In cortical  bone,  the BMUs proceed by osteonal tunnelling,
during  which  osteoclasts  excavate  a  canal  that  is  refilled  by  osteoblasts,  the  so-formed
Haversian  systems  are  100–200  μm  wide  and  may  become  as  long  as  10  mm;  their
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orientation is along the main loading direction trabecular, by contrast, are eroded as grooves
along the bone surface with a depth of 60–70 μm (Figure 2), [36].
Reversal Phase- This phase lasts ~9 days, occurs after the maximum eroded depth has been
achieved. In the reversal period the osteoclasts undergo apoptosis whilst osteoblasts are
recruited and begin to differentiate [44], therefore the reversal phase is a transition from
osteoclast to osteoblast activity [35]. After withdrawal of the osteoclast from the resorption pit,
bone-lining cells enter the lacuna and clean its bottom from bone matrix leftovers. This cleaning
proves to be a prerequisite for the subsequent deposition of a first layer of proteins (collage‐
nous) in the resorption pits and form a cement line (glycoprotein) that helps in attaching
osteoblasts (Figure 2), [28,41].
Formation Phase- The bone formation by the osteoblasts lasts the longest, and is slower than
bone resorption, involves new bone formation and mineralization. It was proposed that the
coupling molecules were stored in the bone matrix and liberated during bone resorption. TGF-
β appears to be a key signal for recruitment of mesenchymal stem cells to sites of bone
resorption and osteoclasts produce the coupling factors [32,45], once mesenchymal stem cells
or early osteoblast progenitors have returned to the resorption lacunae, they differentiate [28,
34,46] and the proliferating osteoblasts forming multilayers of cells. Several genes associated
with formation of the extracellular matrix (Type I collagen, fibronectin, and TGF-β) are actively
expressed and then gradually decline being maintained at a low basal level during subsequent
stages of osteoblast differentiation. Collagen type I is the primary organic component of bone
and accumulation contributes, in part, to the cessation of cell growth. When proliferation
ceases, proteins associated with bone cell phenotype are detected, e.g. alkaline phosphatase
enzyme, osteocalcin [7,47]. Bone matrix is built up of type I collagen (88%) and the remaining
10% is composed of a large number of non-collagenous proteins (e.g. osteocalcin, osteonectin,
bone sialoprotein and various proteoglycans) and lipids and glycosaminoglycans represent 1–
2% [48]. For bone to assume its final form, hydroxylapatite is incorporated into this newly
deposited osteoid [47,49]. The extracellular matrix undergoes a series of modifications in
composition and organization that renders it competent for mineralization that begins ~15 days
after osteoid has been formed, and non-collagenous proteins participate in the process of
matrix maturation, mineralization and may regulate the functional activity of bone cells. With
the onset of mineralization, several other bone expressed genes are induced to maximal levels
(bone sialoprotein, osteopontin and osteocalcin) [32,47]. The composition of bone is approxi‐
mately 10% cells, 60% mineral crystals (crystalline hydroxyapatite), and 30% organic matrix
[48]. When an equal quantity of resorbed bone has been replaced, the remodeling cycle
concludes (Figure 2).
Termination Phase- The termination signals are largely unknown, and include the terminal
differentiation of the osteoblast. The role of osteocytes is emerging [12,32]. The cells then
gradually flatten as they slow production, and finally they become quiescent lining cells. Some
of the osteoblast differentiate into osteocytes and remain in the matrix [12]. The osteocytes may
secrete inhibitory factors that slow the rate of bone formation as the resorbed cavity is nearly
filled. Bone remodeling is mediated by a balance of osteoblast and osteoclast cell activity, which
together, maintain bone mass and mineral homeostasis. Both decreased bone formation and
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that several of these parameters independently have the ability to regulate cellular responses
and influence remodeling events within bone. Furthermore, components of these specific
factors (such as magnitude, frequency, and strain rate) also affect the cellular response [38].
Figure 2. Schematic presentation of trabecular and cortical bone remodeling by BMU. In trabecular, the osteoclast
create Howship´s lacunas that are refilled by osteoblast, and in the cortical bone, the osteoclast erode bone tissue and
are followed by osteoblast that refill the gap with new bone.
The osteocyte, which is uniquely situated in cortical bone to sense mechanical strain and load
generated factors (e.g., fluid flow, streaming and pressure) through a connected network of
sister cells contributes to the perception of and response to loading and unloading [12], this
canalicular network responds to unloading, or a decrease in mechanical signals, with upre‐
gulation of the proteins sclerostin and RANKL that control bone remodeling at multiple levels.
The long osteocytic processes are able to pass information between cells separated by hard
tissue [16,19]. Osteoblast linage cells and bone marrow stromal cells (BMSCs) are thought to
be the major cell types that express RANKL in support of osteoclastogenesis [39,40]; however
the actual major source of RANKL in vivo is the osteocyte [12].
Resorption Phase-  In this  phase,  the formation and activity of  osteoclasts is  controlled by
cells of the osteoblast lineage that recruit osteoclast precursors to the remodeling site with
the expression of the master osteoclastogenesis cytokines, CSF-1, RANKL, and OPG, is also
modulated in response to PTH [32,45,46].  Remodeling is  initiated by osteoclastic resorp‐
tion, which erodes a resorption lacuna, they attach to the bone surface, sealing a resorb‐
ing compartment that they acidify by secreting H+ ions, facilitating dissolution of the bone
mineral and thereby exposing the organic matrix to proteolytic enzymes that degrade it,
during resorption the bone matrix and bone mineral is digested. Some fragments can be
used as biochemical markers for overall bone resorption [43]. The depth of which varies
between 60-40 μm in young and older individuals, and the resorption period has a median
duration of  30–40 days [45].  In cortical  bone,  the BMUs proceed by osteonal tunnelling,
during  which  osteoclasts  excavate  a  canal  that  is  refilled  by  osteoblasts,  the  so-formed
Haversian  systems  are  100–200  μm  wide  and  may  become  as  long  as  10  mm;  their
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orientation is along the main loading direction trabecular, by contrast, are eroded as grooves
along the bone surface with a depth of 60–70 μm (Figure 2), [36].
Reversal Phase- This phase lasts ~9 days, occurs after the maximum eroded depth has been
achieved. In the reversal period the osteoclasts undergo apoptosis whilst osteoblasts are
recruited and begin to differentiate [44], therefore the reversal phase is a transition from
osteoclast to osteoblast activity [35]. After withdrawal of the osteoclast from the resorption pit,
bone-lining cells enter the lacuna and clean its bottom from bone matrix leftovers. This cleaning
proves to be a prerequisite for the subsequent deposition of a first layer of proteins (collage‐
nous) in the resorption pits and form a cement line (glycoprotein) that helps in attaching
osteoblasts (Figure 2), [28,41].
Formation Phase- The bone formation by the osteoblasts lasts the longest, and is slower than
bone resorption, involves new bone formation and mineralization. It was proposed that the
coupling molecules were stored in the bone matrix and liberated during bone resorption. TGF-
β appears to be a key signal for recruitment of mesenchymal stem cells to sites of bone
resorption and osteoclasts produce the coupling factors [32,45], once mesenchymal stem cells
or early osteoblast progenitors have returned to the resorption lacunae, they differentiate [28,
34,46] and the proliferating osteoblasts forming multilayers of cells. Several genes associated
with formation of the extracellular matrix (Type I collagen, fibronectin, and TGF-β) are actively
expressed and then gradually decline being maintained at a low basal level during subsequent
stages of osteoblast differentiation. Collagen type I is the primary organic component of bone
and accumulation contributes, in part, to the cessation of cell growth. When proliferation
ceases, proteins associated with bone cell phenotype are detected, e.g. alkaline phosphatase
enzyme, osteocalcin [7,47]. Bone matrix is built up of type I collagen (88%) and the remaining
10% is composed of a large number of non-collagenous proteins (e.g. osteocalcin, osteonectin,
bone sialoprotein and various proteoglycans) and lipids and glycosaminoglycans represent 1–
2% [48]. For bone to assume its final form, hydroxylapatite is incorporated into this newly
deposited osteoid [47,49]. The extracellular matrix undergoes a series of modifications in
composition and organization that renders it competent for mineralization that begins ~15 days
after osteoid has been formed, and non-collagenous proteins participate in the process of
matrix maturation, mineralization and may regulate the functional activity of bone cells. With
the onset of mineralization, several other bone expressed genes are induced to maximal levels
(bone sialoprotein, osteopontin and osteocalcin) [32,47]. The composition of bone is approxi‐
mately 10% cells, 60% mineral crystals (crystalline hydroxyapatite), and 30% organic matrix
[48]. When an equal quantity of resorbed bone has been replaced, the remodeling cycle
concludes (Figure 2).
Termination Phase- The termination signals are largely unknown, and include the terminal
differentiation of the osteoblast. The role of osteocytes is emerging [12,32]. The cells then
gradually flatten as they slow production, and finally they become quiescent lining cells. Some
of the osteoblast differentiate into osteocytes and remain in the matrix [12]. The osteocytes may
secrete inhibitory factors that slow the rate of bone formation as the resorbed cavity is nearly
filled. Bone remodeling is mediated by a balance of osteoblast and osteoclast cell activity, which
together, maintain bone mass and mineral homeostasis. Both decreased bone formation and
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increased bone resorption may result in bone loss. Therefore, the stimulation of bone formation
may be another important factor for the prevention and treatment of bone loss (Figure 2).
4. Regulation signals into the control of bone remodeling
4.1. Systemic regulation of bone remodeling
The process of bone remodeling is essential for adult bone homeostasis. This control involves
a complex mechanism compound by numerous local and systemic factors, and their expression
and release is controlled finely. The main factor that affects normal bone remodeling is the
regulation of osteoblasts and osteoclasts. Local and systemic factors can affect bone remodeling
by directly or indirectly targeting mature cells and their respective progenitor cells. The
metabolic functions of the bone are mediated by two major calcium-regulating hormones,





Parathyroid hormone (PTH) ↑ ↑*
1,25(OH)2 Vitamin D ↑ ↑*
Calcitonin ↓ ?
Estrogen ↓ ↓#
Growth hormone/IGF ↑ ↑
Thyroid hormone ↑ ↑
? = Effects are not Known
* PTH and vitamin D decrease collagen synthesis in high doses.
# Estrogen decreases bone formation by decreasing remodeling, but formation is decreased less than resorption and
bone mass increases.
Data and modified from Raisz, L. G. (1999). Physiology and pathophysiology of bone remodeling. Clinical chemistry, 45
(8B): 1353-1358.
Table 1. Local and systemic regulation of bone remodeling.
PTH is a stimulator of bone resorption and 1,25-Dihydroxy vitamin D has its greatest effect on
intestinal calcium and phosphate absorption, but it may also have direct effects on bone and
other tissues. It is probably critical for the differentiation of both osteoblasts and osteoclasts
and can stimulate bone resorption and formation under some experimental conditions. A third
hormone, calcitonin (Table 1), in contrast to PTH and 1,25(OH)2 D3, both of which increase
calcium release from the mineralized matrix, calcitonin is an inhibitor of osteoclast activity. It
is a potent inhibitor of bone resorption and is used clinically in the treatment of bone diseases.
Other systemic hormones are keys in regulating bone remodeling, such as: Growth hormone
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acting through both systemic and local insulin-like growth factor (IGF) production, can
stimulate bone formation and resorption. Glucocorticoids are necessary for bone cell differ‐
entiation during development. Indirect effects of glucocorticoids on calcium absorption and
sex hormone production may, however, increase bone resorption (Table 1). O the other hand,
probably the most important systemic hormone in maintaining normal bone turnover is
estrogen. Estrogen deficiency leads to an increase in bone remodeling in which resorption
overcome formation and bone mass decreases (Table 1). The increase in bone remodeling and
in bone resorption in the estrogen deficient state is associated with an increase in bone
formation at the tissue level [51]. Therefore, sex steroid deficiency is associated with a defect
in bone formation. Based on the available evidence, there are currently at least three key
mechanisms by which estrogen deficiency may lead to a relative deficit in bone formation
through direct effects on osteoblasts: increased apoptosis, increased oxidative stress, and an
increase in NF-kB activity (Figure 3). In addition, estrogen inhibits the activation of bone
remodeling, and this effect is most likely mediated via the osteocyte [52].
4.2. Parathyroid hormone (TH) and PTHrP signals
The parathyroid hormone (PTH) increases bone formation in bone diseases. The anabolic
effects of PTH on bone formation are mediated through the PTH/PTH-related peptide (PTHrP)
receptor-dependent mechanisms that generate multiple G protein-dependent signals (Table
1). PTH mediated cyclic AMP/protein kinase phosphorylates the osteoblast transcription factor
Runx2, which in turn upregulates the expression of osteoblast genes. Intermittent PTH also
activates ERK1/2-mitogen-activated protein kinase (MAPK) Erk1/2 and phosphatidylinositol
phosphate (PI3K) signaling, resulting in increased osteoblastogenesis and osteoblast survival
(Figure 3) [53]. PTH induces the synthesis of IGF-I that works with PTH in osteoblasts to
stimulate osteoblast proliferation and differentiation as well as indirectly regulates osteoclast
activity [54,55]. Also, PTH was inferred to interact with various local signaling molecules,
including insulin-like growth factors and Wnt antagonist sclerostin (SOST) [55-57]. It was
recently shown that, in addition to reducing SOST, PTH reduces Dkk1 expression and thereby
increases Wnt signaling, which contributes to the anabolic effect of PTH in bone [58]. This does
not exclude the possibility that PTH receptor signaling may increase bone mass and bone
remodeling by affecting Wnt signaling in other cell types. Recent data indicate that the
activation of the PTH receptor in T lymphocytes plays a role in PTH-induced bone formation
and bone mass by promoting the production of Wnt10b by these cells [59]. These observations
and the finding that PTH signaling also acts by phosphorylating the Wnt coreceptor LRP6 and
β-catenin indicate that direct and indirect crosstalks between PTH and Wnt signaling are
important mechanisms regulating bone formation.
4.3. Wnt and Wnt antagonists
Genetic studies in human and animal models suggest that the canonical Wnt/β-catenin
pathway (Table 2), together with BMP signaling and key transcription factor RUNX2(CBFA1/
AML3), has an key role in skeletal development, osteoblast differentiation and bone formation
[60,61]. Wnt/β-catenin signaling plays a significant role in promoting mesenchymal commit‐
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increased bone resorption may result in bone loss. Therefore, the stimulation of bone formation
may be another important factor for the prevention and treatment of bone loss (Figure 2).
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4.1. Systemic regulation of bone remodeling
The process of bone remodeling is essential for adult bone homeostasis. This control involves
a complex mechanism compound by numerous local and systemic factors, and their expression
and release is controlled finely. The main factor that affects normal bone remodeling is the
regulation of osteoblasts and osteoclasts. Local and systemic factors can affect bone remodeling
by directly or indirectly targeting mature cells and their respective progenitor cells. The
metabolic functions of the bone are mediated by two major calcium-regulating hormones,
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# Estrogen decreases bone formation by decreasing remodeling, but formation is decreased less than resorption and
bone mass increases.
Data and modified from Raisz, L. G. (1999). Physiology and pathophysiology of bone remodeling. Clinical chemistry, 45
(8B): 1353-1358.
Table 1. Local and systemic regulation of bone remodeling.
PTH is a stimulator of bone resorption and 1,25-Dihydroxy vitamin D has its greatest effect on
intestinal calcium and phosphate absorption, but it may also have direct effects on bone and
other tissues. It is probably critical for the differentiation of both osteoblasts and osteoclasts
and can stimulate bone resorption and formation under some experimental conditions. A third
hormone, calcitonin (Table 1), in contrast to PTH and 1,25(OH)2 D3, both of which increase
calcium release from the mineralized matrix, calcitonin is an inhibitor of osteoclast activity. It
is a potent inhibitor of bone resorption and is used clinically in the treatment of bone diseases.
Other systemic hormones are keys in regulating bone remodeling, such as: Growth hormone
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acting through both systemic and local insulin-like growth factor (IGF) production, can
stimulate bone formation and resorption. Glucocorticoids are necessary for bone cell differ‐
entiation during development. Indirect effects of glucocorticoids on calcium absorption and
sex hormone production may, however, increase bone resorption (Table 1). O the other hand,
probably the most important systemic hormone in maintaining normal bone turnover is
estrogen. Estrogen deficiency leads to an increase in bone remodeling in which resorption
overcome formation and bone mass decreases (Table 1). The increase in bone remodeling and
in bone resorption in the estrogen deficient state is associated with an increase in bone
formation at the tissue level [51]. Therefore, sex steroid deficiency is associated with a defect
in bone formation. Based on the available evidence, there are currently at least three key
mechanisms by which estrogen deficiency may lead to a relative deficit in bone formation
through direct effects on osteoblasts: increased apoptosis, increased oxidative stress, and an
increase in NF-kB activity (Figure 3). In addition, estrogen inhibits the activation of bone
remodeling, and this effect is most likely mediated via the osteocyte [52].
4.2. Parathyroid hormone (TH) and PTHrP signals
The parathyroid hormone (PTH) increases bone formation in bone diseases. The anabolic
effects of PTH on bone formation are mediated through the PTH/PTH-related peptide (PTHrP)
receptor-dependent mechanisms that generate multiple G protein-dependent signals (Table
1). PTH mediated cyclic AMP/protein kinase phosphorylates the osteoblast transcription factor
Runx2, which in turn upregulates the expression of osteoblast genes. Intermittent PTH also
activates ERK1/2-mitogen-activated protein kinase (MAPK) Erk1/2 and phosphatidylinositol
phosphate (PI3K) signaling, resulting in increased osteoblastogenesis and osteoblast survival
(Figure 3) [53]. PTH induces the synthesis of IGF-I that works with PTH in osteoblasts to
stimulate osteoblast proliferation and differentiation as well as indirectly regulates osteoclast
activity [54,55]. Also, PTH was inferred to interact with various local signaling molecules,
including insulin-like growth factors and Wnt antagonist sclerostin (SOST) [55-57]. It was
recently shown that, in addition to reducing SOST, PTH reduces Dkk1 expression and thereby
increases Wnt signaling, which contributes to the anabolic effect of PTH in bone [58]. This does
not exclude the possibility that PTH receptor signaling may increase bone mass and bone
remodeling by affecting Wnt signaling in other cell types. Recent data indicate that the
activation of the PTH receptor in T lymphocytes plays a role in PTH-induced bone formation
and bone mass by promoting the production of Wnt10b by these cells [59]. These observations
and the finding that PTH signaling also acts by phosphorylating the Wnt coreceptor LRP6 and
β-catenin indicate that direct and indirect crosstalks between PTH and Wnt signaling are
important mechanisms regulating bone formation.
4.3. Wnt and Wnt antagonists
Genetic studies in human and animal models suggest that the canonical Wnt/β-catenin
pathway (Table 2), together with BMP signaling and key transcription factor RUNX2(CBFA1/
AML3), has an key role in skeletal development, osteoblast differentiation and bone formation
[60,61]. Wnt/β-catenin signaling plays a significant role in promoting mesenchymal commit‐
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ment to the osteoblastic lineage during the embryonic bone development. The canonical Wnt/
β-catenin signaling activity is promoted in the forming osteoblast, and this activity promotes
osteoblast differentiation during endochondral bone formation, and the skeletal development
is affected and the osteoblast differentiation is reduced when Wnt/β-catenin signaling is
interrupted in the mesenchyme (Figure 3) [62]. The in vivo stimulation of the Wnt10b signaling
cascade in the FABP4 promoter-Wnt10b transgenic mice led to a significantly higher bone mass
because of the stimulation of osteoblastogenesis and the inhibition of adipogenesis. In addition,
the Wnt10b−/−mice had decreased trabecular bone and serum osteocalcin [63]. Recent advan‐
ces have been made in our understanding of the role of Wnt proteins in bone cell biology. It
was found that, in addition to Wnt10b [63], several other Wnt proteins (Wnt6a, Wn10a)
influence the differentiation of mesenchymal precursors into osteoblasts or adipocytes, and
thereby control bone mass [64]. The Wnt signal is modulated by various antagonists, including
secreted factors, transmembrane modulators, and intracellular signals. Dickkopf family
members (Dkk1 and Dkk2) and secreted frizzled related proteins (Sfrps) are families of
extracellular proteins that negatively modulate canonical Wnt signalling [60].
4.4. Transforming growth factor-β
The transforming growth factor-β (TGF-β) signaling pathway, is known to control bone
remodeling and maintenance. However, TGF-β exerts both positive and negative effects on
bone cells, causing bone loss or bone gain in mice. There are three isoforms of TGF-β, namely,
TGF-β1, TGF-β2, and TGF-β3. TGF-β1, known as the most abundant TGF-β isoform in the bone
tissue, has been intensively studied during bone remodeling [65]. A study on the mechanism
of TGF-β for osteoblast regulation has indicated that TGF-β1 stimulates bone matrix apposition
and osteoblast proliferation in vitro. Additional research revealed that although TGF-β1
stimulates the early differentiation of osteoblast cells, this factor suppresses the late stage of
osteoblast differentiation. These signals are transduced together by the activation of R-smads
and Cosmads as well as through the mitogen-activated protein kinase (MAPK) pathway (Table
2). A cross talk exists between the TGF-β signal and the parathyroid hormone (PTH) in the
regulation of osteoblastogenesis [66]. PTH stimulates the production of TGF-β1 and TGF-β2
in the osteoblast. In addition to regulating the osteoblastic bone formation, TGF-β1 has a key
role in regulating bone remodeling by connecting bone formation and bone resorption (Figure
3). TGF-β proteins are present in their latent form in the bone matrix, and osteoclasts can
release, as well as activate, TGF-β from the bone matrix via osteoclastic bone resorption. The
released TGF-β may in turn stimulate the osteoblastic bone formation [45].
4.5. Bone morphogenetic proteins
Bone morphogenetic proteins (BMPs), they are so named for their osteoinductive properties,
and regulate differentiation of mesenchymal cells into components of bone, cartilage or
adipose tissue. TGF-β/BMP ligand signal is mediated by serine/threonine protein kinases
(receptor types 1 and 2) and a family of receptor substrates (the Smad proteins) that move into
the nucleus. BMP signaling is important for skeletal development and maintenance of bone
mass through activation of BMP type 1A (BMPR1A) and type 1B receptors that control
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osteoblast function and bone remodeling (Table 2) [67]. Notably, BMPR1A in osteoblasts
negatively regulates bone mass and Wnt/β-catenin signaling through upregulation of the Wnt
inhibitors Sost and Dkk1 in mice [68]. Also, BMPs promote osteoblastogenesis through the
Smad and MAPK pathways, which upregulates the expression of Runx2 and Osx, and thus
stimulate the bone formation (Figure 3). BMP signaling is modulated by multiple agonists and
antagonists acting at the extracellular level, which are also important for bone remodeling and
may be potential therapeutic targets [69]. It was found that the Wnt-induced secreted protein
1 (WISP-1/CCN4) enhances BMP2-induced signaling (Smad-1/5/8 phosphorylation and
activation), resulting in increased osteogenic differentiation and bone mass in mice.
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coupling of bone resorption and bone formation. Eph receptors are tyrosine kinase receptors
activated by ligands called ephrins (Eph receptor interacting proteins). Both Ephs and ephrins
are divided into two A and B groups [70]. To date, ephrinB2, a transmembrane protein
expressed on osteoclasts, and its engagement with its receptor, EphB4, on osteoblasts, lead to
bi-directional signaling between these cells; this is one of the cell-cell contact mechanisms that
mediate crosstalk between these cells. EphrinB2 (as reverse signaling), located on the surface
of osteoclast precursors, suppresses osteoclast precursor differentiation by inhibiting the
osteoclastogenic c-Fos-NFATc1 cascade (Table 2) [71]. In addition, the signaling mediated by
EphB4 (as forward signaling) located on the surface of osteoblast enhances the osteogenic
differentiation. Ephrin B1 induces osteoblast differentiation by transactivating the nuclear
location of transcriptional coactivator with PDZ-binding motif (TAZ), a co-activating protein
of Runx2. TAZ, together with Runx2, induces osteoblast-related gene expression [72]. The
functional role of the EphrinA2–EphA2 complex differs significantly in its interactions
compared with the EphrinB2– EphB4 complex. Both the reversed signaling EphrinA2 and
forward signaling EphA2 stimulate osteoclast differentiation, but EphA2 has a negative role
in bone formation by inhibiting osteoblast differentiation through the regulation of RhoA
activity (Figure 3) [71].
Figure 3. Key signaling pathways for regulating osteoblastogenesis in bone remodeling. BMPs/TGF-β, Wnt, intermit‐
tent PTH and Wnt5a-Ror2 stimulate osteoblast differentiation. Eph–Ephrin and RANKL-RANK signal mediate osteo‐
blast–osteoclast interaction. TGF-β1 secretion mediated by osteoclastic bone resorption induces BMSC migration and
bone formation. Leptin–brainstem-derived serotonin-sympathetic nervous system and Sema4D pathway suppresses
osteoblast proliferation, whereas gut-derived serotonin inhibits osteoblast proliferation.
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4.7. Epidermal growth factor receptor (EGFR)
The epidermal growth factor receptor (EGFR) is a glycoprotein on the cell surface of a variety
of cell types and is characterized by its ligand-dependent tyrosine kinase activity. After ligand
binding to the extracellular domain, the EGFRs are activated by homo- or heterodimerization
with auto- and transphosphorylation on tyrosine residues at the intracellular domain, and then
a variety of signaling pathways, such as Ras-Raf-MAP-kinase and PI-3- kinase-Akt, are
activated to influence cell behaviors, such as proliferation, differentiation, apoptosis, and
migration (Table 2) [73]. In recent years, several experiments indicate that the epidermal
growth factor receptor (EGFR) system plays important roles in skeletal biology and pathology.
This network, including a family of seven growth factors – the EGFR ligands – and the related
tyrosine kinase receptors EGFR (ERBB1), ERBB2, ERBB3 and ERBB4, regulates aspects such as
proliferation and differentiation of osteoblasts, chondrocytes and osteoclasts, parathyroid
hormone-mediated bone formation and cancer metastases in bone (Figure 3) [74]. In addition,
EGFR signaling affects osteoclasts, albeit this could be an indirect effect mediated by inhibition
of OPG expression and increased RANKL expression by osteoblasts [74]. It was recently found
that decreasing EGFR expression in pre-osteoblasts and osteoblasts in mice results in decreased
trabecular and cortical bone mass as a consequence of reduced osteoblastogenesis and
increased bone resorption [48].
4.8. Fibroblast Growth Factors (FGFs)
Signaling induced by Fibroblast Growth Factors (FGFs) regulate osteoblastogenesis and bone
formation. Multiple signaling pathways activated by FGF receptors 1 and 2 control osteoblast
proliferation, differentiation, and survival (Table 2). FGFs bind to high affinity FGF receptors
(FGFR), leading to FGFR dimerization, phosphorylation of intrinsic tyrosine residues and
activation of several signal transduction pathways [75]. Recent studies provided some insights
into specific signaling pathways induced by FGF/FGFR signaling that control osteoblasts.
Activation of ERK1/2 signaling by FGF was found to be essential for promoting cell prolifer‐
ation in osteoblast precursor cells [76]. In addition, activation of ERK1/2 is involved in FGFR2-
mediated osteoblast differentiation. Activation of ERK-MAP kinase by activating FGFR2
mutations results in increased transcriptional activity of Runx2, an essential transcription
factor involved in osteoblastogenesis, and increased osteogenic marker gene expression
(Figure 3) [77]. Recent data indicate that FGF2 stimulates osteoblast differentiation and bone
formation in part by activating Wnt signaling suggesting that Wnt signaling may mediate, at
least in part, the positive effect of FGF/FGFR signaling on bone formation in mice [78]. Besides
Wnt signaling, FGF/FGFR signaling interacts with other pathways. One interaction involves
a negative regulation of the BMP antagonist Noggin by FGF2 during skull development [79].
Another interaction involves the upregulation of the BMP2 gene by endogenous FGF/FGFR
signaling in calvarial osteoblasts. In vivo, FGF2 treatment of developing bone fronts promotes
BMP2 gene expression through the modulation of Runx2 expression [80]. These studies
support a positive role of FGF and BMP signaling crosstalks on bone formation.
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4.9. Insulin-like growth factor-I
The Insulin-like growth factor-I (IGF-I) signaling through its type 1 receptor generates a
complex signaling pathway that stimulates cell proliferation, function, and survival in
osteoblasts (Table 2) [81]. Accordingly, mice lacking functional IGF-I exhibit severe deficiency
in bone formation and a 60% deficit in peak bone mineral density (BMD) [82]. IGF-I can act in
an endocrine, paracrine or autocrine manner and is regulated by a family of six IGF binding
proteins (IGFBPs). The IGFBPs, have received considerable attention as regulators of IGF
actions. The IGFBPs have been reported to have stimulatory or inhibitory actions on the IGFs
in bone, and recent experiments have provided evidence that some of IGFBPs function
independently of IGF to increase parameters of bone formation. The IGFBPs are often found
bound to IGF-I in the circulation or complexed with IGF-I in osteoblasts. IGFBP-3 and -5 are
known stimulators of IGF-I actions, whereas IGFBP-1, -2, -4 and -6 are known inhibitors of
IGF-I action in bone. Once IGF-I binds to its receptor (type 1 IGF receptor) it initiates a complex
signaling pathway including the phosphoinositol 3-kinase (PI3-K)/3-PI-dependent kinase
(PDK)-1/Akt pathway and the Ras/Raf/mitogen-activated protein (MAP) kinase pathway
which stimulate cell function and/or survival (Figure 3) [83]. Recent findings indicate that
many of the IGFBPs and specific proteins in the IGF-I signaling pathways are also potent
anabolic factors in regulating osteoblast function and may serve as potential targets to
stimulate osteoblast function and bone formation locally.
4.10. Leptin–serotonin system pathway regulation of bone formation through gut-derived
serotonin
A new regulation mode of osteoblastic bone formation controlled by leptin-serotonin (BDS)-
sympathetic nervous system pathway has emerged in recent years. Leptin is a hormone
produced by adipocytes that, besides its function in regulating body weight and gonadal
function, can also act as an inhibitor of bone formation (Figure 3) [84]. Latest data indicates
that these leptin functions require brainstem-derived serotonin [85]. Serotonin is a bioamine
produced by neurons of the brainstem (brainstem-derived serotonin, BDS) and enterochro‐
maffin cells of the duodenum (gut-derived serotonin, GDS). BDS acts as a neurotransmitter,
while GDS as an autocrine/paracrine signal that regulates mammary gland biogenesis, liver
regeneration, and gastrointestinal tract motility [86]. There are two Tph genes that catalyze the
rate-limiting step in serotonin biosynthesis: Tph1 expressed mostly, but not only, in entero‐
chromaffin cells of the gut and is responsable for the production of peripheral serotonin [86].
Tph2 is expressed exclusively in raphe neurons of the brainstem and is responsible for the
production of serotonin in the brain [87]. Leptin inhibits BDS synthesis by decreasing the
expression of Tph2, a major enzyme involved in serotonin synthesis in brain [85]. In addition,
other data indicate, the key role of GDS in regulating bone formation as well as the relationship
between GDS, Lrp5, and bone remodeling. Lrp5 controls bone formation by inhibiting GDS
synthesis in the duodenum, and GDS directly acts on the osteoblast cells to inhibit osteoblast
proliferation and suppress bone formation (Table 2) [88]. However, recent data to argue that
Lrp5 affect bone mass mainly through local Wnt signaling pathway, and that the experiments
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did not support the Lrp5-GDS-osteoblast model because they found that there was no
relevance between GDS and bone mass in their mouse model system [89].
4.11. New signals in bone remodeling
More recently, other signaling pathways that link regulation of the osteoclasts and osteoblasts
have been identified. Osteoblast-lineage cells expressed Wnt5a, whereas osteoclast precursors
expressed Ror2. Connection between these two cells leads to Wnt5a-Ror2 signaling between
osteoblast-lineage cells and osteoclast precursors enhanced osteoclastogenesis, through
increased RANK expression mediated by JNK signaling. A soluble form of Ror2 acted as a
decoy receptor of Wnt5a and abrogated bone destruction in the mouse model, suggesting that
the Wnt5a-Ror2 pathway is crucial for osteoclastogenesis in physiological and pathological
environments and may represent a therapeutic target for bone diseases (Figure 3) [90]. Finally,
a recent study reported that semaphorin 4D (Sema4D), previously shown to be an axon
guidance molecule, expressed by osteoclasts and which potently inhibits bone formation [91].
Several studies have suggested that axon-guidance molecules, such as the semaphorins and
ephrins, are involved in the cell-cell communication that occurs between osteoclasts and
osteoblasts. The Binding of Sema4D to its receptor Plexin-B1 in osteoblasts resulted in the
activation of the small GTPase RhoA, which inhibits bone formation by suppressing insulin-
like growth factor-1 IGF-1 signaling and by modulating osteoblast motility. Notably, the
suppression of Sema4D using a specific antibody was found to markedly prevent bone loss in
a model of postmenopausal osteoporosis (Table 2) [91]. This finding identifies a new link
between osteoclasts and osteoblast signaling, and suggests that suppression of the Sema4D-
Plexin-B1-RhoA signaling axis may provide a new therapeutic target for reducing bone loss
and development of bone-increasing drugs.
5. Pathophysiology of bone remodeling (diseases)
Several lines of evidence have established that the cells that remodel the skeleton under
physiological conditions are the same cells that mediate these processes in pathologic states.
Mature bone consists of: an organic matrix (osteoid) composed mainly of type 1 collagen
formed by osteoblasts; a mineral phase which contains the bulk of the body's reserve of calcium
and phosphorus in crystalline form (hydroxyapatite) and deposited in close relation to the
collagen fibers; bone cells; and a blood supply with sufficient levels of calcium and phosphate
to mineralize the osteoid matrix. Bone turnover and remodeling occurs throughout life and
involves the two-coupled processes of bone formation by osteoblasts and bone resorption by
osteoclasts and perhaps osteolytic osteocytes. Abnormalities of bone remodeling can produce
a variety of skeletal disorders (Table 3). The metabolic bone diseases may reflect disturbances
in the organic matrix, the mineral phase, the cellular processes of remodeling, and the
endocrine, nutritional, and other factors that regulate skeletal and mineral homeostasis. These
disorders may be hereditary or acquired and usually affect the entire bony skeleton. The
acquired metabolic bone diseases are the more common and include: osteoporosis, osteoma‐
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lacia, the skeletal changes of hyperparathyroidism and chronic renal failure (renal osteodys‐
trophy), and Paget’s disease [48,50].
5.1. Osteoporosis
Osteoporosis is a common disease of bone remodeling characterized by low bone mass and
defects in the microarchitecture of bone tissue; it causes bone fragility and an increased
vulnerability to fractures. The loss of bone mass and strength can be contributed to by (a) failure
to reach an optimal peak bone mass as a young adult, (b) excessive resorption of bone after
peak mass has been achieved, or (c) an impaired bone formation response during remodeling.
Osteoporosis, is traditionally classified into primary and secondary types. Primary osteopo‐
rosis is the most common metabolic disorder of the skeleton and has been divided into two
subtypes: type I osteoporosis and type II osteoporosis, on the basis of possible differences in
etiology. Type I osteoporosis or postmenopausal osteoporosis is a common bone disorder in
postmenopausal women and is caused primarily by estrogen deficiency resulting from
menopause, whereas type II osteoporosis or age-related osteoporosis is associated primarily
with aging in both women and men (Table 3). In contrast, secondary osteoporosis refers to
bone disorders that are secondary complications of various other medical conditions, conse‐












Table 3. Diseases of bone remodeling.
5.2. Postmenopausal osteoporosis
Postmenopausal osteoporosis is a common disease with a spectrum ranging from asympto‐
matic bone loss to disabling hip fracture (Table 3). The pathogenesis of postmenopausal
osteoporosis is caused primarily by the decline in estrogen levels associated with menopause
[93]. Since the establishment of a central role for estrogen deficiency in the pathogenesis of
postmenopausal osteoporosis, enormous effort has been focused on elucidating the mecha‐
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nisms by which estrogens exert their bone-sparing effects. Since the discovery of the RANKL/
RANK/OPG axis, it has become clear that estrogen also exerts bone-sparing effects by targeting
this regulatory axis. Specifically, estrogen stimulates the expression of OPG in mouse osteo‐
blasts and stromal cells [94]. Moreover, the expression of RANKL was elevated on the surface
of bone marrow cells, such as osteoblasts and lymphocytes, from postmenopausal women with
osteoporosis compared with cells from premenopausal controls [94]; this finding indicates that
RANKL plays an important role in the pathogenesis of postmenopausal osteoporosis.
5.3. Age-related osteoporosis
As the global population ages, the prevalence of age-related osteoporosis (e.g., postmeno‐
pausal osteoporosis, male osteoporosis) and related fractures is likely to increase consider‐
ably (Table 3). Recent studies indicate that significant trabecular bone loss begins as early
as the twenties in men and women long before any major hormonal changes [95]. In women,
however, bone loss accelerates for 5 to 10 years after menopause due to the rapid decline
in estrogen levels; after this phase, bone loss continues at approximately the same rate as
in  elderly  males.  Thus,  the  pathogenesis  of  osteoporosis  in  women  involves  primarily
osteoclasts  (bone  resorption)  and  results  from  changes  in  estrogen  and  FSH  levels  at
menopause and age related,  is  centered on osteoblasts  (bone formation),  and engages a
number of distinct factors associated with the aging process in both men and women. Thus,
age-related  changes  in  the  activity  of  either  cell  type  may lead  to  bone  loss  [96].  Age-
related osteoporosis in men also has a multifactorial etiology. The decreased bone forma‐
tion  caused  by  changes  in  ROS,  IGF-1,  and  PTH  levels  associated  with  aging  plays  a
predominant role in the pathogenesis of age-related osteoporosis in men. However, age-
related changes in the levels of sex steroids, including both estrogen and androgen, also
contribute to the pathogenesis of age-related osteoporosis in men [97].
5.4. Glucocorticoid-induced osteoporosis
Glucocorticoids (GCs) are potent immunomodulatory drugs that are commonly used to treat
a variety of inflammatory conditions and autoimmune disorders. GCs increase bone resorption
and reduce bone formation (Table 3) [98]. Pharmacological doses of GCs induce osteoporosis
primarily by altering normal bone remodeling. GCs exert deleterious effects on the differen‐
tiation, function, and survival of multiple cell types involved in the remodeling process. GCs
have profound effects on osteoblast differentiation and function. As in other target tissues,
glucocorticoids exert their effects on gene expression via cytoplasmic glucocorticoid type 2
receptors. In adult bone, functional glucocorticoid receptors are found in pre-osteoblast/
stromal cells, osteoblasts (the cells that produce bone matrix), but not in osteoclasts [99].
Instead, glucocorticoids stimulate osteoclast proliferation by suppressing synthesis of osteo‐
protegerin, an inhibitor of osteoclast differentiation from hematopoietic cells of the macro‐
phage lineage, and by stimulating production of the receptor activator of nuclear factor kappa-
B (RANK), which is required for osteoclastogenesis. High glucocorticoid levels also stimulate
RANKL synthesis by pre-osteoblast/stromal cells, supporting osteoclast differentiation and
net bone resorption [100].
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One of the major functions of bone remodeling is to adapt bone material and structural
properties to the mechanical demands that are placed on the skeleton, including mechanical
loading and weight bearing (Table 3). The importance of the mechanical balance of bone has
been more recently stressed by the research on the effect of weightlessness on bone, and by
the introduction of the concept of "mechanostat" in the pathogenesis of osteoporotic conditions.
Immobilization osteoporosis has clinical (fractures, sometimes hypercalcemia, urinary
lithiasis) and radiological features. Immobilization has an effect on bone modeling and
remodeling, through an increased activation of remodeling loci, and a decrease of the osteo‐
blastic stimulus. For ordinary individuals, the skeleton is developed in childhood and then
constantly remodeled throughout adulthood to maintain mechanical strength that can
sufficiently support normal weight bearing and routine physical activities. However, for
individuals such as athletes, the mechanical needs increase for certain regions of the skeleton;
consequently, bone modeling results in the formation of stronger bone to replace old bone that
could not adequately meet the increased mechanical demands [101].
5.6. Renal osteodystrophy
Renal osteodystrophy the term used to describe a heterogeneous group of metabolic bone
diseases that accompany chronic kidney disease, is a multifactorial disorder of bone remod‐
eling (Table 3). The bone disorders in renal osteodystrophy include: osteomalacia of adults
and rickets of children (so-called "renal rickets"); osteitis fibrosa and other bone changes of
secondary hyperparathyroidism; osteopenia; and osteosclerosis. Renal osteodystrophy is an
alteration of bone morphology in patients with CKD (Chronic Kidney Disease). The patho‐
physiology of renal osteodystrophy is complex and clearly reflects the importance of PTH and
vitamin D on bone turnover and related pathological abnormalities. The bone changes are
brought about by the abnormal metabolism of vitamin D, the overproduction of parathyroid
hormone (PTH), and chronic metabolic acidosis. The diminished renal mass leads to a
decreased renal conversion of 25-hydroxyvitamin D into 1,25-dihydroxyvitamin D, the active
metabolite of vitamin D, resulting in diminished intestinal absorption of calcium, hypocalce‐
mia, and defective bone mineralization characterized by the presence of wide osteoid seams,
osteomalacia in adults, and rickets in children [102].
5.7. Paget’s disease
Paget’s disease is known as a bone remodeling disorder and that involves abnormal bone
destruction and regrowth, which results in deformity. In Paget’s disease, the bone remodeling
process is disregulated (Table 3). New bone is placed where it is not needed, and old bone is
removed where it is needed. This disregulation can distort the normal skeletal architecture
[103]. Paget’s disease is most commonly diagnosed in the sixth decade, and increases in
prevalence as age increases. Paget's disease is very uncommon in individuals under 40 years
of age. The most common bones affected by Paget’s disease are the pelvis, femur, spine, skull,
and tibia. Paget’s disease is believed to be a primary disorder of increased osteoclast bone
resorption with a secondary marked increase in osteoblast activity and new bone formation.
Topics in Osteoporosis18
The cause of Paget’s disease is not entirely known, but it is thought to be caused in part from
a childhood virus. A virus particle, known as a paramyxovirus nucleocapsid, has been
identified within the bone cells of individuals with Paget’s disease. This virus particle is not
found in normal bone. Genetics plays a role, several genes have been implicated; however, the
most commonly described mutation is a gene that encodes an ubiquitin-binding protein that
plays a role in NF-κB signaling [104].
5.8. Osteopetrosis
There are several syndromes of osteopetrosis or osteosclerosis in which bone resorption is
defective because of impaired formation of osteoclasts or loss of osteoclast function (Table 3).
In these disorders, bone modeling as well as remodeling are impaired, and the architecture of
the skeleton can be quite abnormal [105]. Osteopetrosis is a congenital disease that interferes
with the formation of the bone marrow, and causes abnormal bone development, blindness,
rickets, abnormal tooth development and fragile bones. It results from a defect in cells called
osteoclasts, which are necessary for the formation of the bone marrow. In patients with
osteopetrosis, osteoclasts not function properly, and no cavity is formed to the bone marrow
[106]. The subclassification of these disorders is based upon the mode of inheritance, age of
onset, severity, and clinical symptoms [107]. The pathophysiology of osteopetrosis involves
mutations that affect osteoclast function. The three most important mutations are: carbonic
anhydrase II, proton pump, and chloride channel [48].
6. Conclusions
Bone is a specialized and dynamic tissue, in constant change. It has a complex structure and
undergoes constant remodeling. The basic multicellular unit of bone, which comprises
osteocytes, osteoclasts and osteoblasts, conducts the remodeling process. In the last years, more
knowledge in bone cell biology and genetic studies, have been helped in our understanding
of the essential signaling pathways that control bone remodeling and bone mass. They act in
a coordinated manner to form or resorb bone. Recent advances in molecular biology and a
thorough understanding of the remodeling process bone, many molecules have been discov‐
ered that have important roles in bone biology and novel signaling pathways regulating bone
remodeling have also been identified. Now understand how PTH, Wnt signaling, and growth
factors may trigger anabolic effects in bone. The explosion of this knowledge may serve as a
basis for the development of novel therapeutic approaches targeted on the identified signaling
molecules enable us to define the abnormalities in cells of the osteoblastic and osteoclastic
lineages that lead to bone disease with the hope to the diagnosis and treatment of bone
remodeling disorders. With this knowledge, can expect the development of even more
therapies to evolve from a better understanding of the complex molecular aspects of bone
remodeling.
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1. Introduction
Osteoporosis is a disease entity characterized by the progressive loss of bone mineral density
(BMD) and the deterioration of bone microarchitecture, leading to the development of frac‐
tures. Its classification encompasses two large groups, primary and secondary osteoporosis [1].
Primary osteoporosis is the disease’s most common form and results from the progressive loss
of bone mass related to aging and unassociated with other illness, a natural process in adult
life; its etiology is considered multifactorial and polygenic. This form currently represents a
growing worldwide health problem due in part, to the contemporary environmental condi‐
tions of modern civilization. Risk factors that are considered as “modifiable” also play an
important role and include physical activity, dietary habits and eating disorders. Furthermore,
there is another group of associated risk factors that are considered “non-modifiable”,
including gender, age, race, a personal and/or family history of fractures that in turn, indirectly
reflect the degree of genetic susceptibility to this disease [2-4]. Secondary osteoporosis
encompasses a large heterogeneous group of primary conditions favoring osteoporosis
development. Table 1 summarizes some of the disease entities associated to primary and
secondary osteoporosis.
1.1. Genetic aspects of primary osteoporosis
This form of osteoporosis results from the interaction of several environmental and genetic
factors, leading to difficulties in its study. It is not easy to define the magnitude of the effect of
genetic susceptibility since it is a trait determined by multiple genes whose products affect the
bone phenotype; moreover, the environmental factors compromising bone mineral density are
also difficult to analyze. However, in spite of these barriers, research suggests that inherited
factors affect BMD in ranges between 40 – 70% in the spine, 70 – 85% in the hip and 50 – 60%
© 2013 Valdés-Flores et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Co mons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
Chapter 2
Genetic Diseases Related with Osteoporosis
Margarita Valdés-Flores, Leonora Casas-Avila and
Valeria Ponce de León-Suárez
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55546
1. Introduction
Osteoporosis is a disease entity characterized by the progressive loss of bone mineral density
(BMD) and the deterioration of bone microarchitecture, leading to the development of frac‐
tures. Its classification encompasses two large groups, primary and secondary osteoporosis [1].
Primary osteoporosis is the disease’s most common form and results from the progressive loss
of bone mass related to aging and unassociated with other illness, a natural process in adult
life; its etiology is considered multifactorial and polygenic. This form currently represents a
growing worldwide health problem due in part, to the contemporary environmental condi‐
tions of modern civilization. Risk factors that are considered as “modifiable” also play an
important role and include physical activity, dietary habits and eating disorders. Furthermore,
there is another group of associated risk factors that are considered “non-modifiable”,
including gender, age, race, a personal and/or family history of fractures that in turn, indirectly
reflect the degree of genetic susceptibility to this disease [2-4]. Secondary osteoporosis
encompasses a large heterogeneous group of primary conditions favoring osteoporosis
development. Table 1 summarizes some of the disease entities associated to primary and
secondary osteoporosis.
1.1. Genetic aspects of primary osteoporosis
This form of osteoporosis results from the interaction of several environmental and genetic
factors, leading to difficulties in its study. It is not easy to define the magnitude of the effect of
genetic susceptibility since it is a trait determined by multiple genes whose products affect the
bone phenotype; moreover, the environmental factors compromising bone mineral density are
also difficult to analyze. However, in spite of these barriers, research suggests that inherited
factors affect BMD in ranges between 40 – 70% in the spine, 70 – 85% in the hip and 50 – 60%
© 2013 Valdés-Flores et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Co mons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
in the wrist. Bone density studies in monozygotic (MZ) and dizygotic (DZ) twins suggest that
spinal and femoral neck BMD concordance is higher (6-8:1) in MZ versus DZ twins. Other
studies have estimated that fracture predisposition heritability per se ranges between 25 – 35%
and up to 40% of patients with osteoporotic fractures have a positive family history of fractures,
thus reflecting the great influence of genetic factors in this disease. On the other hand, the
geometry and length of the femoral neck, the bone’s properties on ultrasound, growth speed
and bone remodeling variations are also dependent on genetic factors. The genes associated
with the bone phenotype are distributed throughout the human genome and located in
practically all chromosomes; their products fulfill specific functions and contribute in different
manners to the genetic control of the bone tissue phenotype [5-12]. Some of these genes and
their products are presented in Table 2 [13-23].
It is important to mention that the mechanisms conditioning the hereditary susceptibility
to  osteoporosis  are  determined,  among  other  factors,  by  the  presence  of  mutations  or
genetic polymorphisms (natural genomic variations) in one or several genes involved in
bone phenotype genetic control.  These polymorphisms follow a well-defined inheritance
pattern and their distribution is different among racial groups and populations. There are
several reports in the world literature, of associations between specific genetic variants and
Type of osteoporosis Causes
Primary Multifactorial, polygenic. Senile/Involutional
Secondary Drugs compromising bone quality: anticonvulsants, antidepressants,
anticoagulants, antacids with aluminum, aromatase inhibitors, barbiturates,
cimetidine, corticosteroids, glucocorticoids, birth control pills, cancer drugs,
gonadotropin releasing hormone (GnRH), loop diuretics, methotrexate,
phenobarbital, phenothiazines, among others.
Other entities: nephropathies, malabsorption syndromes, neoplasias,
rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, any process
leading to decreased mobility or prolonged immobility.
Metabolic diseases: diabetes, hyperthyroidism, hyperparathyroidism.
Hypogonadism: Turner and Klinefelter syndromes.
Behavioral disorders: anorexia nervosa, depression, prolonged physical
inactivity, malnutrition, high caffeine intake, smoking and/or chronic
alcoholism.
Monogenic diseases: osteogenesis imperfecta, glioma syndrome, osteoporosis.
Table 1. Osteoporosis classification.
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osteoporosis development or the risk of fractures;  these risks may vary according to the
fractures’ anatomic location [3, 4, 24-30]
Product Function Genes
Matrix components COL1A1, COL1A2, OPN
Hormones and their receptors ESR1, ESR2, AR, VDR, PTHR1, CASR, PTH, CYP1A1, PRL, LEP,
LEPR, INS, INSR
Participants in osteoblastogenic proccesses ALOX12, ALOX15, BMP4, BMP7, IGF-1 LRP5, LRP6, SOST
Participants in osteoclastogenic proccesses P53, RANK, RANK-L
Citokines and their receptors IL1α, IL1β, IL6, TNF, TNFR2
Other MTHFR, APOE
Table 2. Genes involved in bone metabolism.
2. Mendelian diseases and osteoporosis
The description in the literature of some genetic diseases of monogenic inheritance and whose
phenotype includes the loss or increase in bone mineral density and even fractures, has
suggested and even proved that bone phenotype has an important genetic component. These
diseases include idiopathic osteoporosis, osteogenesis imperfecta in all its variants, osteopet‐
rosis, pycnodysostosis and the osteoporosis syndrome associated to pseudoglioma, among
others. In some cases of severe osteoporosis, mutations in the estrogen and even the androgen
receptor genes have been detected.
2.1. Idiopathic juvenile osteoporosis
This is an unusual variety of osteoporosis whose frequency has not been precisely determined.
This disease may develop in females and males, usually around 7 – 10 years of age; children
present difficulty in gait, pain in the lower extremities, ankles, knees, occasionally in the hip
and fractures tend to develop particularly in long bones. Radiologically, it is characterized by
diffuse osteopenia, metaphyseal fractures – especially of the femur -, and vertebral collapse
that may lead to severe kyphoscoliosis or collapse of the thoracic cage. This disease is consid‐
ered potentially reversible whereby in most cases, there is almost complete recovery of the
bone tissue; growth, however, may be compromised.
In these patients, it  is important to exclude other disease entities or conditions manifest‐
ing secondarily as osteoporosis. A differential diagnosis must be made with other genetic
diseases, particularly the different variants of osteogenesis imperfecta; this is relatively easy
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due to its  clinical  characteristics,  lacking in idiopathic  osteoporosis.  The genetic  basis  of
this disease has of yet, not been established but it is possible that genetic mutations with
preferential  tissue  expression in  bone and with  great  impact  on the  tissue’s  phenotype,
may explain some of these cases [31, 32].
2.2. Osteogenesis imperfecta
Osteogenesis imperfecta, also known as “brittle bone disease”, has an estimated incidence of
approximately 1 in 20 000 births. It has great phenotypic variability, different patterns of
inheritance and a wide clinical spectrum ranging from very mild forms of the disease to severe
cases with an unfavorable prognosis. It is caused by the defective synthesis of one of the two
alpha chains of type I collagen (COL1A1 and COL1A2), leading to anomalies in these protein’s
structure; it is normally constituted by 3 coiled sub-units, two α1 chains and one α2 chain. This
type of collagen is considered the most abundant component of structural protein in bone as
well as in ligaments, tendons, sclerae and skin. Quantitative or qualitative defects in this
protein lead to bone fragility and hence, to an increased risk of fractures.
The genes encoding the α1 and α2 chains are located in the 17q21.31-q22 and 7q22.1 chromo‐
somes, respectively. Aside from brittle bones, these patients may also present long bones with
no curvatures, severe deformities preventing appropriate gait and even standing, conductive
deafness due to malformations of the auditory canal, dentinogenesis imperfecta, joint hyper‐
laxity and intervertebral disc herniation. Patients with severe forms of the disease have a long
history of fractures on mild impact and variable bone deformities. The most severe variants
may even lead to fractures in utero and pre or perinatal death. Tables 3 and 4 shows different
forms of the disease [33-35].
2.3. Osteoporosis – Pseudoglioma Syndrome (OPPG)
This  syndrome  is  an  autosomal  recessive  disease  characterized  by  bone  and  visual
abnormalities including short stature, osteoporosis development during infancy, spontane‐
ous  fractures,  scoliosis,  platyspondyly  and  long  bone  deformities.  A  crucial  associated
finding is  the presence of  pseudoglioma that  may be associated to microcephaly,  blind‐
ness  during  childhood,  cataracts  and  iris  atrophy.  Occasionally,  some  patients  present
interventricular  septal  defects  and  mental  retardation.  This  disease  is  conditioned  by
mutations of the LRP5 gene,  located on chromosome 11q13.4 and that encodes the low-
density  lipoprotein  receptor-related  protein  5  (LRP5).  It  was  initially  believed  that  this
entity  was  another  variant  of  osteogenesis  imperfecta  (OI)  but  the  study of  collagen in
patients  with  OPPG  established  that  this  protein  was  normal  and  the  hypothesis  was
discarded; however, this is still the most relevant differential diagnosis [36-41].
2.4. Neuromuscular disorders
Muscular dystrophies, peripheral neuropathies and muscle atrophies of hereditary origin,
represent broad groups of diseases that aside from their characteristic clinical stigmata, can be
associated with osteoporosis as one of their complications. As the disease progresses in these
Topics in Osteoporosis32
patients, there is increased difficulty and limitation in walking and periods of immobility
become progressively more prolonged leading to the gradual loss of the mechanical stimuli
that bone needs to maintain its strength and hence, favoring the development of osteoporosis.
As all Mendelian diseases, these neuromuscular abnormalities follow different inheritance
patterns and present phenotypic variability [42-44].
2.5. Inborn errors of metabolism
This group of genetic diseases encompasses a great number of inborn defects with repercus‐
sions in several aspects of carbohydrate, amino acid, protein, vitamin, mineral, complex
molecule, neurotransmitter and energy metabolism. The genetic basis of most of these entities
hinges on gene mutations encoding proteins, particularly enzymes, leading to partial or
complete blockade of one or several metabolic processes. In these diseases, symptoms arise
for different reasons, including: a deficit of the products generated by the compromised
enzymatic reaction, accumulation of the precursor immediate to the defect, an increase in
alternative products due to increased activation of alternate metabolic pathways or inhibition
of these alternate pathways due to the accumulated substrate. In most cases, inheritance of
these diseases is autosomal recessive and less frequently, X-linked recessive.
In cases of metabolic errors, osteoporosis tends to develop for different reasons: in some cases,
it is secondary to nutritional deficiencies, progressive neurologic or muscular impairment or
as a consequence of the therapeutic measures taken in the management of the primary disease:
their secondary effects directly compromise bone quality (steroids, antiseizure drugs, etc.). The
number of monogenic diseases whose phenotype may include osteoporosis is large and are
shown in Tables 3-5, according to their Mendelian inheritance pattern [45-56].








Osteogenesis imperfecta, Type I; OI1 COL1A1 Collagen, type I, alpha
1 (COL1A1)
17q21.33 33, 34
Osteogenesis imperfecta, Type II; OI2 COL1A1 Collagen, type I, alpha
1 (COL1A1)
17q21.33 33, 59
COL1A2 Collagen, type I, alpha
2 (COL1A2)
7q21.3
Osteogenesis imperfecta, Type III; OI3 COL1A1 Collagen, type I, alpha
1 (COL1A1)
17q21.33 33, 60
COL1A2 Collagen, type I, alpha
2 (COL1A2)
7q21.3
Marfan syndrome; MFS FBN1 Fibrillin 1 (FBN1) 15q21.1 61, 62
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Table 3. Autosomal dominant diseases with bone mineral density loss.
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Disease Gene Product Genomic
location
Reference
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folate reductase
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ERCC6 DNA excision repair
protein ERCC-6
10q11.23 188, 189
Wilson disease; WND ATP7B Copper-transporting
ATPase 2 (ATP7B)
13q14.3 190, 191





Rothmund-thomson syndrome; RTS RECQL4 ATP-dependent DNA
helicase Q4 (RECQL4)
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Cutis laxa, autosomal recessive, Type
IA; ARCL1A
FBLN5 Fibulin-5 (FBLN5) 14q32.12 212, 213
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Laron syndrome GHR Growth hormone
receptor (GHR)
5p13-p12 223, 224





Keutel syndrome MGP Matrix Gla protein
(MGP)
12p12.3 227, 228




isozyme (ALPL / PPBT)
1p36.12 229, 230
Fanconi-Sickel syndrome; FBS SLC2A2 Solute carrier family
2, facilitated glucose
transporter member
2 (SLC2A2 / GTR2)
3q26.2 231, 232










Costello syndrome HRAS GTPase HRas (HRAS/
RASH) (HRAS / RASH)
11p15.5 237, 238
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Table 4. Autosomal recessive diseases with bone mineral density loss.










Androgen insensitivity syndrome; AIS AR Androgen receptor
(AR)
Xq12 243, 244
Fragile X mental retardation
syndrome




Fabry disease GLA Galactosidase, alpha
(AGAL)
Xq22.1 51, 52
Occipital horn syndrome; OHS ATP7A Copper-transporting
ATPase 1 (ATP7A)
Xq21.1 247, 248











(glycerol kinase deficiency; GKD)
GK Glycerol kinase (GK) Xp21.2 253, 254





Terminal osseous dysplasia; TOD or
ODPF
FLNA Filamin-A (FLNA) Xq28 257, 258
Table 5. X-linked recessive diseases with bone mineral density loss.
2.6. Genetic diseases of chromosomal origin and osteoporosis
Within the different categories of genetic diseases, we can include numeric or structural
chromosomal abnormalities. Two of the most common chromosomal diseases are Turner’s
syndrome and Klinefelter’s syndrome, both associated to X chromosome aneuploidy; in the
first case, there is complete or partial absence of an X chromosome and less frequently, it can
be caused by structural anomalies in the short arms of the X chromosome. In Klinefelter’s
syndrome, there is an additional X chromosome and occasionally, there may be more than one
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syndrome and Klinefelter’s syndrome, both associated to X chromosome aneuploidy; in the
first case, there is complete or partial absence of an X chromosome and less frequently, it can
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extra X chromosome. In both syndromes, the phenotypic spectrum includes gonadal dysgen‐
esis, in Turner’s syndrome there are fibrous bands instead of ovaries and in Klinefelter’s, the
testicles are hypoplastic, leading in both cases to hypogonadism and a partial or complete
deficit in the sex hormones that would normally be produced by the ovaries and testicles. Due
to their lack, the development of normal secondary sexual characteristics is stunted and the
various metabolic processes dependent on the hormones are also compromised. One of these
metabolic processes occurs in bone [259-262].
Undoubtedly, bone metabolism is complex and the processes of osteoblastogenesis, osteo‐
clastogenesis and remodeling must occur in a balanced manner; it is important to mention that
the entire family of steroid hormone receptors (estrogen, androgen, vitamin D and retinoids),
are expressed in bone, both in osteoblasts and osteoclasts as well as in chondrocytes. Within
this microenvironment, the action of these hormones on their receptors is key to appropriate
skeletal development; as a matter of fact, individuals with genetic mutations encoding any of
these receptors develop, among other manifestations, bad quality bone mass. These hormones
and their receptors play a pivotal role in female and male bone growth and may also favor
epiphyseal closure at the end of the growth period. It is known that one of effects of steroid
hormones on bone metabolism is resorption inhibition since they promote osteoclast apoptosis
and decrease the frequency of remodeling unit activation. Therefore, the integral treatment of
both entities includes hormone replacement that to a certain extent, will improve bone mass
and will prevent or delay the development of osteoporosis [263, 264].
3. Conclusion
Bone metabolism and the large amount of processes that it involves, such as osteoblastogen‐
esis, osteoclastogenesis and bone remodeling, must be kept in constant balance. Each one
of  these aspects  of  the physiology of  bone shows a particular  gene expression patterns,
which  may  even  differ  according  to  conditions  and  tissue  needs.  As  previously  men‐
tioned the number of genes involved is very large and sometimes their expression might
be  modified  by  multiple  environmental  conditions.  It  is  important  to  mention  that  the
expression  of  these  genes  is  ubiquitous  and  is  not  restricted  to  the  bone  tissue,  which
explains  why the  phenotypic  characteristics  of  a  large  number  of  monogenic  and some
polygenic entities include alterations on bone mineral  density and on the microarchitec‐
ture of this tissue; this includes several degrees of osteopenia,osteoporosis or increased bone
mineral density. Even a good number of these genes have been identified through the study
of human disease whose phenotype includes altered bone mineral density. Without a doubt,
the investigation of several processes that regulate bone metabolism will continue generat‐
ing new knowledge that will allow better understanding of bone physiology and physiopa‐
thology  of  multiple  diseases  and  possibly  new  therapeutic  options  in  diseases  which
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1. Introduction
Osteoporosis is a very important health problem worldwide. It is defined as a disease charac‐
terized by low bone mass and micro-architectural deterioration of bone tissue, leading to
enhanced bone fragility and consequent increase in fracture risk [1]. Osteoporosis is a silent
disease and the health and financial impact of the disease result from fracture, particularly hip
fracture, for which subjects with osteoporosis are at an increased risk [2]. In the UK, one in two
women and one in five men suffer a fracture after the age of 50, with an annual cost to the
health services of around £2 billion [3,4].
In 1990, the number of osteoporotic fractures estimated in Europe was 2.7 million, with an
estimated direct cost in 2004 of €36 billion (£24.5 billion), of which €24.3 billion (£16.6 billion)
were accounted for by hip fracture. Costs are expected to rise to €76.8 billion (£52.4 billion) by
the year 2050 [5]. Similar projections are made for many other regions of the world because of
the increasing numbers of the elderly. In the USA, the annual cost of incident fractures due to
osteoporosis or low bone mass is predicted to rise from $16.9 billion in 2006 to around $25.3
billion by the year 2025 [4]. The direct costs of medical care of hip fractures were over $65
million in 2004 [6].
There are many hormones involved in bone and mineral metabolism, such as oestrogens,
testosterone and parathormone (PTH). The adipocyte also plays an important role in regulat‐
ing bone metabolism by releasing estrogens, and the adipokines, like leptin, resistin, adipo‐
nectin, and many others. After the discovery of leptin receptors in bone many studies have
been done to explore its involvement in bone metabolism. Some studies have shown that leptin
is expressed and secreted from primary cultures of human osteoblasts during the mineraliza‐
tion period, and that it may stimulate osteogenesis in human bone marrow in vitro [7,8].
© 2013 Lateef et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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Furthermore, leptin may reduce ovariectomy-induced osteoporosis in rats and may also be
involved in foetal and growing bone metabolism [9, 10].
Leptin, a fat-derived cytokine-like hormone, was discovered in 1994 by Friedman and
colleagues [11]. A 16-kDa hormone, encoded by the OB gene, is predominantly expressed in
adipose tissue [12] and circulates as a free and as a protein-bound entity. According to
structural studies leptin belongs to the growth hormone four-helical cytokine subfamily. The
leptin receptor was identified in the db locus of mouse chromosome 4. As a member of the
IL-6 receptor family, the leptin receptor contains an extracellular-binding domain, a single
transmembrane domain and a cytoplasmatic signaling domain [13]. Intracellular signaling is
mediated through a non-covalently associated tyrosine kinase of the JAK kinase family [14].
Alternate gene splicing results in five known isoforms of the leptin receptor. The longest form
of the receptor (ObR) is the only isoform capable of complete signal transduction. Conversely,
the shorter isoforms of the leptin receptor have been suggested to participate in leptin clearance
and/or to facilitate transport of leptin across the blood-brain barrier [14]. Circulating levels of
leptin correlate with BMI and the content of fat mass. After crossing the blood–brain barrier,
leptin reaches the hypothalamus, where it acts as a crucial regulator of feeding. Leptin is mainly
regarded as a ‘‘starvation-hormone’’ signaling from the adipose tissue (AT) to the brain,
indicating the size of the AT-stores [15].
Food intake and energy expenditure are controlled by leptin through an interaction with
various neuropeptides in the hypothalamus. Neuropeptide Y (NPY) and agouti-related
peptide (AGRP) expressions are inhibited, whereas pro-opiomelanocortin (POMC) expression
is stimulated by leptin with increased food intake [16, 17]. Moreover, leptin interacts with
neuromedin U (NMU); a novel and recently identified hypothalamic neuropeptide involved
also in the regulation of appetite and locomotor activity [18]. Besides energy metabolism, leptin
demonstrates pleiotropic effects in such areas as hematopoesis, blood pressure, T lymphocyte
function, reproduction and bone mass regulation [14, 19]. Several endocrine and paracrine
factors play a role in the fat-bone relationship. A number of local cytokines secreted by the
adipose tissue, including leptin, have also been related to BMD variations [20]. Leptin because
of its diverse role in bone is being considered one of the main functional connections between
fat and bone.
Leptin, known to regulate appetite & energy expenditure may also contribute to mediate
the effects of fat mass on bone. Interestingly, obesity seems to protect from osteoporosis.
This observation led to researchers at bone formation in mouse models of obesity. Much
effort has been dedicated to the relationship between leptin and bone. This interest stems
from the well-founded knowledge that body weight is a major determinant of bone den‐
sity [21].  It  is  known that  obesity is  generally accompanied by increased bone strength.
Obese persons have stronger bones and lose bone tissue at a slower pace [22]. Leptin has
been  proposed  to  regulate  increased  body  weight  as  well  as  increased  bone  density.
Mice  that  have  congenital  absence  of  leptin  (ob/ob)  have  been  shown to  be  obese  and
have very high bone density.  Leptin makes them lose both fat  and bone [23].  The bone
mass phenotype of  ob/ob mice can be rescued by intracerebroventricular  (ICV) infusion
of leptin, suggesting that leptin exerts an indirect influence on bone mass. There is a re‐
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port which has shown that when leptin injected into the brain of animals it  will  inhibit
bone formation at  doses lower than those that  cause loss  of  body weight  [24].  A lot  of
studies have been done to explore the relationship of serum leptin with bone mass den‐
sity and biochemical bone markers in osteoporosis. In this chapter, the mechanism of ac‐
tion of leptin on bone is reviewed and role of serum leptin in postmenopausal females is
discussed  with  respect  to  its  relation  with  bone  mass  density  and  biochemical  bone
markers.
2. Leptin and its mechanism of action on bone
Leptin acts on bone by two different mechanisms. The first is the indirect mechanism revealed
by Ducy et al (2000) in mutant mice and rats that either cannot produce or cannot respond to
leptin [25]. Leptin secreted from fat cells is carried by the ObRa receptors of vascular endo‐
thelial cells across the blood-brain-barrier where it activates ObRb receptors in the hypothal‐
amus. These signals then stimulate expression of HOBIF (hypothalamic osteoblast inhibitory
factor) which when released, lowers the matrix-making ability of osteoblasts [25-29] and
because of this reason obese Ob (Lep)–/– mice, which should have low bone mass due to lack
of leptin, and thus estrogen, actually have an abnormally high bone mass.
The  second  direct  mechanism  of  leptin  action  is  by  promoting  differentiation  of  bone
marrow  stromal  cells  into  osteoblasts  [8]  and  by  inhibiting  osteoclast  generation  [30].
Bone marrow stromal  cells  (BMSC) can differentiate  into either  adipocytes  or  osteoblast
cell  lineage.  Bone marrow adipocytes may serve as  a  direct  source of  leptin,  which can
inhibits adipogenesis differentiation of BMSC and stimulates differentiation of osteoblasts
[31] while Kim et al. (2003) have shown that very high leptin levels led to BMSC apopto‐
sis  [32].  Reseland et  al.  (2001)  have found that  human osteoblasts  start  making and se‐
creting  leptin  when  they  are  either  in  the  late,  matrix-mineralizing  stage  or  when
changing to osteocytes [7]. Leptin has also stimulates the proliferation of cultured human
osteoblasts [33], and it has been shown to cause human bone marrow stromal cells to ex‐
press  alkaline  phosphatase,  collagen-I,  and  osteocalcin  and  to  mineralize  matrix  [8].
These tissue culture experiments support the dual effect of leptin within the bone micro‐
environment depending on the local leptin concentration.
In the last decade Ducy et al.  (2000a,b) [25,27] have not found any long isoforms of the
leptin  receptors  (Ob-R)  on  osteoblasts,  so  they  assumed that  leptin  acted  centrally  as  a
very potent inhibitor of bone formation. Although the long isoform of Ob-R is abundant‐
ly  expressed  in  the  hypothalamus,  and  in  a  large  number  of  peripheral  tissues  [14].
BMSC, osteoblasts,  osteoclasts  and chondrocytes  also express  leptin receptors  [8].  In  os‐
teoblasts,  leptin acts  through the osteoprotegerin (OPG)/RANKL (Receptor  Activator  for
Nuclear  factor  κB  Ligand)  signaling  pathway.  Treatment  with  leptin  changes  the  OPG/
RANKL  expression  profile  favoring  OPG  [30].  Consequently,  osteoclastogenesis  is  very
likely  suppressed  by  leptin  through  the  OPG/RANKL  pathway.  In  agreement  with  the
previous findings, Burguera et al [10] have also confirmed the previous findings that ad‐
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Furthermore, leptin may reduce ovariectomy-induced osteoporosis in rats and may also be
involved in foetal and growing bone metabolism [9, 10].
Leptin, a fat-derived cytokine-like hormone, was discovered in 1994 by Friedman and
colleagues [11]. A 16-kDa hormone, encoded by the OB gene, is predominantly expressed in
adipose tissue [12] and circulates as a free and as a protein-bound entity. According to
structural studies leptin belongs to the growth hormone four-helical cytokine subfamily. The
leptin receptor was identified in the db locus of mouse chromosome 4. As a member of the
IL-6 receptor family, the leptin receptor contains an extracellular-binding domain, a single
transmembrane domain and a cytoplasmatic signaling domain [13]. Intracellular signaling is
mediated through a non-covalently associated tyrosine kinase of the JAK kinase family [14].
Alternate gene splicing results in five known isoforms of the leptin receptor. The longest form
of the receptor (ObR) is the only isoform capable of complete signal transduction. Conversely,
the shorter isoforms of the leptin receptor have been suggested to participate in leptin clearance
and/or to facilitate transport of leptin across the blood-brain barrier [14]. Circulating levels of
leptin correlate with BMI and the content of fat mass. After crossing the blood–brain barrier,
leptin reaches the hypothalamus, where it acts as a crucial regulator of feeding. Leptin is mainly
regarded as a ‘‘starvation-hormone’’ signaling from the adipose tissue (AT) to the brain,
indicating the size of the AT-stores [15].
Food intake and energy expenditure are controlled by leptin through an interaction with
various neuropeptides in the hypothalamus. Neuropeptide Y (NPY) and agouti-related
peptide (AGRP) expressions are inhibited, whereas pro-opiomelanocortin (POMC) expression
is stimulated by leptin with increased food intake [16, 17]. Moreover, leptin interacts with
neuromedin U (NMU); a novel and recently identified hypothalamic neuropeptide involved
also in the regulation of appetite and locomotor activity [18]. Besides energy metabolism, leptin
demonstrates pleiotropic effects in such areas as hematopoesis, blood pressure, T lymphocyte
function, reproduction and bone mass regulation [14, 19]. Several endocrine and paracrine
factors play a role in the fat-bone relationship. A number of local cytokines secreted by the
adipose tissue, including leptin, have also been related to BMD variations [20]. Leptin because
of its diverse role in bone is being considered one of the main functional connections between
fat and bone.
Leptin, known to regulate appetite & energy expenditure may also contribute to mediate
the effects of fat mass on bone. Interestingly, obesity seems to protect from osteoporosis.
This observation led to researchers at bone formation in mouse models of obesity. Much
effort has been dedicated to the relationship between leptin and bone. This interest stems
from the well-founded knowledge that body weight is a major determinant of bone den‐
sity [21].  It  is  known that  obesity is  generally accompanied by increased bone strength.
Obese persons have stronger bones and lose bone tissue at a slower pace [22]. Leptin has
been  proposed  to  regulate  increased  body  weight  as  well  as  increased  bone  density.
Mice  that  have  congenital  absence  of  leptin  (ob/ob)  have  been  shown to  be  obese  and
have very high bone density.  Leptin makes them lose both fat  and bone [23].  The bone
mass phenotype of  ob/ob mice can be rescued by intracerebroventricular  (ICV) infusion
of leptin, suggesting that leptin exerts an indirect influence on bone mass. There is a re‐
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port which has shown that when leptin injected into the brain of animals it  will  inhibit
bone formation at  doses lower than those that  cause loss  of  body weight  [24].  A lot  of
studies have been done to explore the relationship of serum leptin with bone mass den‐
sity and biochemical bone markers in osteoporosis. In this chapter, the mechanism of ac‐
tion of leptin on bone is reviewed and role of serum leptin in postmenopausal females is
discussed  with  respect  to  its  relation  with  bone  mass  density  and  biochemical  bone
markers.
2. Leptin and its mechanism of action on bone
Leptin acts on bone by two different mechanisms. The first is the indirect mechanism revealed
by Ducy et al (2000) in mutant mice and rats that either cannot produce or cannot respond to
leptin [25]. Leptin secreted from fat cells is carried by the ObRa receptors of vascular endo‐
thelial cells across the blood-brain-barrier where it activates ObRb receptors in the hypothal‐
amus. These signals then stimulate expression of HOBIF (hypothalamic osteoblast inhibitory
factor) which when released, lowers the matrix-making ability of osteoblasts [25-29] and
because of this reason obese Ob (Lep)–/– mice, which should have low bone mass due to lack
of leptin, and thus estrogen, actually have an abnormally high bone mass.
The  second  direct  mechanism  of  leptin  action  is  by  promoting  differentiation  of  bone
marrow  stromal  cells  into  osteoblasts  [8]  and  by  inhibiting  osteoclast  generation  [30].
Bone marrow stromal  cells  (BMSC) can differentiate  into either  adipocytes  or  osteoblast
cell  lineage.  Bone marrow adipocytes may serve as  a  direct  source of  leptin,  which can
inhibits adipogenesis differentiation of BMSC and stimulates differentiation of osteoblasts
[31] while Kim et al. (2003) have shown that very high leptin levels led to BMSC apopto‐
sis  [32].  Reseland et  al.  (2001)  have found that  human osteoblasts  start  making and se‐
creting  leptin  when  they  are  either  in  the  late,  matrix-mineralizing  stage  or  when
changing to osteocytes [7]. Leptin has also stimulates the proliferation of cultured human
osteoblasts [33], and it has been shown to cause human bone marrow stromal cells to ex‐
press  alkaline  phosphatase,  collagen-I,  and  osteocalcin  and  to  mineralize  matrix  [8].
These tissue culture experiments support the dual effect of leptin within the bone micro‐
environment depending on the local leptin concentration.
In the last decade Ducy et al.  (2000a,b) [25,27] have not found any long isoforms of the
leptin  receptors  (Ob-R)  on  osteoblasts,  so  they  assumed that  leptin  acted  centrally  as  a
very potent inhibitor of bone formation. Although the long isoform of Ob-R is abundant‐
ly  expressed  in  the  hypothalamus,  and  in  a  large  number  of  peripheral  tissues  [14].
BMSC, osteoblasts,  osteoclasts  and chondrocytes  also express  leptin receptors  [8].  In  os‐
teoblasts,  leptin acts  through the osteoprotegerin (OPG)/RANKL (Receptor  Activator  for
Nuclear  factor  κB  Ligand)  signaling  pathway.  Treatment  with  leptin  changes  the  OPG/
RANKL  expression  profile  favoring  OPG  [30].  Consequently,  osteoclastogenesis  is  very
likely  suppressed  by  leptin  through  the  OPG/RANKL  pathway.  In  agreement  with  the
previous findings, Burguera et al [10] have also confirmed the previous findings that ad‐
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ministration of leptin reduced ovariectomy induced bone loss in rats by increasing osteo‐
protegerin  mRNA  in  osteoblasts.  Cornish  et  al  in  2001  have  found  that  leptin  given
peripherally  increased  bone  strength  in  mice  and  also  increased  proliferation  of  osteo‐
blasts  in  vitro  [34].  The results  of  these  studies  showed that  direct  peripheral  action of
leptin on bone is to enhance the strength of the bone in contrast to its central effect.
In order to evaluate its central effect, leptin was injected into the brain in the form of an
intra-cerebelo-ventricular infusion [25, 27, 35]. Bone loss occurred in both wild-type mice
and leptin  deficient  mice  confirming that  bone mass  is  partly  regulated via  the  central,
hypothalamic relay [25]. However, bone formation was inhibited at lower doses of leptin
than those necessary to cause the loss of body weight. Ob/ob mice have low sympathetic
activity, which led to the assumption that the central effect of leptin on bone is mediated
by  the  sympathetic  nervous  system (SNS)  [36].  The  effect  of  leptin  on  the  sympathetic
nervous system is an important aspect in the regulation of energy homeostasis as well as
several other physiological functions [37].
3. Serum leptin and Bone Mass Density (BMD)
It is widely recognized that BMD measurement can predict fracture risk in the same way as
cholesterol predicts cardiovascular disease [38]. In fact, the strength of BMD measurement to
predict fracture is approx 3 fold higher than strength of serum cholesterol to predict cardio‐
vascular disease [39]. Bone mass measurement has been found to be a single best predictor of
fracture risk and is required to the early diagnosis of osteoporosis [37,38,39].
It is observed in a study by Lateef et al 2010 that BMD is found to be significantly lower in
postmenopausal females with and without osteoporosis as compared to premenopausal
females [40] and there is a negative correlation between age and BMD found in post meno‐
pausal ostreoporotic females indicating bone loss with age and menopause [41]. A rapid bone
loss is commonly seen in elderly individuals and tends to worsen with advancing age. The
aging population is inevitably proven to be more osteoporotic unless it is intervened first with
diagnostic tools and after preventive therapy [42].
Another study of Lateef et al 2011 showed that plasma leptin levels were positively correlated
with bone mineral density (BMD) values in osteoporotic females [43]. Some reports have
suggested a correlation between serum leptin concentration and BMD while other showed no
such association [44-48]. It has been shown that plasma leptin levels are positively correlated
with BMD at all skeleton sites measured in postmenopausal osteoporosis [49]. It is interesting
to note that the obese are usually protected against osteoporosis and have increased bone
mineral density [50]. This has been attributed to the mechanical effects of their excessive weight
on bone tissue. It has been shown that obese postmenopausal women have a tendency to have
increased bone mineral density compared with lean women [51-53]. The study of Di Carlo et
al. (2007) documented a significant correlation between serum leptin and BMD in early
postmenopausal women but the correlation was lost during progression of the postmeno‐
pausal period [54]. Thomas et al. (2001) have observed that serum leptin correlated with BMD
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in women but not in men [31]. Sato et al. (2001) have found a positive correlation between
serum leptin and calcaneus BMD in men, but the relationship became inverse when adjusted
for body weight [18]. Pasco et al. (2001) have demonstrated a significant positive association
between BMD and serum leptin in non-obese women [55]. Results of Blain et al (2002) reported
that leptin is an independent predictor of whole body and femoral neck BMD in postmeno‐
pausal women [56]. Nagy et al. (2001) found a negative correlation between serum leptin levels
and radial and femoral BMD in postmenopausal women [57]. Hadji et al. (2001) reported that
bone mass is not correlated with the serum leptin level in pre or postmenopausal women [58].
Rauch et al. (1998) also reported no correlation between bone mass and serum leptin levels by
examining total and trabecular bone density at the distal radius in adult women [59]. In leptin
literature, several studies have examined the relationship between serum leptin and BMD in
various cohorts, but the results remain contradictory. This fact reflects the intricacy of the
relationship of leptin and bone.
A study by  Hamrick  and Ferrari  (2008)  has  documented that  the  effect  of  leptin  is  re‐
duced  with  increased  age  and  higher  BMI  in  both  humans  and  laboratory  animals  in
spite  of  high serum leptin levels  [60].  It  has been postulated that  the under-responsive‐
ness  to  leptin,  or  leptin  resistance,  is  mediated  either  by  impaired  transport  of  leptin
through the blood-brain barrier, lower expression of leptin receptors and/or by the inhib‐
ition of  the intracellular  leptin signaling [61].  In plasma,  leptin is  bound to soluble  lep‐
tin  receptor  (SLR),  the  product  of  an  alternate  splicing  of  leptin  receptor  mRNA  or
proteolytic cleavage [14]. Whereas serum leptin levels correlate positively with BMI, SLR
is correlated negatively [14,62]. The inverse relationship between SLR and BMI reflects a
feedback regulation between the body weight  and leptin or  leptin  receptor  expressions.
It  is  observed in a study by Welt  et  al.  (2004)  when low serum leptin levels  in women
with hypothalamic amenorrhea (induced either by exercise or by low body weight) were
treated with recombinant human leptin for three months,  it  led to an increase of  osteo‐
calcin,  bone  alkaline  phosphates  and  IGF-1,  whereas  urinary  N-telopeptide  did  not
change  [63].They  have  demonstrated  that  leptin  administration  in  individuals  with  lep‐
tin  deficiency appeared to  improve the  growth hormone axis  and markers  of  bone for‐
mation [63].
4. Osteoporosis and bone turnover markers (BTMs)
Bone markers are product derived from the bone remodeling process. During this process,
compounds are released either from bone or from the cells involved in the bone remodeling
process (osteoblasts and osteoclasts.) Markers of bone turnover are biochemical products
measured usually in blood or urine that reflect the metabolic activity of bone but which
themselves have no function in controlling skeletal metabolism [64]. Biochemical markers of
bone turnover are broadly divided into two categories: markers of bone resorption, which
reflect osteoclast activity and are for the most part degradation products of type I collagen;
markers of bone formation, which reflect osteoblast activity and are byproducts of collagen
synthesis, matrix proteins or osteoblastic enzymes (Table 1) [65].
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ministration of leptin reduced ovariectomy induced bone loss in rats by increasing osteo‐
protegerin  mRNA  in  osteoblasts.  Cornish  et  al  in  2001  have  found  that  leptin  given
peripherally  increased  bone  strength  in  mice  and  also  increased  proliferation  of  osteo‐
blasts  in  vitro  [34].  The results  of  these  studies  showed that  direct  peripheral  action of
leptin on bone is to enhance the strength of the bone in contrast to its central effect.
In order to evaluate its central effect, leptin was injected into the brain in the form of an
intra-cerebelo-ventricular infusion [25, 27, 35]. Bone loss occurred in both wild-type mice
and leptin  deficient  mice  confirming that  bone mass  is  partly  regulated via  the  central,
hypothalamic relay [25]. However, bone formation was inhibited at lower doses of leptin
than those necessary to cause the loss of body weight. Ob/ob mice have low sympathetic
activity, which led to the assumption that the central effect of leptin on bone is mediated
by  the  sympathetic  nervous  system (SNS)  [36].  The  effect  of  leptin  on  the  sympathetic
nervous system is an important aspect in the regulation of energy homeostasis as well as
several other physiological functions [37].
3. Serum leptin and Bone Mass Density (BMD)
It is widely recognized that BMD measurement can predict fracture risk in the same way as
cholesterol predicts cardiovascular disease [38]. In fact, the strength of BMD measurement to
predict fracture is approx 3 fold higher than strength of serum cholesterol to predict cardio‐
vascular disease [39]. Bone mass measurement has been found to be a single best predictor of
fracture risk and is required to the early diagnosis of osteoporosis [37,38,39].
It is observed in a study by Lateef et al 2010 that BMD is found to be significantly lower in
postmenopausal females with and without osteoporosis as compared to premenopausal
females [40] and there is a negative correlation between age and BMD found in post meno‐
pausal ostreoporotic females indicating bone loss with age and menopause [41]. A rapid bone
loss is commonly seen in elderly individuals and tends to worsen with advancing age. The
aging population is inevitably proven to be more osteoporotic unless it is intervened first with
diagnostic tools and after preventive therapy [42].
Another study of Lateef et al 2011 showed that plasma leptin levels were positively correlated
with bone mineral density (BMD) values in osteoporotic females [43]. Some reports have
suggested a correlation between serum leptin concentration and BMD while other showed no
such association [44-48]. It has been shown that plasma leptin levels are positively correlated
with BMD at all skeleton sites measured in postmenopausal osteoporosis [49]. It is interesting
to note that the obese are usually protected against osteoporosis and have increased bone
mineral density [50]. This has been attributed to the mechanical effects of their excessive weight
on bone tissue. It has been shown that obese postmenopausal women have a tendency to have
increased bone mineral density compared with lean women [51-53]. The study of Di Carlo et
al. (2007) documented a significant correlation between serum leptin and BMD in early
postmenopausal women but the correlation was lost during progression of the postmeno‐
pausal period [54]. Thomas et al. (2001) have observed that serum leptin correlated with BMD
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in women but not in men [31]. Sato et al. (2001) have found a positive correlation between
serum leptin and calcaneus BMD in men, but the relationship became inverse when adjusted
for body weight [18]. Pasco et al. (2001) have demonstrated a significant positive association
between BMD and serum leptin in non-obese women [55]. Results of Blain et al (2002) reported
that leptin is an independent predictor of whole body and femoral neck BMD in postmeno‐
pausal women [56]. Nagy et al. (2001) found a negative correlation between serum leptin levels
and radial and femoral BMD in postmenopausal women [57]. Hadji et al. (2001) reported that
bone mass is not correlated with the serum leptin level in pre or postmenopausal women [58].
Rauch et al. (1998) also reported no correlation between bone mass and serum leptin levels by
examining total and trabecular bone density at the distal radius in adult women [59]. In leptin
literature, several studies have examined the relationship between serum leptin and BMD in
various cohorts, but the results remain contradictory. This fact reflects the intricacy of the
relationship of leptin and bone.
A study by  Hamrick  and Ferrari  (2008)  has  documented that  the  effect  of  leptin  is  re‐
duced  with  increased  age  and  higher  BMI  in  both  humans  and  laboratory  animals  in
spite  of  high serum leptin levels  [60].  It  has been postulated that  the under-responsive‐
ness  to  leptin,  or  leptin  resistance,  is  mediated  either  by  impaired  transport  of  leptin
through the blood-brain barrier, lower expression of leptin receptors and/or by the inhib‐
ition of  the intracellular  leptin signaling [61].  In plasma,  leptin is  bound to soluble  lep‐
tin  receptor  (SLR),  the  product  of  an  alternate  splicing  of  leptin  receptor  mRNA  or
proteolytic cleavage [14]. Whereas serum leptin levels correlate positively with BMI, SLR
is correlated negatively [14,62]. The inverse relationship between SLR and BMI reflects a
feedback regulation between the body weight  and leptin or  leptin  receptor  expressions.
It  is  observed in a study by Welt  et  al.  (2004)  when low serum leptin levels  in women
with hypothalamic amenorrhea (induced either by exercise or by low body weight) were
treated with recombinant human leptin for three months,  it  led to an increase of  osteo‐
calcin,  bone  alkaline  phosphates  and  IGF-1,  whereas  urinary  N-telopeptide  did  not
change  [63].They  have  demonstrated  that  leptin  administration  in  individuals  with  lep‐
tin  deficiency appeared to  improve the  growth hormone axis  and markers  of  bone for‐
mation [63].
4. Osteoporosis and bone turnover markers (BTMs)
Bone markers are product derived from the bone remodeling process. During this process,
compounds are released either from bone or from the cells involved in the bone remodeling
process (osteoblasts and osteoclasts.) Markers of bone turnover are biochemical products
measured usually in blood or urine that reflect the metabolic activity of bone but which
themselves have no function in controlling skeletal metabolism [64]. Biochemical markers of
bone turnover are broadly divided into two categories: markers of bone resorption, which
reflect osteoclast activity and are for the most part degradation products of type I collagen;
markers of bone formation, which reflect osteoblast activity and are byproducts of collagen
synthesis, matrix proteins or osteoblastic enzymes (Table 1) [65].
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Bone formation Detected in
Byproducts of collagen synthesis
Procollagen type I C-terminal propeptides (P1CP) Serum




Bone alkaline phosphatases (BALP) Serum





Cross-linked telopeptides of type I collagen
N-terminal cross-linked telopeptide (NTX) Urine and serum/plasma
C-terminal cross-linked telopeptide (CTX) Urine and serum/plasma
Osteoclast enzymes
Tartrate-resistant acid phosphatases (TRACP) Serum
Table 1. List of important biochemical markers of bone turnover
5. Markers of bone formation
Bone formation markers are direct or indirect products of active osteoblasts expressed during
different phases of osteoblast development and reflecting different aspects of osteoblast
function and bone formation. All markers are measured in serum or plasma [66].
5.1. Alkaline phosphatase
Alkaline phosphatase (ALP) is a ubiquitous enzyme that plays an important role in osteoid
formation and mineralization. The total ALP serum pool consists of several dimeric isoforms
which originate from various tissues such as liver, bone, intestine, spleen, kidney and placenta.
In adults with normal liver function, approximately 50% of the total ALP activity in serum
arises from liver and 50% arise from bone [67].
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5.2. Bone specific alkaline phosphatase
Bone specific alkaline phosphatase (BALP) is one of several isoenzymes of the alkaline
phosphatase (ALP) family. The entire family is encoded by four gene loci, three tissue specific
genes (bone,kidney,liver and other tissues). Although the nonspecific ALPs are the products
of a single gene, the ioenzymes present in tissues such as bone, kidney or liver vary greatly
because of variations in their carbohydrate side chains. These post translational modifications
are exploited to distinguish the various ALP-isoforms from each other, employing methods
including gel electrophoresis, heat denaturation, chemical inhibition or binding through
specific monoclonal antibodies [68]. For therapeutic monitoring of patients, B-ALP measure‐
ments are good indicators of the metabolic activity of bone. Rising ALP concentrations may
indicate estrogen deficiency [69,70].
5.3. Osteocalcin
Osteocalcin (OC) is a small, hydroxyapetite-binding protein synthesized by osteoblasts and to
a lesser extent by hypertrophic chondrocytes. It contains three gamma- carboxyglutamic acid
(Gla) residues which are responsible for calcium binding properties of protein. The precise
function of osteocalcin has yet to be determined but recent studies suggest that OC is involved
in bone remodeling via a negative mechanism. Serum osteocalcin is considered as a specific
marker of osteoblast function, as its levels correlate with bone formation rates. However, the
peptide is rapidly degraded in serum and both intact peptides and OC fragments of various
sizes coexist in the circulation [70]. Osteocalcin is normally considered as bone formation
marker. However, because it is released during bone formation from bone forming cells and
during bone resorption from bone matrix, it reflects the overall turnover of bone. Assays have
been developed to detect the intact protein and or the main breakdown product called N-mid
fragment. OC serum levels follow a circadian rhythm with high values in early morning, but
usually not influenced by food intake. Serum osteocalcin levels reportedly vary significantly
during the menstrual cycle with the highest level observerd during luteal phase [71].
5.4. Amino & carboxyterminal procollagen propeptides of type I collagen
The amino and carboxy terminal procollagen propeptides of type I collagen (PINP, PICP) are
cleaved by specific extracellular endopeptidases from newly translated collagen type I
pepetide. As these extension peptides are generated in a stoichiometric relationship with
collagen biosynthesis, they are considered quantitative measures of newly formed type I
collagen. However, because type I collagen is also a component of several soft tissues (fibro‐
cartilage, tendon, skin, gingival, intestine, heart valve, and large vessels) there is potential
contribution to circulating procollagens from soft tissue synthesis of type I collagen. Both PICP
and PINP demonstrate a cardian rhythm with peak values in the early morning, and are
usually not influenced by food intake. Serum levels of amino and carboxy terminal procollagen
propeptides of type I collagen (PINP, PICP) are measured by type and site specific immuno‐
assays [66]. Moderate correlations between serum PICP levels and the rate of bone formation
have been reported [72].
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arises from liver and 50% arise from bone [67].
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5.2. Bone specific alkaline phosphatase
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because of variations in their carbohydrate side chains. These post translational modifications
are exploited to distinguish the various ALP-isoforms from each other, employing methods
including gel electrophoresis, heat denaturation, chemical inhibition or binding through
specific monoclonal antibodies [68]. For therapeutic monitoring of patients, B-ALP measure‐
ments are good indicators of the metabolic activity of bone. Rising ALP concentrations may
indicate estrogen deficiency [69,70].
5.3. Osteocalcin
Osteocalcin (OC) is a small, hydroxyapetite-binding protein synthesized by osteoblasts and to
a lesser extent by hypertrophic chondrocytes. It contains three gamma- carboxyglutamic acid
(Gla) residues which are responsible for calcium binding properties of protein. The precise
function of osteocalcin has yet to be determined but recent studies suggest that OC is involved
in bone remodeling via a negative mechanism. Serum osteocalcin is considered as a specific
marker of osteoblast function, as its levels correlate with bone formation rates. However, the
peptide is rapidly degraded in serum and both intact peptides and OC fragments of various
sizes coexist in the circulation [70]. Osteocalcin is normally considered as bone formation
marker. However, because it is released during bone formation from bone forming cells and
during bone resorption from bone matrix, it reflects the overall turnover of bone. Assays have
been developed to detect the intact protein and or the main breakdown product called N-mid
fragment. OC serum levels follow a circadian rhythm with high values in early morning, but
usually not influenced by food intake. Serum osteocalcin levels reportedly vary significantly
during the menstrual cycle with the highest level observerd during luteal phase [71].
5.4. Amino & carboxyterminal procollagen propeptides of type I collagen
The amino and carboxy terminal procollagen propeptides of type I collagen (PINP, PICP) are
cleaved by specific extracellular endopeptidases from newly translated collagen type I
pepetide. As these extension peptides are generated in a stoichiometric relationship with
collagen biosynthesis, they are considered quantitative measures of newly formed type I
collagen. However, because type I collagen is also a component of several soft tissues (fibro‐
cartilage, tendon, skin, gingival, intestine, heart valve, and large vessels) there is potential
contribution to circulating procollagens from soft tissue synthesis of type I collagen. Both PICP
and PINP demonstrate a cardian rhythm with peak values in the early morning, and are
usually not influenced by food intake. Serum levels of amino and carboxy terminal procollagen
propeptides of type I collagen (PINP, PICP) are measured by type and site specific immuno‐
assays [66]. Moderate correlations between serum PICP levels and the rate of bone formation
have been reported [72].
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5.5. Markers of bone resorption
Most biochemical markers of bone resorption are degradation products of bone collagen, but
noncollagenous proteins such as bone sialoprotein or tartarate resistant acid phosphatase have
also been investigated [73].
5.6. Hydroxy proline
Hydroxyproline is an amino acid common to and characteristic of all forms of collagen, and
urinary hydroxyproline excretion is the oldest test of bone resorption. However, this test lacks
specificity for bone resorption because excreted hydroxyproline also comes from other tissues,
particularly from skin collagen (which can turn over rapidly in certain disorders), from newly
synthesized collagen that is not incorporated into tissue, and from dietary collagen and gelatin.
Because it is less specific than newer tests, it is no longer widely used [74].
5.7. Pyridinoline (Pyr) and Deoxypyridinoline (DPD)
The pyridinum crosslinks pyridinoline (PYD) and deoxypyridinolin (DPD) are the main
crosslinks in skeletal tissues but act as stabilizers of mature croslinks in type I, II & III collagens
of all major connective tissues (bone, dentin, ligaments, tendons, vascular walls, muscle and
intestine) except skin. While PYD predominates in most tissues, DPD is most abundant in bone
and therefore is considered the more specific marker [75].
5.8. Crosslinked Telopeptides
The term “crosslinked telopeptides” refers to the measurement of collagen degradation
products associated with the crosslink regions in type I collagen. Fragments derived from the
C terminus are also released into circulation as a result of the osteoclast-mediated degradation
of type I collagen and can be measured by various assays [76, 77]. The immuno reactive
epitopes are located on peptide fragments derived from the N terminal (NTX-1) and C terminal
(CTX-1 and ICTP) telopeptides of the collagen type I molecule. The NTX-1 and CTX-1 epitopes
can be measured in both serum and in urine [78, 79].
6. Tatartarate Resistant Acid Phosphatase (TRACP)
Tartarate resistant acid phosphate is synthesized and secreted by osteoclasts during active
bone resorption. The process of resorption occurs after the attachment of osteoclasts to the
bone surface and follows the secretion of acid and enzymes into a space created between the
osteoclast and the bone. The acidic environment is produced by the action of carbonic
anhydrase and an H-ATPase proton pump. TRACP, one of the enzymes secreted into this
space, has been located in the adjacent osteoclast membrane (known as the ruffled border) [80].
Its activity in serum reflects bone resorption rates and more recently it has been possible to
measure the isoenzyme by very specific immunoassays
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The use of biochemical markers of bone remodeling in the monitoring of patients on treatment
for osteoporosis is generally well-recognized [81,82]. However, optimum treatment targets
specific to various therapies and the benefits of monitoring in terms of improvement in fracture
outcomes or in adherence to oral therapies are not established [83].
The changes in BMD and BTMs following the initiation of osteoporosis treatment independ‐
ently correlate with fracture risk reduction [84]. The advantage of BTM over BDM is that the
change in BTMs following treatment explains a greater proportion of treatment as compared
to BMD does, in terms of fracture risk reduction [85,86]. Also, the change in BMD is small and
slow whereas the changes in BTMs are large and occur early after initiation of therapy. Repeat
BMD is not advocated within 12 months after initiation of therapy as the changes do not
generally attain significance within that time, and in fact 18-24 months may be appropriate for
repeat BMD measurements [87]. BTMs on the other hand show significant change by 3-6
months. For example, bone resorption markers can be measured 3 months after initiation of
oral bisphosphonates, and bone formation markers 6 months after start of therapy [88, 89).
Changes in BTMs may be useful in monitoring osteoporosis treatment to confirm compliance
with oral therapies and efficacy of treatment [90].
There are many studies which have demonstrated BTMs and their contribution to fracture risk,
but the results of these studies have been inconsistent [91-95]. Many studies which have shown
positive results with BTMs included bone resorption markers, with increased resorption
marker predicting an increased fracture risk. While for BTMs to predict fracture risk inde‐
pendently of BMD, it is needed to clarify their relationships to other established risk factors.
The changes in BTMs following therapy are well documented. There is a decrease in BTMs
following initiation of anti-resorptive therapy, reflecting inhibition of osteoclastic activity
[96-100]. For example, with bisphosphonate treatment, there is a decrease in bone resorption
markers within days following intravenous therapy, and within weeks following oral therapy.
Vasikaran et al [83] supports the role of BTMs in the management of patients with osteoporosis
and also emphasized on the adoption of international reference standards for enhancing
laboratory consistency and to facilitate their inclusion in routine clinical practice.
The problem in BTMs use is their wide biological and analytical variability, Glover et al [101]
emphasized that reference ranges should be defined and standardized with emphasis on
sample size and age range of the population. Sandhu & Hampson (2011) describe that the best
established clinical use for BTMs is in monitoring treatment efficacy and compliance [102]. In
a study by Kim et al observed that BMT can be used to determine BMD response to antire‐
sorptive therapy in Korean postmenopausal osteoporotic females [103].
The Scientific Advisory Council of Osteoporosis Canada including multidisciplinary working
group stated about the bone turnover markers in the management of postmenopausal
osteoporosis that as far as potential uses of bone turn over markers (BTMs) are concerned, they
can be used to predict bone loss and fracture in untreated postmenopausal women. They can
also be used to monitor osteoporosis therapy, and up to some extent enhance the adherence
to therapy but BTMs should not be used for diagnosis of osteoporosis as s separate and
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independent factor. Similarly it must not be used to select the most appropriate type of
osteoporotic therapy for the treatment. [104].
7. Relationship of leptin with bone markers in post menopausal
osteoporotic females
Data in the literature are inconsistent and conflicting about the relationship of leptin with
bone markers in post menopausal osteoporotic females. The study of Goulding & Taylor
(1998) was the first to examine relationships among plasma levels of leptin, and dynamic bi‐
ochemical markers of bone cell activity in postmenopausal women [46]. This study demon‐
strated no association between circulating plasma levels of leptin and biochemical markers
of either osteoclastic or osteoblastic activity. They concluded that leptin itself does not play
any significant direct role in controlling bone cell activity in postmenopausal women.
Scariano et al reported positive association between serum leptin and bone specific alkaline
phosphatase in postmenopausal women and elderly men after adjustment for BMD, age and
BMI [105]. The association of circulating leptin levels with bAP, a specific marker of osteo‐
blast activity suggests that leptin levels influence osteoblast activity in vivo in elderly wom‐
en and men. In a cross sectional study by Filip R & Raszewski G (2009) a positive association
between leptin and osteocalcin in older patients with hip fracture [106]. Rauch et al. and La‐
teef et al also found no relationship between plasma leptin level and bone turnover markers
in adult women and postmenopausal osteoporotic females respectively [40,59]. Filip & Ras‐
zewski et al, found no correlations of serum leptin with lumber spine BMD, femoral neck
BMD, biochemical markers of bone turnover with leptin, in overweight and obese postme‐
nopausal women, even after stratification of the study group by BMI ratio value (25–29 9,
30–39 9 and ≥ 40), or by waist: hip ratio (WHR), ratio value (< 0 85 and ≥ 0 85) [106]. In a
small study, Iwamoto et al. (2000) found correlations between serum leptin and bone re‐
modelling markers only in premenopausal women [107]. Peng et al (2008) reported no asso‐
ciation between serum leptin and bone turnover biochemical markers in men [108].
In postmenopausal osteoporotic patients with increased bone turnover, serum leptin con‐
centration is not correlated with BMD or with the biomarkers of bone formation or bone re‐
sorption [109]. According to few studies performed in China no correlation found between
serum leptin and bone turnover biochemical markers in post-menopausal Chinese women
[110-112]. Similarly, no correlation observed between leptin and bone turnover markers in
Chinese adolescent dancers and control group in one more study (101) Blain, et al (2002) re‐
ported that serum leptin level was positively correlated with weight, fat mass, BMI, E2, crea‐
tinine clearance, and BAP level and inversely correlated with urine CTx [56]. They
supported the suggestion that circulating leptin exerts its protective effect on bone through
limiting the excessive bone resorption coupled with bone formation that is associated with
bone loss after menopause.
Prouteau et al (2006) suggested a regulatory role of leptin on type I collagen metabolism [113].
The negative association between bone resorption (CTx levels) and serum leptin levels
observed at baseline (stable body weight) was further confirmed by the biochemical changes
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occurring in responses to weight loss and weight regain. The drop in leptin levels was strongly
related to the increase in bone resorption marker occurring in response to weight loss.
Similarly, after weight regain the rise in leptin levels was associated with a concomitant
decrease in bone resorption. The reasons for these discrepancies need to be clarified.
8. Conclusion
The relationship of leptin and bone turnover markers in post menopausal osteoporosis has not
yet been clarified. Although several studies have been done but still there is need to explore
their exact connection. Many studies have recommended that in the treatment of the post-men‐
opausal women, biochemical markers of bone turnover may be useful as adjuncts to BMD and
other diagnostic tests. They can be mainly used to monitor response to treatment and also used
as relatively economical tools for studying bone metabolism. The exact roles of BTM need to be
established in clinical practice. It is suggested that repeated measurements of bone markers
during anti-resorptive therapy may help to improve the management of osteoporotic patients.
Both a peripheral and a central action of leptin on bone metabolism have been suggested. Pe‐
ripherally, leptin is thought to exert positive effects on bone formation, whereas it is thought to
reduce bone formation via a central control mechanism when binding to its specific receptors
located on the hypothalamic nuclei [26]. It has been suggested that circulating leptin may act
positively to maintain bone mass but these effects of serum leptin are not mediated due to these
biochemical markers. Despite a preliminary understanding of leptin–bone mass interactions,
the exact roles of leptin on bone metabolism have not yet been elucidated.
The role of BTMs in monitoring osteoporosis treatment to confirm compliance with oral
therapies, and efficacy of treatment has been established. Further studies with reference to
serum leptin and BTMs in post menopausal osteoporotic females are needed to clarify their
association and significance of that association in treatment targets for various therapies and
optimal monitoring regimes.
Author details
Mehreen  Lateef1*, Mukhtiar  Baig2 and Abid  Azhar3
*Address all correspondence to: meher_khan555@hotmail.com; drmukhtiarbaig@yahoo.com;
abid.azhar@kibge.edu.pk
1 Pharmaceutical Research Centre, Pakistan Council of Scientific and Industrial Research
Complex Laboratories Complex, PCSIR, Karachi, Pakistan
2 Department of Biochemistry, Bahria University Medical and Dental College (BUMDC),
Karachi, Pakistan
3 Karachi Institute of Biotechnology and Genetic Engineering (KIBGE), Karachi, Pakistan
Serum Leptin and Bone Turnover Markers in Postmenopausal Osteoporosis
http://dx.doi.org/10.5772/54527
77
independent factor. Similarly it must not be used to select the most appropriate type of
osteoporotic therapy for the treatment. [104].
7. Relationship of leptin with bone markers in post menopausal
osteoporotic females
Data in the literature are inconsistent and conflicting about the relationship of leptin with
bone markers in post menopausal osteoporotic females. The study of Goulding & Taylor
(1998) was the first to examine relationships among plasma levels of leptin, and dynamic bi‐
ochemical markers of bone cell activity in postmenopausal women [46]. This study demon‐
strated no association between circulating plasma levels of leptin and biochemical markers
of either osteoclastic or osteoblastic activity. They concluded that leptin itself does not play
any significant direct role in controlling bone cell activity in postmenopausal women.
Scariano et al reported positive association between serum leptin and bone specific alkaline
phosphatase in postmenopausal women and elderly men after adjustment for BMD, age and
BMI [105]. The association of circulating leptin levels with bAP, a specific marker of osteo‐
blast activity suggests that leptin levels influence osteoblast activity in vivo in elderly wom‐
en and men. In a cross sectional study by Filip R & Raszewski G (2009) a positive association
between leptin and osteocalcin in older patients with hip fracture [106]. Rauch et al. and La‐
teef et al also found no relationship between plasma leptin level and bone turnover markers
in adult women and postmenopausal osteoporotic females respectively [40,59]. Filip & Ras‐
zewski et al, found no correlations of serum leptin with lumber spine BMD, femoral neck
BMD, biochemical markers of bone turnover with leptin, in overweight and obese postme‐
nopausal women, even after stratification of the study group by BMI ratio value (25–29 9,
30–39 9 and ≥ 40), or by waist: hip ratio (WHR), ratio value (< 0 85 and ≥ 0 85) [106]. In a
small study, Iwamoto et al. (2000) found correlations between serum leptin and bone re‐
modelling markers only in premenopausal women [107]. Peng et al (2008) reported no asso‐
ciation between serum leptin and bone turnover biochemical markers in men [108].
In postmenopausal osteoporotic patients with increased bone turnover, serum leptin con‐
centration is not correlated with BMD or with the biomarkers of bone formation or bone re‐
sorption [109]. According to few studies performed in China no correlation found between
serum leptin and bone turnover biochemical markers in post-menopausal Chinese women
[110-112]. Similarly, no correlation observed between leptin and bone turnover markers in
Chinese adolescent dancers and control group in one more study (101) Blain, et al (2002) re‐
ported that serum leptin level was positively correlated with weight, fat mass, BMI, E2, crea‐
tinine clearance, and BAP level and inversely correlated with urine CTx [56]. They
supported the suggestion that circulating leptin exerts its protective effect on bone through
limiting the excessive bone resorption coupled with bone formation that is associated with
bone loss after menopause.
Prouteau et al (2006) suggested a regulatory role of leptin on type I collagen metabolism [113].
The negative association between bone resorption (CTx levels) and serum leptin levels
observed at baseline (stable body weight) was further confirmed by the biochemical changes
Topics in Osteoporosis76
occurring in responses to weight loss and weight regain. The drop in leptin levels was strongly
related to the increase in bone resorption marker occurring in response to weight loss.
Similarly, after weight regain the rise in leptin levels was associated with a concomitant
decrease in bone resorption. The reasons for these discrepancies need to be clarified.
8. Conclusion
The relationship of leptin and bone turnover markers in post menopausal osteoporosis has not
yet been clarified. Although several studies have been done but still there is need to explore
their exact connection. Many studies have recommended that in the treatment of the post-men‐
opausal women, biochemical markers of bone turnover may be useful as adjuncts to BMD and
other diagnostic tests. They can be mainly used to monitor response to treatment and also used
as relatively economical tools for studying bone metabolism. The exact roles of BTM need to be
established in clinical practice. It is suggested that repeated measurements of bone markers
during anti-resorptive therapy may help to improve the management of osteoporotic patients.
Both a peripheral and a central action of leptin on bone metabolism have been suggested. Pe‐
ripherally, leptin is thought to exert positive effects on bone formation, whereas it is thought to
reduce bone formation via a central control mechanism when binding to its specific receptors
located on the hypothalamic nuclei [26]. It has been suggested that circulating leptin may act
positively to maintain bone mass but these effects of serum leptin are not mediated due to these
biochemical markers. Despite a preliminary understanding of leptin–bone mass interactions,
the exact roles of leptin on bone metabolism have not yet been elucidated.
The role of BTMs in monitoring osteoporosis treatment to confirm compliance with oral
therapies, and efficacy of treatment has been established. Further studies with reference to
serum leptin and BTMs in post menopausal osteoporotic females are needed to clarify their
association and significance of that association in treatment targets for various therapies and
optimal monitoring regimes.
Author details
Mehreen  Lateef1*, Mukhtiar  Baig2 and Abid  Azhar3
*Address all correspondence to: meher_khan555@hotmail.com; drmukhtiarbaig@yahoo.com;
abid.azhar@kibge.edu.pk
1 Pharmaceutical Research Centre, Pakistan Council of Scientific and Industrial Research
Complex Laboratories Complex, PCSIR, Karachi, Pakistan
2 Department of Biochemistry, Bahria University Medical and Dental College (BUMDC),
Karachi, Pakistan
3 Karachi Institute of Biotechnology and Genetic Engineering (KIBGE), Karachi, Pakistan




[1] Consensus Development Conference Diagnosis, prophylaxis and treatment of osteo‐
porosis. American Journal of Medical Sciences 1993; 94:646–65.
[2] Davey DA. Osteoporosis, osteopenia and fracture risk: Widening the therapeutic ho‐
rizons. South African Medical Journal 2012; 102: 285-288.
[3] Dennison E, Cole Z, Cooper C, et al. Diagnosis and epidemiology of osteoporosis.
CurrentOpinion ofRheumatology 2005; 17:456-461.
[4] Burge RT. The cost of osteoporotic fractures in the UK: Projections for 2000-2020.
Journal of Medical Economics 2001;4: 51.
[5] Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in
Europe. Osteoporosis International 2005; 16:229–238.
[6] Lim S, Koo BK, Lee EJ, Park JH, Kim MH, Shin KH, et al. Incidence of hip fractures in
Korea. Journal of Bone & Mineral Metabolism 2008; 26: 400-405.
[7] Reseland J, Syversen U, Bakke I. et al. Leptin is expressed in and secreted from pri‐
mary cultures of human osteoblasts and promotes bone mineralization. Journal of
Bone & Mineral Research 2001;16:1426–1433.
[8] Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human
marrow stromal cells to enhance diff erentiation to osteoblasts and to inhibit differ‐
entiation to adipocytes. Endocrinology 1999; 140:1630–1638.
[9] Steppan CM, Crawford DT, Chidsey-Fink KL, et al.Leptin is a potent stimulator of
bone growth in ob/ob mice. Regulatory Peptides 2000; 92, 73–78.
[10] Burguera B, Hofbauer LC, Thomas, T. et al. Leptin reduces ovariectomy-induced
bone loss in rats. Endocrinology 2001; 142, 3546–3553.
[11] Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and
its human homologue. Nature 1994; 372: 425-432.
[12] Coen G. Leptin and bone metabolism. Journal of Nephrology 2004;17: 187-189.
[13] Tartaglia LA, Dembski M, Weng X,et al. Identification and expression cloning of a
leptin receptor, OB-R. Cell 1995; 83: 1263-1271.
[14] Zhang F, Chen Y., Heiman M, et al. Leptin: structure, function and biology. Vitamins
& Hormones 2005; 71: 345-365.
[15] Krysiak R, Handzlik-Orlik G, Okopien B. The role of adipokines in connective tissue
diseases. European Journal of Nutrition 2012;51:513–528.
Topics in Osteoporosis78
[16] Wardlaw SL. Obesity as a neuroendocrine disease: lessons to be learned from proo‐
piomelanocortin and melanocortin receptor mutations in mice and men.Journal of‐
ClinicalEndocrinology andMetabolism 2001; 86: 1442.
[17] Patel MS, Elefteriou F. The new field of neuroskeletal biology. CalcifedTissue Inter‐
national 2007; 80: 337-347.
[18] Sato S, Hanada R, Kimura A, et al. Central control of bone remodelling by neurome‐
din U. NaturalMedicine 2007; 13: 1234-1240.
[19] Sirotkin AV, Mlynček M, Makarevich AV, et al. Leptin affects proliferation-, apopto‐
sis- and protein kinase A-related peptides in human ovarian granulosa cells. Physio‐
logicalResearch 2008; 57:437-442.
[20] Reid I. Relationships among body mass, its components, and bone. Bone 2002; 13:
547-555.
[21] Mazess RB, Barden, HS, Ettinger M, Johnston C, Dawson-Hughes B, Baran D, Powell,
M. &Notelovitz, M. Spine and femur density using dual-photon absorptiometry in
US white women. Journal of Bone and Mineral Research 1987; 2: 211-219.
[22] Tremollieres F, Pouilles JM,Ribot C.Vertebral postmenopausal bone loss is reduced
in overweight women: a longitudinal study in 155 early postmenopausal women.
Journal of ClinicalEndocrinology & Metabolism 1993; 77: 683-686.
[23] Elias CF, Purohit D. Leptin signaling and circuits in puberty and fertility. Cellular
and Molecular Life Sciences 2012.DOI 10.1007/s00018-012-1095-1(Accessed 12 August
2012).
[24] Mundy GR. Secondary osteoporosis: the potential relevance of leptin and low body
weight. Annals of Internal Medicine 2000; 21: 828-830.
[25] Ducy P, Amling M, Takeda S. Leptin inhibits bone formation through a hypothala‐
mic relay. Cell 2000; 100:197–207.
[26] Amling M, Takeda S, Karsenty GA. Neuro(endo)crine regulation of bone remodel‐
ing. Bioessays 2000; 22: 970–975.
[27] Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under cen‐
tral surveillance. Science 2000; 289:1501–1504.
[28] Karsenty G. Leptin controls bone formation through a hypothalamic relay. Recent
ProgHorm Res 56:401–415, 2001.
[29] Takeda S &Karsenty G. Central control of bone formation. Journal ofBone& Mineral‐
Metabolism 2001;19:195–198.
[30] Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, et al.. Lep‐
tin inhibits osteoclast generation. Journal of Bone and Mineral Research 2002; 17:200–
209.




[1] Consensus Development Conference Diagnosis, prophylaxis and treatment of osteo‐
porosis. American Journal of Medical Sciences 1993; 94:646–65.
[2] Davey DA. Osteoporosis, osteopenia and fracture risk: Widening the therapeutic ho‐
rizons. South African Medical Journal 2012; 102: 285-288.
[3] Dennison E, Cole Z, Cooper C, et al. Diagnosis and epidemiology of osteoporosis.
CurrentOpinion ofRheumatology 2005; 17:456-461.
[4] Burge RT. The cost of osteoporotic fractures in the UK: Projections for 2000-2020.
Journal of Medical Economics 2001;4: 51.
[5] Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in
Europe. Osteoporosis International 2005; 16:229–238.
[6] Lim S, Koo BK, Lee EJ, Park JH, Kim MH, Shin KH, et al. Incidence of hip fractures in
Korea. Journal of Bone & Mineral Metabolism 2008; 26: 400-405.
[7] Reseland J, Syversen U, Bakke I. et al. Leptin is expressed in and secreted from pri‐
mary cultures of human osteoblasts and promotes bone mineralization. Journal of
Bone & Mineral Research 2001;16:1426–1433.
[8] Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human
marrow stromal cells to enhance diff erentiation to osteoblasts and to inhibit differ‐
entiation to adipocytes. Endocrinology 1999; 140:1630–1638.
[9] Steppan CM, Crawford DT, Chidsey-Fink KL, et al.Leptin is a potent stimulator of
bone growth in ob/ob mice. Regulatory Peptides 2000; 92, 73–78.
[10] Burguera B, Hofbauer LC, Thomas, T. et al. Leptin reduces ovariectomy-induced
bone loss in rats. Endocrinology 2001; 142, 3546–3553.
[11] Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and
its human homologue. Nature 1994; 372: 425-432.
[12] Coen G. Leptin and bone metabolism. Journal of Nephrology 2004;17: 187-189.
[13] Tartaglia LA, Dembski M, Weng X,et al. Identification and expression cloning of a
leptin receptor, OB-R. Cell 1995; 83: 1263-1271.
[14] Zhang F, Chen Y., Heiman M, et al. Leptin: structure, function and biology. Vitamins
& Hormones 2005; 71: 345-365.
[15] Krysiak R, Handzlik-Orlik G, Okopien B. The role of adipokines in connective tissue
diseases. European Journal of Nutrition 2012;51:513–528.
Topics in Osteoporosis78
[16] Wardlaw SL. Obesity as a neuroendocrine disease: lessons to be learned from proo‐
piomelanocortin and melanocortin receptor mutations in mice and men.Journal of‐
ClinicalEndocrinology andMetabolism 2001; 86: 1442.
[17] Patel MS, Elefteriou F. The new field of neuroskeletal biology. CalcifedTissue Inter‐
national 2007; 80: 337-347.
[18] Sato S, Hanada R, Kimura A, et al. Central control of bone remodelling by neurome‐
din U. NaturalMedicine 2007; 13: 1234-1240.
[19] Sirotkin AV, Mlynček M, Makarevich AV, et al. Leptin affects proliferation-, apopto‐
sis- and protein kinase A-related peptides in human ovarian granulosa cells. Physio‐
logicalResearch 2008; 57:437-442.
[20] Reid I. Relationships among body mass, its components, and bone. Bone 2002; 13:
547-555.
[21] Mazess RB, Barden, HS, Ettinger M, Johnston C, Dawson-Hughes B, Baran D, Powell,
M. &Notelovitz, M. Spine and femur density using dual-photon absorptiometry in
US white women. Journal of Bone and Mineral Research 1987; 2: 211-219.
[22] Tremollieres F, Pouilles JM,Ribot C.Vertebral postmenopausal bone loss is reduced
in overweight women: a longitudinal study in 155 early postmenopausal women.
Journal of ClinicalEndocrinology & Metabolism 1993; 77: 683-686.
[23] Elias CF, Purohit D. Leptin signaling and circuits in puberty and fertility. Cellular
and Molecular Life Sciences 2012.DOI 10.1007/s00018-012-1095-1(Accessed 12 August
2012).
[24] Mundy GR. Secondary osteoporosis: the potential relevance of leptin and low body
weight. Annals of Internal Medicine 2000; 21: 828-830.
[25] Ducy P, Amling M, Takeda S. Leptin inhibits bone formation through a hypothala‐
mic relay. Cell 2000; 100:197–207.
[26] Amling M, Takeda S, Karsenty GA. Neuro(endo)crine regulation of bone remodel‐
ing. Bioessays 2000; 22: 970–975.
[27] Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under cen‐
tral surveillance. Science 2000; 289:1501–1504.
[28] Karsenty G. Leptin controls bone formation through a hypothalamic relay. Recent
ProgHorm Res 56:401–415, 2001.
[29] Takeda S &Karsenty G. Central control of bone formation. Journal ofBone& Mineral‐
Metabolism 2001;19:195–198.
[30] Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, et al.. Lep‐
tin inhibits osteoclast generation. Journal of Bone and Mineral Research 2002; 17:200–
209.
Serum Leptin and Bone Turnover Markers in Postmenopausal Osteoporosis
http://dx.doi.org/10.5772/54527
79
[31] Thomas T, Burguera B, Melton LJ. Role of serum leptin, insulin, and estrogen levels
as potential mediators of the relationship between fat mass and bone mineral density
in men versus women.Bone 2001; 29:114–120.
[32] Kim GS, Hong JS, Kim SW, et al. Leptin induces apoptosis via ERK/cPLA2/cyto‐
chrome c pathway in human bone marrow stromal cells. Journal of Biological Chem‐
istry 2003; 13: 21920-21929.
[33] Evans BAJ, Elford C, Gregory JW. Leptin control of bone metabolism; direct or indi‐
rect action? Bone 2001; 28:149.
[34] Cornish J, Callon KE, Bava U. The direct actions of leptin on bone cells increase bone
strength in vivo: an explanation of low frequency fracture rates in obesity. Bone
2001;28:S88.
[35] Karsenty G. Convergence between bone and energy homeostasis: leptin regulation of
bone mass. Cell Metabolism 2006; 4: 341-348.
[36] Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the
sympathetic nervous system. Cell 2002; 111: 305-317.
[37] Harlan SM. Rahmouni K. Neuroanatomical determinants of the sympathetic nerve
responsesevoked by leptin. Clinical Autonomic Research Doc 10.1007/
s10286-012-0168-4 (Accessed June 2012).
[38] Sergio RagiEIS, LewiecklME. Peripheral bone densitometry: clinical applications. Ar‐
quivosBrasileiros de Endocrinologia&Metabologia2006; 50 :596-602.
[39] Marshall D, Johnell O, Wedel H. Meta-analysis of how well measured of bone miner‐
al density predict occurrence of osteoporotic fractures. British Medical Journal 1996;
312: 1254-1259.
[40] Lateef M, Baig M, Azhar A. Estimation of osteocalcin and telopeptide-C in postmeno‐
pausal osteoporotic females. Osteoporosis International 2010;21:751-755.
[41] Hans D, Fuerst T, Lang T, Majumdar S, Lu Y, Genant HK & Gluer C.How we can
measure bone quality? Bailliers Clinical Rheumatology 1997; 11: 495-515.
[42] Gluer CC. Quantitative ultrasound techniques for the assessment of osteoporosis: ex‐
pert agreement and current status. Journal of Bone & Mineral Research 1997; 12:
1280-1288.
[43] Lateef M, Baig, M, Azhar A. Relationship of leptin with BMD in postmeopausal os‐
teoporosis. In Kanis JA &Lindlay A. (eds) Osteoporosis International: Abstracts of 1st
IOF-ESCEO Preclinical Symposium and ECCEO-IOF Congress, 22-23 March 2011,
Valencia, Spain.
[44] Ensurd, KE, Palermo, L, Black DM.Cauley, J, Jergas, M, Orwoll, ES, Nevitt, MC, Fox
KM. & Cummings SR. Hip and calcaneous bone loss increase with advancing age:
Topics in Osteoporosis80
longitudinal results from the study of osteoporotic fractures. Journal of Bone and
Mineral Research 1995; 10: 1778-1787.
[45] Miller PD,Zapalowski, C, Kulak CA. &Bilezikian JP.Bone Densitometry: the best way
to detect osteoporosis and to monitor therapy. Journal of Clinical Endocrinologyand
Metabolism 1999;84: 1867-1871.
[46] GouldingA,Taylor RW. Plasma Leptin values in relation to bone mass and density
and to dynamic biochemical markers of bone resorption and formation in postmeno‐
pausal women. Calcified Tissue International 1998; 63: 456 -458.
[47] Rouch F, Blum WF, Klein K. Allolio, B. &Schonau, E. Does leptin have an effect on
bone in adult women? Calcified Tissue International 1998; 63: 453-455.
[48] Iwamoto I, Douchi T, Kosha S, Murakami, M. Fujino T. & Nagata Y. Relationship be‐
tween serum leptin level and regional bone mineral density, bone metabolic markers
in healthy women. ActaObstetriciaetGynecologicaScandinavica 2000; 79: 1060-1064.
[49] Yamauchi M, Sugimoto T, Yamaguchi T. Plasma leptin concentrations are associated
with bone mineral density and the presence of vertebral fractures in postmenopausal
women. ClinicalEndocrinology 2001; 55:341–347.
[50] Albala C, Yanez M, Deveto E, Sostin C, Zeballos, L. & Santos JL. (1996). Obesity as
protective factor for postmenopausal factor postmenopausal osteoporosis. Interna‐
tional Journal of Obesity and Related Metabolic Disorders 1996; 20:1027-1032.
[51] Riggs BL, Melton J. Involutional osteoporosis. New EnglandJournal ofMedicine 1986;
314: 676-685.
[52] Ribot C, Tremollierrs F, Pouilles JM, Bonneu M, Germain F,Louvet JP. Obesity and
postmenopausal bone loss: the influence of obesity on vertebral density and bone
turnover in postmenopausal women. Bone 1987; 8: 327-331.
[53] Dequeker J,Boonen S. Extraskeletal Risk and Protective Factors for fractures In Geu‐
seus P.(ed)Osteoporosis in clinical practice In Springer: London; 1998. p55-58.
[54] Di Carlo C, Tommaselli GA, Gargano V, Sammartino A, Bifulco G, Tauchmanova L
et al. Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprote‐
gerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause 2007;
14:7–9.
[55] Pasco JA, Henry MJ, Kotowicz J A, et al. Serum leptin levels are associated with bone
mass in no obese women. Journal of Clinical Endocrinology andMetabolism; 86:
1884-1887.
[56] Blain H, Vuillemin A, Guillemin F,et al. Serum leptin level is a predictor of bone min‐
eral density in postmenopausal women. Journal of Clinical Endocrinology and Me‐
tabolism 2002; 87, 1030–1035
[57] Nagy Z, Speer G, Takács I, Bajnok Č, Lakatos P. Serum leptin levels and bone miner‐
al density in postmenopausal women In Journal ofBone andMineral Research: Pro‐
Serum Leptin and Bone Turnover Markers in Postmenopausal Osteoporosis
http://dx.doi.org/10.5772/54527
81
[31] Thomas T, Burguera B, Melton LJ. Role of serum leptin, insulin, and estrogen levels
as potential mediators of the relationship between fat mass and bone mineral density
in men versus women.Bone 2001; 29:114–120.
[32] Kim GS, Hong JS, Kim SW, et al. Leptin induces apoptosis via ERK/cPLA2/cyto‐
chrome c pathway in human bone marrow stromal cells. Journal of Biological Chem‐
istry 2003; 13: 21920-21929.
[33] Evans BAJ, Elford C, Gregory JW. Leptin control of bone metabolism; direct or indi‐
rect action? Bone 2001; 28:149.
[34] Cornish J, Callon KE, Bava U. The direct actions of leptin on bone cells increase bone
strength in vivo: an explanation of low frequency fracture rates in obesity. Bone
2001;28:S88.
[35] Karsenty G. Convergence between bone and energy homeostasis: leptin regulation of
bone mass. Cell Metabolism 2006; 4: 341-348.
[36] Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the
sympathetic nervous system. Cell 2002; 111: 305-317.
[37] Harlan SM. Rahmouni K. Neuroanatomical determinants of the sympathetic nerve
responsesevoked by leptin. Clinical Autonomic Research Doc 10.1007/
s10286-012-0168-4 (Accessed June 2012).
[38] Sergio RagiEIS, LewiecklME. Peripheral bone densitometry: clinical applications. Ar‐
quivosBrasileiros de Endocrinologia&Metabologia2006; 50 :596-602.
[39] Marshall D, Johnell O, Wedel H. Meta-analysis of how well measured of bone miner‐
al density predict occurrence of osteoporotic fractures. British Medical Journal 1996;
312: 1254-1259.
[40] Lateef M, Baig M, Azhar A. Estimation of osteocalcin and telopeptide-C in postmeno‐
pausal osteoporotic females. Osteoporosis International 2010;21:751-755.
[41] Hans D, Fuerst T, Lang T, Majumdar S, Lu Y, Genant HK & Gluer C.How we can
measure bone quality? Bailliers Clinical Rheumatology 1997; 11: 495-515.
[42] Gluer CC. Quantitative ultrasound techniques for the assessment of osteoporosis: ex‐
pert agreement and current status. Journal of Bone & Mineral Research 1997; 12:
1280-1288.
[43] Lateef M, Baig, M, Azhar A. Relationship of leptin with BMD in postmeopausal os‐
teoporosis. In Kanis JA &Lindlay A. (eds) Osteoporosis International: Abstracts of 1st
IOF-ESCEO Preclinical Symposium and ECCEO-IOF Congress, 22-23 March 2011,
Valencia, Spain.
[44] Ensurd, KE, Palermo, L, Black DM.Cauley, J, Jergas, M, Orwoll, ES, Nevitt, MC, Fox
KM. & Cummings SR. Hip and calcaneous bone loss increase with advancing age:
Topics in Osteoporosis80
longitudinal results from the study of osteoporotic fractures. Journal of Bone and
Mineral Research 1995; 10: 1778-1787.
[45] Miller PD,Zapalowski, C, Kulak CA. &Bilezikian JP.Bone Densitometry: the best way
to detect osteoporosis and to monitor therapy. Journal of Clinical Endocrinologyand
Metabolism 1999;84: 1867-1871.
[46] GouldingA,Taylor RW. Plasma Leptin values in relation to bone mass and density
and to dynamic biochemical markers of bone resorption and formation in postmeno‐
pausal women. Calcified Tissue International 1998; 63: 456 -458.
[47] Rouch F, Blum WF, Klein K. Allolio, B. &Schonau, E. Does leptin have an effect on
bone in adult women? Calcified Tissue International 1998; 63: 453-455.
[48] Iwamoto I, Douchi T, Kosha S, Murakami, M. Fujino T. & Nagata Y. Relationship be‐
tween serum leptin level and regional bone mineral density, bone metabolic markers
in healthy women. ActaObstetriciaetGynecologicaScandinavica 2000; 79: 1060-1064.
[49] Yamauchi M, Sugimoto T, Yamaguchi T. Plasma leptin concentrations are associated
with bone mineral density and the presence of vertebral fractures in postmenopausal
women. ClinicalEndocrinology 2001; 55:341–347.
[50] Albala C, Yanez M, Deveto E, Sostin C, Zeballos, L. & Santos JL. (1996). Obesity as
protective factor for postmenopausal factor postmenopausal osteoporosis. Interna‐
tional Journal of Obesity and Related Metabolic Disorders 1996; 20:1027-1032.
[51] Riggs BL, Melton J. Involutional osteoporosis. New EnglandJournal ofMedicine 1986;
314: 676-685.
[52] Ribot C, Tremollierrs F, Pouilles JM, Bonneu M, Germain F,Louvet JP. Obesity and
postmenopausal bone loss: the influence of obesity on vertebral density and bone
turnover in postmenopausal women. Bone 1987; 8: 327-331.
[53] Dequeker J,Boonen S. Extraskeletal Risk and Protective Factors for fractures In Geu‐
seus P.(ed)Osteoporosis in clinical practice In Springer: London; 1998. p55-58.
[54] Di Carlo C, Tommaselli GA, Gargano V, Sammartino A, Bifulco G, Tauchmanova L
et al. Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprote‐
gerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause 2007;
14:7–9.
[55] Pasco JA, Henry MJ, Kotowicz J A, et al. Serum leptin levels are associated with bone
mass in no obese women. Journal of Clinical Endocrinology andMetabolism; 86:
1884-1887.
[56] Blain H, Vuillemin A, Guillemin F,et al. Serum leptin level is a predictor of bone min‐
eral density in postmenopausal women. Journal of Clinical Endocrinology and Me‐
tabolism 2002; 87, 1030–1035
[57] Nagy Z, Speer G, Takács I, Bajnok Č, Lakatos P. Serum leptin levels and bone miner‐
al density in postmenopausal women In Journal ofBone andMineral Research: Pro‐
Serum Leptin and Bone Turnover Markers in Postmenopausal Osteoporosis
http://dx.doi.org/10.5772/54527
81
gram and abstracts from the Twenty-Third Annual Meeting of the American Society
for Bone and Mineral Research; October 12–16, 2001; Phoenix, Arizona.
[58] Hadji P, Bock K, Gottschalk M, Kalder M, Emons G, Shulz KD. The influence of se‐
rum leptin concentrations on bone mass assessed by quantitative ultrasonometry
(QUS) in pre- and postmenopausal women In Journal ofBone andMineral Research:
Program and abstracts from the Twenty-Third Annual Meeting of the American Soci‐
ety for Bone and Mineral Research, October 12–16, 2001; Phoenix, Arizona.
[59] Rauch F, Blum WF, Klein K, Allolio B, Schönau E. Does Leptin Have an Effect on
Bone in Adult Women? Calcified Tissue International 1998;63:453–455.
[60] Hamrick MW, Ferrari SI. Leptin and the sympathetic connection of fat to bone. Os‐
teoporosis International 2008; 19:905-912.
[61] Munzberg H, Bjornholm M, Bates SH, et al. Leptin receptor action and metabolisms
of leptin resistance. Cellullar& MolecularLife Sciences 2005; 62: 642-652.
[62] Anderlová K, Křemen J, Doležalová R, et al., The influence of very-low-calorie-diet
on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese
women. Physiological Research 2006; 55: 277-283.
[63] Welt CK, Chan JI, Bullen J, et al. Recombinant human leptin in women with hypo‐
thalamic amenorrhea. New England Journal of Medicine 2004; 351: 987-997.
[64] VasikaranS, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of
fracture risk and monitoring of osteoporosis treatment: a need for international refer‐
ence standards. Osteoporosis International 2011; 22: 391–420.
[65] Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proceedings
of the Nutrition Society 2008; 67:157-162.
[66] Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with
antiresorptive drugs. Osteoporosis International 2000;11::S66- 76.
[67] Green S, Antiss CL, Fishman WH. Automated differential isoenzyme analysis II. The
fractionation of serum alkaline phosphatase into liver, intestinal and other compo‐
nents. Enzymologia 1997; 41: 9 -26.
[68] Seibel MJ. Biochemical markers of bone metabolism in the assessment of osteoporo‐
sis: useful or not? EndocrinologicalInvestigation 2003; 26: 464-471.
[69] Gundberg CM,Nishimoto SK. InSeibel MJ, Robbins SP, Bilezzikian, JP, (eds) Vitamin
K dependent proteins of bone and cartilage. Dynamics of bone and cartilage metabo‐
lism In Academic Press, San Diego; 1999;p43-58.
[70] Vesper HW. Analytical and preanalytical issues in measurement of biochemical bone
markers. Laboratory Medicine 2005; 36: 424-429.
Topics in Osteoporosis82
[71] Gundberg CM, Markowitz ME, Mizruchi M, Rosen JF. Osteocalcin in human serum:
a circadian rhythm. Journal ofClinical andEndocrinologicalMetabolism1985;60:736-739.
[72] Parafitt AM, Simon LS, Villanueva AR, &Krane SM. Procollagen type I carboytermi‐
nal extension propeptide in serum as a marker of collagen biosynthesis in bone.Jour‐
nal ofBone & Mineral Research 1987; 5: 427 -436.
[73] Risteli J, Risteli L. Products of bone collagen metabolism. In: Seibel MJ, Robbins SP,
Bilzekian JP, eds. Dynamics of Bone and Cartilage Metabolism: Principles and Clinical Ap‐
plications. London: Academic Press; 1999:275-287.
[74] Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice.
Cleveland Clinic Journal of Medicine 2008; 75: 739-750.
[75] Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical applicationof biolog‐
ical markers of bone turnover. Endocrinol Review 1996;17:333–368.13.
[76] Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of boneresorption with a new
marker of collagen degradation in patients with metabolic bone disease. Journal of
Clinical andEndocrinologyMetabolism 1994;79:780–785.
[77] Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluationof the Serum
CrossLaps One Step ELISA, a new assay measuring theserum concentration of bone-
derived degradation products oftype I collagen C-telopeptides. ClinicalChemistry
1998; 44:2290–2300.
[78] Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immu‐
noassay for monitoring human bone resorption:quantitation of type I collagen cross-
linked N-telopeptides in urine.Journal ofBone MineralResearch 1992; 7:1251–1258.
[79] Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serumNTx (collagen-
type I N-telopeptides) can act as an immunochemicalmarker of bone resorption.
ClinicalChemistry 1997; 43:2058–2063.
[80] Price CP. Tartarate Resistant Acid Phosphatase as a marker of bone resorption. Clini‐
cal Chemistry1995; 41: 641-643.
[81] Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, Dooley KC, Don-
Wauchope A, Douville P et al., Bone turnover markers in the management of post‐
menopausal osteoporosis. Clinical Biochemistry 2009; 42:929–942.
[82] Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Evi‐
dence-based guidelines for the use of biochemical markers of bone turnover in the
selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus
document of the Belgian Bone Club. International Journal of Clinical Practise 2009;
63:19-26.
Serum Leptin and Bone Turnover Markers in Postmenopausal Osteoporosis
http://dx.doi.org/10.5772/54527
83
gram and abstracts from the Twenty-Third Annual Meeting of the American Society
for Bone and Mineral Research; October 12–16, 2001; Phoenix, Arizona.
[58] Hadji P, Bock K, Gottschalk M, Kalder M, Emons G, Shulz KD. The influence of se‐
rum leptin concentrations on bone mass assessed by quantitative ultrasonometry
(QUS) in pre- and postmenopausal women In Journal ofBone andMineral Research:
Program and abstracts from the Twenty-Third Annual Meeting of the American Soci‐
ety for Bone and Mineral Research, October 12–16, 2001; Phoenix, Arizona.
[59] Rauch F, Blum WF, Klein K, Allolio B, Schönau E. Does Leptin Have an Effect on
Bone in Adult Women? Calcified Tissue International 1998;63:453–455.
[60] Hamrick MW, Ferrari SI. Leptin and the sympathetic connection of fat to bone. Os‐
teoporosis International 2008; 19:905-912.
[61] Munzberg H, Bjornholm M, Bates SH, et al. Leptin receptor action and metabolisms
of leptin resistance. Cellullar& MolecularLife Sciences 2005; 62: 642-652.
[62] Anderlová K, Křemen J, Doležalová R, et al., The influence of very-low-calorie-diet
on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese
women. Physiological Research 2006; 55: 277-283.
[63] Welt CK, Chan JI, Bullen J, et al. Recombinant human leptin in women with hypo‐
thalamic amenorrhea. New England Journal of Medicine 2004; 351: 987-997.
[64] VasikaranS, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of
fracture risk and monitoring of osteoporosis treatment: a need for international refer‐
ence standards. Osteoporosis International 2011; 22: 391–420.
[65] Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proceedings
of the Nutrition Society 2008; 67:157-162.
[66] Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with
antiresorptive drugs. Osteoporosis International 2000;11::S66- 76.
[67] Green S, Antiss CL, Fishman WH. Automated differential isoenzyme analysis II. The
fractionation of serum alkaline phosphatase into liver, intestinal and other compo‐
nents. Enzymologia 1997; 41: 9 -26.
[68] Seibel MJ. Biochemical markers of bone metabolism in the assessment of osteoporo‐
sis: useful or not? EndocrinologicalInvestigation 2003; 26: 464-471.
[69] Gundberg CM,Nishimoto SK. InSeibel MJ, Robbins SP, Bilezzikian, JP, (eds) Vitamin
K dependent proteins of bone and cartilage. Dynamics of bone and cartilage metabo‐
lism In Academic Press, San Diego; 1999;p43-58.
[70] Vesper HW. Analytical and preanalytical issues in measurement of biochemical bone
markers. Laboratory Medicine 2005; 36: 424-429.
Topics in Osteoporosis82
[71] Gundberg CM, Markowitz ME, Mizruchi M, Rosen JF. Osteocalcin in human serum:
a circadian rhythm. Journal ofClinical andEndocrinologicalMetabolism1985;60:736-739.
[72] Parafitt AM, Simon LS, Villanueva AR, &Krane SM. Procollagen type I carboytermi‐
nal extension propeptide in serum as a marker of collagen biosynthesis in bone.Jour‐
nal ofBone & Mineral Research 1987; 5: 427 -436.
[73] Risteli J, Risteli L. Products of bone collagen metabolism. In: Seibel MJ, Robbins SP,
Bilzekian JP, eds. Dynamics of Bone and Cartilage Metabolism: Principles and Clinical Ap‐
plications. London: Academic Press; 1999:275-287.
[74] Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice.
Cleveland Clinic Journal of Medicine 2008; 75: 739-750.
[75] Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical applicationof biolog‐
ical markers of bone turnover. Endocrinol Review 1996;17:333–368.13.
[76] Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of boneresorption with a new
marker of collagen degradation in patients with metabolic bone disease. Journal of
Clinical andEndocrinologyMetabolism 1994;79:780–785.
[77] Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluationof the Serum
CrossLaps One Step ELISA, a new assay measuring theserum concentration of bone-
derived degradation products oftype I collagen C-telopeptides. ClinicalChemistry
1998; 44:2290–2300.
[78] Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immu‐
noassay for monitoring human bone resorption:quantitation of type I collagen cross-
linked N-telopeptides in urine.Journal ofBone MineralResearch 1992; 7:1251–1258.
[79] Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serumNTx (collagen-
type I N-telopeptides) can act as an immunochemicalmarker of bone resorption.
ClinicalChemistry 1997; 43:2058–2063.
[80] Price CP. Tartarate Resistant Acid Phosphatase as a marker of bone resorption. Clini‐
cal Chemistry1995; 41: 641-643.
[81] Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, Dooley KC, Don-
Wauchope A, Douville P et al., Bone turnover markers in the management of post‐
menopausal osteoporosis. Clinical Biochemistry 2009; 42:929–942.
[82] Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Evi‐
dence-based guidelines for the use of biochemical markers of bone turnover in the
selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus
document of the Belgian Bone Club. International Journal of Clinical Practise 2009;
63:19-26.
Serum Leptin and Bone Turnover Markers in Postmenopausal Osteoporosis
http://dx.doi.org/10.5772/54527
83
[83] VasikaranS, Eastell R, Bruyère O et al. Markers of bone turnover for the prediction of
fracture risk and monitoring of osteoporosis treatment: a need for international refer‐
ence standards. Osteoporosis International 2011; 22:391–420.
[84] Riggs BL, Melton LJ, O’Fallon WM. Drug therapy for vertebral fractures in osteopo‐
rosis: evidence that decreases in bone turnover and increases in bone mass both de‐
termine antifracture efficacy. Bone 1996; 18:197S-201S.
[85] Delmas PD,Seeman E. Changes in bone mineral density explain little of the reduction
in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004;
34:599-604.
[86] Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with
antiresorptive drugs. Osteoporosis International 2000; 11:S66- 76.
[87] Clinical guideline for the prevention and treatment of osteoporosis in postmenopaus‐
al women and older men (RACGP) 2012 http://www.racgp.org.au/guidelines/muscu‐
loskeletaldiseases/osteoporosis (accessed on Feb 2010)
[88] Chung SH, Kim TH, Lee HH. Relationship between Vitamin D level and bone miner‐
al density in postmenopausal women from Bucheon area. Jounal ofKorean Society of
Osteoporosis 2009; 7:198-202.
[89] Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects
of strontium ranelate on the risk of vertebral fracture in women with postmenopaus‐
al osteoporosis. New England Journal ofMedicine 2004; 50:459-468.
[90] Lee J, Vasikaran S. Current Recommendations for Laboratory Testing and Use of
Bone Turnover Markers in Management of Osteoporosis. Annals ofLaboratory Medi‐
cine 2012; 32:105-112.
[91] Tromp AM, Ooms ME, Popp-Snijders C, Roos JC, Lips P. Predictors of fractures in
elderly women. OsteoporosisInternational 2000; 11:134-140.
[92] Chapurlat RD, Garnero P, Bréart G, Meunier PJ, Delmas PD. Serum type I collagen
breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EP‐
IDOS study. Bone 2000; 27:283-286.
[93] Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone
turnover,endogenous hormones and the risk of fractures in postmenopausal women:
the OFELY Study. Journal of Bone& Mineral Research 2000; 15: 1526-1536.
[94] Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas PD. Type I collagen racemiza‐
tion and isomerization and the risk of fracture in postmenopausal women: the OFE‐
LY prospective study. Journal of Bone& Mineral Research 2002; 17:826-33.
[95] Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteopor‐
otic fractures in elderly men: the dubbo osteoporosis epidemiology study.Journal of
Bone& Mineral Research 2005; 20:579-587.
Topics in Osteoporosis84
[96] Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemi‐
cal markers of bone turnover in late postmenopausal osteoporotic women in re‐
sponse to alendronate treatment. Journal of ClinicalEndocrinology & Metabolism
1994; 79:1693-1700.
[97] Bell NH, Bilezikian JP, Bone HG, Kaur A, Maragoto A, Santora AC. Alendronate in‐
creases bone mass and reduce bone markers in postmenopausal African-American
women.Journal of ClinicalEndocrinology & Metabolism 2002; 87:2792- 2797.
[98] Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
Early changes in biochemical markers of bone turnover predict the long-term re‐
sponse to alendronate therapy in representative elderly women: a randomized clini‐
cal trial. Journal of ClinicalEndocrinology & Metabolism 1998; 13: 1431-1438.
[99] Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bi‐
sphosphonate and estrogen therapy on free and peptide-bound bone cross-links ex‐
cretion. Journal of ClinicalEndocrinology & Metabolism1995; 10:641-649.
[100] Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Greenspan SL. Utility of biochemi‐
cal markers of bone turnover in the follow-up of patients treated with bisphospho‐
nates. CalcifedTissue International 1998; 63:363-368.
[101] Glover SJ, Garnero P, Naylor K, et al. Establishing a reference range for bone turn‐
over markers in young, healthy women. Bone 2008; 42:623 -630.
[102] Sandhu KS, Hampson G. The pathogenesis, diagnosis, investigation and manage‐
ment of osteoporosis. Journal of ClinicalPathology 2011; 64:1042-1050.
[103] Kim SW, Park DJ, Park KS et al. Early changes in biochemical markers of bone turn‐
over predict bone mineral dnsity response to antiresorptive therapy in Korean post‐
menopausal women with osteoporosis. Endocrine Journal 2005;52:667-674.
[104] Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, et al. Bone turnover
markers in the management of postmenopausal osteoporosis. Clinical Biochemistry
2009; 42:929-442.
[105] Scariano JK, Garry PJ, Montova GD et al. Serum leptin levels, bone mineral density
and osteoblast alkaline phosphatase activity in elderly men and women. Mechanism
of Ageing and Development 2003; 24:281-286.
[106] Filip R &Raszewski G. Bone mineral density and bone turnover in relation to serum
leptin, -α ketoglutarate and sex steroids in overweight and obese postmenopausal
women. Clinical Endocrinology 2009; 70, 214–220.
[107] Iwamoto I, Douchi T, Kosha S, et al. Relationships between serum leptin level and
regional bone mineral density, bone metabolic markers in healthy women. ActaOb‐
stetriciaetGynecologicaScandinavica2000; 79: 1060-1064.
Serum Leptin and Bone Turnover Markers in Postmenopausal Osteoporosis
http://dx.doi.org/10.5772/54527
85
[83] VasikaranS, Eastell R, Bruyère O et al. Markers of bone turnover for the prediction of
fracture risk and monitoring of osteoporosis treatment: a need for international refer‐
ence standards. Osteoporosis International 2011; 22:391–420.
[84] Riggs BL, Melton LJ, O’Fallon WM. Drug therapy for vertebral fractures in osteopo‐
rosis: evidence that decreases in bone turnover and increases in bone mass both de‐
termine antifracture efficacy. Bone 1996; 18:197S-201S.
[85] Delmas PD,Seeman E. Changes in bone mineral density explain little of the reduction
in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004;
34:599-604.
[86] Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with
antiresorptive drugs. Osteoporosis International 2000; 11:S66- 76.
[87] Clinical guideline for the prevention and treatment of osteoporosis in postmenopaus‐
al women and older men (RACGP) 2012 http://www.racgp.org.au/guidelines/muscu‐
loskeletaldiseases/osteoporosis (accessed on Feb 2010)
[88] Chung SH, Kim TH, Lee HH. Relationship between Vitamin D level and bone miner‐
al density in postmenopausal women from Bucheon area. Jounal ofKorean Society of
Osteoporosis 2009; 7:198-202.
[89] Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects
of strontium ranelate on the risk of vertebral fracture in women with postmenopaus‐
al osteoporosis. New England Journal ofMedicine 2004; 50:459-468.
[90] Lee J, Vasikaran S. Current Recommendations for Laboratory Testing and Use of
Bone Turnover Markers in Management of Osteoporosis. Annals ofLaboratory Medi‐
cine 2012; 32:105-112.
[91] Tromp AM, Ooms ME, Popp-Snijders C, Roos JC, Lips P. Predictors of fractures in
elderly women. OsteoporosisInternational 2000; 11:134-140.
[92] Chapurlat RD, Garnero P, Bréart G, Meunier PJ, Delmas PD. Serum type I collagen
breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EP‐
IDOS study. Bone 2000; 27:283-286.
[93] Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone
turnover,endogenous hormones and the risk of fractures in postmenopausal women:
the OFELY Study. Journal of Bone& Mineral Research 2000; 15: 1526-1536.
[94] Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas PD. Type I collagen racemiza‐
tion and isomerization and the risk of fracture in postmenopausal women: the OFE‐
LY prospective study. Journal of Bone& Mineral Research 2002; 17:826-33.
[95] Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteopor‐
otic fractures in elderly men: the dubbo osteoporosis epidemiology study.Journal of
Bone& Mineral Research 2005; 20:579-587.
Topics in Osteoporosis84
[96] Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemi‐
cal markers of bone turnover in late postmenopausal osteoporotic women in re‐
sponse to alendronate treatment. Journal of ClinicalEndocrinology & Metabolism
1994; 79:1693-1700.
[97] Bell NH, Bilezikian JP, Bone HG, Kaur A, Maragoto A, Santora AC. Alendronate in‐
creases bone mass and reduce bone markers in postmenopausal African-American
women.Journal of ClinicalEndocrinology & Metabolism 2002; 87:2792- 2797.
[98] Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
Early changes in biochemical markers of bone turnover predict the long-term re‐
sponse to alendronate therapy in representative elderly women: a randomized clini‐
cal trial. Journal of ClinicalEndocrinology & Metabolism 1998; 13: 1431-1438.
[99] Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bi‐
sphosphonate and estrogen therapy on free and peptide-bound bone cross-links ex‐
cretion. Journal of ClinicalEndocrinology & Metabolism1995; 10:641-649.
[100] Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Greenspan SL. Utility of biochemi‐
cal markers of bone turnover in the follow-up of patients treated with bisphospho‐
nates. CalcifedTissue International 1998; 63:363-368.
[101] Glover SJ, Garnero P, Naylor K, et al. Establishing a reference range for bone turn‐
over markers in young, healthy women. Bone 2008; 42:623 -630.
[102] Sandhu KS, Hampson G. The pathogenesis, diagnosis, investigation and manage‐
ment of osteoporosis. Journal of ClinicalPathology 2011; 64:1042-1050.
[103] Kim SW, Park DJ, Park KS et al. Early changes in biochemical markers of bone turn‐
over predict bone mineral dnsity response to antiresorptive therapy in Korean post‐
menopausal women with osteoporosis. Endocrine Journal 2005;52:667-674.
[104] Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, et al. Bone turnover
markers in the management of postmenopausal osteoporosis. Clinical Biochemistry
2009; 42:929-442.
[105] Scariano JK, Garry PJ, Montova GD et al. Serum leptin levels, bone mineral density
and osteoblast alkaline phosphatase activity in elderly men and women. Mechanism
of Ageing and Development 2003; 24:281-286.
[106] Filip R &Raszewski G. Bone mineral density and bone turnover in relation to serum
leptin, -α ketoglutarate and sex steroids in overweight and obese postmenopausal
women. Clinical Endocrinology 2009; 70, 214–220.
[107] Iwamoto I, Douchi T, Kosha S, et al. Relationships between serum leptin level and
regional bone mineral density, bone metabolic markers in healthy women. ActaOb‐
stetriciaetGynecologicaScandinavica2000; 79: 1060-1064.
Serum Leptin and Bone Turnover Markers in Postmenopausal Osteoporosis
http://dx.doi.org/10.5772/54527
85
[108] Peng XD, Xie H, Zhao Q, et al.Relationships between serum adiponectin, leptin, re‐
sistin, visfatin levels and bone mineral density, and bone biochemical markers in
Chinese men. ClinicaChimicaActa 2008; 387: 31-35.
[109] Shaarawy M, Abassi AE, Hassan H, et al.Relationship between serumleptinconcen‐
trations and bonemineraldensity as well as biochemicalmarkers of boneturnover in
women with postmenopausalosteoporosis. Fertility & Sterility 2003; 79: 919-924.
[110] Zhang H, Xie H, Zhao Q et al. Relationships between serum adiponectin, apelin, lep‐
tin, resistin, visfatin levels and bone mineral density, and bone biochemical markers
in post-menopausal Chinese women. Journal of Endocrinological Investigation 2010;
33:707-711.
[111] Wu N, Wang QP, Li H, et al. Relationships between serum adiponectin, leptin con‐
centrations and bone mineral density, and bone biochemical markers in Chinese
women. ClinicaChemicaActa 2010; 411:771-775.
[112] Yang LC, Lan Y, Hu J et al. Correlation of serumleptinlevel with bonemineraldensity
and boneturnovermarkers in Chineseadolescentdancers. Biomedicaland Enviromen‐
talScience; 2009; 22:369-373.
[113] Prouteau S, L Benhamou L, Courteix D. Relationships between serum leptin and
bone markers during stable weight, weight reduction and weight regain in male and
female judoists. European Journal of Endocrinology 2006; 154: 389–395.
Topics in Osteoporosis86
Chapter 4
Modification of Sex Hormones with RGD-Peptide: A
Strategy of Improving HRT and Other Secondary
Osteoporosis Therapy
Ming Zhao, Yuji Wang, Jianhui Wu and Shiqi Peng
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54361
1. Introduction
In the time of transition from premenopausal state to postmenopausal state the capacity of
ovary producing sex hormones including estrogens, progesterone and testosterone cuts down
[1]. Due to the menopause the level of serum oestrogen dramatically decreases, which increases
the production of bone-resorbing cytokines and osteoblasts and then increases the number and
activity of osteoclast, thereby increasing the bone loss [2]. Hormonal replacement therapy
(HRT) is able to prevent bone loss for sex hormones-deficient menopausal women and
consequently is of clinical importance for the treatment of osteoporosis. [1-3] In Europe and
USA the osteoporosis prevention of 25-50% of the post-menopausal women rely on HRT [2,5,
6]. In past years, however, the large international studies, such as the randomized Woman
Health Initiative, the observational Million Women Study and the Women’s International
Study of long Duration, discussed both of the adverse and beneficial effects of post-menpausal
HRT [7]. In respect of the adverse effects, the discussion was focused on HRT induced risk of
breast cancer [8-11], venous thromboembolism [12], stroke and myocardial infarction [13], as
well as coronary heart diseases [14]. To limit these adverse effects a series of regimens of HRT,
such as continuous combination of oestrogen and progestogen or continuous oestrogen and
interruptted progestogen [15], and with dehydroepiandrosterone as a new strategic tool [16],
were developed. In general these regimens confer no positive result, and thus new strategies
are still needed.
Osteoporosis relates to both the decrease of the formation of osteoblast-modulated bone and
the increase of the resorption osteoclast-modulated bone. Estrogen directly up-modulates the
activity and the proliferation of osteoblasts, and/or regulats the gene expression in osteoblasts
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1. Introduction
In the time of transition from premenopausal state to postmenopausal state the capacity of
ovary producing sex hormones including estrogens, progesterone and testosterone cuts down
[1]. Due to the menopause the level of serum oestrogen dramatically decreases, which increases
the production of bone-resorbing cytokines and osteoblasts and then increases the number and
activity of osteoclast, thereby increasing the bone loss [2]. Hormonal replacement therapy
(HRT) is able to prevent bone loss for sex hormones-deficient menopausal women and
consequently is of clinical importance for the treatment of osteoporosis. [1-3] In Europe and
USA the osteoporosis prevention of 25-50% of the post-menopausal women rely on HRT [2,5,
6]. In past years, however, the large international studies, such as the randomized Woman
Health Initiative, the observational Million Women Study and the Women’s International
Study of long Duration, discussed both of the adverse and beneficial effects of post-menpausal
HRT [7]. In respect of the adverse effects, the discussion was focused on HRT induced risk of
breast cancer [8-11], venous thromboembolism [12], stroke and myocardial infarction [13], as
well as coronary heart diseases [14]. To limit these adverse effects a series of regimens of HRT,
such as continuous combination of oestrogen and progestogen or continuous oestrogen and
interruptted progestogen [15], and with dehydroepiandrosterone as a new strategic tool [16],
were developed. In general these regimens confer no positive result, and thus new strategies
are still needed.
Osteoporosis relates to both the decrease of the formation of osteoblast-modulated bone and
the increase of the resorption osteoclast-modulated bone. Estrogen directly up-modulates the
activity and the proliferation of osteoblasts, and/or regulats the gene expression in osteoblasts
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and osteoclasts [17-20]. Bone resorption is regulated by the adhesion of osteoclasts to the
surface of the bone, which is mediated by the receptor αvβ3 integrin and its recognition to RGD
(Arg-Gly-Asp) containing protein of osteoclasts [21]. These suggest that the activity and
proliferation of osteoblasts and the adhesiveness of osteoclasts can be simultaneously up-
regulated with estrogen and down-regulated with RGD peptide, respectively. On the other
hand, it was explored that the covalent modifications of hydrocortisone and estrone with
kyotorphin (a dipeptide, Tyr-Arg) may increase the analgesic activities of hydrocortisone and
estrone [22], as well as the covalent modifications of hydrocortisone and prednisolone with
urotoxins (Gly-Asp-Gly, His-Gly-Gly, His-Gly-Lys and His-Gly-Lys-NHNH2) may increase
the immunosuppressive activities of hydrocortisone and prednisolone [23]. Similarly, the anti-
osteoporosis activities of estrone and estradiol were enhanced by growth hormone releasing
peptides (GHRPs: Tyr-Gly-Gly-Phe-Met-NH2, Tyr-Gly-Gly-Phe-Met, Tyr-Gly-Gly-Phe-Leu-
NH2, Tyr-Gly-Gly-Phe-Leu, Tyr-Gly-Gly-Phe-Gly-NH2 and Tyr-Gly-Gly-Phe-Gly) [24-26]. In
this context a strategy to enhance anti-osteoporosis potency and reduce adverse effects of HRT
was practiced by covalent modifications of sex hormone with RGD-peptides.
2. Covalent modifications of estrogen with RGD-peptides and ip treated
ovariectomy mice
Estrogens including estrone, estradiol, estriol, conjugated estrogen and tibolone have been
widely used in HRT. Upon the promotion of the enzyme both estrone and estradiol can be
converted to ertriol. Conjugated estrogen is an oral estrogen isolated from the urine of gravid
horse and contains estrone monosodium sulfate (50.0% - 63.0%), equilin monosodium sulfate
(22.5% - 32.5%), a few of 17α-estradiol monosodium sulfate and equilenin monosodium sulfate.
Tibolone is an analog of norethynodrel. Of these estrogens, estrone and estradiol are the
common parents and estradiol is the major agents of HRT. Thus estradiol and estrone were
covalently modified by RGD-peptides (1-9, Figure 1) and evaluated with ip treated ovariec‐
tomy mice [27].
Figure 1. Structures of conjugates of estradiol-RGD-tetrapeptides. In 1, 4,7 AA = Ser, in 2, 5, 8 AA = Val, in 3, 6, 9 AA =
Phe.
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2.1. Covalent modification of estradiol with RGD-tetrapeptides decreasing bone turnover
Using succinyl group as the linker the covalent modifications of the 17β-hydroxy of estradiol
with RGD-tetrapeptides provided conjugates 1-3, and using carbonylmethyl group as the
linker the covalent modifications of the 3-hydroxy of estradiol or estrone with RGD-tetrapep‐
tides provided conjugates 4-9 (Figure 1). The changes of the levels of the serum calcium and
serum alkaline phosphatase (ALP) of the mice receiving ip injection of 1-6 for 4 weeks are
shown in Figure 2. After the treatments of conjugates 1-6 the levels of serum calcium and serum
ALP of the treated mice are significantly lower than that of ovariotomy and estradiol treated
mice. This means that the ip injection efficacy of conjugates 1-6 in decreasing the serum calcium
and serum ALP is significantly higher than that of estradiol. Due to serum ALP been the
biomarker of bone turnover low serum ALP means conjugates 1-6 benefits the inhibition of
bone turnover.
Figure 2. Serum calcium and serum ALP of 1-6 treated mice. Dose = 110.3 μmol/kg, n=12, a) Compared to ovariotomy
P<0.05; b) Compared to ovariotomy P<0.01; c) Compared to ovariotomy and estradiol P<0.01. The statistical analysis
of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
2.2. Covalent modification of estradiol with RGD-tetrapeptides inhibiting bone loss
The effects of ip injection of 1-6 for 4 weeks on the bone loss of the mice are shown in Figure
3. The level of bone loss is represented with the weight of dry femur and the weight of femur
ash. The data indicate that the weight of dry femur and the weight of femur ash of 1-6 treated
mice are significantly higher than those of ovariotomy and estradiol treated mice. This means
that ip injection efficacy of 1-6 in inhibiting the bone loss is significantly higher than that of
estradiol, and the covalent modification of estradiol with RGD-tetrapeptides benefits the
inhibition of bone loss.
2.3. Covalent modification of estrone with RGD-tetrapeptides inhibiting bone turnover
Using carbonylmethyl group as the linker the covalent modifications of the 3-hydroxy of
estrone with RGD-tetrapeptides provided conjugates 7-9 (Figure 4). The effects of ip injection
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regulated with estrogen and down-regulated with RGD peptide, respectively. On the other
hand, it was explored that the covalent modifications of hydrocortisone and estrone with
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NH2, Tyr-Gly-Gly-Phe-Leu, Tyr-Gly-Gly-Phe-Gly-NH2 and Tyr-Gly-Gly-Phe-Gly) [24-26]. In
this context a strategy to enhance anti-osteoporosis potency and reduce adverse effects of HRT
was practiced by covalent modifications of sex hormone with RGD-peptides.
2. Covalent modifications of estrogen with RGD-peptides and ip treated
ovariectomy mice
Estrogens including estrone, estradiol, estriol, conjugated estrogen and tibolone have been
widely used in HRT. Upon the promotion of the enzyme both estrone and estradiol can be
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horse and contains estrone monosodium sulfate (50.0% - 63.0%), equilin monosodium sulfate
(22.5% - 32.5%), a few of 17α-estradiol monosodium sulfate and equilenin monosodium sulfate.
Tibolone is an analog of norethynodrel. Of these estrogens, estrone and estradiol are the
common parents and estradiol is the major agents of HRT. Thus estradiol and estrone were
covalently modified by RGD-peptides (1-9, Figure 1) and evaluated with ip treated ovariec‐
tomy mice [27].
Figure 1. Structures of conjugates of estradiol-RGD-tetrapeptides. In 1, 4,7 AA = Ser, in 2, 5, 8 AA = Val, in 3, 6, 9 AA =
Phe.
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2.1. Covalent modification of estradiol with RGD-tetrapeptides decreasing bone turnover
Using succinyl group as the linker the covalent modifications of the 17β-hydroxy of estradiol
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linker the covalent modifications of the 3-hydroxy of estradiol or estrone with RGD-tetrapep‐
tides provided conjugates 4-9 (Figure 1). The changes of the levels of the serum calcium and
serum alkaline phosphatase (ALP) of the mice receiving ip injection of 1-6 for 4 weeks are
shown in Figure 2. After the treatments of conjugates 1-6 the levels of serum calcium and serum
ALP of the treated mice are significantly lower than that of ovariotomy and estradiol treated
mice. This means that the ip injection efficacy of conjugates 1-6 in decreasing the serum calcium
and serum ALP is significantly higher than that of estradiol. Due to serum ALP been the
biomarker of bone turnover low serum ALP means conjugates 1-6 benefits the inhibition of
bone turnover.
Figure 2. Serum calcium and serum ALP of 1-6 treated mice. Dose = 110.3 μmol/kg, n=12, a) Compared to ovariotomy
P<0.05; b) Compared to ovariotomy P<0.01; c) Compared to ovariotomy and estradiol P<0.01. The statistical analysis
of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
2.2. Covalent modification of estradiol with RGD-tetrapeptides inhibiting bone loss
The effects of ip injection of 1-6 for 4 weeks on the bone loss of the mice are shown in Figure
3. The level of bone loss is represented with the weight of dry femur and the weight of femur
ash. The data indicate that the weight of dry femur and the weight of femur ash of 1-6 treated
mice are significantly higher than those of ovariotomy and estradiol treated mice. This means
that ip injection efficacy of 1-6 in inhibiting the bone loss is significantly higher than that of
estradiol, and the covalent modification of estradiol with RGD-tetrapeptides benefits the
inhibition of bone loss.
2.3. Covalent modification of estrone with RGD-tetrapeptides inhibiting bone turnover
Using carbonylmethyl group as the linker the covalent modifications of the 3-hydroxy of
estrone with RGD-tetrapeptides provided conjugates 7-9 (Figure 4). The effects of ip injection
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of 7-9 for 4 weeks on serum calcium and serum ALP of the mice are shown in Figure 4. The
serum calcium and serum ALP of 7-9 treated mice are significantly lower than that of ovar‐
iotomy and estrone treated mice. This means that the ip injection efficacy of conjugates 7-9 in
decreasing the serum calcium and serum ALP is significantly higher than that of estrone. Due
to serum ALP reflecting the level of bone turnover and low serum ALP corresponding with
low bone turnover, 7-9 benefits the inhibition of bone turnover.
Figure 4. Serum calcium and ALP of 7-9 treated mice. Dose = 110.3 μmol/kg, n=12, a) Compared to ovariotomy
P<0.05; b) Compared to ovariotomy P<0.01; c) Compared to ovariotomy and estrone P<0.01. The statistical analysis of
the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
2.4. Covalent modification of estrone with RGD-tetrapeptides preventing bone loss
The effect of ip injection of 7-9 for 4 weeks on the bone loss of the mice is shown in Figure 5.
The weight of dry femur and the weight of femur ash of 7-9 treated mice are significantly higher
than that of ovariotomy and estrone treated mice. Due to the weight of dry femur and the
weight of femur ash reflecting the level of bone loss of osteoporosis mice this comparison
means that ip injection efficacy of 7-9 in inhibiting bone loss is significantly higher than that
of estrone and the covalent modification enhances the inhibition of estrone in bone loss.
Figure 3. Weight of dry femur and femur ash of 1-6 treated mice. Dose =110.3 μmol/kg, n=12; a) Compared to ovar‐
iotomy P<0.01; b) Compared to ovariotomy and estradiol P<0.01; c) Compared to ovariotomy and estradiol P<0.05; d)
Compared to ovariotomy P<0.01, to estradiol P<0.05. The statistical analysis of the data was carried out by use of an
ANOVA test and p<0.05 was considered significant.
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Figure 5. Weight of dry femur and femur ash of conjugates 7-9 treated mice. Dose =110.3 μmol/kg, n=12; a) Com‐
pared to ovariotomy P<0.01; b) Compared to ovariotomy P<0.05; c) Compared to ovariotomy P<0.01, to estrone
P<0.05. The statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered signifi‐
cant.
2.5. Covalent modification of estrogen with RGD-tetrapeptides inducing no endometrial
cell hyperplasia
The effects of ip injection of 1-9 for 4 weeks on endometrial cell hyperplasia of the mice were
also observed. The weight of the uteri of ovariotomy, estradiol and estrone treated mice is
significantly higher than that of 1-9 treated mice. Due to the weight of the uteri reflecting the
level of endometrial cell hyperplasia of treated mice this comparison means that ip injection
efficacy of 1-9 in inducing endometrial cell hyperplasia is significantly lower than that of
estradiol and estrone and the covalent modification induces no observable endometrial cell
hyperplasia.
2.6. Summary of covalent modification of estrogen with RGD-tetrapeptides
With RGD-tetrapeptides modifying one hydroxyl group of estradiol and estrone resulted in 9
conjugates. On ovariotomy mouse model and at 110.3 μmol/kg of ip dose their anti-osteopo‐
rosis activities were significantly higher than that of estradiol and estrone themselves. In
contrast to estradiol and estrone themselves, the anti-osteoporosis therapy of these conjugates
induced no endometrial cell hyperplasia. It is commonly accepted that osteoporosis relates to
both the decrease in bone formation modulated by osteoblasts and the increase in bone
resorption modulated by osteoclasts. In HRT, estradiol and estrone are used to treat the
decrease in skeletal muscle and bone by the direct modulation of osteoblastic activity and
proliferation or by the regulation of gene expression in osteoblasts and osteoclasts. Bone
resorption is regulated by the binding of osteoclasts to the bone surface and, therefore, depends
upon osteoclast adhesiveness. This bone adhesion process is mediated by RGD-tetrapeptides
binding integrin receptor on cell surface. This action of RGD-tetrapeptides should be respon‐
sible for both the increased anti-osteoporosis activity and the decreased endometrial cell
hyperplasia of the conjugates. Due to ovariotomy mouse model simulates the bone loss
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of 7-9 for 4 weeks on serum calcium and serum ALP of the mice are shown in Figure 4. The
serum calcium and serum ALP of 7-9 treated mice are significantly lower than that of ovar‐
iotomy and estrone treated mice. This means that the ip injection efficacy of conjugates 7-9 in
decreasing the serum calcium and serum ALP is significantly higher than that of estrone. Due
to serum ALP reflecting the level of bone turnover and low serum ALP corresponding with
low bone turnover, 7-9 benefits the inhibition of bone turnover.
Figure 4. Serum calcium and ALP of 7-9 treated mice. Dose = 110.3 μmol/kg, n=12, a) Compared to ovariotomy
P<0.05; b) Compared to ovariotomy P<0.01; c) Compared to ovariotomy and estrone P<0.01. The statistical analysis of
the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
2.4. Covalent modification of estrone with RGD-tetrapeptides preventing bone loss
The effect of ip injection of 7-9 for 4 weeks on the bone loss of the mice is shown in Figure 5.
The weight of dry femur and the weight of femur ash of 7-9 treated mice are significantly higher
than that of ovariotomy and estrone treated mice. Due to the weight of dry femur and the
weight of femur ash reflecting the level of bone loss of osteoporosis mice this comparison
means that ip injection efficacy of 7-9 in inhibiting bone loss is significantly higher than that
of estrone and the covalent modification enhances the inhibition of estrone in bone loss.
Figure 3. Weight of dry femur and femur ash of 1-6 treated mice. Dose =110.3 μmol/kg, n=12; a) Compared to ovar‐
iotomy P<0.01; b) Compared to ovariotomy and estradiol P<0.01; c) Compared to ovariotomy and estradiol P<0.05; d)
Compared to ovariotomy P<0.01, to estradiol P<0.05. The statistical analysis of the data was carried out by use of an
ANOVA test and p<0.05 was considered significant.
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Figure 5. Weight of dry femur and femur ash of conjugates 7-9 treated mice. Dose =110.3 μmol/kg, n=12; a) Com‐
pared to ovariotomy P<0.01; b) Compared to ovariotomy P<0.05; c) Compared to ovariotomy P<0.01, to estrone
P<0.05. The statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered signifi‐
cant.
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also observed. The weight of the uteri of ovariotomy, estradiol and estrone treated mice is
significantly higher than that of 1-9 treated mice. Due to the weight of the uteri reflecting the
level of endometrial cell hyperplasia of treated mice this comparison means that ip injection
efficacy of 1-9 in inducing endometrial cell hyperplasia is significantly lower than that of
estradiol and estrone and the covalent modification induces no observable endometrial cell
hyperplasia.
2.6. Summary of covalent modification of estrogen with RGD-tetrapeptides
With RGD-tetrapeptides modifying one hydroxyl group of estradiol and estrone resulted in 9
conjugates. On ovariotomy mouse model and at 110.3 μmol/kg of ip dose their anti-osteopo‐
rosis activities were significantly higher than that of estradiol and estrone themselves. In
contrast to estradiol and estrone themselves, the anti-osteoporosis therapy of these conjugates
induced no endometrial cell hyperplasia. It is commonly accepted that osteoporosis relates to
both the decrease in bone formation modulated by osteoblasts and the increase in bone
resorption modulated by osteoclasts. In HRT, estradiol and estrone are used to treat the
decrease in skeletal muscle and bone by the direct modulation of osteoblastic activity and
proliferation or by the regulation of gene expression in osteoblasts and osteoclasts. Bone
resorption is regulated by the binding of osteoclasts to the bone surface and, therefore, depends
upon osteoclast adhesiveness. This bone adhesion process is mediated by RGD-tetrapeptides
binding integrin receptor on cell surface. This action of RGD-tetrapeptides should be respon‐
sible for both the increased anti-osteoporosis activity and the decreased endometrial cell
hyperplasia of the conjugates. Due to ovariotomy mouse model simulates the bone loss
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condition of postmenopausal women these RGD-tetrapeptides modified estradiol and estrone
should be promising candidates for HRT use.
3. Covalent modification of estrogen with RGD-octapeptides and orally
treated ovariectomy mice
It was explored that the modification of RGD-tetrapeptides with oligopeptides usually
increased their bioactivities [28, 29], suggesting the modification of RGD-tetrapeptides with
RGD-tetrapeptides may result in increase of the activity of down-regulating proliferation of
osteoblasts and the adhesiveness of osteoclasts. In this context estradiol and estrone were
modified with RGD-octapeptides (10-21, Figure 6) to evaluate the oral activity on ovariectomy
mice [30, 31].
Figure 6. Structures of conjugates of RGD-octapeptides and estradiol. In 10, 13, 16, 19 AA = Ser, in 11, 14, 17, 20 AA
= Val, in 12, 15, 18, 21 AA = Phe.
3.1. Covalent modification of estradiol with RGD-octapeptides inhibiting bone turnover
Using succinyl group as the linker the 17β-hydroxy of estradiol was modified with RGD-
octapeptides and provided 10-12, using carbonylmethyl group as the linker the 3-hydroxy of
estradiol was modified with RGD-octapeptides and provided 13-15 (Figure 6). The effect of
oral administration of 10-15 for 4 weeks on serum calcium and serum ALP of the mice are
shown in Figure 7. The data indicate that the serum calcium and serum ALP of 10-15 treated
mice are significantly lower than that of ovariotomy and estradiol treated mice. This means
that the frequency of bone turnover of 10-15 orally treated mice is significantly lower than that
of estradiol treated mice, the efficacy of oral 10-15 in inhibiting bone turnover is significantly
higher than that of estradiol.
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Figure 7. Serum calcium and ALP of 10-15 treated mice. Dose = 110.3 nmol/kg, n=12, a) Compared to ovariotomy
and estradiol P<0.01; b) Compared to ovariotomy P<0.01; c) Compared to ovariotomy P<0.01, to estradiol P<0.05. The
statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
3.2. Covalent modification of estradiol with RGD-octapeptides preventing bone loss
The effect of orally administration of 10-15 for 4 weeks on the bone loss of the treated mice is
shown in Figure 8, of which the activity is represented with dry femur weight and femur ash
weight. The data indicate that both the weights of dry femur and femur ash of 10-15 treated
mice are significantly higher than that of ovariotomy and estradiol treated mice. This means
that when orally dosed 10-15 effectively inhibit the mice to lose femur and their efficacy is
significantly higher than that of estradiol, and the covalent modification of estradiol benefits
the inhibition of bone loss.
Figure 8. Weight of dry femur and femur ash of conjugates 10-15 treated mice. Dose =110.3 nmol/kg, n=12; a) Com‐
pared to ovariotomy P<0.05; b) Compared to ovariotomy and estradiol P<0.01. The statistical analysis of the data was
carried out by use of an ANOVA test and p<0.05 was considered significant.
3.3. Covalent modification of estrone with RGD-octapeptides inhibiting bone turnover
Using carbonylmethyl group as the linker the 3-hydroxy of estrone was modified with RGD-
octapeptides and provided 16-18 (Figure 6). The effects of oral administration of 16-18 for 4
weeks on serum calcium and serum ALP of the mice are shown in Figure 9. The data indicate
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condition of postmenopausal women these RGD-tetrapeptides modified estradiol and estrone
should be promising candidates for HRT use.
3. Covalent modification of estrogen with RGD-octapeptides and orally
treated ovariectomy mice
It was explored that the modification of RGD-tetrapeptides with oligopeptides usually
increased their bioactivities [28, 29], suggesting the modification of RGD-tetrapeptides with
RGD-tetrapeptides may result in increase of the activity of down-regulating proliferation of
osteoblasts and the adhesiveness of osteoclasts. In this context estradiol and estrone were
modified with RGD-octapeptides (10-21, Figure 6) to evaluate the oral activity on ovariectomy
mice [30, 31].
Figure 6. Structures of conjugates of RGD-octapeptides and estradiol. In 10, 13, 16, 19 AA = Ser, in 11, 14, 17, 20 AA
= Val, in 12, 15, 18, 21 AA = Phe.
3.1. Covalent modification of estradiol with RGD-octapeptides inhibiting bone turnover
Using succinyl group as the linker the 17β-hydroxy of estradiol was modified with RGD-
octapeptides and provided 10-12, using carbonylmethyl group as the linker the 3-hydroxy of
estradiol was modified with RGD-octapeptides and provided 13-15 (Figure 6). The effect of
oral administration of 10-15 for 4 weeks on serum calcium and serum ALP of the mice are
shown in Figure 7. The data indicate that the serum calcium and serum ALP of 10-15 treated
mice are significantly lower than that of ovariotomy and estradiol treated mice. This means
that the frequency of bone turnover of 10-15 orally treated mice is significantly lower than that
of estradiol treated mice, the efficacy of oral 10-15 in inhibiting bone turnover is significantly
higher than that of estradiol.
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Figure 7. Serum calcium and ALP of 10-15 treated mice. Dose = 110.3 nmol/kg, n=12, a) Compared to ovariotomy
and estradiol P<0.01; b) Compared to ovariotomy P<0.01; c) Compared to ovariotomy P<0.01, to estradiol P<0.05. The
statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
3.2. Covalent modification of estradiol with RGD-octapeptides preventing bone loss
The effect of orally administration of 10-15 for 4 weeks on the bone loss of the treated mice is
shown in Figure 8, of which the activity is represented with dry femur weight and femur ash
weight. The data indicate that both the weights of dry femur and femur ash of 10-15 treated
mice are significantly higher than that of ovariotomy and estradiol treated mice. This means
that when orally dosed 10-15 effectively inhibit the mice to lose femur and their efficacy is
significantly higher than that of estradiol, and the covalent modification of estradiol benefits
the inhibition of bone loss.
Figure 8. Weight of dry femur and femur ash of conjugates 10-15 treated mice. Dose =110.3 nmol/kg, n=12; a) Com‐
pared to ovariotomy P<0.05; b) Compared to ovariotomy and estradiol P<0.01. The statistical analysis of the data was
carried out by use of an ANOVA test and p<0.05 was considered significant.
3.3. Covalent modification of estrone with RGD-octapeptides inhibiting bone turnover
Using carbonylmethyl group as the linker the 3-hydroxy of estrone was modified with RGD-
octapeptides and provided 16-18 (Figure 6). The effects of oral administration of 16-18 for 4
weeks on serum calcium and serum ALP of the mice are shown in Figure 9. The data indicate
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that the serum calcium and serum ALP of 16-18 treated mice are significantly lower than that
of ovariotomy and estrone treated mice. This means that the frequency of bone turnover of
16-18 orally treated mice is significantly lower than that of estrone treated mice, the efficacy
of oral 16-18 in inhibiting bone turnover is significantly higher than that of estrone.
Figure 9. Serum calcium and serum ALP of 16-18 treated mice. Dose = 110.3 nmol/kg, n=12, a) Compared to ovariot‐
omy P<0.01, to estrone P<0.05; b) Compared to ovariotomy P<0.05; c) Compared to ovariotomy and estrone P<0.01.
The statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
3.4. Covalent modification of estrone with RGD-octapeptides preventing bone loss
The effect of orally administration of 16-18 for 4 weeks on the bone loss of the treated mice is
shown in Figure 10, their activities are represented with dry femur weight and femur ash
weight. The data indicate that both the weights of dry femur and femur ash of 16-18 treated
mice are significantly higher than that of ovariotomy and estradiol treated mice. This means
that upon oral administration 16-18 effectively inhibit the mice losing femur, their efficacies
are significantly higher than that of estrone, and the covalent modification of estrone prevents
the bone loss.
Figure 10. Weight of dry femur and femur ash of conjugates 16-18 treated mice. Dose =110.3 nmol/kg, n=12; a)
Compared to ovariotomy and estrone P<0.01; b) Compared to ovariotomy P<0.01, to estrone P<0.05. The statistical
analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
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3.5. Covalent modification of estradiol with two RGD-octapeptides inhibiting bone
turnover
Using succinyl group as the linker of the 17β-hydroxy and using carbonylmethyl group as the
linker of the 3-hydroxy estradiol was simultaneously modified with RGD-tetrapeptides and
provided 19-21 (Figure 6). The effects of oral administration of 19-21 for 4 weeks on serum
calcium and serum ALP of the mice are shown in Figure 11. The data indicate that the serum
calcium and serum ALP of 19-21 treated mice are significantly lower than that of ovariotomy
and estradiol treated mice. This means that the frequency of bone turnover of 19-21 orally
treated mice is significantly lower than that of estradiol treated mice, the efficacy of oral 19-21
in inhibiting bone turnover is significantly higher than that of estradiol.
Figure 11. Serum calcium and serum ALP of 19-21 treated mice. Dose = 110.3 nmol/kg, n=12. The statistical analysis
of the data was carried out by use of an ANOVA test and p<0.05 was considered significant. For serum calcium a)
Compared to ovariotomy P<0.05; For serum ALP b) compared to ovariotomy and estradiol P<0.01.
3.6. Covalent modification of estradiol with two RGD-octapeptides preventing bone loss
The effect of orally administration of 19-21 for 4 weeks on the bone loss of the treated mice
is shown in Figure 12, their activities are represented with dry femur weight and femur
ash weight. The data indicate that both the weights of dry femur and femur ash of 19-21
treated mice are significantly higher than that of ovariotomy and estradiol treated mice.
This means that upon oral administration 19-21  effectively inhibit the mice losing femur,
their  efficacies are significantly higher than that  of  estradiol,  and the covalent modifica‐
tion of estrone prevents the bone loss.
3.7. Covalent modification of estradiol with RGD-octapeptides inducing no endometrial
cell hyperplasia
The effect of orally administration of 10-21 for 4 weeks on the endometrial cell hyperplasia of
the mice was observed, of which the inhibition is represented with uteri weight. The data
indicate that the weight of the uteri of 10-21 treated mice is significantly lower than that of
ovariotomy and estradiol treated mice. This means that, in contrast to estradiol and estrone,
oral administration of 10-21 induces no observable endometrial cell hyperplasia, and the
covalent modification of estradiol and estrone with RGD-octapeptides limits the dose-related
adverse effects of estradiol.
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that the serum calcium and serum ALP of 16-18 treated mice are significantly lower than that
of ovariotomy and estrone treated mice. This means that the frequency of bone turnover of
16-18 orally treated mice is significantly lower than that of estrone treated mice, the efficacy
of oral 16-18 in inhibiting bone turnover is significantly higher than that of estrone.
Figure 9. Serum calcium and serum ALP of 16-18 treated mice. Dose = 110.3 nmol/kg, n=12, a) Compared to ovariot‐
omy P<0.01, to estrone P<0.05; b) Compared to ovariotomy P<0.05; c) Compared to ovariotomy and estrone P<0.01.
The statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
3.4. Covalent modification of estrone with RGD-octapeptides preventing bone loss
The effect of orally administration of 16-18 for 4 weeks on the bone loss of the treated mice is
shown in Figure 10, their activities are represented with dry femur weight and femur ash
weight. The data indicate that both the weights of dry femur and femur ash of 16-18 treated
mice are significantly higher than that of ovariotomy and estradiol treated mice. This means
that upon oral administration 16-18 effectively inhibit the mice losing femur, their efficacies
are significantly higher than that of estrone, and the covalent modification of estrone prevents
the bone loss.
Figure 10. Weight of dry femur and femur ash of conjugates 16-18 treated mice. Dose =110.3 nmol/kg, n=12; a)
Compared to ovariotomy and estrone P<0.01; b) Compared to ovariotomy P<0.01, to estrone P<0.05. The statistical
analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
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3.5. Covalent modification of estradiol with two RGD-octapeptides inhibiting bone
turnover
Using succinyl group as the linker of the 17β-hydroxy and using carbonylmethyl group as the
linker of the 3-hydroxy estradiol was simultaneously modified with RGD-tetrapeptides and
provided 19-21 (Figure 6). The effects of oral administration of 19-21 for 4 weeks on serum
calcium and serum ALP of the mice are shown in Figure 11. The data indicate that the serum
calcium and serum ALP of 19-21 treated mice are significantly lower than that of ovariotomy
and estradiol treated mice. This means that the frequency of bone turnover of 19-21 orally
treated mice is significantly lower than that of estradiol treated mice, the efficacy of oral 19-21
in inhibiting bone turnover is significantly higher than that of estradiol.
Figure 11. Serum calcium and serum ALP of 19-21 treated mice. Dose = 110.3 nmol/kg, n=12. The statistical analysis
of the data was carried out by use of an ANOVA test and p<0.05 was considered significant. For serum calcium a)
Compared to ovariotomy P<0.05; For serum ALP b) compared to ovariotomy and estradiol P<0.01.
3.6. Covalent modification of estradiol with two RGD-octapeptides preventing bone loss
The effect of orally administration of 19-21 for 4 weeks on the bone loss of the treated mice
is shown in Figure 12, their activities are represented with dry femur weight and femur
ash weight. The data indicate that both the weights of dry femur and femur ash of 19-21
treated mice are significantly higher than that of ovariotomy and estradiol treated mice.
This means that upon oral administration 19-21  effectively inhibit the mice losing femur,
their  efficacies are significantly higher than that  of  estradiol,  and the covalent modifica‐
tion of estrone prevents the bone loss.
3.7. Covalent modification of estradiol with RGD-octapeptides inducing no endometrial
cell hyperplasia
The effect of orally administration of 10-21 for 4 weeks on the endometrial cell hyperplasia of
the mice was observed, of which the inhibition is represented with uteri weight. The data
indicate that the weight of the uteri of 10-21 treated mice is significantly lower than that of
ovariotomy and estradiol treated mice. This means that, in contrast to estradiol and estrone,
oral administration of 10-21 induces no observable endometrial cell hyperplasia, and the
covalent modification of estradiol and estrone with RGD-octapeptides limits the dose-related
adverse effects of estradiol.
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3.8. Covalent modification of estradiol with RGD-octapeptides having no thrombosis risk
The effect of orally administration of 10-21 for 4 weeks on thrombosis risk of the mice was
observed, of which the risk is represented with tail bleeding time. The data indicate that the
tail bleeding time of 10-21 treated mice is significantly longer than that of ovariotomy, estradiol
and estrone treated mice. This means that, in contrast to estradiol and estrone, oral adminis‐
tration of 10-21 induces no observable thrombosis risk, and the covalent modification of
estradiol and estrone with RGD-octapeptides limits the dose-related adverse effects of
estradiol.
3.9. Summary of covalent modification of estrogen with RGD-octapeptides
With RGD-octapeptides modifying one hydroxyl  group of  estradiol  and estrone or with
RGD-tetrapeptides simultaneously modifying two hydroxyl groups of estradiol resulted in
12 conjugates. On ovariotomy mouse model and at 110.3 nmol/kg of oral dose their anti-
osteoporosis  activities were significantly higher than that  of  estradiol  and estrone them‐
selves. In contrast to estradiol and estrone themselves, the anti-osteoporosis therapy of these
conjugates  induced no  endometrial  cell  hyperplasia  and thrombosis  risk.  Comparing  to
RGD-tetrapeptide  modified  estradiol  and estrone  the  effective  dose  of  RGD-octapeptide
modified estradiol and estrone is 1000 folds lower. This means that the anti-osteoporosis
efficacy of RGD-octapeptide modified estradiol and estrone is 1000 folds higher than that
of  RGD-tetrapeptide  modified  estradiol  and  estrone.  Reasonably,  this  dramatically  en‐
hanced efficacy could attitude to the introduction of RGD-octapeptides. Furthermore, due
to ovariotomy mouse model simulates the bone loss condition of postmenopausal women
and  high  activity  these  RGD-octapeptides  modified  estradiol  and  estrone  should  be
preferentially promising candidates for HRT use.
Figure 12. Weight of dry femur and femur ash of conjugates 19-21 treated mice. Dose =110.3 nmol/kg, n=12,
weights of dry femurs and femur ashes are represented as X±SD mg; a) Compared to ovariotomy, estradiol P<0.01; b)
Compared to ovariotomy P<0.01, to estradiol P<0.05.
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4. Direct covalent modification of androgen with RGD-tetrapeptides
In the improvements of the efficacy of HRT, the anti-osteoporosis efficacy of androgen is found
to be higher than that of estrogen, inducing no endometrial cell hyperplasia and having no
thrombosis risk. Particularly in the research of androgen, 17β-amino-11α-hydroxyandrost-1,4-
diene-3-one is disclosed as a new androgen. Comparing to estrone and estrogen 17β-ami‐
no-11α-hydroxyandrost-1,4-diene-3-one has higher anti-osteoporosis activity and raises no
endometrial cell hyperplasia and thrombosis risk. Thus 17β-amino-11α-hydroxyandrost-1,4-
diene-3-one is selected as the androgen and directly and covalently modified with RGD-
tetrapeptides (22-24, Figure 13) [32].
Figure 13. Structures of conjugates of androgen and RGD-tetrapeptides. In 22 AA = Ser, in 23 AA = Val, in 24 AA =
Phe.
4.1. Direct covalent modification of androgen with RGD-tetrapeptides inhibiting bone
turnover
The direct covalent modification of the 17β-amino of 17β-amino-11α-hydroxyandrost-1,4-
diene-3-one (androgen) with RGD-tetrapeptides provided 22-24 (Figure 13). The effect of oral
administration of 22-24 plus intramuscular prednisone for 4 weeks on serum calcium and
serum ALP of the mice is shown in Figure 14. The data indicate that the serum calcium and
serum ALP of oral administration of 22-24 plus intramuscular prednisone treated mice are
significantly lower than that of prednisone alone and oral administration of estradiol plus
intramuscular prednisone treated mice. This means that the frequency of bone turnover of
22-24 orally treated mice is significantly lower than that of androgen treated mice, the efficacy
of oral 22-24 in inhibiting bone turnover is significantly higher than that of estradiol.
4.2. Direct covalent modification of androgen with RGD-tetrapeptides preventing bone loss
The effect of oral administration of 22-24 plus intramuscular prednisone for 4 weeks on the
bone loss of the treated mice is shown in Figure 15, their activities are represented with dry
femur weight and femur ash weight. The data indicate that both the weights of dry femur and
femur ash of oral adminis-tration of 22-24 plus intramuscular prednisone treated mice are
significantly higher than that of intramuscular prednisone alone and oral administration of
estradiol plus intramuscular prednisone treated mice. This means that upon oral administra‐
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3.8. Covalent modification of estradiol with RGD-octapeptides having no thrombosis risk
The effect of orally administration of 10-21 for 4 weeks on thrombosis risk of the mice was
observed, of which the risk is represented with tail bleeding time. The data indicate that the
tail bleeding time of 10-21 treated mice is significantly longer than that of ovariotomy, estradiol
and estrone treated mice. This means that, in contrast to estradiol and estrone, oral adminis‐
tration of 10-21 induces no observable thrombosis risk, and the covalent modification of
estradiol and estrone with RGD-octapeptides limits the dose-related adverse effects of
estradiol.
3.9. Summary of covalent modification of estrogen with RGD-octapeptides
With RGD-octapeptides modifying one hydroxyl  group of  estradiol  and estrone or with
RGD-tetrapeptides simultaneously modifying two hydroxyl groups of estradiol resulted in
12 conjugates. On ovariotomy mouse model and at 110.3 nmol/kg of oral dose their anti-
osteoporosis  activities were significantly higher than that  of  estradiol  and estrone them‐
selves. In contrast to estradiol and estrone themselves, the anti-osteoporosis therapy of these
conjugates  induced no  endometrial  cell  hyperplasia  and thrombosis  risk.  Comparing  to
RGD-tetrapeptide  modified  estradiol  and estrone  the  effective  dose  of  RGD-octapeptide
modified estradiol and estrone is 1000 folds lower. This means that the anti-osteoporosis
efficacy of RGD-octapeptide modified estradiol and estrone is 1000 folds higher than that
of  RGD-tetrapeptide  modified  estradiol  and  estrone.  Reasonably,  this  dramatically  en‐
hanced efficacy could attitude to the introduction of RGD-octapeptides. Furthermore, due
to ovariotomy mouse model simulates the bone loss condition of postmenopausal women
and  high  activity  these  RGD-octapeptides  modified  estradiol  and  estrone  should  be
preferentially promising candidates for HRT use.
Figure 12. Weight of dry femur and femur ash of conjugates 19-21 treated mice. Dose =110.3 nmol/kg, n=12,
weights of dry femurs and femur ashes are represented as X±SD mg; a) Compared to ovariotomy, estradiol P<0.01; b)
Compared to ovariotomy P<0.01, to estradiol P<0.05.
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4. Direct covalent modification of androgen with RGD-tetrapeptides
In the improvements of the efficacy of HRT, the anti-osteoporosis efficacy of androgen is found
to be higher than that of estrogen, inducing no endometrial cell hyperplasia and having no
thrombosis risk. Particularly in the research of androgen, 17β-amino-11α-hydroxyandrost-1,4-
diene-3-one is disclosed as a new androgen. Comparing to estrone and estrogen 17β-ami‐
no-11α-hydroxyandrost-1,4-diene-3-one has higher anti-osteoporosis activity and raises no
endometrial cell hyperplasia and thrombosis risk. Thus 17β-amino-11α-hydroxyandrost-1,4-
diene-3-one is selected as the androgen and directly and covalently modified with RGD-
tetrapeptides (22-24, Figure 13) [32].
Figure 13. Structures of conjugates of androgen and RGD-tetrapeptides. In 22 AA = Ser, in 23 AA = Val, in 24 AA =
Phe.
4.1. Direct covalent modification of androgen with RGD-tetrapeptides inhibiting bone
turnover
The direct covalent modification of the 17β-amino of 17β-amino-11α-hydroxyandrost-1,4-
diene-3-one (androgen) with RGD-tetrapeptides provided 22-24 (Figure 13). The effect of oral
administration of 22-24 plus intramuscular prednisone for 4 weeks on serum calcium and
serum ALP of the mice is shown in Figure 14. The data indicate that the serum calcium and
serum ALP of oral administration of 22-24 plus intramuscular prednisone treated mice are
significantly lower than that of prednisone alone and oral administration of estradiol plus
intramuscular prednisone treated mice. This means that the frequency of bone turnover of
22-24 orally treated mice is significantly lower than that of androgen treated mice, the efficacy
of oral 22-24 in inhibiting bone turnover is significantly higher than that of estradiol.
4.2. Direct covalent modification of androgen with RGD-tetrapeptides preventing bone loss
The effect of oral administration of 22-24 plus intramuscular prednisone for 4 weeks on the
bone loss of the treated mice is shown in Figure 15, their activities are represented with dry
femur weight and femur ash weight. The data indicate that both the weights of dry femur and
femur ash of oral adminis-tration of 22-24 plus intramuscular prednisone treated mice are
significantly higher than that of intramuscular prednisone alone and oral administration of
estradiol plus intramuscular prednisone treated mice. This means that upon oral administra‐
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tion 22-24 effectively inhibit the mice losing femur, their efficacies are significantly higher than
that of estradiol, and the direct covalent modification of androgen prevents the bone loss.
Figure 15. Weight of dry femur and femur ash of conjugates 22-24 treated mice. ip Dose of prednisone (PDN): 6.3
mg/kg, twice a week; oral dose of 22-24: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a
day; n = 12. a) Compared to NS + PND and E2 + PND p< 0.01; b) Compared to NS + PND and E2 + PND p< 0.05. The
statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
4.3. Direct covalent modification of androgen with RGD-tetrapeptides increasing total
vBMD
CT measured 3D bone geometry and the size-independent vBMD, as well as pQCT quantita‐
tively measured 3D bone geometry and size-independent vBMD were used to represent the
anti-osteoporosis efficacy of 22-24 and are shown in Figure 16. The data indicates that the total
vBMD of the femurs of NS plus intramuscular prednisone treated mice is significantly lower
than that of the femurs of NS alone treated mice. This means that intramuscular administration
of prednisone effectively induces the mice to decrease the total vBMD. The total vBMDs of the
Figure 14. Serum calcium and ALP of 22-24 treated mice. ip Dose of prednisone (PDN): 6.3 mg/kg, twice a week; oral
dose of 22-24: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a day; n = 12. a) Compared to
NS + PND and E2 + PND p< 0.01; b) Compared to NS + PND p< 0.01, to E2 + PND p< 0.05; c) Compared to NS + PND p<
0.05; d) Compared to NS + PND and E2 + PND p< 0.01. The statistical analysis of the data was carried out by use of an
ANOVA test and p<0.05 was considered significant.
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femurs of oral administration of 22-24 plus intramuscular prednisone treated mice are
significantly higher than that of the femurs of NS plus intramuscular prednisone treated mice.
This means that upon oral administration 22-24 effectively prevent intramuscular adminis‐
tration of prednisone treated mice decreasing total vBMD.
4.4. Direct covalent modification of androgen with RGD-tetrapeptides increasing trabecular
vBMD
Figure 17 indicates that the trabecular vBMD of the femurs of NS plus intramuscular admin‐
istration of prednisone treated mice is significantly lower than that of the femurs of NS alone
treated mice. This means that prednisone effectively induces the mice to decrease trabecular
vBMD. The trabecular vBMDs of the femurs of oral administration of 22-24 plus intramuscular
administration of prednisone treated mice are significantly higher than those of the femurs of
NS plus intramuscular administration of prednisone treated mice. This means that upon oral
administration 22-24 effectively prevent intra-muscular administration of prednisone treated
mice decreasing trabecular vBMD.
4.5. Direct covalent modification of androgen with RGD-tetrapeptides inducing no
endomtrial cell hyperplasia
The effect of oral administration of 22-24 plus intramuscular administration of prednisone for
4 weeks on the endometrial cell hyperplasia of the mice was observed, and their inhibition
activities are represented with uteri weight. The data indicate that the weight of the uteri of
oral administration of 22-24 plus intramuscular administration of prednisone treated mice is
significantly lower than that of intramuscular administration of prednisone alone and oral
administration of estradiol plus intramuscular administration of prednisone treated mice. This
means that, in contrast to oral administration of estradiol, oral administration of 19-21 induces
no observable endometrial cell hyperplasia, and the direct covalent modification of androgen
with RGD-tetrapeptides induces no dose-related adverse effects of estradiol.
Figure 16. Total vBMD and images of pQCT scanning at a distance from the proximal femur growth palate corre‐
sponding to < 6 % of the total length of the femur of 22-24 treated mice. ip Dose of prednisone (PDN): 6.3 mg/kg,
twice a week; oral dose of 22-24: 110 nmol/kg, once a day; n = 12. a) Compared to NS alone , NS + PND, 23 + PDN and
22 + PDN p< 0.01; b) Compared to NS alone , NS + PND and 22 + PDN c) Compared to NS alone and NS + PND p< 0.01.
The statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
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tion 22-24 effectively inhibit the mice losing femur, their efficacies are significantly higher than
that of estradiol, and the direct covalent modification of androgen prevents the bone loss.
Figure 15. Weight of dry femur and femur ash of conjugates 22-24 treated mice. ip Dose of prednisone (PDN): 6.3
mg/kg, twice a week; oral dose of 22-24: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a
day; n = 12. a) Compared to NS + PND and E2 + PND p< 0.01; b) Compared to NS + PND and E2 + PND p< 0.05. The
statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
4.3. Direct covalent modification of androgen with RGD-tetrapeptides increasing total
vBMD
CT measured 3D bone geometry and the size-independent vBMD, as well as pQCT quantita‐
tively measured 3D bone geometry and size-independent vBMD were used to represent the
anti-osteoporosis efficacy of 22-24 and are shown in Figure 16. The data indicates that the total
vBMD of the femurs of NS plus intramuscular prednisone treated mice is significantly lower
than that of the femurs of NS alone treated mice. This means that intramuscular administration
of prednisone effectively induces the mice to decrease the total vBMD. The total vBMDs of the
Figure 14. Serum calcium and ALP of 22-24 treated mice. ip Dose of prednisone (PDN): 6.3 mg/kg, twice a week; oral
dose of 22-24: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a day; n = 12. a) Compared to
NS + PND and E2 + PND p< 0.01; b) Compared to NS + PND p< 0.01, to E2 + PND p< 0.05; c) Compared to NS + PND p<
0.05; d) Compared to NS + PND and E2 + PND p< 0.01. The statistical analysis of the data was carried out by use of an
ANOVA test and p<0.05 was considered significant.
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femurs of oral administration of 22-24 plus intramuscular prednisone treated mice are
significantly higher than that of the femurs of NS plus intramuscular prednisone treated mice.
This means that upon oral administration 22-24 effectively prevent intramuscular adminis‐
tration of prednisone treated mice decreasing total vBMD.
4.4. Direct covalent modification of androgen with RGD-tetrapeptides increasing trabecular
vBMD
Figure 17 indicates that the trabecular vBMD of the femurs of NS plus intramuscular admin‐
istration of prednisone treated mice is significantly lower than that of the femurs of NS alone
treated mice. This means that prednisone effectively induces the mice to decrease trabecular
vBMD. The trabecular vBMDs of the femurs of oral administration of 22-24 plus intramuscular
administration of prednisone treated mice are significantly higher than those of the femurs of
NS plus intramuscular administration of prednisone treated mice. This means that upon oral
administration 22-24 effectively prevent intra-muscular administration of prednisone treated
mice decreasing trabecular vBMD.
4.5. Direct covalent modification of androgen with RGD-tetrapeptides inducing no
endomtrial cell hyperplasia
The effect of oral administration of 22-24 plus intramuscular administration of prednisone for
4 weeks on the endometrial cell hyperplasia of the mice was observed, and their inhibition
activities are represented with uteri weight. The data indicate that the weight of the uteri of
oral administration of 22-24 plus intramuscular administration of prednisone treated mice is
significantly lower than that of intramuscular administration of prednisone alone and oral
administration of estradiol plus intramuscular administration of prednisone treated mice. This
means that, in contrast to oral administration of estradiol, oral administration of 19-21 induces
no observable endometrial cell hyperplasia, and the direct covalent modification of androgen
with RGD-tetrapeptides induces no dose-related adverse effects of estradiol.
Figure 16. Total vBMD and images of pQCT scanning at a distance from the proximal femur growth palate corre‐
sponding to < 6 % of the total length of the femur of 22-24 treated mice. ip Dose of prednisone (PDN): 6.3 mg/kg,
twice a week; oral dose of 22-24: 110 nmol/kg, once a day; n = 12. a) Compared to NS alone , NS + PND, 23 + PDN and
22 + PDN p< 0.01; b) Compared to NS alone , NS + PND and 22 + PDN c) Compared to NS alone and NS + PND p< 0.01.
The statistical analysis of the data was carried out by use of an ANOVA test and p<0.05 was considered significant.
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4.6. Direct covalent modification of androgen with RGD-tetrapeptides having no
thrombosis risk
The effect of oral administration of 22-24 plus intramuscular administration of prednisone for
4 weeks on thrombosis risk of the mice was observed, and the risk is represented with tail
bleeding time. The data indicate that the tail bleeding time of oral administration of 22-24 plus
intramuscular administration of prednisone treated mice is significantly longer than that of
ntramuscular administration of prednisone alone and oral administration of estradiol plus
intramuscular administration of prednisone treated mice. This means that, in contrast to oral
administration of estradiol, oral administration of 22-24 induces no observable thrombosis risk,
and the direct covalent modification of androgen with RGD-tetrapeptides induces no dose-
related adverse effects of estradiol.
4.7. Summary of direct covalent modification of androgen with RGD-tetrapeptides
RGD-octapeptides directly modifying the 17β-amino group of 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one  was  performed  by  amidation  and  resulted  in  3  conjugates.  On
prednisone treated mouse model and at 110 nmol/kg of oral dose their anti-osteoporosis
activities were significantly higher than that of estradiol. In contrast to estradiol, the anti-
osteoporosis  therapy  of  these  conjugates  induced  no  endometrial  cell  hyperplasia  and
thrombosis risk. Comparing to RGD-tetrapeptide modified estradiol the effective dose of
RGD-octapeptide  modified  17β-amino-11α-hydroxyandrost-1,4-diene-3-one  is  1000  folds
lower.  This  means  that  the  anti-osteoporosis  efficacy  of  RGD-octapeptide  modified 17β-
amino-11α-hydroxyandrost-1,4-diene-3-one is 1000 folds higher than that of RGD-tetrapep‐
tide modified estradiol. Reasonably, this dramatically enhanced efficacy could attitude to
the introduction of 17β-amino-11α-hydroxyandrost-1,4-diene-3-one. In addition to premeno‐
pausal women and in older men, secondary osteoporosis is common in the patients treated
with glucocorticoids and in prostate cancer patients receiving androgen deprivation therapy
(ADT) in particular. Glucocorticoids are ubiquitously prescribed in the fields of rheumatol‐
Figure 17. Trabecular vBMD of the femurs of the treated mice at a distance from the proximal femur growth palate
corresponding with < 6 % of the total length of the femurs of 22-24 treated mice. a) Trabecular vBMD is represented
with mean ± SD mg/cm3, n = 12, PDN = prednisone, dose = 110 nmol/kg. b) Compared to NS + PDN, 22 + PDN and 23
+ PDN p< 0.01; c) Compared to NS + PDN and 22 + PDN p< 0.01; d) Compared to NS + PDN p< 0.01.
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ogy,  respirology,  neurology,  hematology,  dermatology,  gastroenterology,  and  transplant
medicine.  Chronic exposure to pharmacological  doses of  glucocorticoids causes multiple
deleterious effects on osteopenia, osteoporosis and bone fracture. Prostate cancer is one of
the most common diseases in the older men. After the surgery or radiation therapy the
male patients with localized or metastatic prostate cancer are generally given ADT. Though
male  patients  on  ADT  usually  have  good  prognosis,  osteoporosis  is  a  very  common
consequence of this therapy and up to 20% of the patients will fracture within 5 years. To
prevent osteoporotic fracture in the female patients treated with glucocorticoids and the
male patients receiving ADT novel effective agents are needed. The ability of these RGD-
octapeptides  modified  17β-amino-11α-hydroxyandrost-1,4-diene-3-one  to  prevent  predni‐
sone  treated  mouse  developing  osteoporosis  suggests  that  these  conjugates  should  be
promising candidates of secondary osteoporosis therapies.
5. Indirect covalent modification of androgen with RGD-tetrapeptides
For androgen a parallel covalent modification with the direct covalent modification is an
indirect strategy. In brief, between the 17β-amino group of 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one and RGD-tetrapeptides as a linker, succinyl group, is inserted to provide
RGD-tetrapeptides indirectly modified androgen (Figure 18) [33].
Figure 18. Structures of conjugates of androgen, succinyl group and RGD-tetrapeptides. In 25 AA = Ser, in 26 AA =
Val, in 27 AA = Phe.
5.1. Indirect covalent modification of androgen with RGD-tetrapeptides inhibiting bone
turnover
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on serum calcium and serum ALP of the mice is shown in Figure 19. The data indicate
that the serum calcium and serum ALP of oral administration of 25-27 plus intramuscular
administration of prednisone treated mice are significantly lower than those of intramuscular
administration of prednisone alone and oral administration of estradiol plus intramuscular
administration of prednisone treated mice. This means that the frequency of bone turnover of
oral administration of 25-27 treated mice is significantly lower than that of oral administration
of estradiol treated mice, the efficacy of oral administration of 25-27 in inhibiting bone turnover
is significantly higher than that of oral administration of estradiol.
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4.6. Direct covalent modification of androgen with RGD-tetrapeptides having no
thrombosis risk
The effect of oral administration of 22-24 plus intramuscular administration of prednisone for
4 weeks on thrombosis risk of the mice was observed, and the risk is represented with tail
bleeding time. The data indicate that the tail bleeding time of oral administration of 22-24 plus
intramuscular administration of prednisone treated mice is significantly longer than that of
ntramuscular administration of prednisone alone and oral administration of estradiol plus
intramuscular administration of prednisone treated mice. This means that, in contrast to oral
administration of estradiol, oral administration of 22-24 induces no observable thrombosis risk,
and the direct covalent modification of androgen with RGD-tetrapeptides induces no dose-
related adverse effects of estradiol.
4.7. Summary of direct covalent modification of androgen with RGD-tetrapeptides
RGD-octapeptides directly modifying the 17β-amino group of 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one  was  performed  by  amidation  and  resulted  in  3  conjugates.  On
prednisone treated mouse model and at 110 nmol/kg of oral dose their anti-osteoporosis
activities were significantly higher than that of estradiol. In contrast to estradiol, the anti-
osteoporosis  therapy  of  these  conjugates  induced  no  endometrial  cell  hyperplasia  and
thrombosis risk. Comparing to RGD-tetrapeptide modified estradiol the effective dose of
RGD-octapeptide  modified  17β-amino-11α-hydroxyandrost-1,4-diene-3-one  is  1000  folds
lower.  This  means  that  the  anti-osteoporosis  efficacy  of  RGD-octapeptide  modified 17β-
amino-11α-hydroxyandrost-1,4-diene-3-one is 1000 folds higher than that of RGD-tetrapep‐
tide modified estradiol. Reasonably, this dramatically enhanced efficacy could attitude to
the introduction of 17β-amino-11α-hydroxyandrost-1,4-diene-3-one. In addition to premeno‐
pausal women and in older men, secondary osteoporosis is common in the patients treated
with glucocorticoids and in prostate cancer patients receiving androgen deprivation therapy
(ADT) in particular. Glucocorticoids are ubiquitously prescribed in the fields of rheumatol‐
Figure 17. Trabecular vBMD of the femurs of the treated mice at a distance from the proximal femur growth palate
corresponding with < 6 % of the total length of the femurs of 22-24 treated mice. a) Trabecular vBMD is represented
with mean ± SD mg/cm3, n = 12, PDN = prednisone, dose = 110 nmol/kg. b) Compared to NS + PDN, 22 + PDN and 23
+ PDN p< 0.01; c) Compared to NS + PDN and 22 + PDN p< 0.01; d) Compared to NS + PDN p< 0.01.
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ogy,  respirology,  neurology,  hematology,  dermatology,  gastroenterology,  and  transplant
medicine.  Chronic exposure to pharmacological  doses of  glucocorticoids causes multiple
deleterious effects on osteopenia, osteoporosis and bone fracture. Prostate cancer is one of
the most common diseases in the older men. After the surgery or radiation therapy the
male patients with localized or metastatic prostate cancer are generally given ADT. Though
male  patients  on  ADT  usually  have  good  prognosis,  osteoporosis  is  a  very  common
consequence of this therapy and up to 20% of the patients will fracture within 5 years. To
prevent osteoporotic fracture in the female patients treated with glucocorticoids and the
male patients receiving ADT novel effective agents are needed. The ability of these RGD-
octapeptides  modified  17β-amino-11α-hydroxyandrost-1,4-diene-3-one  to  prevent  predni‐
sone  treated  mouse  developing  osteoporosis  suggests  that  these  conjugates  should  be
promising candidates of secondary osteoporosis therapies.
5. Indirect covalent modification of androgen with RGD-tetrapeptides
For androgen a parallel covalent modification with the direct covalent modification is an
indirect strategy. In brief, between the 17β-amino group of 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one and RGD-tetrapeptides as a linker, succinyl group, is inserted to provide
RGD-tetrapeptides indirectly modified androgen (Figure 18) [33].
Figure 18. Structures of conjugates of androgen, succinyl group and RGD-tetrapeptides. In 25 AA = Ser, in 26 AA =
Val, in 27 AA = Phe.
5.1. Indirect covalent modification of androgen with RGD-tetrapeptides inhibiting bone
turnover
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on serum calcium and serum ALP of the mice is shown in Figure 19. The data indicate
that the serum calcium and serum ALP of oral administration of 25-27 plus intramuscular
administration of prednisone treated mice are significantly lower than those of intramuscular
administration of prednisone alone and oral administration of estradiol plus intramuscular
administration of prednisone treated mice. This means that the frequency of bone turnover of
oral administration of 25-27 treated mice is significantly lower than that of oral administration
of estradiol treated mice, the efficacy of oral administration of 25-27 in inhibiting bone turnover
is significantly higher than that of oral administration of estradiol.
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Figure 19. Serum calcium and ALP of 25-27 treated mice. ip Dose of prednisone (PDN): 6.3 mg/kg, twice a week; oral
dose of 25-27: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a day; n = 12. For serum Ca+2:
a) Compared to NS + PND p< 0.01, to E2 + PND p< 0.05; b) Compared to NS + PND p< 0.05. For serum ALP: a) Com‐
pared to NS + PND and E2 + PND p< 0.01; b) Compared to NS + PND p< 0.05.
5.2. Indirect covalent modification of androgen with RGD-tetrapeptides preventing bone loss
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on the bone loss of the treated mice is shown in Figure 20, their activities are repre‐
sented with dry femur weight and femur ash weight. The data indicate that both the weights
of dry femur and femur ash of oral administration of 25-27 plus intramuscular administration
of prednisone treated mice are significantly higher than those of intramuscular administration
of prednisone alone and oral administration of estradiol plus intramuscular administration of
prednisone treated mice. This means that upon oral administration 25-27 effectively inhibit
the mice to losing femur, their efficacies are significantly higher than that of oral administration
of estradiol, and the direct covalent modification of androgen prevents the bone loss.
Figure 20. Weight of dry femur and femur ash of conjugates 25-27 treated mice. ip Dose of prednisone (PDN): 6.3
mg/kg, twice a week; oral dose of 25-27: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a
day; n = 12. For dry femur: a) Compared to NS + PND and E2 + PND p< 0.05; b) Compared to NS + PND and E2 + PND
p< 0.05. For femur ash: a) Compared to NS + PND and E2 + PND p< 0.01.
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5.3. Indirect covalent modification of androgen with RGD-tetrapeptides increasing total
vBMD
CT measured 3D bone geometry and the size-independent vBMD, as well as pQCT quantita‐
tively measured 3D bone geometry and size-independent vBMD were used to represent the
anti-osteoporosis efficacy of 25-27 and are shown in Figure 21. The data indicates that the total
vBMD of the femurs of NS plus intramuscular administration of prednisone treated mice is
significantly lower than that of the femurs of NS alone treated mice. This means that intra‐
muscular administration of prednisone effectively induces the mice to decrease the total
vBMD. The total vBMDs of the femurs of oral administration of 25-27 plus intramuscular
administration of prednisone treated mice are significantly higher than that of the femurs of
NS plus intramuscular administration of prednisone treated mice. This means that upon oral
administration 25-27 effectively inhibit intramuscular administration of prednisone treated
mice decreasing total vBMD.
Figure 21. Total vBMD and images of pQCT scanning at a distance from the proximal femur growth palate corre‐
sponding to < 6 % of the total length of the femur of 25-27 treated mice.
5.4. Indirect covalent modification of androgen with RGD-tetrapeptides increasing
trabecular vBMD
Figure 22 indicates that the trabecular vBMD of the femurs of NS plus intramuscular admin‐
istration of prednisone treated mice is significantly lower than that of the femurs of NS alone
treated mice. This means that prednisone effectively induces the mice to decrease trabecular
vBMD. The trabecular vBMDs of the femurs of oral administration of 25-27 plus intramuscular
administration of prednisone treated mice are significantly higher than that of the femurs of
NS plus intramuscular administration of prednisone treated mice. This means that upon oral
administration 25-27 effectively inhibit intramuscular administration of prednisone treated
mice decreasing trabecular vBMD.
Modification of Sex Hormones with RGD-Peptide: A Strategy of Improving HRT and Other Secondary…
http://dx.doi.org/10.5772/54361
103
Figure 19. Serum calcium and ALP of 25-27 treated mice. ip Dose of prednisone (PDN): 6.3 mg/kg, twice a week; oral
dose of 25-27: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a day; n = 12. For serum Ca+2:
a) Compared to NS + PND p< 0.01, to E2 + PND p< 0.05; b) Compared to NS + PND p< 0.05. For serum ALP: a) Com‐
pared to NS + PND and E2 + PND p< 0.01; b) Compared to NS + PND p< 0.05.
5.2. Indirect covalent modification of androgen with RGD-tetrapeptides preventing bone loss
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on the bone loss of the treated mice is shown in Figure 20, their activities are repre‐
sented with dry femur weight and femur ash weight. The data indicate that both the weights
of dry femur and femur ash of oral administration of 25-27 plus intramuscular administration
of prednisone treated mice are significantly higher than those of intramuscular administration
of prednisone alone and oral administration of estradiol plus intramuscular administration of
prednisone treated mice. This means that upon oral administration 25-27 effectively inhibit
the mice to losing femur, their efficacies are significantly higher than that of oral administration
of estradiol, and the direct covalent modification of androgen prevents the bone loss.
Figure 20. Weight of dry femur and femur ash of conjugates 25-27 treated mice. ip Dose of prednisone (PDN): 6.3
mg/kg, twice a week; oral dose of 25-27: 110 nmol/kg, once a day; oral dose of estradiol (E2): 110 nmol/kg, once a
day; n = 12. For dry femur: a) Compared to NS + PND and E2 + PND p< 0.05; b) Compared to NS + PND and E2 + PND
p< 0.05. For femur ash: a) Compared to NS + PND and E2 + PND p< 0.01.
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5.3. Indirect covalent modification of androgen with RGD-tetrapeptides increasing total
vBMD
CT measured 3D bone geometry and the size-independent vBMD, as well as pQCT quantita‐
tively measured 3D bone geometry and size-independent vBMD were used to represent the
anti-osteoporosis efficacy of 25-27 and are shown in Figure 21. The data indicates that the total
vBMD of the femurs of NS plus intramuscular administration of prednisone treated mice is
significantly lower than that of the femurs of NS alone treated mice. This means that intra‐
muscular administration of prednisone effectively induces the mice to decrease the total
vBMD. The total vBMDs of the femurs of oral administration of 25-27 plus intramuscular
administration of prednisone treated mice are significantly higher than that of the femurs of
NS plus intramuscular administration of prednisone treated mice. This means that upon oral
administration 25-27 effectively inhibit intramuscular administration of prednisone treated
mice decreasing total vBMD.
Figure 21. Total vBMD and images of pQCT scanning at a distance from the proximal femur growth palate corre‐
sponding to < 6 % of the total length of the femur of 25-27 treated mice.
5.4. Indirect covalent modification of androgen with RGD-tetrapeptides increasing
trabecular vBMD
Figure 22 indicates that the trabecular vBMD of the femurs of NS plus intramuscular admin‐
istration of prednisone treated mice is significantly lower than that of the femurs of NS alone
treated mice. This means that prednisone effectively induces the mice to decrease trabecular
vBMD. The trabecular vBMDs of the femurs of oral administration of 25-27 plus intramuscular
administration of prednisone treated mice are significantly higher than that of the femurs of
NS plus intramuscular administration of prednisone treated mice. This means that upon oral
administration 25-27 effectively inhibit intramuscular administration of prednisone treated
mice decreasing trabecular vBMD.
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Figure 22. Trabecular vBMD in the femurs of treated mice at a distance from the proximal femur. Growth plate corre‐
sponds with < 6% of the total length of the femur of the treated mice. Trabecular vBMD is represented with mean ±
SD mg/cm3, n = 12, PDN = prednisone, dose of 25-27 = 110 nmol/kg. a) Compared to NS + PDN, 25 + PDN and 26 +
PDN p< 0.01; b) Compared to NS + PDN and 27 + PDN p< 0.01; c) Compared to NS + PDN p< 0.01.
5.5. Indirect covalent modification of androgen with RGD-tetrapeptides inducing no
endomtrial cell hyperplasia
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on the endometrial cell hyperplasia of the mice was observed, and their inhibition
activities are represented with uteri weight. The data indicate that the weight of the uteri of
oral administration of 25-27 plus intramuscular administration of prednisone treated mice is
significantly lower than that of intramuscular administration of prednisone alone and oral
administration of estradiol plus intramuscular administration of prednisone treated mice. This
means that, in contrast to oral administration of estradiol, upon oral administration 25-27
induces no observable endometrial cell hyperplasia, and the direct covalent modification of
androgen with RGD-octapeptides induces no dose-related adverse effects of estradiol.
5.6. Indirect covalent modification of androgen with RGD-tetrapeptides having no
thrombosis risk
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on thrombosis risk of the mice was observed, and the risk is represented with tail
bleeding time. The data indicate that the tail bleeding time of oral administration of 25-27 plus
intramuscular administration of prednisone treated mice is significantly longer than that of
ntramuscular administration of prednisone alone and oral administration of estradiol plus
intramuscular administration of prednisone treated mice. This means that, in contrast to oral
administration of estradiol, upon oral administration 25-27 induces no observable thrombosis
risk, and the indirect covalent modification of androgen with RGD-octapeptides induces no
dose-related adverse effects of estradiol.
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5.7. Summary of indirect covalent modification of androgen with RGD-tetrapeptides
RGD-tetrapeptides indirectly modifying the 17β-amino group of 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one was performed by inserting a succinyl functional group and result‐
ed in 3 conjugates. On prednisone treated mouse model and at 110 nmol/kg of oral dose
their  anti-osteoporosis  activities  were  significantly  higher  than that  of  estradiol.  In  con‐
trast to estradiol, the anti-osteoporosis therapy of these conjugates induced no endometri‐
al cell hyperplasia and thrombosis risk. In respect to inhibiting the prednisone treated mice
to  lose  total  vBMD,  trabecular  vBMD,  femur  ash  weight,  femur  Ca2+  and bone  mineral
content 110 nmol/kg of RGD-tetrapeptides indirectly modified 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one was more effective than 110 nmol/kg of RGD-tetrapeptides directly
modified 17β-amino-11α-hydroxyandrost-1,4-diene-3-one, and this increased efficacy could
be  attributed  to  the  insertion  of  a  succinyl  group.  Similarly,  the  ability  of  these  RGD-
octapeptides  indirectly  modified  17β-amino-11α-hydroxyandrost-1,4-diene-3-one  to  pre‐
vent  prednisone  treated  mouse  developing  osteoporosis  and high  activity  suggests  that
these conjugates should be preferentially promising candidates for secondary osteoporo‐
sis therapies.
6. Nano-structures of RGD-peptides modified estrogen and androgen
Self-organization or self-assembly practically leads to the formation of various ordered
nanostructures in solution, at bulk state, and on a solid surface [34,35]. Numerous self-
assembling substances, such as highly fluorinated amphiphilic molecules[36], amphiphilic
triblock copolymers with polyrotaxane as a central block [37], amphiphilic dodecyl ester
derivatives from aromatic amino acids [38], dendritic molecules [39], the shape anisotropy of
non-spherical colloidal building blocks [40], alkylated polycyclic aromatic hydrocarbons [41],
porphyrins, graphenes and fullerenes [42], were designed. Of the self-assembling molecules,
peptides have been considered a set of particular substance [43-51]. In respect of the self-
assembly the formation of nano-structure is an inherent property of organic compounds. In
this context, the nano-structures of 10-15 and 22-27 in aqueous are given below to explore the
relationships between the nano-structure and the concentration or pH, as well as to correlate
the nano-feature with the pharmacological activity.
6.1. Nano-aggregators from modification of 17β-hydroxy of estradiol with RGD-
octapeptides
As explained by Figure 6, using succinyl group and RGD-octapeptides modifying the 17β-
hydroxy of estradiol provides 10-12. Figure 23 demonstrates that in water 10 forms stick like
nano-aggregators of 161.1 nm in diameter and 222.2-888.9 nm in length, 11 forms maize like
nano-aggregator of 388.9 nm in length, 12 forms solid pipe like nano-aggregator of 3.6 nm in
diameter and 263.9 nm in length.
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Figure 22. Trabecular vBMD in the femurs of treated mice at a distance from the proximal femur. Growth plate corre‐
sponds with < 6% of the total length of the femur of the treated mice. Trabecular vBMD is represented with mean ±
SD mg/cm3, n = 12, PDN = prednisone, dose of 25-27 = 110 nmol/kg. a) Compared to NS + PDN, 25 + PDN and 26 +
PDN p< 0.01; b) Compared to NS + PDN and 27 + PDN p< 0.01; c) Compared to NS + PDN p< 0.01.
5.5. Indirect covalent modification of androgen with RGD-tetrapeptides inducing no
endomtrial cell hyperplasia
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on the endometrial cell hyperplasia of the mice was observed, and their inhibition
activities are represented with uteri weight. The data indicate that the weight of the uteri of
oral administration of 25-27 plus intramuscular administration of prednisone treated mice is
significantly lower than that of intramuscular administration of prednisone alone and oral
administration of estradiol plus intramuscular administration of prednisone treated mice. This
means that, in contrast to oral administration of estradiol, upon oral administration 25-27
induces no observable endometrial cell hyperplasia, and the direct covalent modification of
androgen with RGD-octapeptides induces no dose-related adverse effects of estradiol.
5.6. Indirect covalent modification of androgen with RGD-tetrapeptides having no
thrombosis risk
The effect of oral administration of 25-27 plus intramuscular administration of prednisone for
4 weeks on thrombosis risk of the mice was observed, and the risk is represented with tail
bleeding time. The data indicate that the tail bleeding time of oral administration of 25-27 plus
intramuscular administration of prednisone treated mice is significantly longer than that of
ntramuscular administration of prednisone alone and oral administration of estradiol plus
intramuscular administration of prednisone treated mice. This means that, in contrast to oral
administration of estradiol, upon oral administration 25-27 induces no observable thrombosis
risk, and the indirect covalent modification of androgen with RGD-octapeptides induces no
dose-related adverse effects of estradiol.
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5.7. Summary of indirect covalent modification of androgen with RGD-tetrapeptides
RGD-tetrapeptides indirectly modifying the 17β-amino group of 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one was performed by inserting a succinyl functional group and result‐
ed in 3 conjugates. On prednisone treated mouse model and at 110 nmol/kg of oral dose
their  anti-osteoporosis  activities  were  significantly  higher  than that  of  estradiol.  In  con‐
trast to estradiol, the anti-osteoporosis therapy of these conjugates induced no endometri‐
al cell hyperplasia and thrombosis risk. In respect to inhibiting the prednisone treated mice
to  lose  total  vBMD,  trabecular  vBMD,  femur  ash  weight,  femur  Ca2+  and bone  mineral
content 110 nmol/kg of RGD-tetrapeptides indirectly modified 17β-amino-11α-hydroxyan‐
drost-1,4-diene-3-one was more effective than 110 nmol/kg of RGD-tetrapeptides directly
modified 17β-amino-11α-hydroxyandrost-1,4-diene-3-one, and this increased efficacy could
be  attributed  to  the  insertion  of  a  succinyl  group.  Similarly,  the  ability  of  these  RGD-
octapeptides  indirectly  modified  17β-amino-11α-hydroxyandrost-1,4-diene-3-one  to  pre‐
vent  prednisone  treated  mouse  developing  osteoporosis  and high  activity  suggests  that
these conjugates should be preferentially promising candidates for secondary osteoporo‐
sis therapies.
6. Nano-structures of RGD-peptides modified estrogen and androgen
Self-organization or self-assembly practically leads to the formation of various ordered
nanostructures in solution, at bulk state, and on a solid surface [34,35]. Numerous self-
assembling substances, such as highly fluorinated amphiphilic molecules[36], amphiphilic
triblock copolymers with polyrotaxane as a central block [37], amphiphilic dodecyl ester
derivatives from aromatic amino acids [38], dendritic molecules [39], the shape anisotropy of
non-spherical colloidal building blocks [40], alkylated polycyclic aromatic hydrocarbons [41],
porphyrins, graphenes and fullerenes [42], were designed. Of the self-assembling molecules,
peptides have been considered a set of particular substance [43-51]. In respect of the self-
assembly the formation of nano-structure is an inherent property of organic compounds. In
this context, the nano-structures of 10-15 and 22-27 in aqueous are given below to explore the
relationships between the nano-structure and the concentration or pH, as well as to correlate
the nano-feature with the pharmacological activity.
6.1. Nano-aggregators from modification of 17β-hydroxy of estradiol with RGD-
octapeptides
As explained by Figure 6, using succinyl group and RGD-octapeptides modifying the 17β-
hydroxy of estradiol provides 10-12. Figure 23 demonstrates that in water 10 forms stick like
nano-aggregators of 161.1 nm in diameter and 222.2-888.9 nm in length, 11 forms maize like
nano-aggregator of 388.9 nm in length, 12 forms solid pipe like nano-aggregator of 3.6 nm in
diameter and 263.9 nm in length.
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Figure 23. TEM images of 10 - 12 formed nano-aggregators. A) Stick like nano-aggregators of 10; B) Maize like nano-
aggregators of 11; C) Solid pipe like nano-aggregator of 12.
6.2. Nano-aggregators from modification of 3-hydroxy of estradiol with RGD-
octapeptides
As seen in Figure 6, carbonylmethyl and RGD-octapeptides modifying the 3-hydroxy of
estradiol provides 13-15. Figure 24 demonstrates that in water 13 forms porous nano-aggre‐
gators of 133.3-430.6 nm in length, 14 forms maize like nano-aggregator of 111.1-600.0 nm in
length, 15 forms nano-globes of 66.7-237.5 nm in diameter.
Figure 24. TEM images of 13 - 15 formed nano-aggregators. A) Porous nano-aggregators of 13; B) Porous nano-ag‐
gregators of 14; C) Nano-globes of 15.
6.3. TEM image of nano-globes of androgen having RGD-tetrapeptides modified 17β-
hydroxy
The nano-structures of 22-24 were explained with TEM nano-images and are shown with
Figures  25-27.  Figure  26  indicates  that  in  1.1  mM aqueous solution 22  forms numerous
smaller globes aggregated nano-globe of 400 nm in diameter, dispersing globes of 55 - 200
nm in diameter, and dispersing globes of 18 - 146 nm in diameter. Figure 41 indicates that
in 1.1 mM aqueous solution  23  forms nano-globe of  312.5 nm in diameter having small
globes, blocks and awls on surface, nano-globes of 21.9 - 82.9 nm in diameter and nano-
globes of 22.9 -  194.3 nm in diameter.  Figure 27 indicates that in 1.1 mM aqueous solu‐
tion 24  forms nano-globe of  183  nm in  diameter  having a  number  of  nano-particles  on
surface,  hemisphere  of  275  nm  in  diameter  having  some  smaller  globes  on  incomplete
surface and nano-globes of 48 - 188 nm in diameter.
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Figure 25. TEM images of 1.1 mM of 22 in ultrapure water. A) Numerous smaller globes aggregated nano-globe of
400 nm in diameter; B) Dispersing globes of 55 - 200 nm in diameter; C) Dispersing globes of 18 - 146 nm in diameter.
Figure 26. TEM images of 1.1 mM of 23 in ultrapure water. A) Nano-globe of 312.5 nm in diameter having small
globes, blocks and awls on surface; B) Nano-globes of 21.9 - 82.9 nm in diameter; C) Nano-globes of 22.9 - 194.3 nm
in diameter.
Figure 27. TEM images of 1.1 mM of 24 in ultrapure water. A) Nano-globe of 183 nm in diameter having a number of
nano-particles on surface; B) A hemisphere of 275 nm in diameter having some smaller globes on incomplete surface;
C) Nano-globes of 48 - 188 nm in diameter.
6.4. SEM image of nano-globes of androgen having RGD-tetrapeptides modified 17β-
hydroxy
The nano-structures of 22-24 were explained with SEM nano-images and are shown with
Figures 28-30. Figure 29 indicates that in solid state 22 exists as globes of 3.3 - 14.2 μm in
diameter. Figure 44 indicates that in solid state 23 exists as eggs of 9.6 × 11.5 μm to 19.5 × 27.0
μm in diameter, of which surfaces have small eggs, and one egg remains its tail been incom‐
plete. Figure 30 indicates that in solid state 24 exists as beads of 9.2 × 10.0 μm to 21.4 × 22.8 μm
in diameter, and beads remain been incomplete.
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Figure 26. TEM images of 1.1 mM of 23 in ultrapure water. A) Nano-globe of 312.5 nm in diameter having small
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in diameter.
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nano-particles on surface; B) A hemisphere of 275 nm in diameter having some smaller globes on incomplete surface;
C) Nano-globes of 48 - 188 nm in diameter.
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The nano-structures of 22-24 were explained with SEM nano-images and are shown with
Figures 28-30. Figure 29 indicates that in solid state 22 exists as globes of 3.3 - 14.2 μm in
diameter. Figure 44 indicates that in solid state 23 exists as eggs of 9.6 × 11.5 μm to 19.5 × 27.0
μm in diameter, of which surfaces have small eggs, and one egg remains its tail been incom‐
plete. Figure 30 indicates that in solid state 24 exists as beads of 9.2 × 10.0 μm to 21.4 × 22.8 μm
in diameter, and beads remain been incomplete.
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Figure 28. SEM images of 22 in solid state. A) Globes of 3.3 - 6.6 µm in diameter; B) Globes of 3.3 - 14.2 µm in diame‐
ter; C) Globes of 3.3 - 11.7 µm in diameter.
Figure 29. SEM images of 23 in solid state. A) Egg of 12.9 × 14.4 µm in diameter; B) Egg of 19.5 × 27.0 µm in diame‐
ter; C) Egg of 9.6 × 11.5 µm in diameter and egg remains its tail been incomplete.
Figure 30. SEM images of 24 in solid state. A) Bead of 9.2 × 10.0 µm in diameters, and bead remains been incomplete;
B) Hollow bead of 21.4 × 22.8 µm in diameters; C) Bead of 12.6 × 21.1 µm in diameter, and bead of 15.3 × 22.1 µm in
diameter.
6.5. TEM image of nano-globes of androgen having RGD-tetrapeptides and succinyl
modified 17β-hydroxy
The TEM images (Figures 31-33) demonstrate that in water 25-27 consistently form nano-
globes with porous surface. The comparison of the nano-globes of 22-24 having no porous
surface and the nano-globes of 25-27 having porous surface gave us an impression that the
insertion of succinyl was a key to form the nano-globes with porous surface, 17β-ethyl-car‐
bonylaminoandrost-1,4-diene-3-one was responsible for forming nano-globe, and RGD-tet‐
rapeptide was responsible for characterizing the surface feature and size of the nano-globes,
in particular. For instance, RGDS causes 25 to form dispersing nano-globes of 8 - 150 nm in
diameter and having porous surfaces, RGDV causes 26 to form dispersing nano-globes of 29
- 150 nm in diameter and having porous surfaces, and RGDF causes 27 to form dispersing
nano-globes of 76 - 343 nm in diameter and having porous surfaces.
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Figure 31. TEM images of 1.1 μM of 25 in ultrapure water. A) Dispersing globes of 8 - 150 nm in diameter; B) Dispers‐
ing globes of 17 - 94 nm in diameter; C) Dispersing globes of 27 - 82 nm in diameters.
Figure 32. TEM images of 1.1 μM of 26 in ultrapure water. A)Dispersing globes of 29 - 69 nm in diameter; B) Dispers‐
ing globes of 70 - 120 nm in diameter; C) Dispersing globes of 67 - 150 nm in diameter.
Figure 33. TEM images of 1.1 μM of 27 in ultrapure water. A) Dispersing globes of 320 - 343 nm in diameter; B) Dis‐
persing globes of 76 - 139 nm in diameter; C) Dispersing globes of 120 - 171 nm in diameter.
6.6. SEM image of nano-globes of androgen having RGD-tetrapeptides and succinyl
modified 17β-hydroxy
The SEM image (Figures 34-36) demonstrates that in solid state 25-27 exist as nano-globes of
15 nm - 6.4 μm in diameter, nano-pine seeds of 286 nm - 2.7 μm in length, nano-eggs of 1.3 -
12.9 μm in length, nano-pinecones of 5.0 - 5.6 μm in length, nano-gear of 10 μm in diameter,
nano-calabash of 4 μm in length, and uncompleted nano-calabash of 11.3 μm in length. The
coexistence of nano-globe having nano-egg, nano-pine seed having nano-pinecone, and
uncompleted nano-calabash having nano-calabash implies that the nano-egg, nano-pinecone
and nano-calabash are built by nano-globes, nano-pine seeds and uncompleted nano-calabash.
The correlation of the molecular constitutions and the nano-structures gave us an impression
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Figure 28. SEM images of 22 in solid state. A) Globes of 3.3 - 6.6 µm in diameter; B) Globes of 3.3 - 14.2 µm in diame‐
ter; C) Globes of 3.3 - 11.7 µm in diameter.
Figure 29. SEM images of 23 in solid state. A) Egg of 12.9 × 14.4 µm in diameter; B) Egg of 19.5 × 27.0 µm in diame‐
ter; C) Egg of 9.6 × 11.5 µm in diameter and egg remains its tail been incomplete.
Figure 30. SEM images of 24 in solid state. A) Bead of 9.2 × 10.0 µm in diameters, and bead remains been incomplete;
B) Hollow bead of 21.4 × 22.8 µm in diameters; C) Bead of 12.6 × 21.1 µm in diameter, and bead of 15.3 × 22.1 µm in
diameter.
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insertion of succinyl was a key to form the nano-globes with porous surface, 17β-ethyl-car‐
bonylaminoandrost-1,4-diene-3-one was responsible for forming nano-globe, and RGD-tet‐
rapeptide was responsible for characterizing the surface feature and size of the nano-globes,
in particular. For instance, RGDS causes 25 to form dispersing nano-globes of 8 - 150 nm in
diameter and having porous surfaces, RGDV causes 26 to form dispersing nano-globes of 29
- 150 nm in diameter and having porous surfaces, and RGDF causes 27 to form dispersing
nano-globes of 76 - 343 nm in diameter and having porous surfaces.
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The SEM image (Figures 34-36) demonstrates that in solid state 25-27 exist as nano-globes of
15 nm - 6.4 μm in diameter, nano-pine seeds of 286 nm - 2.7 μm in length, nano-eggs of 1.3 -
12.9 μm in length, nano-pinecones of 5.0 - 5.6 μm in length, nano-gear of 10 μm in diameter,
nano-calabash of 4 μm in length, and uncompleted nano-calabash of 11.3 μm in length. The
coexistence of nano-globe having nano-egg, nano-pine seed having nano-pinecone, and
uncompleted nano-calabash having nano-calabash implies that the nano-egg, nano-pinecone
and nano-calabash are built by nano-globes, nano-pine seeds and uncompleted nano-calabash.
The correlation of the molecular constitutions and the nano-structures gave us an impression
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that for 25 - 27 17β-ethylcarbonyl-amino-androst-1,4-diene-3-one was responsible for forming
a globe-like body, and RGD-tetrapeptide was responsible for characterizing globe-like body.
Figure 34. SEM images of 25 in solid state. A) Nano-globes of 15 nm - 2 µm in diameter and nano-calabash of 4 µm in
length; B) Nano-globes of 600 nm - 1.3 µm in diameter and nano-egg of 1.3 µm in length; C) Nano-globes of 3.0 - 5.0
µm in diameter and uncompleted nano-calabash of 11.3 µm in length.
Figure 35. SEM images of 26 in solid state. A) Globe of 2.9 µm in diameter; B) Globes of 5.0 - 6.4 µm in diameter and
eggs of 5.7 - 12.9 µm in length; C) Globes of 2.8 - 3.5 µm in diameter.
Figure 36. SEM images of 27 in solid state. A) Pine seeds of 7.1 - 9.4 µm in length; B) Globe of 8.1 µm in diameter; C)
Gear of 10 µm in diameter.
6.7. Summary of the nano-structures of RGD-peptides modified sex hormones
In water RGD-peptides modified sex hormones generally formed diverse nano-species via self-
assembly. Due to all non-covalent bond interactions could be involved into the self-assembly
the size and the feature of the nano-species of RGD-peptides modified sex hormones clearly
depend on the concentration of their aqueous solution. Similarly, due to all non-covalent bond
interactions could be involved into the self-assembly the size and the feature of the nano-
species usually depend on the chemical structures of the sex hormones and the sequence of
the RGD-peptides. In addition, the RGD-peptides modified sex hormones possessed various
anti-osteoporosis activities. Thus the feature and the size of their nano-species could be
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correlated with their anti-osteoporosis activities. Therefore by selecting the concentration and
by modifying the chemical structure we are able to optionally get the desirable nano-structure
and consequently to optionally get desirable anti-osteoporosis activity.
7. Conclusions
Secondary osteoporosis is common in premenopausal women with osteoporosis and in older
men, and is a major problem in clinical practice. More than one third of women with postme‐
nopausal osteoporosis have identifiable secondary causes that contribute to bone loss. The
secondary causes of osteoporosis in older men account for 50% - 80% of the cases of bone loss
leading to fracture. Besides, secondary osteoporosis is common in the patients treated with
glucocorticoids and in prostate cancer patients receiving ADT in particular. Glucocorticoids
are ubiquitously prescribed in the fields of rheumatology, respirology, neurology, hematology,
dermatology, gastroenterology, and transplant medicine. Chronic exposure to pharmacolog‐
ical doses of glucocorticoids causes multiple deleterious effects on osteopenia, osteoporosis
and bone fracture. Prostate cancer is one of the most common diseases in the older men. After
the surgery or radiation therapy the male patients with localized or metastatic prostate cancer
are generally given ADT. Though male patients on ADT usually have good prognosis,
osteoporosis is a very common consequence of this therapy and up to 20% of the patients will
fracture within 5 years. To prevent osteoporotic fracture in premenopausal women with
osteoporosis, the female patients treated with glucocorticoids and the male patients receiving
ADT RGD-peptides modified sex hormones were provided. On ovariotomy and prednisone
induced osteoporosis mice either ip injection or orally dosed the modified hormones were able
to enhance the efficacy and minimize the adverse effects. By forming nano-species their
therapy could be further improved.
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that for 25 - 27 17β-ethylcarbonyl-amino-androst-1,4-diene-3-one was responsible for forming
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Figure 34. SEM images of 25 in solid state. A) Nano-globes of 15 nm - 2 µm in diameter and nano-calabash of 4 µm in
length; B) Nano-globes of 600 nm - 1.3 µm in diameter and nano-egg of 1.3 µm in length; C) Nano-globes of 3.0 - 5.0
µm in diameter and uncompleted nano-calabash of 11.3 µm in length.
Figure 35. SEM images of 26 in solid state. A) Globe of 2.9 µm in diameter; B) Globes of 5.0 - 6.4 µm in diameter and
eggs of 5.7 - 12.9 µm in length; C) Globes of 2.8 - 3.5 µm in diameter.
Figure 36. SEM images of 27 in solid state. A) Pine seeds of 7.1 - 9.4 µm in length; B) Globe of 8.1 µm in diameter; C)
Gear of 10 µm in diameter.
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1. Introduction
Osteoporosis is a metabolic bone disease known as “the silent thief” because the gradual loss
of bone associated with this disease usually occurs over the years, and there are usually no
noticeable symptoms until the bones are so fragile that a fracture occurs [1]. Although most
statistics on the prevalence of osteoporosis quoted in the literature are from those published
in 1991 to 2004 [2,3] the projection is nevertheless very consistent. Thus, osteoporosis is
estimated to affect over 200 million people worldwide and 75 million people in Europe, the
United States, and Japan [4]. Approximately 1 in 2 women and 1 in 5 men older than 50 years
will eventually experience osteoporotic fractures [5] An increase in the worldwide incidence
of hip fracture by 240% in women and 310% in men is projected by the year 2050 [6]. Osteo‐
porosis is “a major public health threat” that is projected to results to 8.1 million fractures (78
% women, 22 % men) during the period between 2010 and 2050 [7]. The condition costs our
healthcare system $18 billion per year [8]. Records show that Osteoporosis has been known to
exist since the Egyptian mummies have been found with suspected dowager’s hump [9].
Newer findings on all aspects of osteoporosis have increased exponentially. The more
importantly ones are the introduction and improvement in more sensitive diagnostic instru‐
ments, discovering an ever increasing number of risk factors including oxidative stress,
opening up new knowledge on the involvement of the bone forming cells osteoblasts and the
bone resorbing cells osteoclasts in the development of osteoporosis and finding new drugs
and the nutritional alternatives for the prevention and treatment of osteoporosis. Advances in
knowledge on osteoporosis is not without pitfalls. Hormone Replacement Therapy (HRT),
once a first line of treatment for osteoporosis has been discontinued due to side effects [10]. It
is becoming more evident that the drugs known as bisphosphonates, although effective in
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stopping the resoption of bone and preventing osteoporosis in women, are associated with a
number of side effects [11,12]. The side effects have been alarming a number of women with
osteoporosis in such a way that they are now resorting to other mode of treatment, including
that from natural food components. Our laboratory has carried out studies on the use of
antioxidants such as lycopene and polyphenols as possible alternatives and/or complementa‐
ries to drugs in the treatment and prevention of osteoporosis. This chapter will include an
overview on osteoporosis, the role of oxidative stress in bone cells osteoclasts and osteoblasts,
oxidative stress as a risk factor in the development of osteoporosis and a review of studies on
the use of antioxidants in counteracting oxidative stress in the prevention of osteoporosis.
These topics should put our research in perspective and offer a rationale to our study ap‐
proaches. Finally we will highlight our pioneering studies on the effects of the lipid-soluble
antioxidant lycopene and the water-soluble antioxidant polyphenols present in a nutritional
supplement in an in vitro cultures of osteoblasts and osteoclasts and our clinical studies in the
prevention of risk for osteoporosis in postmenopausal women.
2. Osteoporosis — Overview
2.1. Bone cells involved in the development of osteoporosis
Bone as a dynamic tissue continuously renews itself throughout life by the process of bone
remodeling carried out by a functional and anatomic structure known as the basic multicellular
unit (BMU) that requires the coordinated action of three major types of bone cells: osteoclasts,
osteoblasts and osteocytes [13,14]. The remodeling process is the result of interactions between
these cells and multiple molecular agents, including hormones, growth factors, and cytokines.
Bone remodeling is a physiological process that follows a time sequence lasting approximately
six months wherein osteoclasts eliminate old or damaged bone which is subsequently replaced
with new bone formed by osteoblasts, while the osteocytes functions in the transduction of
signals necessary to sustain mechanical loads. The coupled process of bone formation and bone
resorption in mature, healthy bone is tightly regulated and maintained in order to prevent a
significant alterations in bone mass or mechanical strength after each remodeling cycle [14,15].
At menopause when estrogen production is decreased, the increase in resorption cavities due
to increased bone resorption, but insufficient increase in bone formation, results to incomplete
filling of resorption cavities with new bone leading to a permanent loss of bone mass. Distur‐
bances in the remodeling process of this nature can lead to metabolic bone diseases. One such
disturbance caused by oxidative stress, shown to control the functions of both osteoclasts and
osteoblasts, may contribute to the pathogenesis of skeletal system including osteoporosis, the
most prevalent metabolic bone disease [16].
2.2. Prevalence of osteoporosis
Women over the age of 50 become susceptible to osteoporosis because of the loss of estrogen
at menopause [17]. As well, men’s susceptibility to osteoporosis is due to low levels of the sex
hormone testosterone [18-20]. In the past, a majority of men view osteoporosis as solely a
Topics in Osteoporosis118
“woman’s disease.” This is because men in their fifties do not experience the rapid loss of bone
mass that women do in the years following menopause, and therefore men osteoporosis does
not set in until later in life [21,22]. However, by age 65 to 70, men and women are losing bone
mass at the same rate [23]. The World Health Organization (WHO) aptly defined osteoporosis
as a systemic disease that is characterized by low bone mass and deterioration of the micro‐
architecture of bone, resulting in an increased risk of fracture. Bone mass or bone mineral
density (BMD) is measured using a dual-energy x-ray absorptiometry, or DXA, at various
skeletal sites, including the spine, hip and wrist [24].
2.3. Bone mineral density as predictor of osteoporosis
BMD is expressed as T-score which is a value compared to the expected value for young adults
of the same sex and race. WHO has established that for normal BMD, the T-score is between
standard deviation of +2.5 and -1.0; for osteopenia/low BMD, T-score is between -1.0 and -2.5,
inclusive; for osteoporosis, T-score is lower than -2.5 and for severe osteoporosis,T-score is
lower than -2.5 with the presence of one or more fragility fractures [25]. Thus BMD values can
identify osteoporosis, determine the risk for fractures (broken bones), and measure the
response to osteoporosis treatment [26]. In the case of severe osteoporosis, minimal trauma
such as a minor fall or just a hug from a loved one can result to fragility fracture. Fragility
fracture is defined by WHO as “a fracture caused by injury that would be insufficient to cause
fracture normally. The spine, hip and distal forearm are the most common sites of fragility
fracture [27]. Some doctors recommend that people be tested on a regular basis for bone loss.
For women, those tests should begin after menopause. For men, they should begin after the
age of sixty-five. Such tests are important since there are seldom other signs of osteoporosis.
Therefore, those who have a higher rate of bone loss and are at higher risk for a fracture need
a better diagnostic tool. Recently, the WHO introduced a prognostic tool to evaluate fracture
risk of patients called the FRAX® [28]. The FRAX tool takes into account country, bone mineral
density of the hip (when available), age, sex, and 8 clinical risk factors to calculate the 10-year
probability of a major osteoporotic fracture and the 10-year probability of a hip fracture [29].
It assesses the 10-year risk of osteoporosis based on individual patient models that combines
clinical risk factors (CRF) as well as BMD at the femoral neck [30].
2.4. Bone turnover markers for detecting osteoporosis
During bone remodeling in healthy young adult, bone formation by osteoblasts equals bone
resorption by osteoclasts. However In postmenopausal bone loss, the remodeling process
becomes significantly more active with a primary increase in bone resorption and a corre‐
sponding, but an insufficient increase in bone formation [31]. Enzymes and/or other proteins
are released into the blood that are considered to reflect either bone formation or bone
resorption [32] and are termed as bone turnover markers. Molecular markers of bone turnover
have been developed as a product of bone remodeling [31] in the diagnostic and therapeutic
assessment of metabolic bone disease [33]. They are now used for the individual monitoring
of osteoporotic patients treated with antiresorptive agents [34]. Specific and sensitive assess‐
ment of the rate of bone formation and bone resorption and prediction of fracture [35] can now
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stopping the resoption of bone and preventing osteoporosis in women, are associated with a
number of side effects [11,12]. The side effects have been alarming a number of women with
osteoporosis in such a way that they are now resorting to other mode of treatment, including
that from natural food components. Our laboratory has carried out studies on the use of
antioxidants such as lycopene and polyphenols as possible alternatives and/or complementa‐
ries to drugs in the treatment and prevention of osteoporosis. This chapter will include an
overview on osteoporosis, the role of oxidative stress in bone cells osteoclasts and osteoblasts,
oxidative stress as a risk factor in the development of osteoporosis and a review of studies on
the use of antioxidants in counteracting oxidative stress in the prevention of osteoporosis.
These topics should put our research in perspective and offer a rationale to our study ap‐
proaches. Finally we will highlight our pioneering studies on the effects of the lipid-soluble
antioxidant lycopene and the water-soluble antioxidant polyphenols present in a nutritional
supplement in an in vitro cultures of osteoblasts and osteoclasts and our clinical studies in the
prevention of risk for osteoporosis in postmenopausal women.
2. Osteoporosis — Overview
2.1. Bone cells involved in the development of osteoporosis
Bone as a dynamic tissue continuously renews itself throughout life by the process of bone
remodeling carried out by a functional and anatomic structure known as the basic multicellular
unit (BMU) that requires the coordinated action of three major types of bone cells: osteoclasts,
osteoblasts and osteocytes [13,14]. The remodeling process is the result of interactions between
these cells and multiple molecular agents, including hormones, growth factors, and cytokines.
Bone remodeling is a physiological process that follows a time sequence lasting approximately
six months wherein osteoclasts eliminate old or damaged bone which is subsequently replaced
with new bone formed by osteoblasts, while the osteocytes functions in the transduction of
signals necessary to sustain mechanical loads. The coupled process of bone formation and bone
resorption in mature, healthy bone is tightly regulated and maintained in order to prevent a
significant alterations in bone mass or mechanical strength after each remodeling cycle [14,15].
At menopause when estrogen production is decreased, the increase in resorption cavities due
to increased bone resorption, but insufficient increase in bone formation, results to incomplete
filling of resorption cavities with new bone leading to a permanent loss of bone mass. Distur‐
bances in the remodeling process of this nature can lead to metabolic bone diseases. One such
disturbance caused by oxidative stress, shown to control the functions of both osteoclasts and
osteoblasts, may contribute to the pathogenesis of skeletal system including osteoporosis, the
most prevalent metabolic bone disease [16].
2.2. Prevalence of osteoporosis
Women over the age of 50 become susceptible to osteoporosis because of the loss of estrogen
at menopause [17]. As well, men’s susceptibility to osteoporosis is due to low levels of the sex
hormone testosterone [18-20]. In the past, a majority of men view osteoporosis as solely a
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“woman’s disease.” This is because men in their fifties do not experience the rapid loss of bone
mass that women do in the years following menopause, and therefore men osteoporosis does
not set in until later in life [21,22]. However, by age 65 to 70, men and women are losing bone
mass at the same rate [23]. The World Health Organization (WHO) aptly defined osteoporosis
as a systemic disease that is characterized by low bone mass and deterioration of the micro‐
architecture of bone, resulting in an increased risk of fracture. Bone mass or bone mineral
density (BMD) is measured using a dual-energy x-ray absorptiometry, or DXA, at various
skeletal sites, including the spine, hip and wrist [24].
2.3. Bone mineral density as predictor of osteoporosis
BMD is expressed as T-score which is a value compared to the expected value for young adults
of the same sex and race. WHO has established that for normal BMD, the T-score is between
standard deviation of +2.5 and -1.0; for osteopenia/low BMD, T-score is between -1.0 and -2.5,
inclusive; for osteoporosis, T-score is lower than -2.5 and for severe osteoporosis,T-score is
lower than -2.5 with the presence of one or more fragility fractures [25]. Thus BMD values can
identify osteoporosis, determine the risk for fractures (broken bones), and measure the
response to osteoporosis treatment [26]. In the case of severe osteoporosis, minimal trauma
such as a minor fall or just a hug from a loved one can result to fragility fracture. Fragility
fracture is defined by WHO as “a fracture caused by injury that would be insufficient to cause
fracture normally. The spine, hip and distal forearm are the most common sites of fragility
fracture [27]. Some doctors recommend that people be tested on a regular basis for bone loss.
For women, those tests should begin after menopause. For men, they should begin after the
age of sixty-five. Such tests are important since there are seldom other signs of osteoporosis.
Therefore, those who have a higher rate of bone loss and are at higher risk for a fracture need
a better diagnostic tool. Recently, the WHO introduced a prognostic tool to evaluate fracture
risk of patients called the FRAX® [28]. The FRAX tool takes into account country, bone mineral
density of the hip (when available), age, sex, and 8 clinical risk factors to calculate the 10-year
probability of a major osteoporotic fracture and the 10-year probability of a hip fracture [29].
It assesses the 10-year risk of osteoporosis based on individual patient models that combines
clinical risk factors (CRF) as well as BMD at the femoral neck [30].
2.4. Bone turnover markers for detecting osteoporosis
During bone remodeling in healthy young adult, bone formation by osteoblasts equals bone
resorption by osteoclasts. However In postmenopausal bone loss, the remodeling process
becomes significantly more active with a primary increase in bone resorption and a corre‐
sponding, but an insufficient increase in bone formation [31]. Enzymes and/or other proteins
are released into the blood that are considered to reflect either bone formation or bone
resorption [32] and are termed as bone turnover markers. Molecular markers of bone turnover
have been developed as a product of bone remodeling [31] in the diagnostic and therapeutic
assessment of metabolic bone disease [33]. They are now used for the individual monitoring
of osteoporotic patients treated with antiresorptive agents [34]. Specific and sensitive assess‐
ment of the rate of bone formation and bone resorption and prediction of fracture [35] can now
Oxidative Stress and Antioxidants in the Risk of Osteoporosis — Role of the Antioxidants Lycopene and Polyphenols
http://dx.doi.org/10.5772/54703
119
be possible using commercially available biochemical markers [36]. It remained to be seen
whether bone turnover markers might contribute a useful independent risk factor for inclusion
in FRAX [30]. The bone turnover markers we used for our clinical studies were crosslinked N-
telopeptide of type I collagen (NTx) [37-39] and crosslinked C-telopeptide of type I collagen
(CTx) [40,41] as bone resorption markers and bone alkaline phosphatase (BAP) [37-39] and
Procollagen type I N-terminal propeptide (PINP) [40,41] for a measure of bone formation in
the serum of participants.
Although BMD is considered the best parameter for determining the osteoporotic status of
men and women, BMD is static and cannot predict changes that may occur post-measurement
[42]. As well, changes in BMD occur slowly and can take up to one to two years to be detected
during the course of therapy [43,44]. An alternative or additional parameters now measured
clinically as either formation or resorption markers in the urine or serum of participants are
bone turnover markers which can reveal changes much earlier in the course of therapy
compared to changes in BMD [34]. When combined with BMD measurement, changes in bone
turnover markers have been significantly linked to fracture risk due to a significant positive
correlation between high bone turnover markers and loss of BMD [35]. Bone turnover markers
are therefore very useful in assessing treatment protocol for a short duration period, e.g., 3 to
6 months. Measurement of bone turnover markers was therefore utilized in our clinical study
during which postmenopausal women were given the antioxidant lycopene for 3 months
[37-39] and in another study during which nutritional supplement greens+bone builderTM were
administered for a period of eight weeks [40,41]. As will be reviewed in later sections, during
the short period of treatment, positive changes were measured that correlated decreased bone
resorption markers with decreases in oxidative stress parameters and thereby to decrease of
risk for osteoporosis in postmenopausal women.
2.5. Risk factors of osteoporosis
Some of the risk factors for osteoporosis [45,46] are presented in Table 1 [47]. The risk factors
that are of interest in our studies are oxidative stress-generating factors, including smoking,
alcohol intake, low antioxidant status, nutrition deficiency, excessive sports activity and
excessive caffeine intake. Oxidative stress will be reviewed in detail below.
2.6. Prevention and treatment of osteoporosis
Up until 10 years ago, the first line of treatment for women who have gone through menopause
and was diagnosed with osteoporosis was hormone replacement therapy (HRT). However, re‐
sults of the Women’s Health Initiative (WHI) warned women that HRT leads to higher risks for
breast cancer, cardiovascular events, blood clots, cognitive decline, and more [10]. This treat‐
ment for osteoporosis has since been discontinued and is prescribed only for a short period of
time to alleviate hot flashes in menopausal women [48]. A wide range of pharmaceuticals are
available for the treatment of osteoporosis. The current antiresorptive treatments approved by
the Food and Drug Administration (FDA) include a number of bisphosphonates under specific
trademarks which inhibit bone resorption [49]. Some are taken daily while others are formulat‐
ed for weekly, monthly or intermittent oral use [50,51]. The newer bisphophonates are injecta‐
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bles  such as  ibandronate  and Zoledronate  [51]  Other  drugs available  include calcitonin,
strontium renalate and the Selective Estrogen Receptor Modulator (SERM), Raloxifene (Evista)
[52]. Parathyroid hormone, PTH1-34 or teriparatide (Forteo), is the only anabolic agent current‐
ly approved for use by the FDA [24,53]. The new class of osteoporosis medications now ap‐
proved for use is a fully human monoclonal antibody (Denosumab) which bind to RANKL,
imitating the effects of OPG and acting as an inhibitor of RANKL [54]. A number of other drugs




















Table 1. Risk Factors for Osteoporosis
None of the drugs are without side effects. Side effects that emerged in clinical trials include
esophageal irritation with oral administration and acute phase response with iv treatment or
high-dose oral therapy. Uncommon side effects that have been noted with wide clinical use in‐
clude osteonecrosis of the jaw, musculoskeletal complaints, and atypical fractures. The num‐
bers of events are small, and a clear cause-and-effect relationship between these events and
bisphosphonate treatment has not been established. Because Bisphosphonates accumulate in
the bone, they create a reservoir leading to continued release from bone for months or years and
provide some residual antifracture reduction when treatment is stopped. For this reason, there
is a recommendation for a drug holiday after 5 –10 yr of bisphosphonate treatment [12,55]. The
length of the holiday is based on fracture risk and previous duration of treatment and BMD sta‐
tus. Studies with risedronate and alendronate suggest that if treatment is stopped after 3–5 yr,
there is persisting antifracture efficacy, at least for 1–2 yr. For those who are not on holiday, the
consensus from expert panels [12] suggest not stopping the use of drug since the side effects are
often rare, and that the benefits outweigh the side effects. In the balance, most individuals who
have osteoporosis are much better taking an osteoporosis medication [11].
2.7. Alternative approach to prevention and treatment of osteoporosis
Considering the possible adverse side effects of HRT and the ever increasing reports on the
side effects of bisphosphonates in the management of postmenopausal osteoporosis, there is
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the short period of treatment, positive changes were measured that correlated decreased bone
resorption markers with decreases in oxidative stress parameters and thereby to decrease of
risk for osteoporosis in postmenopausal women.
2.5. Risk factors of osteoporosis
Some of the risk factors for osteoporosis [45,46] are presented in Table 1 [47]. The risk factors
that are of interest in our studies are oxidative stress-generating factors, including smoking,
alcohol intake, low antioxidant status, nutrition deficiency, excessive sports activity and
excessive caffeine intake. Oxidative stress will be reviewed in detail below.
2.6. Prevention and treatment of osteoporosis
Up until 10 years ago, the first line of treatment for women who have gone through menopause
and was diagnosed with osteoporosis was hormone replacement therapy (HRT). However, re‐
sults of the Women’s Health Initiative (WHI) warned women that HRT leads to higher risks for
breast cancer, cardiovascular events, blood clots, cognitive decline, and more [10]. This treat‐
ment for osteoporosis has since been discontinued and is prescribed only for a short period of
time to alleviate hot flashes in menopausal women [48]. A wide range of pharmaceuticals are
available for the treatment of osteoporosis. The current antiresorptive treatments approved by
the Food and Drug Administration (FDA) include a number of bisphosphonates under specific
trademarks which inhibit bone resorption [49]. Some are taken daily while others are formulat‐
ed for weekly, monthly or intermittent oral use [50,51]. The newer bisphophonates are injecta‐
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proved for use is a fully human monoclonal antibody (Denosumab) which bind to RANKL,
imitating the effects of OPG and acting as an inhibitor of RANKL [54]. A number of other drugs
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bers of events are small, and a clear cause-and-effect relationship between these events and
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the bone, they create a reservoir leading to continued release from bone for months or years and
provide some residual antifracture reduction when treatment is stopped. For this reason, there
is a recommendation for a drug holiday after 5 –10 yr of bisphosphonate treatment [12,55]. The
length of the holiday is based on fracture risk and previous duration of treatment and BMD sta‐
tus. Studies with risedronate and alendronate suggest that if treatment is stopped after 3–5 yr,
there is persisting antifracture efficacy, at least for 1–2 yr. For those who are not on holiday, the
consensus from expert panels [12] suggest not stopping the use of drug since the side effects are
often rare, and that the benefits outweigh the side effects. In the balance, most individuals who
have osteoporosis are much better taking an osteoporosis medication [11].
2.7. Alternative approach to prevention and treatment of osteoporosis
Considering the possible adverse side effects of HRT and the ever increasing reports on the
side effects of bisphosphonates in the management of postmenopausal osteoporosis, there is
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an increasing demand for complementary and alternative medicine (CAM) for the prevention
and treatment of osteoporosis [56]. CAM is the term for medical practices, services and
products that are not a part of standard care. Some of the approaches include exercise,
acupuncture, diet, herbs rich in polyphenols and nutritional supplements including calcium,
zinc, magnesium boron and other vitamins and minerals. Recent dietary guidelines for the
prevention of chronic diseases have recommended an increase in the consumption of fruits
and vegetables worldwide [57] that are good sources of dietary antioxidants [58]. The beneficial
effects of antioxidants in bone health and osteoporosis are demonstrated epidemiologically
and through clinical intervention. Given that many nutrients have been identified as being
beneficial to bone health [59,60], there is strong scientific support for the potential benefits of
incorporating therapeutic nutritional interventions with contemporary pharmaceutical
treatments [61]. Diet is now recognized as an important life-style factor in the management of
bone health [62]. As will be reviewed in this chapter, our clinical studies on lycopene treatment
and nutritional supplements containing polyphenols and other nutritional components
showed positive results on bone health.
3. Oxidative stress
Oxidative stress is caused by reactive oxygen species (ROS) which are the main by-products
formed in the cells of aerobic organisms that can initiate autocatalytic reactions in such a way
that the target molecules gets converted into free radicals causing a chain of damage [63]. There
is ample evidence to show that oxidative stress induced by ROS increases the rate of bone loss
and is therefore a risk factor for osteoporosis. Epidemiological evidence in humans and studies
in animals indicate that aging and the associated increase in ROS are responsible for bone loss
[64]. As will be reviewed in later sections, oxidative stress is associated with the activity and
function of both the osteoblasts and osteoclasts cells, the two major bone cells involved in the
pathogenesis of osteoporosis.
Oxidative stress results from the weakening of antioxidant defense or an over production of
ROS in the body. ROS contains one or more unpaired electrons, a state that makes them highly
reactive as they seek out another electron to fill their orbital and stabilize their electron balance
[65]. Therefore, ROS are a family of highly reactive, oxygen-containing molecules and free
radicals, including hydroxyl (OH –), superoxide radicals (O2 –), hydrogen peroxide (H2O2),
singlet oxygen, and lipid peroxides [66]. ROS have an extremely short half-life and are difficult
to measure in humans, but it is possible to measure the damage they cause to protein, lipids,
and DNA and the damage is manifested as chronic diseases including osteoporosis [67]. This
can occur by the induction of apoptosis, reduction of cellular proliferation, cell cycle arrest and
modulation of cellular differentiation [68]. The major intracellular sites for the generation of
ROS are via electron transport chains in the mitochondria, endoplasmic reticulum and nuclear
membranes [69]. Oxidative stress may result from normal metabolic activity [70]; during acute
or chronic immune responses [71]; lifestyle factors such as cigarette smoke [72,73], high alcohol
intake [74,75], low antioxidant status [76], nutrition deficiency [74] excessive sports activity
[77], excessive caffeine [78]; and environmental factors such as ultraviolet radiation, chemicals,
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pollution and toxins [79]. ROS production increases with age [80,81] and is associated with
several chronic diseases including osteoporosis.
4. Antioxidants
Under normal physiological conditions, the cells can fight free radical attack or oxidative stress
by promoting antioxidant defenses. A number of endogenous defense mechanisms are present
in the body, including the metal chelating proteins and the endogenous antioxidant enzymes
catalase (CAT), glutathione peroxidase (GPx) and superoxide dismutase (SOD). [82]. Exoge‐
nous antioxidants come from dietary sources present in fruits and vegetables containing
several phytonutrient antioxidants such as the carotinoids potent antioxidant lipid-soluble
lycopene; the water-soluble antioxidant polyphenols; and vitamins such as C and E [83]. In
cases where the endogenous antioxidants or antioxidants from diet fail to prevent oxidative
damage, the repair antioxidants come into play which include DNA repair enzymes, lipase,
protease and transferase [69]. When antioxidants loses its fight with oxidative stress, diseases
associated with oxidative stress develop, which include cardiovascular disease, cancer,
diabetes, neurological diseases and osteoporosis [84].
The phytochemical antioxidants that are naturally present in plant- and animal-derived foods
include the carotenoids, which are lipid-soluble, to which the potent antioxidant lycopene
belongs and the water-soluble antioxidants such as polyphenols [85]. Figure 1 is a cartoon
depicting the production of oxidative stress from ROS, the damaging effects they exert on
DNA, lipid and protein which subsequently leads to chronic diseases and the protection
afforded by antioxidants.
Figure 1. Oxidative Stress/Antioxidants & Chronic Diseases
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4.1. Lycopene, a carotinoid lipid-soluble antioxidant
Lycopene is a potent antioxidant that is not synthesized in the body. It is a carotenoid acyclic
isomer of ß-carotene, with no vitamin A activity [86]. It is a highly unsaturated, straight-
chained hydrocarbon containing a total of 13 double bonds, of which 11 are conjugated, making
it one of the most potent antioxidants [84,87]. The singlet oxygen-quenching ability of lycopene
is twice that of ß-carotene and 10 times that of α-tocopherol [88]. The chemistry and antioxidant
properties of lycopene have been comprehensively reviewed [87]. Other than from tomatoes
and processed tomato, the dietary lycopene source of 85% of North Americans, lycopene can al‐
so be obtained from watermelon, pink guavas, and pink grapefruit [85]. Lycopene in an all-
trans configuration such as that found in raw tomatoes, is not readily absorbed. Lycopene is
absorbed more efficiently from processed tomato products than from raw tomatoes because it
is converted from the all-trans to the cis-isomeric configuration with heat processing [89,90].
Since lycopene is a lipid-soluble compound that is absorbed via a chylomicron-mediated mech‐
anism [91], the presence of small amounts of lipids further enhance its absorption [92]. The
health benefits of lycopene may be due to its potent antioxidant property, although there is evi‐
dence for other mechanisms such as its effects on gap junction communication [93] and cell cy‐
cling [94]. The reported average daily intake levels of lycopene vary considerably from country
to country, from 0.7 mg per day in Finland to 25 mg per day in Canada. However, a generally ac‐
cepted universal level of daily intake is 2.5 mg. There is no official recommended daily intake of
lycopene, but based on published research, a daily intake of 7 mg is suggested [95].
The role of lycopene in the prevention of human diseases is supported by a number of evidence
[96]. Giovannicci was the first to publish the initial epidemiological observations suggesting
an inverse relationship between the intake of tomatoes and lycopene and the incidence of
prostate cancer [97]. Since then, there have been several epidemiological as well as clinical
intervention studies showing the relationship between lycopene intake and the prevention of
cancers at other sites, as well as coronary heart disease, hypertension, diabetes, macular
degenerative disease, male infertility, and neurodegenerative disease [84]. The role of lycopene
in bone health has so far been based on its potent antioxidant properties, the well known role
of oxidative stress in bone health, and the limited studies on the effects of lycopene in bone
cells in culture (see below) and more recently, the results of epidemiological studies [39,98].
To date our clinical intervention studies at St. Michael’s Hospital on the role of lycopene and
elucidation of its mechanism in lowering the risk for osteoporosis in postmenopausal women
(aged 50 to 60 years) are so far the only studies reported in the literature.
4.2. Polyphenols, the water-soluble antioxidant
Polyphenols are a class of water-soluble molecules naturally found in plants. They are defined
as compounds having molecular masses ranging from 500 to 3000–4000 Da and possessing 12
to 16 phenolic hydroxy groups on five to seven aromatic rings per 1000 Da of relative molecular
mass [99]. It is estimated that there are 10,000 different phytonutrients (phyto, meaning from
plants). To date, over 8000 polyphenols have been identified [100]. Polyphenols can be divided
into 2 main groups: flavonoids and non-flavonoids [101-103]. The health benefits associated
with fruits, vegetables, red wine, tea, and Mediterranean diets are probably linked to the
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polyphenol antioxidants they contain [59,104,105]. The polyphenols of interest in our study
are a mixture of flavonoids such as quercetin, apigenin, kaempferol and luteolin present in the
supplement greens+TM [106]. greens+TM in combination with another supplement, bone
builderTM, were used in our study on osteoblasts cells and in clinical intervention studies on
the prevention of risk of osteoporosis in postmenopausal women. Studies on polyphenols and
bone will be reviewed in later sections.
5. Studies on the damaging effects of oxidative stress and the beneficial
effects of antioxidants
(Studies involving lycopene and polyphenols will be reviewed at a later section)
5.1. Studies on osteoblasts
The evidence being reported on the role of oxidative stress in osteoblasts has increased
exponentially. Up until 2002, only a few studies were reported. Thus, it was reported that
treatment of rat osteosarcoma ROS 17/2.8 cells with tumor necrosis factor-alpha (TNF-a)
suppressed bone sialoprotein (BSP) gene transcription through a tyrosine kinase-dependent
pathway that generates ROS [107]. Osteoblasts can be induced to produce intracellular ROS
[108,109], which can cause a decrease in alkaline phosphatase (ALP) activity that is partially
inhibited by vitamin E and cause cell death [108,109]. The intracellular calcium (Ca++) activity
in osteoblasts is modulated by H2O2 by increasing Ca++ release from the intracellular Ca++
stores [110]. High concentrations of ROS can damage osteoblast cells to prevent normal growth
and development [111] and have been shown to induce osteoblast death [112]. In osteoblasts,
H2O2 has been shown to decrease cell growth, ALP activity, calcification, mineralization and
gene expression of osteogenic markers such as ALP, bone sailoprotein (BSP) and runt-related
transcription factor 2 (Runx2) [113,114]. More recently, Ueno et al induced oxidative stress by
adding 100 microM H2O2 to osteoblasts cultured from rat bone marrow, and showed that this
treatment substantially impaired the proliferation, differentiation, and mineralization and that
addition of the antioxidant N-acetyl cysteine into the culture restored these damages to a near
normal level [115]]. With their study on hydrogen sulphide, Xu et al concluded that hydrogen
sulfide (H2S) protected MC3T3-E1 osteoblastic cells via a MAPK (p38 and ERK1/2)-dependent
mechanism against hydrogen peroxide (H2O2)-induced oxidative injury that cause the
suppression of proliferation and differentiation of the cells [116].
More recently reported inducers of oxidative stress include Arsenic trioxide [117], Cobalt and
Chromium ion [118] and Vanadium Compounds [119].
In vitro studies suggest an important role for antioxidants in abrogating the effects of oxidative
stress on bone. Trolox, a water soluble vitamin E analogue, was shown to enhance ALP activity
in MC3T3-E1 osteoblast-like cells, thus enhancing osteoblast differentiation by decreasing the
generation of ROS [111]. The addition of metallothionein, a metal-chelating preventative anti‐
oxidant, to primary mouse bone marrow stromal cells impaired H2O2-stimulated NfκΒ signal‐
Oxidative Stress and Antioxidants in the Risk of Osteoporosis — Role of the Antioxidants Lycopene and Polyphenols
http://dx.doi.org/10.5772/54703
125
4.1. Lycopene, a carotinoid lipid-soluble antioxidant
Lycopene is a potent antioxidant that is not synthesized in the body. It is a carotenoid acyclic
isomer of ß-carotene, with no vitamin A activity [86]. It is a highly unsaturated, straight-
chained hydrocarbon containing a total of 13 double bonds, of which 11 are conjugated, making
it one of the most potent antioxidants [84,87]. The singlet oxygen-quenching ability of lycopene
is twice that of ß-carotene and 10 times that of α-tocopherol [88]. The chemistry and antioxidant
properties of lycopene have been comprehensively reviewed [87]. Other than from tomatoes
and processed tomato, the dietary lycopene source of 85% of North Americans, lycopene can al‐
so be obtained from watermelon, pink guavas, and pink grapefruit [85]. Lycopene in an all-
trans configuration such as that found in raw tomatoes, is not readily absorbed. Lycopene is
absorbed more efficiently from processed tomato products than from raw tomatoes because it
is converted from the all-trans to the cis-isomeric configuration with heat processing [89,90].
Since lycopene is a lipid-soluble compound that is absorbed via a chylomicron-mediated mech‐
anism [91], the presence of small amounts of lipids further enhance its absorption [92]. The
health benefits of lycopene may be due to its potent antioxidant property, although there is evi‐
dence for other mechanisms such as its effects on gap junction communication [93] and cell cy‐
cling [94]. The reported average daily intake levels of lycopene vary considerably from country
to country, from 0.7 mg per day in Finland to 25 mg per day in Canada. However, a generally ac‐
cepted universal level of daily intake is 2.5 mg. There is no official recommended daily intake of
lycopene, but based on published research, a daily intake of 7 mg is suggested [95].
The role of lycopene in the prevention of human diseases is supported by a number of evidence
[96]. Giovannicci was the first to publish the initial epidemiological observations suggesting
an inverse relationship between the intake of tomatoes and lycopene and the incidence of
prostate cancer [97]. Since then, there have been several epidemiological as well as clinical
intervention studies showing the relationship between lycopene intake and the prevention of
cancers at other sites, as well as coronary heart disease, hypertension, diabetes, macular
degenerative disease, male infertility, and neurodegenerative disease [84]. The role of lycopene
in bone health has so far been based on its potent antioxidant properties, the well known role
of oxidative stress in bone health, and the limited studies on the effects of lycopene in bone
cells in culture (see below) and more recently, the results of epidemiological studies [39,98].
To date our clinical intervention studies at St. Michael’s Hospital on the role of lycopene and
elucidation of its mechanism in lowering the risk for osteoporosis in postmenopausal women
(aged 50 to 60 years) are so far the only studies reported in the literature.
4.2. Polyphenols, the water-soluble antioxidant
Polyphenols are a class of water-soluble molecules naturally found in plants. They are defined
as compounds having molecular masses ranging from 500 to 3000–4000 Da and possessing 12
to 16 phenolic hydroxy groups on five to seven aromatic rings per 1000 Da of relative molecular
mass [99]. It is estimated that there are 10,000 different phytonutrients (phyto, meaning from
plants). To date, over 8000 polyphenols have been identified [100]. Polyphenols can be divided
into 2 main groups: flavonoids and non-flavonoids [101-103]. The health benefits associated
with fruits, vegetables, red wine, tea, and Mediterranean diets are probably linked to the
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polyphenol antioxidants they contain [59,104,105]. The polyphenols of interest in our study
are a mixture of flavonoids such as quercetin, apigenin, kaempferol and luteolin present in the
supplement greens+TM [106]. greens+TM in combination with another supplement, bone
builderTM, were used in our study on osteoblasts cells and in clinical intervention studies on
the prevention of risk of osteoporosis in postmenopausal women. Studies on polyphenols and
bone will be reviewed in later sections.
5. Studies on the damaging effects of oxidative stress and the beneficial
effects of antioxidants
(Studies involving lycopene and polyphenols will be reviewed at a later section)
5.1. Studies on osteoblasts
The evidence being reported on the role of oxidative stress in osteoblasts has increased
exponentially. Up until 2002, only a few studies were reported. Thus, it was reported that
treatment of rat osteosarcoma ROS 17/2.8 cells with tumor necrosis factor-alpha (TNF-a)
suppressed bone sialoprotein (BSP) gene transcription through a tyrosine kinase-dependent
pathway that generates ROS [107]. Osteoblasts can be induced to produce intracellular ROS
[108,109], which can cause a decrease in alkaline phosphatase (ALP) activity that is partially
inhibited by vitamin E and cause cell death [108,109]. The intracellular calcium (Ca++) activity
in osteoblasts is modulated by H2O2 by increasing Ca++ release from the intracellular Ca++
stores [110]. High concentrations of ROS can damage osteoblast cells to prevent normal growth
and development [111] and have been shown to induce osteoblast death [112]. In osteoblasts,
H2O2 has been shown to decrease cell growth, ALP activity, calcification, mineralization and
gene expression of osteogenic markers such as ALP, bone sailoprotein (BSP) and runt-related
transcription factor 2 (Runx2) [113,114]. More recently, Ueno et al induced oxidative stress by
adding 100 microM H2O2 to osteoblasts cultured from rat bone marrow, and showed that this
treatment substantially impaired the proliferation, differentiation, and mineralization and that
addition of the antioxidant N-acetyl cysteine into the culture restored these damages to a near
normal level [115]]. With their study on hydrogen sulphide, Xu et al concluded that hydrogen
sulfide (H2S) protected MC3T3-E1 osteoblastic cells via a MAPK (p38 and ERK1/2)-dependent
mechanism against hydrogen peroxide (H2O2)-induced oxidative injury that cause the
suppression of proliferation and differentiation of the cells [116].
More recently reported inducers of oxidative stress include Arsenic trioxide [117], Cobalt and
Chromium ion [118] and Vanadium Compounds [119].
In vitro studies suggest an important role for antioxidants in abrogating the effects of oxidative
stress on bone. Trolox, a water soluble vitamin E analogue, was shown to enhance ALP activity
in MC3T3-E1 osteoblast-like cells, thus enhancing osteoblast differentiation by decreasing the
generation of ROS [111]. The addition of metallothionein, a metal-chelating preventative anti‐
oxidant, to primary mouse bone marrow stromal cells impaired H2O2-stimulated NfκΒ signal‐
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ling, consequently preventing any inhibition of osteoblast differentiation [114]. Osteoblasts
have been shown to produce antioxidants such as GPx which can protect against the damaging
effects of ROS [120]. In MC3T3-E1 osteoblast-like cells, treatment with H2O2 to induce oxidative
stress was associated with the prolonged up-regulation in gene expression of the transcription
factor nuclear factor E2 p45-related factor 2 (Nrf2), which regulates antioxidant enzymes by as‐
sisting with recognition of the antioxidant-response element [113]. Using xanthine/xanthine
oxidase to generate ROS, Fatokun et al.[120] showed that damage induced by ROS, as evi‐
denced by decreased cell viability, was prevented by CAT in MC3T3-E1 osteoblast-like cells.
This effect is attributed to the ability of CAT to neutralize H2O2 [120]. Newer mechanism of ac‐
tion of ROS is beginning to come to light. It has been shown that increased ROS production di‐
verts the limited pool of β-catenin from TCF/LEF to FOXO-mediated transcription, converting
the beneficial effects of Wnt/β-catenin on bone, eventually leading to decrease osteoblasts num‐
ber and activity and eventually leading to osteoporosis [121-124].
In recent years, the number of antioxidants reported to prevent oxidative stress in osteoblasts
are as follows: Tetrahydrostibene [125,126], Curculigoside [127], Green tea [128], Simvastatin
[129], N-acetylcysteine [115], flavonoids from parsimmon [130], prevastatin [131], Linarin
[132], Panaxnotaginseng saponin [133], crysoeriol from surya cilliata leaves [134], quercetin
[135] Drynaria fortunei [136], cathamus tinctorium flower extract [137], estrogen [138],
diazoxide, atractylodes japonica root extract [139]. and Myrcetin, a naturally occurring
flavonoid [140]. The mechanism of osteblastic defense against oxidative stress was shown to
involve β-Catenin which serves as a cofactor of the forkhead box O (FOXO) transcription
factors [121].
5.2. Studies on osteoclasts
The mechanisms involved in the differentiation of osteoclasts and their ability to resorb bone
is beginning to be unraveled, and evidence shows that ROS may be involved in this process
[141]. Superoxide was detected both at the osteoclast-bone interface and intracellularly using
nitroblue tetrazolium (NBT), which is reduced to purple-colored formazan by ROS, suggesting
the participation of superoxide in bone resorption [142]. Both the H2O2 produced by endothelial
cells [143] intimately associated with osteoclasts and the H2O2 that is produced by osteoclasts
[144] increase osteoclastic activity and bone resorption. H2O2 may also be involved in osteoclast
motility [144], differentiation of osteoclast precursors [145] and the regulation of osteoclast
formation [146]. Osteoclastic superoxide is produced by NADPH oxidase [147]. The degrada‐
tion of collagen and other proteins is caused by highly destructive ROS as a result of the
reaction of H2O2 with tartrate-resistant acid phosphatase (TRAP), found on the surface of
osteoclasts [148]. 1,25-Dihydroxyvitamin D3 had a direct nongenomic effect on the generation
of superoxide anion (O2_), which was inhibited by estrogen [149]. Estrogen has been reported
to have an antioxidant property [150]. Hormones known to stimulate bone resorption, such as
parathyroid hormone (PTH) [151] and 1,25(OH)2D3, have stimulatory effects on ROS produc‐
tion in osteoclasts [149] and hormones known to have inhibitory effects on bone resorption,
such as calcitonin, inhibit ROS production [151].
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Antioxidants also play a role in osteoclast activity. Osteoclasts produce the antioxidant enzyme
SOD in the plasma membrane [152]. ROS production in osteoclasts was inhibited after treating
the cells with antioxidant enzymes such as SOD [142] and catalase [146]. ROS production in
osteoclasts was also inhibited by estrogen [149], the superoxide scavenger deferoxamine
mesylatemanganese complex [153], pyrrolidine dithiocarbamate (PDTC), and N-acetyl
cysteine (NAC) [154].
Other more recent antioxidant shown to affect osteoclasts include polyphenol extracts from
dried plums [155], curcumerin [156], ascorbic acid [157], salvia miltorrhiza [158], coffee
diterpene Kahweol [159], delthametrin [160], to name a few. The use of antioxidants from
natural sources, such as fruits and vegetables, could be another way of inhibiting ROS. The
use of lycopene and polyphenols in this regard is reviewed in a later section.
5.3. Studies of on animal
OVXed rats were treated with Strontium ranelate and at the end of the treatment, oxidative
parameters including malondialdehyde (MDA) level, superoxide dismutase (SOD), gluta‐
thione peroxidase (GSH-Px) and catalase (CAT) activities were determined by biochemical
analysis methods. Their results showed that Sr has preventive effect on oxidative damage in
ovariectomized rats [161]. Yin et al showed that protection against osteoporosis by statins is
linked to a reduction of oxidative stress and restoration of NO formation in aged and ovar‐
iectomized rats [162]. To investigate the anti-osteoporosis effect of Rhizoma Drynariae (RD),
an effectively traditional Chinese medicine and its action mechanism, Liu et al administered
with or without RD extract at a therapeutic dose to a group of rats for 12 weeks and showed
that the anti-osteoporosis effect of RD has been reliably confirmed by the metabonomics
method and that the osteoporosis might be prevented by RD via, among other things, through
intervening antioxidant-oxidation balance in vivo in rats [163]. Treatment of OVXed rats with
Salvia miltiorrhiza ethanol extract significantly ameliorated the decrease in BMD and trabec‐
ular bone mass according to DEXA and trabecular bone architecture analysis of trabecular
bone structural parameters by μ-CT scanning. As well, SM decreased the released TRAP-5b,
an osteoclast activation marker and oxidative stress parameters including MDA and NO
induced by OVX [164]. Oxidative stress (OS) was assessed 100 days postovariectomy by
measuring the activity of several enzymes, including catalase (CAT), superoxide dismutase
(SOD), and glutathione peroxidase, as well as the concentrations of malondialdehyde (MDA),
nitric oxide (NO), and total sulfhydryl groups in plasma and bone homogenates of OVXed rats
treated with or without vitamin C. Their results suggest that ovariectomy may produce
osteoporosis and oxidative stress in females, and vitamin C supplementation may provide
alterations regarding improvement in OS and BMD values [165]. Curcumin was shown to
inhibit OVX-induced bone loss, at least in part by reducing osteoclastogenesis as a result of
increased antioxidant activity and impaired RANKL signaling [166]. In order to investigate
the pathologic significance of oxidative stress in bones, Nojiri et al showed that mice deficient
in cytoplasmic copper/zinc superoxide dismutase exhibited a distinct weakness in bone
stiffness and decreased BMD, aging-like changes in collagen cross-linking, and transcriptional
alterations in the genes associated with osteogenesis. They further demonstrated that intra‐
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ling, consequently preventing any inhibition of osteoblast differentiation [114]. Osteoblasts
have been shown to produce antioxidants such as GPx which can protect against the damaging
effects of ROS [120]. In MC3T3-E1 osteoblast-like cells, treatment with H2O2 to induce oxidative
stress was associated with the prolonged up-regulation in gene expression of the transcription
factor nuclear factor E2 p45-related factor 2 (Nrf2), which regulates antioxidant enzymes by as‐
sisting with recognition of the antioxidant-response element [113]. Using xanthine/xanthine
oxidase to generate ROS, Fatokun et al.[120] showed that damage induced by ROS, as evi‐
denced by decreased cell viability, was prevented by CAT in MC3T3-E1 osteoblast-like cells.
This effect is attributed to the ability of CAT to neutralize H2O2 [120]. Newer mechanism of ac‐
tion of ROS is beginning to come to light. It has been shown that increased ROS production di‐
verts the limited pool of β-catenin from TCF/LEF to FOXO-mediated transcription, converting
the beneficial effects of Wnt/β-catenin on bone, eventually leading to decrease osteoblasts num‐
ber and activity and eventually leading to osteoporosis [121-124].
In recent years, the number of antioxidants reported to prevent oxidative stress in osteoblasts
are as follows: Tetrahydrostibene [125,126], Curculigoside [127], Green tea [128], Simvastatin
[129], N-acetylcysteine [115], flavonoids from parsimmon [130], prevastatin [131], Linarin
[132], Panaxnotaginseng saponin [133], crysoeriol from surya cilliata leaves [134], quercetin
[135] Drynaria fortunei [136], cathamus tinctorium flower extract [137], estrogen [138],
diazoxide, atractylodes japonica root extract [139]. and Myrcetin, a naturally occurring
flavonoid [140]. The mechanism of osteblastic defense against oxidative stress was shown to
involve β-Catenin which serves as a cofactor of the forkhead box O (FOXO) transcription
factors [121].
5.2. Studies on osteoclasts
The mechanisms involved in the differentiation of osteoclasts and their ability to resorb bone
is beginning to be unraveled, and evidence shows that ROS may be involved in this process
[141]. Superoxide was detected both at the osteoclast-bone interface and intracellularly using
nitroblue tetrazolium (NBT), which is reduced to purple-colored formazan by ROS, suggesting
the participation of superoxide in bone resorption [142]. Both the H2O2 produced by endothelial
cells [143] intimately associated with osteoclasts and the H2O2 that is produced by osteoclasts
[144] increase osteoclastic activity and bone resorption. H2O2 may also be involved in osteoclast
motility [144], differentiation of osteoclast precursors [145] and the regulation of osteoclast
formation [146]. Osteoclastic superoxide is produced by NADPH oxidase [147]. The degrada‐
tion of collagen and other proteins is caused by highly destructive ROS as a result of the
reaction of H2O2 with tartrate-resistant acid phosphatase (TRAP), found on the surface of
osteoclasts [148]. 1,25-Dihydroxyvitamin D3 had a direct nongenomic effect on the generation
of superoxide anion (O2_), which was inhibited by estrogen [149]. Estrogen has been reported
to have an antioxidant property [150]. Hormones known to stimulate bone resorption, such as
parathyroid hormone (PTH) [151] and 1,25(OH)2D3, have stimulatory effects on ROS produc‐
tion in osteoclasts [149] and hormones known to have inhibitory effects on bone resorption,
such as calcitonin, inhibit ROS production [151].
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Antioxidants also play a role in osteoclast activity. Osteoclasts produce the antioxidant enzyme
SOD in the plasma membrane [152]. ROS production in osteoclasts was inhibited after treating
the cells with antioxidant enzymes such as SOD [142] and catalase [146]. ROS production in
osteoclasts was also inhibited by estrogen [149], the superoxide scavenger deferoxamine
mesylatemanganese complex [153], pyrrolidine dithiocarbamate (PDTC), and N-acetyl
cysteine (NAC) [154].
Other more recent antioxidant shown to affect osteoclasts include polyphenol extracts from
dried plums [155], curcumerin [156], ascorbic acid [157], salvia miltorrhiza [158], coffee
diterpene Kahweol [159], delthametrin [160], to name a few. The use of antioxidants from
natural sources, such as fruits and vegetables, could be another way of inhibiting ROS. The
use of lycopene and polyphenols in this regard is reviewed in a later section.
5.3. Studies of on animal
OVXed rats were treated with Strontium ranelate and at the end of the treatment, oxidative
parameters including malondialdehyde (MDA) level, superoxide dismutase (SOD), gluta‐
thione peroxidase (GSH-Px) and catalase (CAT) activities were determined by biochemical
analysis methods. Their results showed that Sr has preventive effect on oxidative damage in
ovariectomized rats [161]. Yin et al showed that protection against osteoporosis by statins is
linked to a reduction of oxidative stress and restoration of NO formation in aged and ovar‐
iectomized rats [162]. To investigate the anti-osteoporosis effect of Rhizoma Drynariae (RD),
an effectively traditional Chinese medicine and its action mechanism, Liu et al administered
with or without RD extract at a therapeutic dose to a group of rats for 12 weeks and showed
that the anti-osteoporosis effect of RD has been reliably confirmed by the metabonomics
method and that the osteoporosis might be prevented by RD via, among other things, through
intervening antioxidant-oxidation balance in vivo in rats [163]. Treatment of OVXed rats with
Salvia miltiorrhiza ethanol extract significantly ameliorated the decrease in BMD and trabec‐
ular bone mass according to DEXA and trabecular bone architecture analysis of trabecular
bone structural parameters by μ-CT scanning. As well, SM decreased the released TRAP-5b,
an osteoclast activation marker and oxidative stress parameters including MDA and NO
induced by OVX [164]. Oxidative stress (OS) was assessed 100 days postovariectomy by
measuring the activity of several enzymes, including catalase (CAT), superoxide dismutase
(SOD), and glutathione peroxidase, as well as the concentrations of malondialdehyde (MDA),
nitric oxide (NO), and total sulfhydryl groups in plasma and bone homogenates of OVXed rats
treated with or without vitamin C. Their results suggest that ovariectomy may produce
osteoporosis and oxidative stress in females, and vitamin C supplementation may provide
alterations regarding improvement in OS and BMD values [165]. Curcumin was shown to
inhibit OVX-induced bone loss, at least in part by reducing osteoclastogenesis as a result of
increased antioxidant activity and impaired RANKL signaling [166]. In order to investigate
the pathologic significance of oxidative stress in bones, Nojiri et al showed that mice deficient
in cytoplasmic copper/zinc superoxide dismutase exhibited a distinct weakness in bone
stiffness and decreased BMD, aging-like changes in collagen cross-linking, and transcriptional
alterations in the genes associated with osteogenesis. They further demonstrated that intra‐
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cellular oxidative resulted in the decrease in osteoblast number and accompanied by suppres‐
sion of RANKL/M-CSF osteoclastogenic signaling in bone; treatment with an antioxidant,
vitamin C, effectively improved bone fragility and osteoblastic survival [167].
5.4. Epidemiological and clinical studies on osteoporosis
The detrimental effect of oxidative stress and the beneficial role of antioxidant in osteoporosis
have been reviewed [58,83,168,169]. There is now ample evidence to suggest that ROS-induced
oxidative stress is associated with the pathogenesis of osteoporosis. Thus, epidemiological
studies demonstrated the adverse effect on bone of oxidative stress produced during strenuous
exercise [170]; among heavy smokers [171] and that antioxidants including vitamin C, E and
β-carotene may counteract these adverse effects and reduce the risk of osteoporosis [170-173].
A study of severe osteoporotic syndrome in relatively young males showed evidence linking
osteoporosis to an increase in oxidative stress [174]. Maggio et al [175] demonstrated that
women with osteoporosis had markedly decreased plasma antioxidants. A biochemical link
between reduced bone density and increased oxidative stress biomarker 8-iso-prostaglandin
F alpha (8-iso-PGF) has been reported [176,177]. Positive correlation was found between the
severity of osteoporosis and the level of oxidative stress marker lactic acid in 2 men with
mitochondrial deletion (mtDNA) [178].
Evidence points to the fact that Postmenopausal women are more prone to osteoporosis due
to reduction in estrogen, but there is also ample evidence to support the theory that oxidative
stress which accompanies the reduction in estrogen level may be the cause of osteoporosis
[179]. Indeed, estrogen has been shown to have antioxidant properties [150]. Earlier reports
on the association of oxidative stress with osteoporosis were confined mainly to epidemio‐
logical studies. Vitamins C, E, and A, uric acid, the antioxidant enzymes SOD in plasma and
erythrocytes and GPx in plasma were consistently lower in osteoporotic than in control
subjects. An epidemiological study by Hahn et al [180] found that GPx activity was significantly
higher in postmenopausal women with osteopenia than that of postmenopausal women with
a normal BMD, likely as a primary defense against the high levels of H2O2 in osteopenic women
[180]. Osteoporotic women were found to have significantly depressed activities of CAT, GPx
and SOD, compared to those found in healthy control women [177,181,182]. Furthermore,
concentrations of the antioxidant enzymes SOD and CAT have been positively correlated with
BMD which demonstrates a link between antioxidant status and BMD in postmenopausal
women[182]. Surprisingly, a cross sectional analysis in healthy postmenopausal women aged
60-78 years revealed a negative association between 8-OH-dG levels and BMD of the lumbar
spine, total hip, femoral neck, and trochanter and positive association with type I collagen C-
telopeptide (ICTP) levels, showing that oxidative stress is associated with increased bone
resorption and low bone mass even in otherwise healthy women. Medications used to treat
postmenopausal osteoporosis such as HRT and Raloxifene [183] may act in part to decrease
oxidative stress by acting in part as antioxidants. A 3-month course of Raloxifene therapy
significantly decreased the lipid peroxidation and increased the CAT activity in women with
postmenopausal osteoporosis [177,181,182]. Raloxifene treatment for 12 months significantly
decreased protein oxidation in osteoporotic participants compared to matched, non-osteopor‐
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otic controls [183]. Supplementation of ascorbic acid and alpha-tocopherol was found useful
in preventing bone loss linked to oxidative stress in elderly [181].
Postmenopausal women with osteoporosis have been shown to have markedly reduced serum
concentrations of retinol, β-cryptoxanthin, zeaxanthin and α- and β-carotene, compared to
healthy postmenopausal women [175]. Overall carotenoid intake has been found to be
inversely associated with risk of fracture [184]. Sadly, the effect of β-carotene on the risk of
osteoporosis is still controversial. There are studies which suggest that β-carotene has benefi‐
cial effect on bone [98,185,186], while other studies suggest a null or even detrimental effect,
most probably due to its association with vitamin A [187].
In summary, the studies presented above provide evidence of the detrimental effects of
oxidative stress and beneficial effects of antioxidants on the risk of osteoporosis.
6. Studies on lycopene
The direct role of lycopene in osteoblasts and osteoclasts, the cells involved in the pathogenesis
of osteoporosis is now being unraveled. This involvement is further supported by both
epidemiological and clinical intervention with lycopene in postmenopausal women men who
are at risk of osteoporosis.
6.1. In vitro studies of lycopene in osteoblasts
Only few studies on the effects of lycopene in osteoblasts have been reported. This is most
likely because lycopene is not soluble in the culture medium and needed to be solubilized in
organic solvent before it can be added to the cell culture. In our study, we used lyc-o-mato
preparation that is partially dispersed in micelle form in water. When added to the human
osteoblast-like SaOS-2 cells, lycopene had a stimulatory effect on cell proliferation as well as
a stimulatory effect on alkaline phosphatase activity, a marker of osteoblastic differentiation
in more mature cells but, depending on the time of addition, it had an inhibitory or no effect
on younger SaOS-Dex cells. These findings comprised the first report on the effect of lycopene
on human osteoblasts [188]. In another study, the effect of lycopene on MC3T3 cells (the
osteoblastic cells of mice) was contrary to the findings of Kim et al. [188] in that lycopene had
an inhibitory effect on cell proliferation [189]. The discrepancy in the effects of lycopene on
cell proliferation could be a result of species differences, age of the cells when lycopene was
added or experimental conditions. Both studies, however, reported an effect of lycopene on
the differentiation of the cells by stimulating the alkaline phosphatase activity [188,189] and
gene expression of BSP [189]. The lycopene used in our study is the trans-configuration (95%
trans, 5% cis). Subsequently, we studied which configuration of lycopene will prevent the
damaging effect of oxidative stress as well as repair this damage in human osteoblast cultures.
Lycopene with varying content of cis- and trans- configuration (45:55, 28:72 or 5:95 cis:trans
lycopene) were added to cell cultures before and after challenging with H2O2 and the effect on
the generation of ROS and stimulation of mineralized bone nodule were assessed. Our results
demonstrated that the addition of H2O2 resulted in significant increase in generation of ROS
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cellular oxidative resulted in the decrease in osteoblast number and accompanied by suppres‐
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have been reviewed [58,83,168,169]. There is now ample evidence to suggest that ROS-induced
oxidative stress is associated with the pathogenesis of osteoporosis. Thus, epidemiological
studies demonstrated the adverse effect on bone of oxidative stress produced during strenuous
exercise [170]; among heavy smokers [171] and that antioxidants including vitamin C, E and
β-carotene may counteract these adverse effects and reduce the risk of osteoporosis [170-173].
A study of severe osteoporotic syndrome in relatively young males showed evidence linking
osteoporosis to an increase in oxidative stress [174]. Maggio et al [175] demonstrated that
women with osteoporosis had markedly decreased plasma antioxidants. A biochemical link
between reduced bone density and increased oxidative stress biomarker 8-iso-prostaglandin
F alpha (8-iso-PGF) has been reported [176,177]. Positive correlation was found between the
severity of osteoporosis and the level of oxidative stress marker lactic acid in 2 men with
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Evidence points to the fact that Postmenopausal women are more prone to osteoporosis due
to reduction in estrogen, but there is also ample evidence to support the theory that oxidative
stress which accompanies the reduction in estrogen level may be the cause of osteoporosis
[179]. Indeed, estrogen has been shown to have antioxidant properties [150]. Earlier reports
on the association of oxidative stress with osteoporosis were confined mainly to epidemio‐
logical studies. Vitamins C, E, and A, uric acid, the antioxidant enzymes SOD in plasma and
erythrocytes and GPx in plasma were consistently lower in osteoporotic than in control
subjects. An epidemiological study by Hahn et al [180] found that GPx activity was significantly
higher in postmenopausal women with osteopenia than that of postmenopausal women with
a normal BMD, likely as a primary defense against the high levels of H2O2 in osteopenic women
[180]. Osteoporotic women were found to have significantly depressed activities of CAT, GPx
and SOD, compared to those found in healthy control women [177,181,182]. Furthermore,
concentrations of the antioxidant enzymes SOD and CAT have been positively correlated with
BMD which demonstrates a link between antioxidant status and BMD in postmenopausal
women[182]. Surprisingly, a cross sectional analysis in healthy postmenopausal women aged
60-78 years revealed a negative association between 8-OH-dG levels and BMD of the lumbar
spine, total hip, femoral neck, and trochanter and positive association with type I collagen C-
telopeptide (ICTP) levels, showing that oxidative stress is associated with increased bone
resorption and low bone mass even in otherwise healthy women. Medications used to treat
postmenopausal osteoporosis such as HRT and Raloxifene [183] may act in part to decrease
oxidative stress by acting in part as antioxidants. A 3-month course of Raloxifene therapy
significantly decreased the lipid peroxidation and increased the CAT activity in women with
postmenopausal osteoporosis [177,181,182]. Raloxifene treatment for 12 months significantly
decreased protein oxidation in osteoporotic participants compared to matched, non-osteopor‐
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otic controls [183]. Supplementation of ascorbic acid and alpha-tocopherol was found useful
in preventing bone loss linked to oxidative stress in elderly [181].
Postmenopausal women with osteoporosis have been shown to have markedly reduced serum
concentrations of retinol, β-cryptoxanthin, zeaxanthin and α- and β-carotene, compared to
healthy postmenopausal women [175]. Overall carotenoid intake has been found to be
inversely associated with risk of fracture [184]. Sadly, the effect of β-carotene on the risk of
osteoporosis is still controversial. There are studies which suggest that β-carotene has benefi‐
cial effect on bone [98,185,186], while other studies suggest a null or even detrimental effect,
most probably due to its association with vitamin A [187].
In summary, the studies presented above provide evidence of the detrimental effects of
oxidative stress and beneficial effects of antioxidants on the risk of osteoporosis.
6. Studies on lycopene
The direct role of lycopene in osteoblasts and osteoclasts, the cells involved in the pathogenesis
of osteoporosis is now being unraveled. This involvement is further supported by both
epidemiological and clinical intervention with lycopene in postmenopausal women men who
are at risk of osteoporosis.
6.1. In vitro studies of lycopene in osteoblasts
Only few studies on the effects of lycopene in osteoblasts have been reported. This is most
likely because lycopene is not soluble in the culture medium and needed to be solubilized in
organic solvent before it can be added to the cell culture. In our study, we used lyc-o-mato
preparation that is partially dispersed in micelle form in water. When added to the human
osteoblast-like SaOS-2 cells, lycopene had a stimulatory effect on cell proliferation as well as
a stimulatory effect on alkaline phosphatase activity, a marker of osteoblastic differentiation
in more mature cells but, depending on the time of addition, it had an inhibitory or no effect
on younger SaOS-Dex cells. These findings comprised the first report on the effect of lycopene
on human osteoblasts [188]. In another study, the effect of lycopene on MC3T3 cells (the
osteoblastic cells of mice) was contrary to the findings of Kim et al. [188] in that lycopene had
an inhibitory effect on cell proliferation [189]. The discrepancy in the effects of lycopene on
cell proliferation could be a result of species differences, age of the cells when lycopene was
added or experimental conditions. Both studies, however, reported an effect of lycopene on
the differentiation of the cells by stimulating the alkaline phosphatase activity [188,189] and
gene expression of BSP [189]. The lycopene used in our study is the trans-configuration (95%
trans, 5% cis). Subsequently, we studied which configuration of lycopene will prevent the
damaging effect of oxidative stress as well as repair this damage in human osteoblast cultures.
Lycopene with varying content of cis- and trans- configuration (45:55, 28:72 or 5:95 cis:trans
lycopene) were added to cell cultures before and after challenging with H2O2 and the effect on
the generation of ROS and stimulation of mineralized bone nodule were assessed. Our results
demonstrated that the addition of H2O2 resulted in significant increase in generation of ROS
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(p<0.001), which long-term resulted in a decreased number and area of mineralized bone
nodules (both: p<0.001). Pre- and post-treatment with 45:55 or 28:72 cis:trans lycopene resulted
in significantly lower ROS generation (p<0.001) and higher mineralized bone nodule area
(p<0.05), compared to treatment with H2O2 alone, vehicle or 5:95 cis:trans lycopene. These
findings support the hypothesis that the cis isomers of lycopene are capable of preventing and
repairing the damaging effects of H2O2-induced oxidative stress on the formation of mineral‐
ized bone nodules (unpublished observation) [169,190].
6.2. In vitro studies of lycopene in osteoclasts
To date, there have been only 2 studies on the effects of lycopene in osteoclasts [191,192]. Rao
et al. cultured cells from bone marrow prepared from rat femur in 16 well, calcium phosphate-
coated OsteologicTM multi-test slides. Lycopene was added to the cells in the absence or
presence of the resorbing agent parathyroid hormone (PTH) (1-34) and mineral resorption,
TRAP+ multinucleated osteoclast formation, and NBT-staining were measured. Lycopene
inhibited TRAP+ multinucleated cell formation in both vehicle- and PTH-treated cultures. The
cells that were stained with the NBT reduction product formazan were decreased in number
after treatment with lycopene, indicating that lycopene inhibited the formation of ROS-
secreting osteoclasts [192]. The effect of lycopene on osteoclast formation and bone resorption
was also reported by Ishimi et al in murine osteoclasts formed in co-culture with calvarial
osteoblasts [191]. Their results differed from those of Rao et al [192] in that they found that
lycopene inhibited PTH-induced, but not basal, TRAP+ multinucleated cell formation.
Furthermore, they could not demonstrate any effect of lycopene on bone resorption. They also
did not study the effect of lycopene on ROS production.
6.3. Lycopene intervention studies in animals
Other than our intervention studies to be discussed in the next section, most of the intervention
studies with lycopene were carried out in animals. Liang et al investigated the beneficial effect
of lycopene on bone biomarkers in ovariectomized (OVX) rats. Their results showed that
administration of lycopene (20, 30 and 40 mg/kg b.w.) for 8 weeks to OVXed rats significantly
enhanced BMD, concluding that the consumption of lycopene may have the most protective
effect on bone in OVX [193]. Ke et al fed OVXed rats for 3 months with EM-X, an antioxidant
beverage derived from ferment of unpolished rice, sea weeds and papaya with combinations
of microorganisms and contains, among other things, lycopene. Results showed that rats
receiving EM-X for 3 months after sham operation or ovariectomy had increased bone density
of the middle of femur that was statistically significantly different from unreated rats [194].
6.4. Epidemiological studies on lycopene
A systematic review of the experimental studies on Mediterranean diet and disease prevention
was made and analyzed [195]. Although the Mediterrenean diet comprised of many different
food components, it is striking that one of the components is abundance of plant foods
including fruits, vegetables [195]. The two possible active components in its properties to
prevent diseases are lycopene [196] and polypenols [197]. Epidemiological evidence support
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the beneficial effects of tomatoes and tomato products in the prevention of osteoporosis in the
Mediterranean population [104].
The role of lycopene in the prevention of risk for osteoporosis has recently been reviewed [58,
83,168,169]. Maggio et al [175] and Yang et al [198] both demonstrated that serum lycopene
concentrations are lower in women with osteoporosis than in healthy women of the same age.
The antioxidant mechanistic effect of lycopene is demonstrated by Misra et al. who have shown
that HRT has the same antioxidant effects as lycopene in postmenopausal women by demon‐
strating that lipid peroxidation was significantly decreased while GSH significantly increased
by both [199]. Epidemiological studies revealed the relationship between lycopene and BMD
[185,186,200]. A cross-sectional and longitudinal analyses in men and women were carried out
to evaluate the associations between total and individual carotenoid intakes (a-carotene, β-
carotene, β-cryptoxanthin, lycopene, lutein and zeaxanthin) with BMD at the hip, spine, and
radial shaft and the 4-y change in BMD. Their analyses showed significant associations
between lycopene intake and 4-y change in lumbar spine BMD for women [200] protective
associations by total carotenoids against 4-y loss in trochanter BMD in men and in lumbar
spine in women [98]. On the other hand, radial BMD was not correlated with serum lycopene
in postmenopausal Japanese participants, while there was a weak correlation between radial
BMD and β-cryptoxanthin and β-carotene [185]. These discrepancy maybe resolved by further
in-depth study into the effect of lycopene on BMD. On the positive note, lycopene was shown
to contribute to a decrease in the risk of fragility fracture related to osteoporosis.
We carried out a cross-sectional study in which 33 postmenopausal women aged 50–60 years
provided seven-day dietary records and blood samples for analysis of oxidative stress
parameters and bone turnover markers. Our results showed that postmenopausal women who
consumed an average of 7.4 mg of lycopene per day had significantly higher serum lycopene.
Our finding that the estimated dietary lycopene had a significant and direct correlation with
serum lycopene suggests that lycopene from the diet is bioavailable. Our finding that a higher
serum lycopene was associated with a low NTx (p<0.005) and lower protein oxidation (p<0.05).
supports the antioxidative properties of lycopene involvement in its mechanisms of action in
bone [39].
The overrall conclusions from the epidemiological studies support the beneficial role of
lycopene in the prevention of risk for osteoporosis. Further clinical studies described below
support this conclusion.
6.5. Clinical intervention studies on lycopene
Since our laboratory is the only one to this date that reported clinical intervention studies with
lycopene, this section will focus on reviewing our studies on the role of lycopene in the
prevention of risk for osteoporosis in postmenopausal women.
We carried out 4 different clinical studies. In the first study, the objective was to determine the
effects of a lycopene-restricted diet on oxidative stress parameters and bone turnover markers
in postmenopausal women [38]. To avoid the effects of compounding factors with antioxidants,
women who smoked or were on medications which may affect bone metabolism or have anti‐
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administration of lycopene (20, 30 and 40 mg/kg b.w.) for 8 weeks to OVXed rats significantly
enhanced BMD, concluding that the consumption of lycopene may have the most protective
effect on bone in OVX [193]. Ke et al fed OVXed rats for 3 months with EM-X, an antioxidant
beverage derived from ferment of unpolished rice, sea weeds and papaya with combinations
of microorganisms and contains, among other things, lycopene. Results showed that rats
receiving EM-X for 3 months after sham operation or ovariectomy had increased bone density
of the middle of femur that was statistically significantly different from unreated rats [194].
6.4. Epidemiological studies on lycopene
A systematic review of the experimental studies on Mediterranean diet and disease prevention
was made and analyzed [195]. Although the Mediterrenean diet comprised of many different
food components, it is striking that one of the components is abundance of plant foods
including fruits, vegetables [195]. The two possible active components in its properties to
prevent diseases are lycopene [196] and polypenols [197]. Epidemiological evidence support
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concentrations are lower in women with osteoporosis than in healthy women of the same age.
The antioxidant mechanistic effect of lycopene is demonstrated by Misra et al. who have shown
that HRT has the same antioxidant effects as lycopene in postmenopausal women by demon‐
strating that lipid peroxidation was significantly decreased while GSH significantly increased
by both [199]. Epidemiological studies revealed the relationship between lycopene and BMD
[185,186,200]. A cross-sectional and longitudinal analyses in men and women were carried out
to evaluate the associations between total and individual carotenoid intakes (a-carotene, β-
carotene, β-cryptoxanthin, lycopene, lutein and zeaxanthin) with BMD at the hip, spine, and
radial shaft and the 4-y change in BMD. Their analyses showed significant associations
between lycopene intake and 4-y change in lumbar spine BMD for women [200] protective
associations by total carotenoids against 4-y loss in trochanter BMD in men and in lumbar
spine in women [98]. On the other hand, radial BMD was not correlated with serum lycopene
in postmenopausal Japanese participants, while there was a weak correlation between radial
BMD and β-cryptoxanthin and β-carotene [185]. These discrepancy maybe resolved by further
in-depth study into the effect of lycopene on BMD. On the positive note, lycopene was shown
to contribute to a decrease in the risk of fragility fracture related to osteoporosis.
We carried out a cross-sectional study in which 33 postmenopausal women aged 50–60 years
provided seven-day dietary records and blood samples for analysis of oxidative stress
parameters and bone turnover markers. Our results showed that postmenopausal women who
consumed an average of 7.4 mg of lycopene per day had significantly higher serum lycopene.
Our finding that the estimated dietary lycopene had a significant and direct correlation with
serum lycopene suggests that lycopene from the diet is bioavailable. Our finding that a higher
serum lycopene was associated with a low NTx (p<0.005) and lower protein oxidation (p<0.05).
supports the antioxidative properties of lycopene involvement in its mechanisms of action in
bone [39].
The overrall conclusions from the epidemiological studies support the beneficial role of
lycopene in the prevention of risk for osteoporosis. Further clinical studies described below
support this conclusion.
6.5. Clinical intervention studies on lycopene
Since our laboratory is the only one to this date that reported clinical intervention studies with
lycopene, this section will focus on reviewing our studies on the role of lycopene in the
prevention of risk for osteoporosis in postmenopausal women.
We carried out 4 different clinical studies. In the first study, the objective was to determine the
effects of a lycopene-restricted diet on oxidative stress parameters and bone turnover markers
in postmenopausal women [38]. To avoid the effects of compounding factors with antioxidants,
women who smoked or were on medications which may affect bone metabolism or have anti‐
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oxidant properties were excluded from participating. Twenty-three healthy postmenopausal
women, 50-60 years old, provided blood samples at baseline and after a one-month lycopene-
depletion period. Serum samples were analyzed for carotenoids; the oxidative stress parame‐
ters protein thiols and lipid peroxidation TBARS; the antioxidant enzymes SOD, CAT and GPx,
and the bone turnover markers BAP and NTX. Results revealed that lycopene restriction result‐
ed in significant decrease in serum lycopene, lutein/zeaxanthin and α-/β-carotene as shown in
Table 2, However, the overall percent change in these serum carotenoids was not as high as that
seen for lycopene. Figure 2 demonstrates that all configurations of lycopene (all trans, 5-cis- and
other cis lycopene) were all decreased after lycopene restriction. The antioxidant enzymes CAT
and SOD were significantly depressed (data not shown). These changes were accompanied by a
significant increase in the bone resorption marker NTx [Figure 3].
Carotenoid




(mean ± SEM)Baseline (mean ±
SEM)
lycopene restricted , (mean
± SEM)
α-carotene 408.4 ± 131.4 334.4 ± 110.6 p<0.05 -13.03 ± 6.88
β-carotene 1443.0 ± 278.9 1035.0 ± 221.7 p<0.0005 -22.84 ± 5.09
β-cryptoxanthin 403.2 ± 58.4 367.6 ± 47.3 p = 0.229 -1.29 ± 8.21
Lycopene 1171.0 ± 111.1 494.9 ± 48.46 p<0.0001 -54.86 ± 3.59a
Lutein/zeaxanthin 516.4 ± 49.57 443.0 ± 47.04 p<0.01 -12.77 ± 5.03
1 Wilcoxon matched pairs test used for these non-normally distributed data sets.
a Average percent change in lycopene was significantly higher than that seen for all the other carotenoids (p<0.0001),
as determined by unpaired t-test or Mann-Whitney test.
Table 2. Change in serum carotenoid concentrations after postmenopausal women were assigned to Lycopene-
restricted diet for a period of 1 month.
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Figure 3. Increase in the concentrations of the bone resorption marker, NTx, in the serum of postmenopausal women
after lycopene restriction.
To our knowledge, this is the first study on the effects of dietary lycopene restriction on
increasing the risk for osteoporosis in postmenopausal women which proves that lycopene
may be beneficial in reducing this risk. It can be speculated that this significant increase in the
bone res rption marker NTx may lead to a long-term ecrease in BMD and increased fracture
risk as was observed by Brown et al [42], and that a longer restriction period may be detrimental
to a group of postmenopausal women who were already at high risk for osteoporosis. It can
also mean that shorter wash-out peri ds of no lyc pene co su ption is all that is needed in
clinical trials examining the effects of lycopene on bone health. In addition, lycopene is present
in a select number of foods; therefore not consuming these products as a part of the regular
daily diet may result in negative health consequences to bone health.
In a second study [37], clinical intervention was carried out to investigate directly the effects
of supplementation with lycopene on decreasing the risk for osteoporosis. Sixty post eno‐
pausal women, 50-60 years old, were recruited for a fully randomized controlled intervention.
Following a one-month washout without lycopene consumption, participants consumed
either (N=15/group): (1) regular tomato juice, (2) lycopene-rich tomato juice, (3) tomato
lycopene capsules or (4) placebo capsules, twice daily for total lycopene intakes of 30, 70, 30
and 0 mg/day, respectively for 4 months. Serum collected was assayed for oxidative stress
parameters and bone turnover markers. Lycopene-supplem ntation for 4 months significantly
increased serum lycopene compared to placebo (p<0.001). Since the increase in serum lycopene
was similar for all three supplements, the participants were pooled into a “LYCOPENE-
supplemented” and PLACEBO-supplement group for further statistical analyses. LYCO‐
PENE-supplementation for 4 months resulted in significant increase in total antioxidant
capacity as shown in Figure 4, decreased in oxidative stress parameters protein oxidation
[Figure 5] and lipid peroxidation [Figure 6] which correlated to a decrease in NTx [Figure 7]
in the LYCOPENE-supplemented group; all changes were significantly different from the
PLACEBO group. These findings suggest that it did not matter whether lycopene was in the
form of tomato juice or capsule to exert its potent antioxidant properties beneficial in reducing
the risk of osteoporosis in postmenopausal women [37].
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oxidant properties were excluded from participating. Twenty-three healthy postmenopausal
women, 50-60 years old, provided blood samples at baseline and after a one-month lycopene-
depletion period. Serum samples were analyzed for carotenoids; the oxidative stress parame‐
ters protein thiols and lipid peroxidation TBARS; the antioxidant enzymes SOD, CAT and GPx,
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seen for lycopene. Figure 2 demonstrates that all configurations of lycopene (all trans, 5-cis- and
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as was observed by Brown et al [42], and that a longer restriction period may be detrimental to a group of postmenopausal 
women who were already at high risk for osteoporosis. It can also mean that shorter wash-out periods of no lycopene 
consumption is all that is needed in clinical trials examining the effects of lycopene on bone health. In addition, lycopene is 
present in a select number of foods; therefore not consuming these products as a part of the regular daily diet may result in 
negative health consequences to bone health.  
 
 
In a second study [37], clinical intervention was carried out to investigate directly the effects of supplementation with 
lycopene on decreasing the risk for osteoporosis. Sixty postmenopausal women, 50-60 years old, were recruited for a fully 
randomized controlled intervention. Following a one-month washout without lycopene consumption, participants consumed 
either (N=15/group): (1) regular tomato juice, (2) lycopene-rich tomato juice, (3) tomato lycopene capsules or (4) placebo 

























Figure 3: Increase in the concentrations of the bone resorption marker, NTx, in the 














Figure 2: Decrease in all configurations of lycopene (all trans, 5-cis- and other cis lycopene) in the 





Figure 3. Increase in the concentrations of the bone resorption marker, NTx, in the serum of postmenopausal women
after lycopene restriction.
To our knowledge, this is the first study on the effects of dietary lycopene restriction on
increasing the risk for osteoporosis in postmenopausal women which proves that lycopene
may be beneficial in reducing this risk. It can be speculated that this significant increase in the
bone res rption marker NTx may lead to a long-term ecrease in BMD and increased fracture
risk as was observed by Brown et al [42], and that a longer restriction period may be detrimental
to a group of postmenopausal women who were already at high risk for osteoporosis. It can
also mean that shorter wash-out peri ds of no lyc pene co su ption is all that is needed in
clinical trials examining the effects of lycopene on bone health. In addition, lycopene is present
in a select number of foods; therefore not consuming these products as a part of the regular
daily diet may result in negative health consequences to bone health.
In a second study [37], clinical intervention was carried out to investigate directly the effects
of supplementation with lycopene on decreasing the risk for osteoporosis. Sixty post eno‐
pausal women, 50-60 years old, were recruited for a fully randomized controlled intervention.
Following a one-month washout without lycopene consumption, participants consumed
either (N=15/group): (1) regular tomato juice, (2) lycopene-rich tomato juice, (3) tomato
lycopene capsules or (4) placebo capsules, twice daily for total lycopene intakes of 30, 70, 30
and 0 mg/day, respectively for 4 months. Serum collected was assayed for oxidative stress
parameters and bone turnover markers. Lycopene-supplem ntation for 4 months significantly
increased serum lycopene compared to placebo (p<0.001). Since the increase in serum lycopene
was similar for all three supplements, the participants were pooled into a “LYCOPENE-
supplemented” and PLACEBO-supplement group for further statistical analyses. LYCO‐
PENE-supplementation for 4 months resulted in significant increase in total antioxidant
capacity as shown in Figure 4, decreased in oxidative stress parameters protein oxidation
[Figure 5] and lipid peroxidation [Figure 6] which correlated to a decrease in NTx [Figure 7]
in the LYCOPENE-supplemented group; all changes were significantly different from the
PLACEBO group. These findings suggest that it did not matter whether lycopene was in the
form of tomato juice or capsule to exert its potent antioxidant properties beneficial in reducing
the risk of osteoporosis in postmenopausal women [37].
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In a third study [169]. Serum lycopene, bone turnover markers and oxidative stress parame‐
ter data were compared between postmenopausal women who were supplemented with ly‐
copene and those who obtained lycopene from both a low and high daily food intake of
lycopene to determine whether the elevated dose obtained through supplementation was
more beneficial in reducing bone turnover markers than intakes typically obtained from the
usual daily diet. Table 3 showed that women supplemented with lycopene had significantly
lower TBARS and marginally significant lower NTx values than participants who obtained a
low intake (or high intake lycopene, data not show) through their usual daily diets. These
differences in NTx and TBARS may be attributed to a significantly higher concentration of
serum 5-cis in lycopene-supplemented participants compared to low or high usual daily in‐
take participants. This suggests that it is the 5-cis isomer, with the most potent antioxidant
capacity which, at higher concentrations, decreases bone turnover markers due to its ability
to provide the greatest protection against oxidative stress. It also appears to show that sup‐
plementation with lycopene may be necessary in spite of the daily intake of lycopene.
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Figure 4. Increase in the serum total antioxidant capacity of postmenopausal women supplemented with LYCOPENE 
compared to placebo capsules for 4 months. Values are mean  SEM. Values compared within supplement group was 
determined to be statistically significant using repeated-measures ANOVA (*p<0.05).   



















Figure 5. Increase the serum concentration of thiol (meaning decreased protein oxidation) in postmenopausal women 
supplemented with LYCOPENE compared to placebo capsules for a period of 4 months. Values are mean  SEM. 
Values compared within supplement group was determined to be statistically significant using repeated-measures 
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determined to be statistically significant using repeated-measures ANOVA (*p<0.05).
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Figure 5. Increase the serum concentration of thiol (meaning decreased protein oxidation) in postmenopausal women 
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Figure 5. I crease the serum con entr tion f thiol (me ning dec e sed protein oxidation) in postmenopausal wom‐
en supplemented with LYCOPENE compared to placebo capsules for a period of 4 months. Values are mean ± SEM.
























In a fourth study, we investigated whether the 172TA or 584AG polymorphisms of the paraoxonase 1 (PON 1) 
modulated the effects of serum lycopene on bone turnover markers, oxidative stress parameters and antioxidant capacity in 
women between the ages of 25-70 years. We showed that the PON1 polymorphism modified the association between 
lycopene and NTx and BAP (p<0.02 and p<0.05 for interaction). In the combined 172TT and 584G genotype, high serum 
lycopene was associated with decreased BAP (p<0.01) and NTx (p<0.05). Among those with the combined 172A and 584G 
genotype, however, increased serum lycopene was associated with increased BAP (p<0.05) and NTx (p<0.05). These 















Figure 7. Decrease in the serum concentration of bone resorption marker NTx in postmenopausal women supplemented 
with LYCOPENE compared to placebo capsules  for a period of 4 months. Values are mean  SEM. Values compared 
within supplement group was determined to be statistically significant at 2 and 4 months using repeated-measures 
ANOVA (*p<0.01 and **p<0.001).   


















Figure 6. Decrease in the serum concentration of TBARS or lipid peroxidation in postmenopausal women 
supplemented with LYCOPENE compared to placebo capsules  for a period of 4 months. Values are mean  SEM. 
Values compared within supplement group was determined to be statistically significant using repeated-measures 
ANOVA (*p<0.001).  
Table 3. Comparison of lycopene values, oxidative stress parameters and bone turnover markers between women who were 
supplemented with lycopene with those who obtained a low lycopene (not shown) intake from their usual daily diet (unpaired t-
test). 
Parameter measured 
Mean ± SEM p 






Lycopene intake (mg/day) 2.59 ± 0.32a 43.33 ± 2.84 <0.0001 
Serum lycopene (nM) Total 1094 ± 80.24 2012 ± 88.56 <0.0001 
all-trans 539.0 ± 40.07 979.0 ± 48.48 <0.0001 
5-cis 342.4 ± 26.13 685.0 ± 30.22 <0.0001 
other-cis 212.6 ± 15.96 347.7 ± 17.36 <0.0001 
Total antioxidant capacity (mM) 1.65 ± 0.03 1.66 ± 0.05 0.190 
Bone turnover markers NTx (nM BCE) 21.97 ± 1.11 19.19 ± 0.79 0.047 





454.7 ± 15.37 455.2 ± 15.50 0.982 
TBARS 
(nmol/mL) 
9.06 ± 0.35 6.80 ± 0.35 <0.0001 
Antioxidant enzymes CAT (K/g Hb) 81.50 ± 4.13 58.59 ± 2.06 <0.0001 
SOD (U/mg Hb) 47.60 ± 2.44 39.22 ± 4.72 0.001 
GPx (U/g Hb) 15.44 ± 1.40 32.82 ± 2.85 <0.0001 
1 Data that were not normally distributed were compared using the Mann-Whitney test 
 a The range of lycopene intake for the low usual daily intake group is 0.0-6.07 mg/day. 
Figure 6. Decrease in the serum concentration of TBARS or lipid peroxidation in postmenopausal women supple‐
mented with LYCOPENE compared to placebo capsules for a period of 4 months. Values are mean ± SEM. Values com‐
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Figure 7. Decrease in the serum concentration of bone resorption marker NTx in postmenopausal women supplemented 
with LYCOPENE compared to placebo capsules  for a period of 4 months. Values are mean  SEM. Values compared 
within supplement group was determined to be statistically significant at 2 and 4 months using repeated-measures 
ANOVA (*p<0.01 and **p<0.001).   
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Figure 7. Decrease in the serum concentration of bone resorption marker NTx in postmenopausal women supple‐
mented with LYCOPENE compared to placebo capsules for a period of 4 months. Values are mean ± SEM. Values com‐
pared within supplement group was determined to be statistically significant at 2 and 4 months using repeated-
measures ANOVA (*p<0.01 and **p<0.001).
In a fourth study, we investigated whether the 172T→A or 584A→G polymorphisms of the
paraoxonase 1 (PON 1) modulated the effects of serum lycopene on bone turnover markers,
oxidative stress parameters and antioxidant capacity in women betwe n the ages of 25-70
years. We showed that the PON1 polymorphism modified the association between lycopene
and NTx and BAP (p<0.02 and p<0.05 for interaction). In the combined 172TT and 584G
genotype, high serum lycopene was associated with decreased BAP (p<0.01) and NTx (p<0.05).
Among those with the combined 172A and 584G genotype, however, increased serum
lycopene was associated with increased BAP (p<0.05) and NTx (p<0.05). These findings show
that PON1 polymorphisms modified the association between serum concentrations of
lycopene and oxidative stress parameters and bone turnover markers and may, therefore,
moderate the risk of osteoporosis [201].
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In a third study [169]. Serum lycopene, bone turnover markers and oxidative stress parame‐
ter data were compared between postmenopausal women who were supplemented with ly‐
copene and those who obtained lycopene from both a low and high daily food intake of
lycopene to determine whether the elevated dose obtained through supplementation was
more beneficial in reducing bone turnover markers than intakes typically obtained from the
usual daily diet. Table 3 showed that women supplemented with lycopene had significantly
lower TBARS and marginally significant lower NTx values than participants who obtained a
low intake (or high intake lycopene, data not show) through their usual daily diets. These
differences in NTx and TBARS may be attributed to a significantly higher concentration of
serum 5-cis in lycopene-supplemented participants compared to low or high usual daily in‐
take participants. This suggests that it is the 5-cis isomer, with the most potent antioxidant
capacity which, at higher concentrations, decreases bone turnover markers due to its ability
to provide the greatest protection against oxidative stress. It also appears to show that sup‐
plementation with lycopene may be necessary in spite of the daily intake of lycopene.
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assayed for oxidative stress parameters and bone turnover markers. Lycopene-supplementation for 4 months significantly 
increased serum lycopene compared to placebo (p<0.001). Since the increase in serum lycopene was similar for all three 
supplements, the participants were pooled into a “LYCOPENE-supplemented” and PLACEBO-supplement group for further 
statistical analyses. LYCOPENE-supplementation for 4 months resulted in significant increase in total antioxidant capacity as 
shown in Figure 4, decreased in oxidative stress parameters protein oxidation [Figure 5] and lipid peroxidation [Figure 6] 
which correlated to a decrease in NTx [Figure 7] in the LYCOPENE-supplemented group; all changes were significantly 
different from the PLACEBO group. These findings suggest that it did not matter whether lycopene was in the form of tomato 
juice or capsule to exert its potent antioxidant properties beneficial in reducing the risk of osteoporosis in postmenopausal 
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Figure 4. Increase in the serum total antioxidant capacity of postmenopausal women supplemented with LYCOPENE 
compared to placebo capsules for 4 months. Values are mean  SEM. Values compared within supplement group was 
determined to be statistically significant using repeated-measures ANOVA (*p<0.05).   



















Figure 5. Increase the serum concentration of thiol (meaning decreased protein oxidation) in postmenopausal women 
supplemented with LYCOPENE compared to placebo capsules for a period of 4 months. Values are mean  SEM. 
Values compared within supplement group was determined to be statistically significant using repeated-measures 
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compared to placebo capsules for 4 months. Valu s are mean ± SEM. Values compared within supplement group was
determined to be statistically significant using repeated-measures ANOVA (*p<0.05).
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Figure 5. Increase the serum concentration of thiol (meaning decreased protein oxidation) in postmenopausal women 
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Figure 5. I crease the serum con entr tion f thiol (me ning dec e sed protein oxidation) in postmenopausal wom‐
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In a fourth study, we investigated whether the 172TA or 584AG polymorphisms of the paraoxonase 1 (PON 1) 
modulated the effects of serum lycopene on bone turnover markers, oxidative stress parameters and antioxidant capacity in 
women between the ages of 25-70 years. We showed that the PON1 polymorphism modified the association between 
lycopene and NTx and BAP (p<0.02 and p<0.05 for interaction). In the combined 172TT and 584G genotype, high serum 
lycopene was associated with decreased BAP (p<0.01) and NTx (p<0.05). Among those with the combined 172A and 584G 
genotype, however, increased serum lycopene was associated with increased BAP (p<0.05) and NTx (p<0.05). These 















Figure 7. Decrease in the serum concentration of bone resorption marker NTx in postmenopausal women supplemented 
with LYCOPENE compared to placebo capsules  for a period of 4 months. Values are mean  SEM. Values compared 
within supplement group was determined to be statistically significant at 2 and 4 months using repeated-measures 
ANOVA (*p<0.01 and **p<0.001).   


















Figure 6. Decrease in the serum concentration of TBARS or lipid peroxidation in postmenopausal women 
supplemented with LYCOPENE compared to placebo capsules  for a period of 4 months. Values are mean  SEM. 
Values compared within supplement group was determined to be statistically significant using repeated-measures 
ANOVA (*p<0.001).  
Table 3. Comparison of lycopene values, oxidative stress parameters and bone turnover markers between women who were 
supplemented with lycopene with those who obtained a low lycopene (not shown) intake from their usual daily diet (unpaired t-
test). 
Parameter measured 
Mean ± SEM p 






Lycopene intake (mg/day) 2.59 ± 0.32a 43.33 ± 2.84 <0.0001 
Serum lycopene (nM) Total 1094 ± 80.24 2012 ± 88.56 <0.0001 
all-trans 539.0 ± 40.07 979.0 ± 48.48 <0.0001 
5-cis 342.4 ± 26.13 685.0 ± 30.22 <0.0001 
other-cis 212.6 ± 15.96 347.7 ± 17.36 <0.0001 
Total antioxidant capacity (mM) 1.65 ± 0.03 1.66 ± 0.05 0.190 
Bone turnover markers NTx (nM BCE) 21.97 ± 1.11 19.19 ± 0.79 0.047 





454.7 ± 15.37 455.2 ± 15.50 0.982 
TBARS 
(nmol/mL) 
9.06 ± 0.35 6.80 ± 0.35 <0.0001 
Antioxidant enzymes CAT (K/g Hb) 81.50 ± 4.13 58.59 ± 2.06 <0.0001 
SOD (U/mg Hb) 47.60 ± 2.44 39.22 ± 4.72 0.001 
GPx (U/g Hb) 15.44 ± 1.40 32.82 ± 2.85 <0.0001 
1 Data that were not normally distributed were compared using the Mann-Whitney test 
 a The range of lycopene intake for the low usual daily intake group is 0.0-6.07 mg/day. 
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Figure 7. Decrease in the serum concentration of bone resorption marker NTx in postmenopausal women supplemented 
with LYCOPENE compared to placebo capsules  for a period of 4 months. Values are mean  SEM. Values compared 
within supplement group was determined to be statistically significant at 2 and 4 months using repeated-measures 
ANOVA (*p<0.01 and **p<0.001).   
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Figure 7. Decrease in the serum concentration of bone resorption marker NTx in postmenopausal women supple‐
mented with LYCOPENE compared to placebo capsules for a period of 4 months. Values are mean ± SEM. Values com‐
pared within supplement group was determined to be statistically significant at 2 and 4 months using repeated-
measures ANOVA (*p<0.01 and **p<0.001).
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lycopene was associated with increased BAP (p<0.05) and NTx (p<0.05). These findings show
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Lycopene intake (mg/day) 2.59 ± 0.32a 43.33 ± 2.84 <0.0001
Serum lycopene (nM)
Total 1094 ± 80.24 2012 ± 88.56 <0.0001
all-trans 539.0 ± 40.07 979.0 ± 48.48 <0.0001
5-cis 342.4 ± 26.13 685.0 ± 30.22 <0.0001
other-cis 212.6 ± 15.96 347.7 ± 17.36 <0.0001
Total antioxidant capacity (mM) 1.65 ± 0.03 1.66 ± 0.05 0.190
Bone turnover markers
NTx (nM BCE) 21.97 ± 1.11 19.19 ± 0.79 0.047





454.7 ± 15.37 455.2 ± 15.50 0.982
TBARS (nmol/mL) 9.06 ± 0.35 6.80 ± 0.35 <0.0001
Antioxidant enzymes
CAT (K/g Hb) 81.50 ± 4.13 58.59 ± 2.06 <0.0001
SOD (U/mg Hb) 47.60 ± 2.44 39.22 ± 4.72 0.001
GPx (U/g Hb) 15.44 ± 1.40 32.82 ± 2.85 <0.0001
1 Data that were not normally distributed were compared using the Mann-Whitney test
a The range of lycopene intake for the low usual daily intake group is 0.0-6.07 mg/day.
Table 3. Comparison of lycopene values, oxidative stress parameters and bone turnover markers between women
who were supplemented with lycopene with those who obtained a low lycopene (not shown) intake from their usual
daily diet (unpaired t-test).
A similar investigation was carried out in a fifth study to assesses whether the PON1 172T→A
polymorphism affects the response to dietary intervention with lycopene. We showed that
supplementation in the TT genotype and carriers of the A allele significantly increased serum
lycopene (both: p<0.0001) while decreasing protein oxidation (p<0.005 and p<0.05, respective‐
ly) and lipid peroxidation (p<0.005 and p<0.0005). However, participants with the TT genotype
responded more favourably to lycopene, with corresponding significant increase in total
antioxidant capacity (TAC) (p<0.01) and significant decrease in NTx (p<0.001); this effect was
not significant in carriers of the A allele. Further analyses showed that there was a significant
interaction between PON1 genotype and change in TBARS (p<0.05) suggesting that supple‐
mentation with lycopene resulted in decreased lipid peroxidation, which interacted with the
PON1 genotype to decrease bone resorption markers in postmenopausal women. These
findings provide mechanistic evidence of how intervention with lycopene may act to decrease
lipid peroxidation and thus the risk of osteoporosis in postmenopausal women [169,202].
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6.6. Concluding remark
There is now ample evidence to show that oxidative stress brought about by the accumulation
of ROS in the body is one of the causes of the development of several chronic diseases including
osteoporosis and that antioxidants such as lycopene can counteract this damaging effect. The
evidence includes studies on their role in osteoclastic resorption and osteoblastic bone
formation, animal intervention studies, epidemiological studies and, more recently, clinical
intervention studies. Considering the possible adverse side effects of the conventional therapy
(eg, HRT and bisphosphonates) in the management of postmenopausal osteoporosis, there is
an increasing demand for the use of antioxidants naturally present in foods. The results of
these studies indicate that lycopene maybe useful either as a dietary alternative to drug therapy
or as a complement to the drugs presently used by women at risk for osteoporosis.
7. Studies on polyphenols
Polyphenols have long been known to have a role in the prevention of chronic diseases such
as cardiovascular diseases, cancers, neurodegenerative diseases, diabetes, or osteoporosis.
Only in the last 10 years has there been an increase in the interest on polyphenols and bone
health [203-206]. Horcajada [204] has recently reviewed the anabolic role of phytonutrients
and especially polyphenols in bone while Trzeciakiewicz [205] reviewed the mechanisms of
action of polyphenol in osteoblast function and its interaction with osteoclasts. The beneficial
effects of green tea polyphenols has been reviewed [207,208].
Currently, most of the research on polyphenols and their effects have emerged from in vitro
and in vivo animal studies with only a few clinical studies available. In our recent review, we
have included tables listing all the studies on polyphenols in vitro bone cell culture and the
epidemiologic studies on the protective effects of polyphenol consumption against osteopo‐
rosis [209] and only a few studies will be reviewed here.
7.1. In vitro studies on polyphenols in bone cells
The most commonly studied polyphenol abundant in green tea is epigallocatechin-3-Gallate
(EGCG). We have shown that epigallocathechin-3-gallate (EGCG) increased the formation of
mineralized bone nodules by human osteoblast-like cells [210]. EGCG has been shown to
inhibit the expression of matrix metalloproteinase 9 (MMP-9) and the formation of osteoclasts
[211]. H2O2-induced alterations of osteoblast viability and reduction in alkaline phosphatase
activity were prevented by pre-incubating the osteoblasts with green tea polyphenol [212].
Green tea was shown to protect human osteoblasts from cigarette smoke-induced injury [128].
EGCG was shown to inhibit thyroid hormone-stimulated osteocalcin synthesis in osteoblasts
[213], suppressed the differentiation of murine osteoblastic MC3T3-E1 cells [214], inhibit rat
osteoclast formation and differentiation [215] and induces apoptosis via caspase activation in
osteoclasts differentiated from RAW 264.7 cells [216]. Horcajada suggested that most studies
investigating the effects of polyphenols on osteoblast cells have reported involvement of
complex networks of anabolic signaling pathways such as BMPs or estrogen receptor mediated
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pathways [204]. Trzeciakiewicz describing a more detailed mechanisms, suggested that
polyphenols modulate the expression of transcription factors in osteoblasts such as runt-
related transcription factor-2 (Runx2) and Osterix, NFkappaB and activator protein-1 (AP-1)
[205]. In agreement with Hocajada (2012), Trzeciakiewicz (2009) stated in his review that
polyphenol may act on cellular signaling such as mitogen-activated protein kinase (MAPK),
bone morphogenetic protein (BMP), oestrogen receptor and osteoprotegerin/receptor activator
of NF-kappaB ligand (OPG/RANKL) and thus may affect osteoblast functions. The two
reviews complement each other and paint a better understanding of the mechanisms of action
of polyphenols in bone cells, with the warning that it is also important to take into account the
possible interaction of these compounds on osteoblasts metabolism.
Other polyphenols/sources of polyphenols which were found to have beneficial effects on bone
cells include the dried plum polyphenols found to attenuate the detrimental effects of
TNFalpha on osteoblast function coincident with up-regulation of Runx2, Osterix and IGF-I
and increasing lysyl oxidase expression, and at the same time attenuate osteoclastogenesis
signalling [217]; black tea polyphenol which affects the MMP activity and osteoclast formation
and differentiation in vitro [215]; phenolic leaf extract of Heimia myrtifolia (Lythraceae) found
to stimulate mineralization of SaOS-2 osteosarcoma cells) [218]; Oleuropein which enhances
osteoblastogenesis and inhibits adipogenesis and the effects on differentiation in stem cells
derived from bone marrow [219] and the polyphenol component of red wine resveratrol which
promotes osteogenic differentiation and protects against dexamethasone damage in murine-
induced pluripotent stem cells [220] and facilitates in vitro mineralization and in vivo bone
regeneration [221]. A number of animal studies have been reported and this was reviewed by
Rao et al [209].
Other good sources of polyphenols that are frequently studied are extracts containing
combinations of polyphenols. One such source is the nutritional supplement greens+TM, a blend
of several herbal and botanical products containing a substantial amount of polyphenols
including quercetin, apigenin and luteolin [106] which act as antioxidants and therefore should
be able to counteract oxidative stress. Our laboratory has shown that the polyphenolic extracts
from greens+TM have stimulatory effect on mineralized bone nodule formation in human
osteoblast cells in a dose- and time- dependent manner and is more effective than epicatechin
(EC) as shown in Figure 8 [222]. We have further shown that this stimulatory effect is accom‐
panied by decreases in the reactive oxygen species H2O2 shown in Figure 9 [223], thus proving
that greens+TM is able to counteract oxidative stress in human osteoblastic cells and may
therefore be a good candidate as a nutritional supplement to prevent the risk of osteoporosis.
Two additional nutritional supplements have since been formulated which may prove to be
good for bone health. These are the bone builderTM and the greens+bone builderTM ; the latter
is the original greens+TM product that has been supplemented with the bone builderTM formula
containing several compounds including vitamins, minerals, and antioxidants. These various
components have been separately shown to have some beneficial effect on bone [224]. Using
the human osteoblast SaOS-2 cells, we showed that similarly to the greens+TM, the water-
soluble bone-builderTM extract had a significant dose-dependent stimulatory effect on bone
nodules formation (Figure 10) [225]. Figure 11 shows that when the two supplements, greens
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+TM and bone builderTM, were tested as combination, the effects were six times more effective
than either one alone in stimulating bone formation in osteoblast culture [226].
Figure 8. Effect of continuous addition of greens+TM extract on the number of SaOS-2 cells cultured in the presence of
EC, or varying dilutions of greens+TM at an early time points and number of nodules analyzed at the indicated time
points. An asterix, *, on a bar indicates statistical significance (p <.05) between a treatment and the control.
Figure 9. Dose-dependent inhibitory effects of phenolic extracts of greens+TM on intracellular ROS levels stimulated by
20 uM H2O2 in SaOS-2 cells. Data are mean ± SEM of 6 replicates. *p = < 0.05.
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Figure 10. Time and Dose-dependent Effects of bone builderTM on mineralized bone nodule area in SaOS-2 cells. indi‐
cates significant difference from vehicle: p<0.0001; p<0.0005; p<0.005, #, p<0.01 and ##, p< 0.05. There is a signifi‐
cant dose-dependent effect both at day 17 and day 20, according to One-way ANOVA; p<0.0001.
Figure 11. Dose dependent effect of greens + (g+) with and without 0.5 mg/ml of bone builder (bb) on the area of
mineralized bone nodules in osteoblasts SaOS-2 Cells. Significant differences were found compared to respective con‐
trols. g+bb was more effective than either g+ or bb alone.
7.2. Clinical intervention studies of polyphenol
We have recently reviewed earlier clinical studies on polyphenols and osteoporosis [209]. Only
the more recent reports, as well as our own clinical studies will be reviewed here. Shen et al
[227] have extended their studies in osteopenic women and showed that dietary supplement
in the form of green tea combined with tai-chi, a mind-body exercise, can alleviating bone loss
in osteopenic women. The effect of catechin was studied in perimenopausal Scottish women
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and it was found that catechin was negatively associated with bone-resorption markers,
association between energy-adjusted total flavonoid intakes and BMD at the femoreal neck
and lumbar spine while annual percent change in BMD was associated with intakes of
procyanidins and catechins [228].
Other than these clinical studies in the last two years, there has not been not been anymore
reported clinical studies on polyphenols in human subjects except our studies.
Our  results  on the  in  vitro  effects  of  greens+TM,  bone builderTM  and greens+bone build‐
erTM on bone formation in osteoblasts encouraged us formed the rationale for our clinical
studies to test whether these products can prevent the risk of osteoporosis in postmeno‐
pausal women. We chose to study the greens+bone builderTM since of the three products,
it  gave the greatest  stimulatory effect  on bone formation,  being six times more effective
than the  other  two.  The first  randomized cross-sectional  clinical  intervention study was
carried out  to  test  whether  a  daily  supplementation with  greens+  bone builderTM may
be important in reducing oxidative damage in postmenopausal women at risk for osteo‐
porosis.  [40].  Forty-seven postmenopausal  women,  50-60  years  old  were  randomized to
either Treatment group consuming 1 scoop (equivalent to ¼ cup) daily of  greens+ bone
builderTM  (N=23) or Placebo (N=24) group for a period of 8 weeks.  Blood samples were
collected at 0, 4 and 8 weeks of supplementation, processed and assayed for serum total
antioxidant capacity (TAC), lipid peroxidation and protein oxidation as markers of oxida‐
tive stress. Results revealed that there was an increase in total antioxidant capacity (Fig‐
ure 12, as well as a decrease in both protein oxidation (Figure 13) and lipid peroxidation
(Figure 14) over a 4 and 8-weeks of intervention with greens+ bone builderTM  compared
to placebo. This suggests that the nutritional supplement may have a beneficial effect on



























Figure 12. Change relative to baseline in serum concentrations of trolox, a measure of total antioxidant capacity, in
greens+bone builderTM-treated postmenopausal women was significantly increased after 4 and 8 weeks while that in
the placebo-treated control was marginally decreased. Treated values were also higher than the placebo [unpaired t-
test (*p<0.01, **p<0.0001)]. Values are mean ± SEM.
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Figure 13. Change relative to baseline in serum concentrations of thiol in greens+bone builder-treated postmeno‐
pausal women was significantly increased after 4 and 8 weeks (meaning decreased protein oxidation) while that in
the placebo-treated control was unchanged; treated values were also higher than the placebo. Mann-Whitney test































Figure 14. Change relative to baseline in serum concentrations of TBARS in greens+bone builderTM-treated postmeno‐
pausal women was significantly decreased after 4 and 8 weeks (meaning decreased lipid peroxidation) while that in
the placebo-treated control was unchanged; treated values were also lower than the placebo. Mann-Whitney test
(*p<0.05, **p<0.001). Values are mean ± SEM.
In order to test whether the antioxidant properties of greens+bone builderTM can prevent the
risk of osteoporosis in postmenopausal women, we also measured the serum bone turnover
markers, C-terminal telopeptide of type I collagen (CTX) as indicator of bone resorption, and
procollagen type I N-terminal propeptide (PINP) as indicator of bone formation, in addition
to the serum antioxidant capacity, and the oxidative stress parameters lipid peroxidation,
protein oxidation. As shown in Figure 15, statistical analysis showed that at 8 weeks, the greens
+bone builderTM supplement group significantly decreased the bone resorption marker CTX,
while the Placebo group showed no significant changes. The supplement group was also
significantly different from that of the Placebo group in all parameters measured. This decrease
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in CTX correlated to the increase in their serum total antioxidant capacity [Figure 12] and
decreases in oxidative parameters protein oxidation [Figure 13] lipid peroxidation [Figure
14]. These results suggest that a daily supplementation with polyphenols and micronutrients
may be important in reducing oxidative damage by reducing bone resorption, thereby































Figure 15. Change relative to baseline in serum concentrations of CTX in greens+bone builderTM-treated postmeno‐
pausal women was significantly decreased after 8 weeks (meaning decreased bone resorption marker) compared to
that of the placebo-treated control (a paired t-test (*p<0.05).. Values are mean ± SEM.
7.3. Concluding remarks
Studies reported in the literature on the role of polyphenols in bone health have explod‐
ed in  the  last  10  years,  but  most  of  the  reports  involved in  vitro  studies  in  osteoclasts
and  osteoblasts,  animal  studies  and  epidemiologicai  studies.  There  is  little  doubt  from
the excellent studies reported that oxidative stress is one of the primary culprits responsi‐
ble for the pathogenesis of osteoporosis via its role in osteoclastic resoption and the detri‐
mental  effects  on  the  bone-forming  osteoblasts.  To  date,  only  four  clinical  intervention
studies  have  been  reported,  including ours.  It  is  easy  to  see  why it  is  very  difficult  to
evaluate the role of polyphenols since, as we learned from this review, there are at least
8,000 different polyphenols identified to date, and each one probably having different ef‐
fects  on  humans.  Additionally,  polyphenols  are  present  in  food with  other  constituents
that may also be beneficial to bone health. In our clinical study, we combined the effects
of  a  combination  of  polyphenols  present  in  the  nutritional  supplement  from  greens+TM
with  the  nutritional  components  present  in  bone  builderTM  such  as  minerals,  vitamins
and other nutrients.  It  is  possible  that  the effects  of  greens+bone buildertm  in increasing
total  antioxidant capacity,  decreasing the oxidative stress markers protein oxidation and
lipid peroxidation which correlated to the decrease in bone turnover marker for bone re‐
sorption is a result of the combined effects of the different polyphenols it contained with
those of the other nutritional components present in the bone builderTM. It  remained for
future studies to zero in on specific component that is responsible for its beneficial effect.
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Figure 13. Change relative to baseline in serum concentrations of thiol in greens+bone builder-treated postmeno‐
pausal women was significantly increased after 4 and 8 weeks (meaning decreased protein oxidation) while that in
the placebo-treated control was unchanged; treated values were also higher than the placebo. Mann-Whitney test































Figure 14. Change relative to baseline in serum concentrations of TBARS in greens+bone builderTM-treated postmeno‐
pausal women was significantly decreased after 4 and 8 weeks (meaning decreased lipid peroxidation) while that in
the placebo-treated control was unchanged; treated values were also lower than the placebo. Mann-Whitney test
(*p<0.05, **p<0.001). Values are mean ± SEM.
In order to test whether the antioxidant properties of greens+bone builderTM can prevent the
risk of osteoporosis in postmenopausal women, we also measured the serum bone turnover
markers, C-terminal telopeptide of type I collagen (CTX) as indicator of bone resorption, and
procollagen type I N-terminal propeptide (PINP) as indicator of bone formation, in addition
to the serum antioxidant capacity, and the oxidative stress parameters lipid peroxidation,
protein oxidation. As shown in Figure 15, statistical analysis showed that at 8 weeks, the greens
+bone builderTM supplement group significantly decreased the bone resorption marker CTX,
while the Placebo group showed no significant changes. The supplement group was also
significantly different from that of the Placebo group in all parameters measured. This decrease
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in CTX correlated to the increase in their serum total antioxidant capacity [Figure 12] and
decreases in oxidative parameters protein oxidation [Figure 13] lipid peroxidation [Figure
14]. These results suggest that a daily supplementation with polyphenols and micronutrients
may be important in reducing oxidative damage by reducing bone resorption, thereby































Figure 15. Change relative to baseline in serum concentrations of CTX in greens+bone builderTM-treated postmeno‐
pausal women was significantly decreased after 8 weeks (meaning decreased bone resorption marker) compared to
that of the placebo-treated control (a paired t-test (*p<0.05).. Values are mean ± SEM.
7.3. Concluding remarks
Studies reported in the literature on the role of polyphenols in bone health have explod‐
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studies  have  been  reported,  including ours.  It  is  easy  to  see  why it  is  very  difficult  to
evaluate the role of polyphenols since, as we learned from this review, there are at least
8,000 different polyphenols identified to date, and each one probably having different ef‐
fects  on  humans.  Additionally,  polyphenols  are  present  in  food with  other  constituents
that may also be beneficial to bone health. In our clinical study, we combined the effects
of  a  combination  of  polyphenols  present  in  the  nutritional  supplement  from  greens+TM
with  the  nutritional  components  present  in  bone  builderTM  such  as  minerals,  vitamins
and other nutrients.  It  is  possible  that  the effects  of  greens+bone buildertm  in increasing
total  antioxidant capacity,  decreasing the oxidative stress markers protein oxidation and
lipid peroxidation which correlated to the decrease in bone turnover marker for bone re‐
sorption is a result of the combined effects of the different polyphenols it contained with
those of the other nutritional components present in the bone builderTM. It  remained for
future studies to zero in on specific component that is responsible for its beneficial effect.
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8. General summary and conclusion
In conclusion, we showed that oxidative stress due to ROS that are shown to cause the
development of osteoporosis may be prevented by supplementation with the antioxidants
lycopene and polyphenols. Results of in vitro studies in osteoblasts and osteoclasts, animal
intervention studies, epidemiological studies and clinical intervention studies on lycopene and
polyphenols are evidence for their potential use as alternative or complementary agent with
other established drugs approved for the prevention or treatment of osteoporosis in postme‐
nopausal women.
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1. Introduction
People with chronic kidney disease (CKD) develop changes in circulating blood levels of
calcium and phosphorus. The kidney gradually loses the ability to remove phosphorus from
the blood and cannot produce adequate amounts of active vitamin D to maintain normal
levels of calcium. This occurs mainly because of decreased renal excretion of phosphate and
diminished renal hydroxylation of 25-hydroxyvitamin D to calcitriol due to low expression
of alpha-1-hydroxylase in the failed kidneys [1]. Further compensation to maintain normal
serum calcium and phosphorus homeostasis includes increased production and release of
parathyroid hormone (PTH) and potentially other phosphaturic factors, such as fibroblast
growth factor-23 (FGF23) [2].
Two main complications follow to the above mentioned molecular responses namely secon‐
dary hyperparathyroidism (sHPT) and vascular calcification (VC), which occur in a high
percentage of CKD patients [1]. These molecular disorders alter bone metabolism which
leads to bone abnormalities including altered bone production and resorption. In turn, bony
changes may result in bone deformation, bone pain, and more risks of fracture [3]. All of the
above biochemical abnormalities (calcium, phosphorus, vitamin D and PTH disturbances)
and vascular calcification as well as changes in bone metabolism such as variation in turn‐
over and bone mineralization can be included under the descriptions for CKD-associated
mineral and bone disorders (CKD-MBD) [4].
This review explains the main pathological causes and mechanisms of CKD-MBD and the
possible animal models for basic research on this disease. It also describes some clinically
applicable diagnosis techniques and treatment methods with their advantages and side ef‐
fects for CKD-MBD.
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2. Potential pathological mechanisms
2.1. sHPT-related bone disorders
The first changes that usually occur with the decline of renal function involve the deficiency
of active vitamin D and decrease in phosphorus excretion by the remaining functional neph‐
rons [5]. In CKD, the failed kidney is inefficient in alpha-1-hydroxylase expression resulting
in low synthesis of calcitriol. Simultaneously the kidney with lower function has reduced
ability to reabsorb calcium from urine [6]. Therefore, low serum calcium level, high serum
phosphorus level and impaired renal 1, 25-dihydroxyvitamin D synthesis with attendant re‐
duction in serum calcitriol concentration and decrease in vitamin D receptor expression in
the parathyroid glands contribute to excess PTH secretion in patients with CKD [7].
PTH strongly influences the exchange of calcium to and from bone through its involvement
in bone cell apoptosis mechanisms and effects on the receptor activator of NF-kappa B
(RANK)/receptor activator of NF-kappa B ligand (RANKL)/osteoprotegerin (OPG) axis.
Continuously elevated PTH could upregulate RANKL expression, leading to an increase in
the formation rate and survival time of bone-resorbing osteoclasts and net bone loss [8, 9].
Excess PTH also leads to high bone turnover, a condition characterized by accelerated rates
of bone formation and bone resorption [1]. The high bone turnover due to sHPT is accompa‐
nied by about 5% (up to 10%) lower bone mass, which is partly reversible (low mineral
bone, increased remodeling space) and partly irreversible (cortical thinning) [10]. The new
formed bone in the course of sHPT is structurally inferior and fragile, and carries an in‐
creased risk of fractures.
Another main molecular mechanism underlying sHPT is attributed to Klotho-fibroblast
growth factor-23 (FGF-23) system. Humans with CKD experience decreased Klotho expres‐
sion as early as stage 1 CKD. Klotho continues to decline as CKD progresses, causing
FGF-23 resistance and provoking large FGF-23 and parathyroid hormone increases [11].
FGF-23 is a novel bone-derived hormone, in conjunction with its co-receptor, Klotho, acti‐
vates FGF receptor 1 (FGFR1) and acts on the kidney to induce renal phosphate wasting and
to suppress 1,25-dihydroxyvitamin D synthesis [12]. In patients with CKD, circulating
FGF23 levels are progressively increased to compensate for persistent phosphate retention,
but this result in reduced renal production of 1, 25-dihydroxyvitamin D through suppress‐
ing 1α-hydroxylase activity, which leads to sHPT [13].
2.2. VC-related bone disorders
Vascular calcification is very common in patients with CKD, appearing in 30-65% of patients
with stage 3-5 CKD, 50-80% of patients with stage 5 CKD [14]. Calcium, a divalent cation,
and phosphate, a trivalent anion, have a high binding affinity for one another and as the
concentration of one or both ions increases in serum, there is an increased risk for an ionic
bond to form, creating an insoluble complex which leads to vascular calcification [5]. Clini‐
cally, when the serum calcium-phosphate product exceeds 60 mg2/dl2, widespread tissue
deposition of amorphous calcium phosphate occurs [15].
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There are a large number of promoters and inhibitors involved in vascular calcification and
there are more vascular calcification inhibitors circulating in the blood under normal condi‐
tions [1]. Phosphorus is the most significant studied vascular calcification promoter which is
available at higher level in patients with low renal function. Hyperphosphatemia reverses
the normal process in which calcification inhibitors are down-regulated, while promoters
are up-regulated [1].
On the other hand, many bone-associated proteins including osteocalcin, osteopontin and
osteoprotegerin,  and many bone morphogenetic  proteins  are  involved in  the  process  of
VC [16].  Previous studies have proven that active mineralization mechanisms clearly re‐
sembling those of skeletal endochondral and membranous ossification participate in vas‐
cular  calcium accumulation [17].  The findings  of  bone-related factors  in  the  vasculature
and  the  vascular  calcification  observed  in  several  gene-knockout  mouse  models  imply
that  CKD-MBD  is  an  actively  regulated  process  that  may  be  preventable  or  even  re‐
versed [18]. The most striking among these mouse models is the matrix gamma-carboxy‐
glutamic acid (Gla)  protein (MGP) knockout mouse,  which exhibits  extensive and lethal
calcification and cartilaginous metaplasia of the media of all elastic arteries as early as 2
weeks after  birth [19,  20],  indicating that  this  protein may be of  primary importance in
human vascular calcification [18].
3. Clinical diagnosis
3.1. Biomarkers
According to the standardized diagnostic criteria for CKD-MBD developed and published
by the international expert consensus group, kidney disease improving global outcomes
(KDIGO), monitoring serum levels of calcium, phosphorus, PTH, and alkaline phosphatase
is strongly recommended, and the frequency of monitoring is based on the occurrence and
extent of abnormalities as well as the rate of CKD progression [21]. Phosphorus level equal
to the upper phosphorus level of 5.5 mg/dL and calcium level more than 9.5 mg/dL have
been suggested to be associated with increased mortality in CKD patients [22]. The com‐
bined use of second- and third-generation PTH assays allows to measure PTH (1–84) and
PTH (7–84) as PTH (7-84) interacts with distinct receptors and thereby may have important
roles in the regulation of bone resorption and serum calcium concentration [23]. The fre‐
quency of measurement on alkaline phosphatases is very similar to that of PTH and can pro‐
vide additional information on bone turnover. The recent more KDIGO guidelines
recommend that the measurement on alkaline phosphatase levels should commence in stage
3 of CKD, and that in patients with stage 4-5 of CKD, alkaline phosphatase should be meas‐
ured at least every 12 months [24].
The first measurable biomarker in urine is the decline of secreted Klotho expression (as de‐
tected by western blotting of concentrated urine samples, normalized to the same creatinine
content) occurs as early as stage 1 of CKD [25], therefore, Kuro-O contends that decreased
Klotho expression is the initiator of CKD-MBD pathophysiology and is potentially an early
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clinical marker of CKD [11]. The study, performed on sixty pre-dialysis patients with CKD
1-5, showed that the changing of serum OPG level happened at the earliest time (CKD 3)
and its correlation coefficient with estimated glomerular filtration rate (eGFR) and BMD of
Ward's triangle was statistically high, suggesting serum OPG may be a useful biomarker for
early diagnosis of CKD-MBD [26], additionally, the multivariate analysis demonstrated that
OPG was associated with aortic stiffness in patients with CKD stages 3-4, indicating OPG is
also a marker to evaluate the cardiomyocyte dysfunction of CKD-MBD [27].
3.2. Imaging
Histomorphometry remains the gold standard to evaluate bone, but it is rarely performed in
clinical practice. Areal measurement of bone mineral density by dual-energy x-ray absorpti‐
ometry (DEXA) is routinely performed to evaluate bone mass. However, this technique
presents some limitations. In 2000, the United States National Institutes of Health defined
new "quality" criteria for the diagnosis of osteoporosis in addition to decreased bone mass.
Bone strength actually integrates two concepts: bone quantity and bone quality (i.e., micro‐
architectural organization, bone turnover, bone material properties such as mineralization,
collagen traits, and micro-damage) that cannot be evaluated by DEXA. New three-dimen‐
sional, noninvasive bone-imaging techniques have thus been developed, e.g., high-resolu‐
tion peripheral quantitative computed tomography (HR-pQCT). HR-pQCT allows
evaluation of both volumetric density and microarchitecture in different compartments of
bone [28]. Bacchetta reported for the first time an early impairment of trabecular microarchi‐
tecture in stage 2-4 CKD patients using a noninvasive bone-imaging device, HR-pQCT [29].
Physicians usually use a variety of noninvasive imaging tools to identify VC, some with
merely qualitative and others with both qualitative and quantitative capabilities. Plain x-
rays and ultra-sonography can be used to identify macroscopic calcification of aorta and pe‐
ripheral arteries, and computed tomography technologies constitute the gold standard for
quantification of cardiovascular calcification [30].
4. Clinical treatment strategy
The clinical treatment for CKD-MBD targets the possible pathological mechanisms of main‐
ly sHPT and VC in patients with kidney failure as treating these abnormalities will have a
direct positive impact on preventing the metabolic bone disease. However, the heterogenei‐
ty of CKD-MBD makes strict protocol-driven therapeutic approaches difficult. Accordingly,
considerable individualized therapy is required [31]. The followings are currently the most
common and effective intervening methods.
4.1. Phosphate binders
In patients at stage 3-5 of CKD, multiple studies from different parts of the world have
shown that higher levels of serum phosphorus have been associated with an increased rela‐
tive risk of mortality [24]. Many clinical trials show that phosphate binders are effective in
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reducing serum phosphorus and PTH levels [32]. Therefore, the use of phosphate binders
might be a promising and most practical strategy for the prevention of VC and sHPT which
are the main pathological manifestations of the metabolic bone disease in CKD patients. The
following categories of phosphate binders are being applied clinically so far:
1. Aluminum-based phosphate binders are the first type of phosphate binders to be used.
They are very effective at controlling phosphorus. The most common binder of this type
is aluminum hydroxide. However, aluminum has toxic effects on bone and nervous
system. For this reason, aluminum-based phosphate binders are not often used much
anymore [33].
2. Calcium-based phosphate binders are effective in binding phosphates and can be
source of calcium. Common types of calcium-based binders include calcium acetate and
calcium carbonate, both of which could cause the elevation of free calcium cation level
in the gastrointestinal tract and the subsequent increase of intestinal calcium absorption
[34]. The Japanese Society of Dialysis Therapy (JSDT) clinical practice guideline has rec‐
ommended a higher level of these oral phosphate binders as the upper limit for clinical
use [35]. These binders can also serve as calcium supplements if the calcium is low.
However, if the patient is taking vitamin D supplements, he/she may already have high
calcium levels, and these types of phosphate binders may provide more calcium than
the normal level (i.e., excess calcium load). Therefore using calcium based phosphate
binders should be accompanied with monitoring calcium levels and it should be pre‐
scribed while limiting total calcium intake.
3. Aluminum-free, calcium-free phosphate binders are newer binders that are effective at
controlling phosphorus. Because they do not contain aluminum or calcium, they do not
cause problems with excess aluminum or calcium load. Lanthanum carbonate is a novel
non-calcium, non-aluminum phosphate-binding agent, and has been approved for clini‐
cal use in patients on hemodialysis in Japan on March in 2009 [33]. Sevelamer is a poly‐
meric amine, which is the only non-absorbed, non-calcium-based phosphate binder
currently indicated for phosphate control. The first formulation of sevelamer to be ap‐
proved was sevelamer hydrochloride, while a newer formulation, sevelamer carbonate,
has more recently become available [36]. Sevelamer carbonate was developed to offer
phosphorus lowering while eliminating the risk of worsening metabolic acidosis associ‐
ated with sevelamer hydrochloride and the consequent need to monitor for changes in
serum chloride or bicarbonate levels [37].
4.2. Vitamin D compounds
Vitamin D analogues suppress PTH synthesis and secretion in patients with sHPT. Reple‐
tion with native vitamin D may lead to improved control of secondary hyperparathyroidism
in patients with CKD which reduces the risk of bone mineral disease. It has been demon‐
strated that treatment with vitamin D analogues can decrease mortality in dialysis patients
[38]. There might be some differences in clinical outcomes among vitamin D compounds
with fewer calcemic and phosphatemic effects [39], such as paricalcitol, doxercalciferol, and
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maxacalcitol. Therefore, it is important for desirable active vitamin D compounds to achieve
optimal vitamin D receptor (VDR) activation without inducing hypercalcemia. It is likely
that the elevated calcium levels caused by calcitriol may be directly and/or indirectly re‐
sponsible for the relative risk of the cardiovascular diseases that are aggravated by hypercal‐
cemia in patient populations.
4.3. Calcimimetics
Calcimimetics bind to the calcium sensing receptor (CaSR) in parathyroid gland and mimic
the effect of an elevated extracellular ionized calcium concentration. These molecules reduce
serum levels of PTH and calcium, with a leftward shift in the set-point for calcium-regulated
PTH secretion [40]. Cinacalcet is the only clinically available calcimimetic and has been
shown to be a very effective therapeutic compound in the metabolic bone disease associated
with CKD. Many clinical trials with cinacalcet in hemodialysis patients have shown a reduc‐
tion in parathyroid hormone, calcium, phosphate and calcium × phosphate product levels,
allowing far greater success in reaching therapeutic goals as recommended by international
guidelines [41]. In addition to effective control of secondary hyperparathyroidism, treatment
with cinacalcet may improve the mineral balance in patients with dialysis who have serum
phosphate/calcium disequilibrium, and furthermore helps treating the vascular calcification
as well. While, calcimimetics are not approved for use in paediatric patients with CKD and
long-term data on their effects on bone, growth and biochemical parameters in children are
lacking. Thus, further studies are warranted to determine the optimal strategy for control‐
ling secondary hyperparathyroidism in the paediatric CKD population [42].
4.4. Administering BMP-7
One of the bone morphogenetic proteins,  BMP-7, also known as osteogenic protein 1,  is
highly expressed in the adult kidney, and circulates in the bloodstream [43]. Therefore, it
is apparent that the decrease of renal mass results in the decreased production of BMP-7,
causing mineral bone disease in CKD patients [44].  One may expect an accumulation of
osteoblast precursors as stimulated by PTH in CKD. While, these progenitors may be un‐
able to differentiate mature osteoblasts because of BMP-7 deficiency considering it is im‐
portant  in  osteoblast  development  and  function.  In  this  situation,  the  subsequent
accumulation of fibrous cells could then offer an explanation for the marrow fibrosis ob‐
served in secondary hyperparathyroidism in the setting of CKD and applying BMP-7 ex‐
ternally  can  heal  the  disorder.  There  are  an  increasing  number  of  recent  clinical  trials
that provide supportive evidence for the use of BMP-7 in the treatment of fractures and
bone  nonunions  [45].  It  is  not  yet  started  to  use  BMP-7  as  a  routine  clinical  treatment
tool except for trials in patients even though many of the studies have shown the bone
healing efficacy of this molecule.
4.5. Surgery on thyroid gland
A surgical  correction in the parathyroid gland is  the final,  symptomatic  therapy for the
most severe forms of sHPT which cannot be controlled by the above medical treatments.
Topics in Osteoporosis168
The  2009  KDIGO  guideline  suggested  parathyroidectomy  to  patients  who  are  at  CKD
stages 3-5 with severe hyperparathyroidism and fail to respond to medical/pharmacologi‐
cal  therapy  [46].  There  are  two  main  surgical  procedures  which  are  generally  used,
namely  subtotal  parathyroidectomy  and  total  parathyroidectomy  with  immediate  auto‐
transplantation. The number and size of affected parathyroid glands are the most impor‐
tant  factors  for  selecting  the  treatment  procedure  [47,  48].  Clinical  studies  proved  that
parathyroidectomy with autotransplantation from forearm was significantly effective and
safe in patients in whom medical  treatment had failed,  particularly in terms of improv‐
ing calcium and phosphate control [49, 50]. The procedure need to be performed as early
as  possible  to  avoid  the  adverse,  irreversible  effects  of  prolonged hyperparathyroidism,
and to improve osteoarticular symptoms. Future strategies may focus on the stimulation
of apoptotic activity of hyperplastic parathyroid cells [51].
5. Animal models
5.1. 5/6 nephrectomy model
Experimental model of 5/6 nephrectomy or the remnant kidney model represents one of
the most used animal models of progressive renal failure by reducing nephron number,
best-characterized in rats  [52].  The reduction of  renal  mass is  achieved by either  infarc‐
tion or surgical excision of both poles, with removal of the contra-lateral kidney. The 5/6
nephroctomy model has been found to produce serum creatinine level which is on aver‐
age 2.2-fold higher than control animals, and thereafter, if without the concurrent use of
vitamin  D,  the  phosphorus  level  after  8  weeks  of  surgery  would  range  up  to  2.6-fold
higher than control animals [53].  Increased fibrosis,  increased number of osteoblasts and
osteoclasts as well as a mineralization defect (increased osteoid volumes and osteoid sur‐
face),  those  of  which  are  typical  bone  changes  upon  sHPT,  have  been  observed  in  5/6
nephrectomy animal models [14].
The operation of 5/6 nephrectomy, combining with a diet containing 1.2% P plus 0.6% Ca,
could effectively induce sHPT in rats [54]. Additionally, the progressive partial nephrecto‐
my with thyroparathyroidectomy (TPTx-Nx) reduced the storage modulus, which is a me‐
chanical factor, in CKD model rats as compared with controls that underwent
thyroparathyroidectomy alone (TPTx). Moreover, the TPTx-Nx rats exerted different cortical
bone chemical composition and increased enzymatic crosslinks ratio and pentosidine to ma‐
trix ratio [55].
As concerned as VC associated with CKD-MBD, it can be induced in 5/6 nephrectomy rat
model by feeding a high-phosphorus, high-lactose diet (1.2% P, 1% Ca, and 20% lactose) af‐
ter 10 weeks follow up for the reason that lactose increases calcium and phosphorus absorp‐
tion in intestine [56].
Pathogenesis, Clinical Diagnosis and Treatment, and Animal Models for Ckd-Mbd
http://dx.doi.org/10.5772/54238
169
maxacalcitol. Therefore, it is important for desirable active vitamin D compounds to achieve
optimal vitamin D receptor (VDR) activation without inducing hypercalcemia. It is likely
that the elevated calcium levels caused by calcitriol may be directly and/or indirectly re‐
sponsible for the relative risk of the cardiovascular diseases that are aggravated by hypercal‐
cemia in patient populations.
4.3. Calcimimetics
Calcimimetics bind to the calcium sensing receptor (CaSR) in parathyroid gland and mimic
the effect of an elevated extracellular ionized calcium concentration. These molecules reduce
serum levels of PTH and calcium, with a leftward shift in the set-point for calcium-regulated
PTH secretion [40]. Cinacalcet is the only clinically available calcimimetic and has been
shown to be a very effective therapeutic compound in the metabolic bone disease associated
with CKD. Many clinical trials with cinacalcet in hemodialysis patients have shown a reduc‐
tion in parathyroid hormone, calcium, phosphate and calcium × phosphate product levels,
allowing far greater success in reaching therapeutic goals as recommended by international
guidelines [41]. In addition to effective control of secondary hyperparathyroidism, treatment
with cinacalcet may improve the mineral balance in patients with dialysis who have serum
phosphate/calcium disequilibrium, and furthermore helps treating the vascular calcification
as well. While, calcimimetics are not approved for use in paediatric patients with CKD and
long-term data on their effects on bone, growth and biochemical parameters in children are
lacking. Thus, further studies are warranted to determine the optimal strategy for control‐
ling secondary hyperparathyroidism in the paediatric CKD population [42].
4.4. Administering BMP-7
One of the bone morphogenetic proteins,  BMP-7, also known as osteogenic protein 1,  is
highly expressed in the adult kidney, and circulates in the bloodstream [43]. Therefore, it
is apparent that the decrease of renal mass results in the decreased production of BMP-7,
causing mineral bone disease in CKD patients [44].  One may expect an accumulation of
osteoblast precursors as stimulated by PTH in CKD. While, these progenitors may be un‐
able to differentiate mature osteoblasts because of BMP-7 deficiency considering it is im‐
portant  in  osteoblast  development  and  function.  In  this  situation,  the  subsequent
accumulation of fibrous cells could then offer an explanation for the marrow fibrosis ob‐
served in secondary hyperparathyroidism in the setting of CKD and applying BMP-7 ex‐
ternally  can  heal  the  disorder.  There  are  an  increasing  number  of  recent  clinical  trials
that provide supportive evidence for the use of BMP-7 in the treatment of fractures and
bone  nonunions  [45].  It  is  not  yet  started  to  use  BMP-7  as  a  routine  clinical  treatment
tool except for trials in patients even though many of the studies have shown the bone
healing efficacy of this molecule.
4.5. Surgery on thyroid gland
A surgical  correction in the parathyroid gland is  the final,  symptomatic  therapy for the
most severe forms of sHPT which cannot be controlled by the above medical treatments.
Topics in Osteoporosis168
The  2009  KDIGO  guideline  suggested  parathyroidectomy  to  patients  who  are  at  CKD
stages 3-5 with severe hyperparathyroidism and fail to respond to medical/pharmacologi‐
cal  therapy  [46].  There  are  two  main  surgical  procedures  which  are  generally  used,
namely  subtotal  parathyroidectomy  and  total  parathyroidectomy  with  immediate  auto‐
transplantation. The number and size of affected parathyroid glands are the most impor‐
tant  factors  for  selecting  the  treatment  procedure  [47,  48].  Clinical  studies  proved  that
parathyroidectomy with autotransplantation from forearm was significantly effective and
safe in patients in whom medical  treatment had failed,  particularly in terms of improv‐
ing calcium and phosphate control [49, 50]. The procedure need to be performed as early
as  possible  to  avoid  the  adverse,  irreversible  effects  of  prolonged hyperparathyroidism,
and to improve osteoarticular symptoms. Future strategies may focus on the stimulation
of apoptotic activity of hyperplastic parathyroid cells [51].
5. Animal models
5.1. 5/6 nephrectomy model
Experimental model of 5/6 nephrectomy or the remnant kidney model represents one of
the most used animal models of progressive renal failure by reducing nephron number,
best-characterized in rats  [52].  The reduction of  renal  mass is  achieved by either  infarc‐
tion or surgical excision of both poles, with removal of the contra-lateral kidney. The 5/6
nephroctomy model has been found to produce serum creatinine level which is on aver‐
age 2.2-fold higher than control animals, and thereafter, if without the concurrent use of
vitamin  D,  the  phosphorus  level  after  8  weeks  of  surgery  would  range  up  to  2.6-fold
higher than control animals [53].  Increased fibrosis,  increased number of osteoblasts and
osteoclasts as well as a mineralization defect (increased osteoid volumes and osteoid sur‐
face),  those  of  which  are  typical  bone  changes  upon  sHPT,  have  been  observed  in  5/6
nephrectomy animal models [14].
The operation of 5/6 nephrectomy, combining with a diet containing 1.2% P plus 0.6% Ca,
could effectively induce sHPT in rats [54]. Additionally, the progressive partial nephrecto‐
my with thyroparathyroidectomy (TPTx-Nx) reduced the storage modulus, which is a me‐
chanical factor, in CKD model rats as compared with controls that underwent
thyroparathyroidectomy alone (TPTx). Moreover, the TPTx-Nx rats exerted different cortical
bone chemical composition and increased enzymatic crosslinks ratio and pentosidine to ma‐
trix ratio [55].
As concerned as VC associated with CKD-MBD, it can be induced in 5/6 nephrectomy rat
model by feeding a high-phosphorus, high-lactose diet (1.2% P, 1% Ca, and 20% lactose) af‐
ter 10 weeks follow up for the reason that lactose increases calcium and phosphorus absorp‐
tion in intestine [56].




In the mouse electrocautery model, CKD is induced by surgical ablation of the kidneys. This
is a two-step procedure. Initially the cortex of one kidney is electrocauterized paying careful
attention to avoid destroying the adrenals and the hilum of kidney. One week later, once the
animals have recovered, the second kidney is nephrectomized [44]. This procedure appears
to produce variable severity of CKD with blood urea levels ranging from 1.5- to 4.8-fold
higher than normal animals [53]. This murine model displayed an increase in osteoblast sur‐
face and osteoid accumulation as well as increased activation frequency and increased os‐
teoclast surface consistent with high turnover renal osteodystrophy [44]. Lund developed a
standard CKD rat models by involving electrocauthery of the right kidney followed by
nephroctomy of the left kidney, and found that there was a significant hyperosteoidosis pro‐
duced in this model as a result of the secondary hyperparathyroidism [57].
5.3. Adenine-contained diet
Normally, adenine is efficiently salvaged by adenine phosphoribosyltransferase (APRT) and is
present at very low level in blood and urine. APRT is involved in the conversion of adenine to
adenosine monophosphate. When adenine is administered in high level, APRT activity is satu‐
rated and adenine is oxidized to 2,8-dihydroxyadenine. Adenine and 2,8-dihydroxyadenine
are excreted in the urine. However, the very low solubility of 2,8-dihydroxyadenine results in
its precipitation in the kidney. The accumulation of insoluble 2,8-dihydroxyadenine results in
nephrolithiasis and renal failure with permanent kidney damage. Induction of chronic renal
failure (CRF) in mice by dietary administration of 0.75% adenine for 4 weeks results in irrever‐
sible renal dysfunction and then CKD [53]. High-adenine feeding in rats results in the forma‐
tion  of  crystals  in  the  renal  tubules,  with  subsequent  tubular  injury  and  inflammation,
obstruction, and marked fibrosis [56]. Future investigations of the biochemical basis for the link
between vascular calcification and bone resorption will be facilitated by the present discovery
that a synthetic, 2.5% protein diet containing 0.75% adenine produces consistent and dramatic
medial calcification in adult rats within just 4 weeks [58].
5.4. Gene knockout mice
JCK mouse is a genetic model of polycystic kidney disease. At 6 weeks of age, the mice
have  normal  renal  function  and  no  evidence  of  bone  disease  but  exhibit  continual  de‐
cline in renal  function and death by 20 weeks of  age,  when approximately 40% to 60%
of them have vascular calcification. Temporal changes in serum parameters of JCK mice
relative to wild-type mice from 6 through 18 weeks of age were shown to largely mirror
serum  changes  commonly  associated  with  clinical  CKD-MBD.  Bone  histomorphometry
revealed  progressive  changes  associated  with  increased  osteoclast  activity  and  elevated
bone formation [59].
Klotho null mice display premature aging and CKD-MBD-like phenotypes mediated by hyper‐
phosphatemia and remediated by phosphate-lowering interventions (diets low in phosphate or
vitamin D; knockouts of 1α-hydroxylase, vitamin D receptor, or NaPi cotransporter) [11].
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5.5. Obstructive nephropathy
The mouse with unilateral ureteral obstruction (UUO) is a well-established model of tubuloin‐
terstitial fibrosis of the kidney as the interstitial fibrosis is a hallmark of chronic renal failure
[60]. We previously reported the vitamin D signaling attenuates renal fibrosis in obstructive
nephropathy by suppressing the renin-angiotensin system (RAS) [61], furthermore, we found
the mice developed hypocalcaemia and hyperparathyroidism after 7 days of ureteric obstruc‐
tion [62], and the down-regulation of Cbfa1 and Col mRNA expression (Fig. 1) and the up-regu‐
lation of Tgf-β, CtsK, CaII, Opg and Rankl mRNA expression (Fig. 2) in tibia of UUO mice as well
as the microarchitectural changes in the proximal tibia, likely to be precursors of the early stage
during CKD-MBD [62]. The pathological alterations of proximal tibia in UUO group were char‐
acterized by a marked expansion of hypertrophic zone of chondrocytes and a dramatic de‐
crease  in  osteoid  content  of  the  primary  spongiosa  zone,  where  the  immature,  poorly
mineralized woven bones were present,  indicating impaired mineralization of the newly
formed bones (Fig. 3B). Above all, in addition to established genetic pathways, we suggest that
the local skeletal renin-angiotensin system may be involved in the bone deteriorations associat‐
ed with CKD as demonstrated by the marked up-regulation of protein expression of angioten‐
sin II and its type 2 receptor in tibia of UUO mice (Fig. 4) [62].
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Figure 3 Hematoxylin and Eosin staining of the proximal tibia. The chondrocyte zone at growth plate 
was shown in A (Sham) and B (UUO) and it was visually separated into two areas, proliferative zone 
(PZ) and hypertrophic zone (HZ). Calcified cartilage with overlying newly bone underneath growth 
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Figure 4. Protein expression of RAS components in mice tibia
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6. Conclusion
In summary, the present review demonstrates that the main pathological mechanisms in‐
volved in CKD-MBD are secondary hyperparathyroidism and vascular calcification. There‐
fore the main focus of the therapeutic research and the further molecular investigations
should be on these main abnormalities associated with CKD. This can be achieved by em‐
ploying the proper animal models for each of these complications including genetically
modified mouse models. The animal models can play a great role in understanding the un‐
derlying mechanisms for CKD-MBD. The clinical treatment approaches should depend on
the specific levels of the biomarkers of CKD patients. Further studies are needed to discover
other pathological mechanisms for CKD-MBD other than those explained here. More ad‐
vanced basic medical sciences should also be performed on the research and development of
novel drugs with less adverse effects.
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In summary, the present review demonstrates that the main pathological mechanisms in‐
volved in CKD-MBD are secondary hyperparathyroidism and vascular calcification. There‐
fore the main focus of the therapeutic research and the further molecular investigations
should be on these main abnormalities associated with CKD. This can be achieved by em‐
ploying the proper animal models for each of these complications including genetically
modified mouse models. The animal models can play a great role in understanding the un‐
derlying mechanisms for CKD-MBD. The clinical treatment approaches should depend on
the specific levels of the biomarkers of CKD patients. Further studies are needed to discover
other pathological mechanisms for CKD-MBD other than those explained here. More ad‐
vanced basic medical sciences should also be performed on the research and development of
novel drugs with less adverse effects.
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1. Introduction
Osteoporosis affects millions of people all around the world and it is the most common
metabolic bone disease, characterized by low bone mass, disrupted bone micro architecture
and increased bone brittleness [1].
Interaction of numerous factors, such as: genetic, medical, anthropometric, pharmacological,
lifestyle and nutrition, lead to loss of bone mass and to increased risk for the osteoporotic
fractures in female [2].
The most of the studies which have explored the effect of calcium on bone mass in females,
demonstrated that high calcium intake is related to greater bone mass, compared to smaller
bone mass in respondents who had less dietary calcium intake [3]. Besides calcium, sufficient
dietary intake of other micronutrients, such as: zinc, magnesium, potassium, dietary fibers as
well as vitamin C are believed to have favorable effect on the bone metabolism too [4].
The study of osteoporotic fractures reports that higher intake of animal proteins compared to
vegetable proteins is associated to increased risk of loss of the bone mass and occurrence of
the osteoporotic fractures [5]. High protein and sodium intake increases calcium excretion in
urine, which increases the need for dietary calcium. It has been also found that a high dietary
total protein intake, increases production of endogenous acid, which results in accelerated
bone resorption and reduced bone formation. This is especially expressed in diets high in
animal proteins [6]. It is believed that unfavorable effect of the animal proteins on the bone
metabolism can be repaired by higher fruit and vegetable intake [7].
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Recent  researches  indicate  a  risk  of  excessive  fat  intake,  which leads  to  metabolic  bone
disorders.  High  fat  intake  is  considered  to  be  a  risk  factor  for  osteoporosis,  because  it
reduces  the  calcium  absorption,  since  calcium  forms  insoluble  compounds  with  fatty
acids [7].
The aim of this study was to quantify the intake of trace elements in fruit and vegetable: zinc,
magnesium, potassium and dietary fats as well as fat derivatives intake in examinees and to
explore their relation to the bone mass. The aim was to examine the extent to which these
nutritional parameters are predictors of values of bone mineral density.
2. Patients and methods
2.1. Subjects
The study population consisted of women with sedentary occupations in age ranged from 40
to 67 years. Women are inhabitants of the down town Rijeka, Croatia. Exclusion criteria for
further participation in the survey were: smoking and any medical therapy which can alter
bone metabolism, including food supplements with added calcium. Dietary habits, anthropo‐
metric characteristics, serum concentration of the biochemical markers and values of the bone
densitometry parameters were comprised by this study. 200 women were included in this
investigation, of which 120 menopausal women constituted experimental group, and 80 fertile
women represents the control group.
2.2. Dietary intakes
Participants completed an anonymous, encrypted questionnaire, conducted in accordance
with ethical and bioethical principles and their privacy and protection of confidential infor‐
mation was ensured.
For the assessment of dietary habits and the average daily energy and nutrients intake, we
used data obtained from semi- quantitative Food Frequency Questionnaire- sq-FFQ, the main
method for collecting data about a foodstuff choice, as well as the type and quantity of food
intake in the study population. This method of identifying the dietary habits is a questionnaire
validated by the Department of Nutrition, Harvard School of Public Health [8], from which
are obtained informations about daily intake of energy and nutrients. Women were asked to
note the frequency and the quantity of offered food items. The amount of each food item was
offered as one portion and declared as small, medium and large. This method quantified the
values of nutritional parameters that are essential for bone health, such as: calcium, phospho‐
rus, vitamin D, proteins, zinc, magnesium, potassium, dietary fibers and vitamin C. We also
determined a total fat intake and the emphasis was placed on the intake of total fat, saturated
fatty acids, monounsaturated fatty acids and polyunsaturated fatty acids. The nutritive and
energy values of each food noted were calculated using the composition tables of raw and
cooked food [9].
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2.3. Anthropometric, biochemical and bone mineral status measurements
Bodyweight was measured on a portable electronic scale (SECA, Hamburg, Germany), with
accuracy of ± 0,1 kg. Body height was measured on a portable stadiometer, which is a part of
a specified scale (SECA, Hamburg, Germany), to the nearest ± 0,5 cm. Body mass index was
calculated as bodyweight divided by body height squared, BMI (kg/m²) [10].
Biochemical indicator of bone resorption, deoxypyridinolin (DPD) and biochemical indicator
of bone formation, bone alkaline phosphatase (ALP) and vitamin D were determined from
urine and blood of the respondents by immune-enzymatic method (Enzyme Linked Immu‐
nosorbent Assay, ELISA), according to manufacturer's protocol [11,12,13].
Bone density in the anterior-posterior images of the spine and hip was measured using the
device for bone densitometry (Hologic, Bedford, MA, USA). The obtained values were
quantified according to the following parameters: bone mineral content (BMC, mg), bone
mineral density (BMD, mg/cm2) and T-score (represents a deviation from the BMD measured
values of peak bone mass of young people expressed in standard deviations) and Z-score
(deviation of the measured values BMD of the average bone mass of persons of the same age,
expressed in standard deviations) [14].
2.4. Statistical analysis
Statistical analysis of data was performing by using Statistica for Windows, release 9.1 (Stasoft,
INC, Tulsa, USA). Normality of distribution for the data interval scale (quantitative data), was
tested using the Kolmogorov- Smirinov test. The results were shown as arithmetic mean and
standard deviation. Results were distributed normally and in the analytical statistics, one-way
analysis of variance (one-way ANOVA) was used. To determine the significance of the
contribution of the percentage of nutrients on the metabolic bone status, multiple regression
analysis was used. All statistical values were considered significant at the level P<0,05 [15].
2.5. Results
Age, anthropometric characteristics, values of the bone densitometry parameters and concen‐
trations of the bone remodeling markers are presented in Table 1. Women of generative age
are significantly taller than women in menopause (P=0,01) and have significantly higher body
weight than women in menopause (P<0,001). The average value of Body Mass Index (BMI)
was 27 kg/m².
Subjects of generative age have significantly higher values of BMD and BMC of the spine
(P<0,001, P<0,001), as well as the values of T-score and Z-score (P<0,001, P<0,001), than
menopausal women, respectively. Values of BMD and BMC of the hip (P<0,001, P<0,001) and
the value of T-score (P<0,001) were also significantly higher in women of generative age.
Regarding the bone remodeling markers, significantly lower values of DPD (P<0,001) and bone
ALP (P=0,004) were found in fertile women compared to menopausal women.
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Age 47,6 ±4,1 59,9 ± 5,1 54,9 ± 7,7 <0,001*
Body height (cm) 74,0 ± 6,4 71,7 ± 13,3 72,6 ± 11,1 0,001*
Body weight (kg) 166,8 ± 0,05 161,9 ± 0,06 163,8 ± 0,06 <0,001*
BMI (kg/m2) 26,6 ± 2,3 27,3 ± 4,7 27,0 ±3,9 0,210
BMD LS (g/cm2) 1,074 ± 0,1 0,897 ± 0,1 0,968 ± 0,2 <0,001*
BMC LS (g) 67,49 ± 9,4 52,84 ± 9,7 58,70 ± 11,9 <0,001*
T-score 0,400 ± 1,3 -1,325 ± 1,3 -0,635 ± 1,9 <0,001*
Z-score 0,835 ± 1,3 0,033 ± 1,4 0,354 ± 1,4 <0,001*
BMD LH (g/cm2) 0,944 ± 0,1 0,860 ± 0,1 0,893 ± 0,1 <0,001*
BMC LH (g) 37,29 ± 5,9 30,83 ± 5,5 33,41 ± 6,5 <0,001*
T-score 0,122 ± 0,8 -0,647 ± 1,1 -0,339 ± 1,1 <0,001*
Z-score 0,453 ± 0,9 0,298 ± 1,0 0,360 ± 1,0 0,269
DPD (nmol/l) 5,26 ± 1,4 6,85 ± 2,5 6,22 ± 2,2 <0,001*
ALP (ng/ml) 22,77 ± 8,1 26,0 ± 7,4 24,71 ± 7,8 0,004*
Vitamin D (nmol/l) 62,03 ± 25,8 68,90 ± 29,1 66,16 ± 27,9 0,09
* statistical significance on level P < 0,05
LS – lumbar spine
LH – left hip
Table 1. Age, anthropometry, bone densitometry parameters, bone remodeling markers and vitamin D (X̄ ± SD)
Dietary habits of the study participants are presented in the Table 2. One-way analysis of
variance (ANOVA) showed that women of generative age have significantly higher average
daily intake of vitamin D, vitamin C, potassium, magnesium and zinc, while menopausal










Energetic food equivalent kcal
kJ
2851,91 ± 1034,4 2448,65 ± 716,37 2609,95 ± 877,9 <0,001*
11932,38 ± 4327,8 10,245 ± 2997,3 10920,04 ± 3673,5 <0,001*
Proteins (total) (g) 90,76 ± 65,4 60,52 ± 28,9 75,64 ± 50,7 <0,001*
Proteins (vegetable) (g) 21,95 ± 22,5 19,70 ± 9,2 20,71 ±16,7 <0,001*
Proteins (animal) (g) 67,88 ± 45,5 40,20 ± 24,7 54,04 ± 37,0 <0,001*
Total fat (g) 101,74 ± 63,9 74,76 ± 45,37 87,30 ± 56,3 <0,001*
Saturated fatty acids (g) 45,35 ± 28,3 31,41 ± 22,6 38,38 ± 25,8 <0,001*
Monounsaturated fatty acids (g) 34,40 ± 25,32 26,37 ± 18,2 30,39 ± 22,1 <0,001*
Polyunsaturated fatty acids (g) 20,89 ± 13,05 16,98 ± 8,2 18,94 ± 11,5 <0,001*
Carbohydrates (g) 180,16 ± 215,9 152,05 ± 90,2 166,10 ± 163,8 <0,001*
Vegetable fibers (g) 26,72 ± 24,1 14,27 ± 11,5 20,50 ± 18,7 <0,001*
Vitamin D (μg) 9,91 ± 5,1 6,32 ± 7,6 7,76 ± 6,9 <0,001*
Vitamin C (mg) 131,62 ± 111,1 118,36 ± 112,0 123,66 ± 166,8 <0,001*
Calcium (mg) 953,91 ± 316,32 918,79 ± 232,0 932,74 ± 268,7 0,366
Phosphorus (mg) 1012,23 ± 315,23 1132,21 ± 235,25 1072,22 ± 235,2 <0,001*
Potassium (mg) 6441,99 ± 3231,4 4453,70 ± 1362,0 5294,02 ± 2482,4 <0,001*
Magnesium (mg) 546,16 ± 245,9 404,70 ± 136,1 461,28 ± 199,8 <0,001*
Zinc (mg) 17,38 ± 8,0 13,02 ± 4,2 14,77 ± 6,4 <0,001*
* statistical significance on the level P < 0,05
Table 2. The average daily nutrient intake in fertile and in menopausal women (X̄ ± SD)
DXA parameters which were extracted by ROC analyses as excellent predictors of bone
metabolism were included in multiple regression analyses. Those include: LS BMC, LS BMD,
LS T-score, LS Z-score, LH BMC, LH T-score.
The results of multiple regression analysis by which are defined total shares and significance
of contributions of menstrual status, age, anthropometry and nutrition on the bone densitom‐
etry parameters. The largest total share of contributions to all the bone densitometry param‐
eters was observed for menstrual status and diet (Table 3).
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LS BMC 40,1 8,4 8,5 44,8
LS BMD 29,6 3,3 16,6 12,7
LS T-score 29,6 6,1 19,3 27,4
LS Z-score 20,8 7,2 13,0 12,7
LH BMC 27,8 12,0 24,2 23,2
LH T-score 24,5 0,5 27,0 18,6
LS – lumbar spine
LH – left hip
Table 3. Total shares of contributions of menstrual status, age, anthropometry and nutrition on DXA (%)
Parameters LS BMC LS BMD LS T-score LS Z-score LH BMC LH T-score
ß P ß P ß P ß P ß P ß P
Menstrual status -0,632 <0,001* -0,560 <0,001* -0,632 <0,001* -0,529 <0,001* -0,568 <0,001* -0,389 <0,001*
Age -0,156 0,057 -0,097 0,251 -0,156 0,057 -0,365 0,001* -0,210 0,010* -0,017 0,831
Nutrition
Energy 0,346 0,014* 0,238 0,150 0,667 0,016* 0,627 0,002* 0,400 0,048* 0,063 0,529
Proteins (g) 0,008 0,580 0,010 0,445 0,081 0,481 0,004 0,978 0,349 <0,001* 0,786 0,082
Total fat (g) -0,273 0,036* -0,103 0,386 -0,098 0,016* -0,191 0,127 -0,427 0,016* -0,500 0,054
Saturated fatty
acids (g)
-0,234 0,810 -0,141 0,166 0,148 0,005* -0,016 0,332 -0,414 0,053 -0,259 0,244
Monounsaturated
fatty acids (g)
0,079 0,551 0,029 0,875 0,144 0,019* 0,031 0,145 0,328 0,182 0,258 0,312
Polyunsaturated
fatty acids (g)
0,086 0,546 0,044 0,782 0,209 0,049* 0,013 0,104 0,310 0,069 0,329 0,063
Calcium (mg) 2,045 0,256 0,538 0,168 0,007 0,145 -0,219 0,032* 0,034 0,626 0,023 0,748
Potassium (mg) 0,211 0,004* 0,536 0,006* 0,213 0,005* 0,103 0,004* 0,089 0,001* 0,750 0,414
Phosphorus (mg) -0,623 0,277 -0,078 0,053 0,139 0,031* 0,071 0,033* -0,078 0,851 -0,234 0,588
Magnesium (mg) 0,073 0,002* 0,054 0,053 0,133 0,036* 0,031 0,010* 0,157 0,002* 0,422 0,187
*statistical significance on level P < 0,05
β – regression coefficient
LS – lumbar spine
LH – left hip
Table 4. Statistically significant interactions of predictors (menstrual status, age, and nutrients) to categorical variables
(LS BMC, LS BMD, LS T-score, LS Z-score, LH BMC, LH T-score) are shown
Menstrual status, age, total fat, saturated fatty acids, are inversely proportional to the values
of the bone densitometry parameters, while energy, proteins, monounsaturated fatty acids,
polyunsaturated fatty acids, calcium, potassium and magnesium are exactly proportional to
the values of the bone densitometry parameters.
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Parameters Milkand milk products Fish Vegetables Fruit
LS BMD β P β P β P β P
0,008 0,169 0,031 0,677 0,034 0,742 0,027 0,733
LS BMC 0,109 0,128 0,171 0,014* 0,006 0,346 0,016 0,645
LS T-score 0,077 0,301 0,043 0,577 0,089 0,150 0,047 0,556
LS Z-score 0,105 0,163 0,008 0,024* 0,127 0,135 0,092 0,256
LH BMC 0,039 0,598 0,086 0,005* 0,214 0,002* 0,156 0,050
LH T-score 0,178 0,015* 0,135 <0,001* 0,178 0,004* 0,107 0,178
*statistical significance on level P < 0,05
β – regression coefficient
LS – lumbar spine
LH – left hip
Table 5. Interactions of predictors (milk and milk products, fish, vegetables and fruit) to categorical variables (LS BMD,
LS BMC, LS T-score, LS Z-score, LH BMC, LH T-score) are shown
Milk and milk products, fish, vegetables and fruit are exactly proportional to the bone
densitometry parameters.


















Menstrual status 40,1 29,6 29,6 20,8 27,8 24,5
Age 8,4 3,3 6,1 7,2 12,0 0,5
Energy 2,7 0,5 2,8 3,2 1,4 0,2
Proteins (g) 0,2 0,1 0,2 0 5,8 4,8
Total fat (g) 5,8 0,9 2,4 1,8 1,5 2,4
Saturated fatty acids
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0,5 1,6 3,3 0,2 1,7 0,7
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fatty acids (g)
1,4 0,2 2,2 0,3 1,5 0,7
Polyunsaturated
fatty acids (g)
1,6 0,5 1,6 0,1 0,2 0,6
Calcium (mg) 0,9 0,7 1,0 1,8 0,2 0
Potassium (mg) 8,8 5,9 3,4 4,1 7,3 5,1
Phosphorus (mg) 5,3 0,6 3,5 4,5 0 0,9
Magnesium (mg) 10,1 0,2 3,1 2,4 2,8 0,8
Table 6. Total shares of contributions of menstrual status, age and nutrition on DXA (%)
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It  is  considered that  menopausal  women have the highest  risk of  osteoporotic  fractures
and the incidence of  osteoporosis  in this  group is  increased by 25% compared to fertile
women  [3].  Furthermore,  the  frequency  of  osteoporotic  vertebral  and  hip  fractures  in
both  genders  increases  exponentially  with  age  [1].  Results  obtained by  this  study coin‐
cide  with  the  majority  of  results  of  similar  studies,  showing  that  menopausal  women
have significantly lower values of the bone densitometry parameters [17,18,19]. The latter
is  additionally  confirmed by our  finding of  inversely  proportional  relationship between
menopause  and  bone  mineral  density  parameters.  Our  result  of  inversely  proportional
relationship  between age  and bone mineral  density  parameters,  corresponds  to  a  study
conducted on 450 000 participants from Sweden [20].
Bone remodeling markers  provide  information about  the  dynamic  state  of  bone  metab‐
olism,  and  those  are  very  useful  tools  to  predict  early  changes  in  the  bone  metabo‐
lism.  Along  with  the  bone  densitometry,  bone  remodeling  markers  are  needy  in
diagnosis  and  follow  up  of  diseases  of  the  bone  mass  deficit  [21].  We  have  demon‐
strated that  women of  generative  age  have  significantly  lower  values  of  DPD (P<0,001)
than  women  in  menopause.  This  is  consistent  to  increased  excretion  of  DPD  in  post‐
menopausal  women  [22].  Menopausal  women  had  significantly  higher  levels  of  bone
ALP (P=0,004)  compared to women in generative age.  The latter  could be explained by
the  fact  that  high  serum  concentration  of  bone  formation  markers  is  associated  with
greater  bone  loss  [23].  Average  concentration  of  vitamin  D  in  all  study  participants
amounted  66,16  nmol/l,  out  of  which  average  value  in  fertile  women  amounted  62,03
nmol/l,  and  68,9  nmol/l  in  menopausal  women  (Table  2).  Similar  values  of  vitamin  D
concentrations  were  observed  in  a  study  of  postmenopausal  women  of  nine  European
countries  [24].  By adding our results  of  low vitamin D concentrations to  similar  results
published  by  Kraljević  et  al.  [25]  and  by  Žerjavić  et  al.  [26],  we  can  summarize  that
some action should be done by Croatian Health Care system,  such as  food-based strat‐
egies,  to  prevent  vitamin D deficiency in Croatia.
Nutrition has a unique role in processes of growth and modeling of the human skeleton,
as well as in maintaining the peak bone mass in adulthood [2].  The most of the studies
are  focused  on  dietary  calcium  intake  [19],  some  of  the  researchers  have  analyzed  the
impact  of  some  other  nutrients  such  as  proteins,  carbohydrates,  fat  and  energy  intake
[27],  and  only  a  few  studies  have  explored  the  influence  of  vitamins  and  minerals  on
bone mass [7].  Calcium in a form of the calcium phosphate or calcium carbonate is  the
major mineral constituent of the bone tissue. High calcium intake, within the normal di‐
et,  does not protect against fractures,  but low calcium intake represents a risk factor for
the osteoporosis [19].
By means of the multiple regression analysis we have determined that the greatest con‐
tribution of  the  anthropometry  is  to  values  of  the  BMC and the  T-score  of  the  left  hip
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(Table  3).  A  positive  relationship  between  increased  body  weight  or  body  mass  index
(BMI)  to  bone  mass  has  been  already  reported  [28,29].  Some  authors  have  considered
that increased body weight can improve bone mass, by stimulation of the osteoblast dif‐
ferentiation.  Body  weight  increase  in  postmenopausal  period  is  correlated  to  increased
number of adipocytes. Adipocytes are an important source of estrogen, a hormone which
stimulates  bone formation [30].  The opposite  theories  to  afore  mentioned have been re‐
ported too [31]  and amongst  those  is  a  research of  Kroke et  al.  [32],  who did not  find
strong influence of anthropometric parameters on bone mineral density neither in wom‐
en of generative age, nor in postmenopausal women.
It has been proposed that high energy intake, leads to body weight increase and finally to
increased values of the bone mineral density [33,34]. Similarly to results obtained by Kumar
et al. [35], our results indicate that daily energy intake is exactly proportional to the values of
the bone densitometry parameters (Table 4).
Total daily protein intake is directly proportional to the values of the bone densitometry
parameters,  which was significant for the LH BMC (P<0,001) (Table 4).  Such result  is  in
agreement to results obtained by Misra et al. [36]. These researchers have documented a
positive correlation between total protein intake and increased bone mineral density. Fur‐
ther  protein  analysis  revealed  a  positive  influence  of  proteins  of  vegetable  origin  and
negative  influence  of  proteins  of  animal  origin  on the  bone mass.  SOF study (Study of
osteoporotic  fractures)  found  that  women  with  increased  animal  proteins  intake  have
low values of the bone mineral density and increased risk of osteoporotic fractures [5].
Total  fat  and saturated fatty acids are inversely proportional  to  DXA parameters,  while
monounsaturated  and  polyunsaturated  fatty  acids  are  exactly  proportional  to  DXA  pa‐
rameters (Table 4).  Greater shares of contribution of all four types of fat were found for
DXA parameters of the lumbar spine than of the left hip (Table 6).  Significance was ob‐
served for the T-score of the lumbar spine (Table 4). Corwin et al., conducted the survey
on  menopausal  women,  and  found  a  negative  correlation  between  total  fat  intake  and
bone mineral  density  [37].  Another  research of  Hogstroma et  al.  corresponds to  our re‐
sults  since  they  have  also  found  positive  correlation  between  monounsaturated  fatty
acids intake and bone mineral density [38].
Regarding daily  calcium intake,  total  shares  of  calcium contribution are  greater  in  lum‐
bar  spine  than  in  the  left  hip.  Interestingly  calcium  does  not  contribute  at  all  to  the
values  of  the  LH  T-score  (Table  6).  Calcium  is  directly  proportional  to  the  values  of
DXA  parameters,  but  the  only  statistical  significance  relates  to  LS  Z-score  (Table  4).
Similarly  was found in  the study of  H.  F.  Saadi  et  al.,  where dietary calcium intake of
fertile  women  and  postmenopausal  women  is  positively,  but  not  significantly  correlat‐
ed  to  bone  mineral  density  [39].  Average  daily  calcium  intake  amounted  932,74  g,
which are  adequate  amounts  of  dietary  calcium according to  existing recommendations
in Croatia  (Table  2).
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Daily intake of  the minerals  magnesium and potassium has the greatest  contribution of
all  the  given  minerals  to  DXA  parameters  (Table  6).  Both  of  the  minerals  are  directly
proportional to DXA parameters (Table 4).  Studies published so far argue that sufficient
magnesium and potassium intake is related to increased bone mineral density [40,41], or
as contrast opinions state, to reduced bone mass and increased risk of wrist fracture [43].
Magnesium is important in processes of bone mineralization,  and potassium has impor‐
tant role in systemic acid-base (pH) homeostasis.  Potassium salts neutralize bone-deplet‐
ing metabolic acids, and therefore conditions that require drain of alkalizing compounds
from bone lead to loss of bone tissue. Positive influence of potassium on bone health has
been reported [3,4,40,45].
Zinc  is  a  cofactor  for  alkaline  phosphatase,  an  enzyme,  necessary  for  bone  mineraliza‐
tion. Low concentration of the zinc in serum and its increased secretion in urine is asso‐
ciated with osteoporosis  [44].  Considering that  calcification of  the bone is  reduced with
insufficient zinc intake, we analyzed influence of the dietary zinc on bone health. Results
revealed that daily zinc intake is directly proportional to DXA parameters, but the influ‐
ence was not significant (data not shown).
Analyzing  the  impact  of  fruit  and  vegetables  on  DXA parameters  in  women,  we  have
found that  vegetables  are  directly  proportional  to  the  parameters  of  the  left  hip,  which
is  statistically  significant  (table  5).  Similar  results  were  obtained by New et  al.  [3]  who
have  that  bone  mineral  density  in  premenopausal  women  was  positively  related  to
fruit  and  vegetable  intake,  as  well  as  to  magnesium,  calcium,  zinc  and  plant  fibers.
Similarly,  Tucker  et  al.  have  found  better  bone  mass  in  women  who  consumed  more
fruits,  vegetables,  potassium and magnesium [41].  However,  other  study which  has  in‐
cluded postmenopausal  women,  showed no relationship between bone mass  to  fruit  or
vegetable  intake [7,46].
Regarding the mechanisms fruit  and vegetables  influence bone metabolism,  it  is  impor‐
tant to mention that these nutrients create an alkaline environment and therefore reduce
urinary calcium excretion. Besides, fruits and vegetables are rich in vitamins with antiox‐
idant properties such as vitamin C and beta-carotene. Vegetables are an important source
of vitamin K, which also has a role in the mineralization of bone since it induces carbox‐
ylation of osteocalcin [40].
4. Conclusion
Analyses of the impact of age, anthropometric parameters, menstrual status and nutrition on
the bone status, represents the age and menstrual status as predictors with the highest
influence on the bone mineral density in women.
Fruits and vegetables have pleiotropic effects on bone metabolism, which include: alkalinity,
antioxidant properties of vitamins and as it was determined by this study, beneficial influence
of minerals magnesium, potassium and zinc.
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[6] Weikert, C, Dietmar, W, Hoffman, K, Kroke, A, Bergmann, M. M, & Boeing, H. The
Relation between Dietary Protein, Calcium and Bone Health in Women: Results from
the EPIC-Postdam Cohort. Ann Nutr Metab (2005). , 49, 312-318.
[7] Mecdonald, H. M, New, S. A, Golden, M. H, Cambel, M. K, & Reid, D. M. Nutritional
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Daily intake of  the minerals  magnesium and potassium has the greatest  contribution of
all  the  given  minerals  to  DXA  parameters  (Table  6).  Both  of  the  minerals  are  directly
proportional to DXA parameters (Table 4).  Studies published so far argue that sufficient
magnesium and potassium intake is related to increased bone mineral density [40,41], or
as contrast opinions state, to reduced bone mass and increased risk of wrist fracture [43].
Magnesium is important in processes of bone mineralization,  and potassium has impor‐
tant role in systemic acid-base (pH) homeostasis.  Potassium salts neutralize bone-deplet‐
ing metabolic acids, and therefore conditions that require drain of alkalizing compounds
from bone lead to loss of bone tissue. Positive influence of potassium on bone health has
been reported [3,4,40,45].
Zinc  is  a  cofactor  for  alkaline  phosphatase,  an  enzyme,  necessary  for  bone  mineraliza‐
tion. Low concentration of the zinc in serum and its increased secretion in urine is asso‐
ciated with osteoporosis  [44].  Considering that  calcification of  the bone is  reduced with
insufficient zinc intake, we analyzed influence of the dietary zinc on bone health. Results
revealed that daily zinc intake is directly proportional to DXA parameters, but the influ‐
ence was not significant (data not shown).
Analyzing  the  impact  of  fruit  and  vegetables  on  DXA parameters  in  women,  we  have
found that  vegetables  are  directly  proportional  to  the  parameters  of  the  left  hip,  which
is  statistically  significant  (table  5).  Similar  results  were  obtained by New et  al.  [3]  who
have  that  bone  mineral  density  in  premenopausal  women  was  positively  related  to
fruit  and  vegetable  intake,  as  well  as  to  magnesium,  calcium,  zinc  and  plant  fibers.
Similarly,  Tucker  et  al.  have  found  better  bone  mass  in  women  who  consumed  more
fruits,  vegetables,  potassium and magnesium [41].  However,  other  study which  has  in‐
cluded postmenopausal  women,  showed no relationship between bone mass  to  fruit  or
vegetable  intake [7,46].
Regarding the mechanisms fruit  and vegetables  influence bone metabolism,  it  is  impor‐
tant to mention that these nutrients create an alkaline environment and therefore reduce
urinary calcium excretion. Besides, fruits and vegetables are rich in vitamins with antiox‐
idant properties such as vitamin C and beta-carotene. Vegetables are an important source
of vitamin K, which also has a role in the mineralization of bone since it induces carbox‐
ylation of osteocalcin [40].
4. Conclusion
Analyses of the impact of age, anthropometric parameters, menstrual status and nutrition on
the bone status, represents the age and menstrual status as predictors with the highest
influence on the bone mineral density in women.
Fruits and vegetables have pleiotropic effects on bone metabolism, which include: alkalinity,
antioxidant properties of vitamins and as it was determined by this study, beneficial influence
of minerals magnesium, potassium and zinc.
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1. Introduction
Population aging has exhibited a significant increase in the last decades. For instance, in Brazil,
recent projections by the IBGE 1 (Instituto Brasileiro de Geografia e Estatística/Brazilian
Institute of Geography and Statistics) forecast a threefold increase of the elderly population
by 2050 from the current 10.8% to 29.7% of the country’s total population, corresponding to
almost 65 million people. The life expectancy at birth of the overall population increased to 73
years in the last decade (1999-2009), ranging from 73.9 to 77 years among females and 66.3 to
69 years among males. Such aging of the Brazilian population will pose increasing challenges
to the national public health system, SUS (Sistema Único de Saúde/Unified Health System), as
older adults exhibit a larger number of chronic diseases, which contribute to loss of function‐
ality and decline of the quality of life.
The expected and, indeed, already occurring consequences include the progressive increase
of the demand for public healthcare services, higher numbers of hospital admissions, and the
use of long-term care facilities [2, 3]. The growth of the elderly population may cause a
significant increase of the prevalence of chronic diseases, frailty syndrome, and femoral head
fractures, which are frequent occurrences in developed countries.
In a Brazilian population-based study involving more than 2,400 individuals older than 40
years, Pinheiro et al. 4 reported incidences of frailty fractures of 15.1% among females and
12.8% among males. A study conducted by the National Institute of Traumatology and
Orthopedics (Instituto Nacional de Traumato-Ortopedia - INTO) in Rio de Janeiro reported
that the incidence of osteoporosis was 36.4% among men older than 80 years 5. Cost studies
indicate that the average cost of in-hospital intervention and surgery per patient is approxi‐
mately BRL 24,000.00 (USD 11,700.00) 6.
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1. Introduction
Population aging has exhibited a significant increase in the last decades. For instance, in Brazil,
recent projections by the IBGE 1 (Instituto Brasileiro de Geografia e Estatística/Brazilian
Institute of Geography and Statistics) forecast a threefold increase of the elderly population
by 2050 from the current 10.8% to 29.7% of the country’s total population, corresponding to
almost 65 million people. The life expectancy at birth of the overall population increased to 73
years in the last decade (1999-2009), ranging from 73.9 to 77 years among females and 66.3 to
69 years among males. Such aging of the Brazilian population will pose increasing challenges
to the national public health system, SUS (Sistema Único de Saúde/Unified Health System), as
older adults exhibit a larger number of chronic diseases, which contribute to loss of function‐
ality and decline of the quality of life.
The expected and, indeed, already occurring consequences include the progressive increase
of the demand for public healthcare services, higher numbers of hospital admissions, and the
use of long-term care facilities [2, 3]. The growth of the elderly population may cause a
significant increase of the prevalence of chronic diseases, frailty syndrome, and femoral head
fractures, which are frequent occurrences in developed countries.
In a Brazilian population-based study involving more than 2,400 individuals older than 40
years, Pinheiro et al. 4 reported incidences of frailty fractures of 15.1% among females and
12.8% among males. A study conducted by the National Institute of Traumatology and
Orthopedics (Instituto Nacional de Traumato-Ortopedia - INTO) in Rio de Janeiro reported
that the incidence of osteoporosis was 36.4% among men older than 80 years 5. Cost studies
indicate that the average cost of in-hospital intervention and surgery per patient is approxi‐
mately BRL 24,000.00 (USD 11,700.00) 6.
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As the number of hospital admissions due to bone fractures among the Brazilian population
older than 40 years is higher than 250,000 per year [7], a total cost of approximately 3 billion
dollars (BRL 6.5 billion) might be estimated. This estimate comprises only hospital expenses;
the cost of home and outpatient care and the loss of patient and caregiver productivity must
be added to this estimate together with the incalculable costs associated with loss of quality of
life and health. Consequently population aging is an emerging and serious problem.
2. Frailty
Aging is associated with progressive manifestations of frailty, poorer capacity of adaptation,
and less resilience, which is defined as the ability of individuals to address problems, overcome
obstacles, or resist the pressure imposed by adverse conditions.
The conference on frailty in older adults sponsored by the American Geriatrics Society (AGS)
and the National Institute on Aging (NIA) defined frailty as a “state of greater vulnerability
to stressors due to age and declines related with the neuromuscular, metabolic and immune
physiological reserve [8].
The correlation between frailty and orthopedic risks is patent among older adults.
Fried et al. [9] created a definition of the phenotype of frailty that is widely used in research
protocols and was validated in the Cardiovascular Health Study (CHS), which was conducted
with more than 5,000 men and women aged 65 years or older. According to this study, frailty
corresponds to the presence of three or more of the following criteria (pre-frailty corresponds
to the presence of less than three):
1. Weight loss (≥ 5% of the body weight in the past year)
2. Exhaustion (positive answers to questions on the effort needed for physical activity)
3. Weakness (reduced grip strength)
4. Slow walking speed (> 6 to 7 minutes to walk 15 m)
5. Low physical activity (Kcal per week: men < 383 Kcal, women < 270 Kcal)
In a study on the index of osteoporotic fractures, Ensrud et al. [10] applied a simpler index to
define frailty, whereby it corresponds to the presence of at least two out of the three following
criteria:
1. Loss of 5% of the body weight in the past year
2. Inability to rise from a chair five times without using the arms
3. Answering “no” to the question, “Do you feel full of energy?”
Several studies [11, 12] found that the two abovementioned indices were comparable in the
prediction of the risk of fall, deficiency, fracture, hospital admission, and death.
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There is a clear correlation between the criteria used in the definition of frailty and the factors
related with fall risk and osteoporosis. From the syndromic perspective, a strong correlation
exists indicating that frailty as such might be considered as a predisposing factor for falls,
fractures, and their complications among the elderly population.
3. Falls
Falls are most likely the main health problem among the elderly population, frail people in
particular. The risks of fractures and their complications increase together with osteoporosis.
A cohort study conducted in the city of São Paulo and involving more than 1,500 participants
[13] found that 35% to 40% of the elderly individuals aged 60 years or older fall at least once
per year, and this rate grows to 50% among individuals older than 80 years.
In the abovementioned study, the variables that independently and significantly correlated
with increased probability of falls were female gender, previous history of fractures, difficulty
to perform physical activity, and reported poor or very poor vision.
Upon investigating falls, another cohort study in São Paulo involving more than 2,000 older
adults [14] reported that 33.5% of the studied population reported falls in the past year,
whereby 20.2% of the participants reported one single episode, 5.9% reported two episodes,
and 7.4% reported three or more episodes.
That same study clearly established a direct correlation between frailty and number and
severity of falls.
4. Osteoporosis and aging
Osteoporosis and falls represent the main risk factors for the occurrence of fractures, which
possibly are the main health problem of older adults.
4.1. Physiopathology
The skeleton performs a double function related with metabolism and body support.
A reduction of bone mass associated with deterioration of its microarchitecture predisposes
an individual to fractures. The bone is a metabolically active tissue, undergoing constant
remodeling through the action of the cells responsible for bone resorption (osteoclasts –
derived from the monocyte lineage) and formation (osteoblasts – derived from the fibroblast
lineage).
The control of bone resorption and formation is coordinated and synchronized by a system
known as RANK-RANKL-OPG, which allows for a better understanding of bone physiology
and paves the way for the development of novel treatments1.
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The cytokine RankL, a member of the TNF (tumor necrosis factor) superfamily, is expressed
and secreted by osteoblasts. Interaction between RankL (expressed on the osteoblast surface)
and RanK (expressed on the surface of the osteoclast precursors) mediates differentiation and
activation of osteoclasts in the presence of M-CSF (macrophage colony-stimulating factor).
Mature osteoclasts initiate the process of bone resorption. The interaction between RankL and
its receptor on osteoclasts is controlled by osteoprotegerin (OPG). OPG is a soluble receptor
belonging to the TNF family that inhibits the binding of RankL to RanK, thus preventing the
recruitment, proliferation, and activation of osteoclasts, and this receptor also exerts inhibitory
effects on the osteoclast precursor cells. The balance between OPG and RankL controls bone
remodeling.
The balance of the RANK/RANKL/OPG system is regulated by cytokines and hormones.
Parathormone (PTH), glucocorticoids, and E2 prostaglandins increase the activity of RANKL
and reduce the activity of OPG. However, transforming growth factor beta (TGF-β), 17 β-
estradiol, interleukin 1 (IL-1), and TNF-α exhibit the opposite actions, i.e., they reduce the
activity of RANKL and activate OPG. [3]
During growth and aging, the predominance of formation and resorption alternate in the
development of bone. Formation is greater until the age of 25 years, stabilizes until the age of
35 years, then decreases progressively, exhibiting a greater decline starting at the age of 70
years. Resorption predominates starting at the age of 35 years and accelerates during the
postmenopausal period and until the age of 70 years.
Osteoporosis can be classified as primary or secondary. In turn, primary osteoporosis is
subdivided into
• Type I or postmenopausal, which is characterized by increased bone resorption.
• Type II or senile, which is characterized by decreased bone formation.
Secondary osteoporosis, resulting from other pathologies, may be triggered by
• Endocrine disorders: Hyperthyroidism, Diabetes, Hyperparathyroidism, Hypercortisolism,
Hypogonadism
• Rheumatic disorders: Rheumatoid arthritis, Spondylitis
• Malabsorption syndromes, Inflammatory Bowel Disease, Coeliac Disease, Post-Gastrecto‐
my
• Kidney Failure
• Neoplasias: Myeloma, Lymphoma
• Drugs: corticosteroids, anticonvulsants, alcohol, thyroid hormone.
Osteoporosis is universal among the elderly population, exhibits progressive incidence, and
is directly correlated with age and lifestyle, including the practice of sports.
1 RANK – is the abbreviation of receptor activator of nuclear factor kappa B; RANKL – receptor activator of nuclear factor
kappa-B ligand; and OPG –osteoprotegerin.
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5. Physical activity
Given the growth of the elderly population, the establishment of health promotion measures
to reduce the prevalence of chronic diseases, improve functionality, and control multimor‐
bidity is notably important. The goal in this regard is to improve the quality of life of older
adults and to reduce healthcare expenses. Among such health-promoting measures, physical
activity is one of the main factors associated with control of comorbidities and the reduction
of the risk of morbimortality by cardiovascular diseases [15], diabetes [16], obesity [17], and
osteoporosis [18]. Physical activity has also been correlated with improved cognition [19, 20,
21, 22] and reduced risk of the incidence of Alzheimer’s disease [23].
Regular exercise is important for healthy aging because it has an influence on chronic diseases
and functionality. Exercise seems to be a protective factor against genetic and molecular aging
and is associated with longevity [24]. Exercise protects [25] the organism against oxidative
stress [26] and inflammation [27], which cause damage to the deoxyribonucleic acid (DNA)
and other cell structures, resulting in progressive loss of metabolic and physiological functions
and greater propensities for cardiovascular, neurodegenerative, and oncological diseases.
The beneficial effects of physical exercise have been demonstrated in the prevention and
control of cardiovascular and osteomuscular diseases and diabetes and in the prevention of
neoplasias. [28] In recent years, research has focused on the beneficial effects of physical
activity on cognitive functions and prevention of dementias [29].
Together with nutritional measures, hormone and calcium replacement, and use of bisphosph‐
onates, programmed physical exercise has been reported as a protective factor against
osteoporosis in older adults. Programmed physical exercise is an acknowledged source of
countless benefits in all population sectors, including the elderly. Several authors have
correlated the absence or reduction of such physical activity with a higher prevalence of
osteoporosis.
Nevertheless, the prescription of physical activity involves a heterogeneous range of inter‐
ventions, with each one possessing particular risks and benefits. Therefore, in addition to
stimulating the practice of physical activities by their patients, healthcare professionals must
carefully and thoroughly analyze the types of activity that are most appropriate for their
intended purposes.
6. The rule of aerobic exercises
Aerobic exercises and, more particularly, walking and running, are the activities most often
recommended by healthcare professionals and most widely practiced by the elderly population.
However, overly intense exercise (ultramarathon, running > 64 km per week) is associated
with a larger number of osteoarticular lesions and immunosuppression. In addition, the ideal
level of physical activity promoting cognitive benefits and modulating neuroprotectors and
the inflammatory activity is still unknown.
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Data in the literature regarding the benefits of long-distance running in the prevention of
osteoporosis among older adults are controversial. Novotny et al. [30] assessed an Olympic
and world champion long-distance runner 35 years after the end of his racing career and found
that his joints were free of signs of arthrosis but that he presented with exceptionally advanced
osteoporosis. Conversely, Maud et al. [31] studied a similar case of a long-distance runner older
than 70 years who had more than 50 years of training and did not find any alterations in any
system (including musculoskeletal). Additionally, regarding resistance exercise, the consensus
seems to point to reduction of falls [32] and thus of fractures [33], although not necessarily of
osteoporosis [34].
Several authors reported increases in bone density among high-performance runners, mainly
in the femoral neck [35], whereas according to other authors, similarly to what appears to be
the case of women [36], such runners exhibited reductions in bone mass 37 with debatable
physiopathology but with a possible association with the metabolism of PTH. Finally, a third
group of investigators did not identify any significant differences in bone density among the
various groups. [38, 39]
When aerobic activity is combined with resistance training, the increase in bone mass becomes
more evident, at least at the experimental level. [40]
6.1. Metanalyses
As the literature data concerning the benefits of aerobic activity in the elderly are conflicting,
conducting metanalysis can be a real benefit in his assessment.
Metanalyses of studies on anaerobic exercise and osteoporosis in women produced notably
modest results [41]. Several meta-analyses studies published by the Cochrane Collaboration
[42] report that both resistance and aerobic exercises might improve bone density among
women, and even walking might increase bone density at the hip. It is worth noting that the
authors of the abovementioned study stated that the quality of the articles included in the
review was modest, whereby the reliability of the results is limited. Still, in this regard,
Yamasaki et al. reported that walking improved bone density at the lumbar spine and hip in
postmenopausal women. [43]
7. Our experience
To analyze the effects of high-performance physical activity among older Brazilian adults, a
cohort of senior athletes from IOTFMUSP (Instituto de Ortopedia e Traumatologia do Hospital
das Clínicas da USP/Institute of Orthopedics and Traumatology of the Clinical Hospital of
USP) was established in 2001. During the last 11 years, athletes older than 60 years and a control
group consisting of healthy non-athlete individuals older than 60 years have been followed
periodically by the assessment of several parameters, including bone density and body
composition.
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To analyze those parameters, 44 male athletes older than 60 years (mean 64 years) who
regularly run more than 15,000 meters were compared; this group included several marathon
runners and a number of super-marathon runners. The control group included 18 non-athlete
individuals older than 60 years (mean 66.72 years) who had positive self-perceptions of their
health and were independent in their everyday life activities. The groups were comparable
with p=0,419.
Data were collected by means of double-absorption densitometry and were subjected to
descriptive statistical analysis and Student’s t-test for paired samples; the chi-square test was
used in calculating sport activity as an intervention factor in controls and study subjects in a
2 x 2 table.
Comparisons of bone density, measured at the femoral neck and lumbar spine, between
athletes and controls did not reveal any statistical significance (tables 1 and 2).
As a complementary measure, comparative analysis of the bone density in a subgroup of
athletes over a 6-year period was performed. Although that group maintained its physical
activity, no significant differences were identified among the measurements (table 3).
Athletes –Femoral Neck Density




Controls –Femoral Neck Density





BMD – Bone Mass Density in g/cm2 /T-Score or Young Adults compared in standard deviations
Table 1. Density of the femoral neck in athletes and controls
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Athletes –Lumbar Spine Density




Controls –Lumbar Spine Density





BMD – Bone Mass Density in g/cm2 /T-Score or Young Adults compared in standard deviations
Table 2. Density of the lumbar spine in athletes and controls
Athlete Year






T-Score or Young Adults compared in standard deviations
Table 3. Progression of bone density in athletes, 2001-2007
8. Discussion and conclusions
The first noteworthy aspect of our study is that only men were included, whereas most studies
on osteoporosis, including those addressing physical activity, focus on women. This condition,
resulting from the overall design of our cohort, was employed because although osteoporosis
is less frequent among men, the consequences of its major complication, i.e., fractures, are more
severe, resulting in higher indices of morbimortality among men compared to women [44].
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In addition, several studies demonstrated that the incidence of osteoporosis among men
increases quickly and progressively with age; in the studied area, osteoporosis may affect up
to 40% of the male population older than 80 years [5].
Our data showed that predominantly aerobic activity, such as high-performance running, did
not exhibit a statistically significant correlation with increased bone density; however, the
density also did not decrease over a 6-year period. Therefore, our data agree with the findings
by Kemmler [37] and Wisswell [38].
However, this finding places us at the center of the debates on aerobic exercise and osteoporosis.
The participants of this study belonged to a group of senior athletes with good athletic
performance. An average running distance of 15 km and the fact that those athletes exhibited
statistically significant improvement over the years denote effective training and follow-up.
As a measurement of bone mineral density (BMD), the femoral neck was preferentially used
because it is location one most commonly tested. However, our data show that there is a
statistically significant difference between the femoral neck and total body bone density that
prevents their undifferentiated use.
In regard to the incidence of osteoporosis among older adults, analysis of the participants’
bone densities in 2001 and 2007 (table 3) did not reveal any statistically significant differences.
Despite the small number of controls in this group, which may compromise its reliability, the
data couldn’t show us any perceptible difference between athletes and controls in respect to
incidence of osteoporosis in concordance with international refereed data.
In the other hand we could not find alterations in bone density between comparisons with
seven years of interval in the athletes group. This find may indicate that, if there were no gain
in bone mass, on the other hand there were no losses, which might lead us to imagine a
protective effect of bone loss in this group, confirming literature data.
These data lead us to conclude that regarding the prevention or treatment of osteoporosis in
older adults, the practice of aerobic physical activity alone is controversial. In the best of cases,
physical activity leads to reduced bone loss, although this finding is also poorly supported by
evidence.
We are currently studying a subgroup of our cohort consisting of senior athletes practicing
high-performance aerobic activity and simultaneously being subjected to parallel resistance
training. We believe that the results obtained from this group might shed new light on this
currently unclear aspect of the prevention and treatment of osteoporosis in older adults.
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severe, resulting in higher indices of morbimortality among men compared to women [44].
Topics in Osteoporosis200
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In the other hand we could not find alterations in bone density between comparisons with
seven years of interval in the athletes group. This find may indicate that, if there were no gain
in bone mass, on the other hand there were no losses, which might lead us to imagine a
protective effect of bone loss in this group, confirming literature data.
These data lead us to conclude that regarding the prevention or treatment of osteoporosis in
older adults, the practice of aerobic physical activity alone is controversial. In the best of cases,
physical activity leads to reduced bone loss, although this finding is also poorly supported by
evidence.
We are currently studying a subgroup of our cohort consisting of senior athletes practicing
high-performance aerobic activity and simultaneously being subjected to parallel resistance
training. We believe that the results obtained from this group might shed new light on this
currently unclear aspect of the prevention and treatment of osteoporosis in older adults.
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1. Introduction
Maintaining adequate nutritional status, is an essential factor for bone growth and minerali‐
zation. Both processes, both the increase in size and development through the deposit of min‐
erals pass alongside and under the regulation by different factors [1]. In this sense, acquired
during childhood and adolescence adequate bone mass will be a prime target for complica‐
tions, not only in childhood and adolescence but during adulthood [2].
Currently, in developed countries, osteoporosis is a serious public health problem that affects
mainly children and adolescents as a consequence of sedentary lifestyle and unhealthy eating
habits [3].
Recent studies suggest that osteoporosis prevention should begin in childhood. Children and
adolescents should achieve an adequate peak bone mass (PMO) before the end of its growth.
Otherwise, they may develop osteopenia or osteoporosis early, with a high risk of fractures
and consequently a lower quality of life [4].
Given that  the  risk  of  developing osteoporosis  depends in  60-80% of  genetic  factors  on
which we can not intervene, we must act on those other environmental factors involved
which if capable of being corrected, mainly food [5]. It is known that bone mineral den‐
sity (BMD) is  modifiable by diet and exercise as much as 20%. Nutrients ingested daily
through food involved in the development and maintenance of adequate bone minerali‐
zation by means of  different  processes,  favoring the  differentiation of  bone tissue  func‐
tional  cells  (osteoblasts  and  osteoclasts)  and  acting  as  plastics  elements.  In  addition,
provide adequate nutrition essential vitamins involved in bone matrix synthesis and cal‐
cium absorption at  intestinal  level,  also allowing the synthesis  of  certain hormones and
growth factors involved [6].
© 2013 González-Jiménez; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
Maintaining adequate nutritional status, is an essential factor for bone growth and minerali‐
zation. Both processes, both the increase in size and development through the deposit of min‐
erals pass alongside and under the regulation by different factors [1]. In this sense, acquired
during childhood and adolescence adequate bone mass will be a prime target for complica‐
tions, not only in childhood and adolescence but during adulthood [2].
Currently, in developed countries, osteoporosis is a serious public health problem that affects
mainly children and adolescents as a consequence of sedentary lifestyle and unhealthy eating
habits [3].
Recent studies suggest that osteoporosis prevention should begin in childhood. Children and
adolescents should achieve an adequate peak bone mass (PMO) before the end of its growth.
Otherwise, they may develop osteopenia or osteoporosis early, with a high risk of fractures
and consequently a lower quality of life [4].
Given that  the  risk  of  developing osteoporosis  depends in  60-80% of  genetic  factors  on
which we can not intervene, we must act on those other environmental factors involved
which if capable of being corrected, mainly food [5]. It is known that bone mineral den‐
sity (BMD) is  modifiable by diet and exercise as much as 20%. Nutrients ingested daily
through food involved in the development and maintenance of adequate bone minerali‐
zation by means of  different  processes,  favoring the  differentiation of  bone tissue  func‐
tional  cells  (osteoblasts  and  osteoclasts)  and  acting  as  plastics  elements.  In  addition,
provide adequate nutrition essential vitamins involved in bone matrix synthesis and cal‐
cium absorption at  intestinal  level,  also allowing the synthesis  of  certain hormones and
growth factors involved [6].
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Therefore, based on the above premises, childhood and adolescence are important periods in
which an adequate nutrition will firmly prevent the development of osteopenia or osteoporosis
at an early age [7].
2. Nature of bone tissue and skeletal development
Bone consists of cells (2-5%) and in a largely inert matter (95-98%), ie basically protein and
minerals [8]. From a structural standpoint, the protein component is composed of fibers of
collagen type I and gla protein (osteocalcin, osteonectin, fibronectin, osteopontin and bone
sialoprotein). Its component consists mainly of hydroxyapatite mineral-rich carbonates
(37-40% calcium and phosphate 50-58%) and to a lesser extent sodium, potassium, magnesium
and citrate [8].
At birth,  the  newborn already has  70  to  95  grams of  bone mass  approximately  equiva‐
lent to 4% by weight. During adolescence, girls have 2,400 grams of bone [9].  The boys,
meanwhile, are at increased volume estimated at approximately 3,300 grams. Both quan‐
tities  correspond to  a  85% to  development  of  the  cortical  bone  and 15% of  the  cancel‐
lous bone development [9].
In this sense, it is considered that the girls get their peak bone mass at age 18 as opposed to
boys who reach it some years later, at the age of 23 years or so [9]. The gain of this peak is
mediated by the action of sex hormones on growth factor 1 (IGF-1), which is stimulated in
parallel mode by proteins [10].
Once acquired peak bone mass, it will tend to stabilize. After bone mass will be reduced only
to certain pathological processes involving a state of prostration of the patient or following the
administration of certain drugs such as glucocorticoids [11]. Although the bone loss does not
occur evenly across the skeleton. Normally, women aged between 20 and 30 begin to develop
a reduced bone loss (<1%) level of the vertebrae [12]. It will be during the first 5 years post‐
menopause when the loss increases between 2 and 6% annually. Among men, the loss occurs
at older ages, ie from 50 years of age [12].
3. Nutritional factors involved in the process of bone mineralization
Energy intake
Maintain adequate caloric intake permitted during childhood and adolescence to ensure
growth, maturation and bone mineralization process [13].
Protein intake
Protein intake, is another important factor for the formation of bone matrix. However, protein
intake appears to be important risk factor among our child population as they often exceed
recommendations [14]. This mainly because the food in Western countries usually contain
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plenty of eggs, meat, fish and dairy products which guarantees a significant amount of protein
[14]. Moreover, low consumption of protein (less than 45-55 g/day in men or 45 g/day in wom‐
en) are usually accompanied by a lower muscle mass and bone, this mainly due to a reduction
in bone structure protein. Meanwhile, a high protein intake (greater than 2 grams/kilogram/
day) may also cause a loss of bone mass, since for each gram of protein intake in excess through
the diet, results in a loss of 1 mg of calcium [14].
Calcium and phosphorus
Both nutrients are the substances most studied for their influence on the prevention and treat‐
ment of osteoporosis. Calcium is the most abundant mineral in the human skeleton. 99% is
deposited in the bone and passing about 30 grams at birth [10 grams per kilogram of body
weight) to about 1,300 grams in adult (19 grams per kilogram of body weight) [15]. Now, by
weight, calcium accounts for 40% of bone mineral and 60% phosphorus. From a metabolic
point of view, the absorption of calcium from food depends on several factors. First of its
bioavailability in the diet, the deposits of vitamin D, the calcium / phosphorus (Ca/P) and the
presence in food of substances that facilitate or interfere with its absorption [16]. In the case of
phosphorus (P), this also deposits in the bone by 85%. The high presence among foods in our
diet (60-70%), guaranteed to meet the needs of our food without difficulty, especially among
the young. While its excessive intake may alter the Ca/P thus hindering the absorption of
calcium [17].
Calcium-phosphorus balance
The  study  of  calcium-phosphorus  balance  is  complex  when you consider  its  high  fecal
excretion.  In  the  case  of  calcium,  their  daily  loss  (through  excretion  in  the  urine,  fecal
and dermal) are estimated at 420 mg/day. Calcium is absorbed in the intestine not ever
exceeding 30% of the total  amount ingested [18].  For absorption,  calcium must compete
with other substances such as phytates and oxalates act by inhibiting its absorption. The
solubilized  calcium in  foods  like  milk  or  juice  is  absorbed  supplemented  with  ease.  In
the  case  of  phosphates,  these  are  found in  a  wide  variety  of  foods  thereby  showing  a
higher  bioavailability  than  calcium.  His  diet  recommendations  are  estimated  at  700-800
mg  /  day  in  adults  compared  to  1200  mg/day  estimated  as  necessary  during  adoles‐
cence.  For  its  part,  has  a  phosphorus  antiosificante  effect  by  increasing the  secretion of
PTH and reduced intestinal calcium absorption [18].
Recommendations for calcium intake
In the case of calcium, recommendations vary depending on the stage of life where we are. For
children under 1 year and for both sexes, the recommended intake of between 400-600 mg/day
of calcium. During adolescence, the recommendations are found up to 1200 mg/day for both
sexes [19]. For adult males, the recommendations provide a daily intake of between 800 to 1000
mg/day. For adult women the recommendations are higher, between 1200 and 1500 mg/day
for those postmenopausal women in gestation and during lactation [20]. According to recent
studies, 60% of the calcium in our diet comes from foods such as dairy products, followed by
13% from foods such as cereals, 15% from fruits, vegetables, legumes, while not as only 6%
comes from foods like meat, fish or eggs. This entails risks if it is very sedentary children and
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mediated by the action of sex hormones on growth factor 1 (IGF-1), which is stimulated in
parallel mode by proteins [10].
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administration of certain drugs such as glucocorticoids [11]. Although the bone loss does not
occur evenly across the skeleton. Normally, women aged between 20 and 30 begin to develop
a reduced bone loss (<1%) level of the vertebrae [12]. It will be during the first 5 years post‐
menopause when the loss increases between 2 and 6% annually. Among men, the loss occurs
at older ages, ie from 50 years of age [12].
3. Nutritional factors involved in the process of bone mineralization
Energy intake
Maintain adequate caloric intake permitted during childhood and adolescence to ensure
growth, maturation and bone mineralization process [13].
Protein intake
Protein intake, is another important factor for the formation of bone matrix. However, protein
intake appears to be important risk factor among our child population as they often exceed
recommendations [14]. This mainly because the food in Western countries usually contain
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plenty of eggs, meat, fish and dairy products which guarantees a significant amount of protein
[14]. Moreover, low consumption of protein (less than 45-55 g/day in men or 45 g/day in wom‐
en) are usually accompanied by a lower muscle mass and bone, this mainly due to a reduction
in bone structure protein. Meanwhile, a high protein intake (greater than 2 grams/kilogram/
day) may also cause a loss of bone mass, since for each gram of protein intake in excess through
the diet, results in a loss of 1 mg of calcium [14].
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deposited in the bone and passing about 30 grams at birth [10 grams per kilogram of body
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weight, calcium accounts for 40% of bone mineral and 60% phosphorus. From a metabolic
point of view, the absorption of calcium from food depends on several factors. First of its
bioavailability in the diet, the deposits of vitamin D, the calcium / phosphorus (Ca/P) and the
presence in food of substances that facilitate or interfere with its absorption [16]. In the case of
phosphorus (P), this also deposits in the bone by 85%. The high presence among foods in our
diet (60-70%), guaranteed to meet the needs of our food without difficulty, especially among
the young. While its excessive intake may alter the Ca/P thus hindering the absorption of
calcium [17].
Calcium-phosphorus balance
The  study  of  calcium-phosphorus  balance  is  complex  when you consider  its  high  fecal
excretion.  In  the  case  of  calcium,  their  daily  loss  (through  excretion  in  the  urine,  fecal
and dermal) are estimated at 420 mg/day. Calcium is absorbed in the intestine not ever
exceeding 30% of the total  amount ingested [18].  For absorption,  calcium must compete
with other substances such as phytates and oxalates act by inhibiting its absorption. The
solubilized  calcium in  foods  like  milk  or  juice  is  absorbed  supplemented  with  ease.  In
the  case  of  phosphates,  these  are  found in  a  wide  variety  of  foods  thereby  showing  a
higher  bioavailability  than  calcium.  His  diet  recommendations  are  estimated  at  700-800
mg  /  day  in  adults  compared  to  1200  mg/day  estimated  as  necessary  during  adoles‐
cence.  For  its  part,  has  a  phosphorus  antiosificante  effect  by  increasing the  secretion of
PTH and reduced intestinal calcium absorption [18].
Recommendations for calcium intake
In the case of calcium, recommendations vary depending on the stage of life where we are. For
children under 1 year and for both sexes, the recommended intake of between 400-600 mg/day
of calcium. During adolescence, the recommendations are found up to 1200 mg/day for both
sexes [19]. For adult males, the recommendations provide a daily intake of between 800 to 1000
mg/day. For adult women the recommendations are higher, between 1200 and 1500 mg/day
for those postmenopausal women in gestation and during lactation [20]. According to recent
studies, 60% of the calcium in our diet comes from foods such as dairy products, followed by
13% from foods such as cereals, 15% from fruits, vegetables, legumes, while not as only 6%
comes from foods like meat, fish or eggs. This entails risks if it is very sedentary children and
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adolescents and women with menopause. In some cases this will be indicated calcium sup‐
plementation, especially through the diet is not achieved optimal calcium intake. In the study
by Johsnton et al (1992) [21], from a population of prepubertal twins who are supplemented
with a dose of 700 mg/day of calcium, managed to increase its process of mineralization and
bone mass in a 5%.
Sodium intake
Excessive sodium intake in the diet may be accompanied by a reduction in bone mineral den‐
sity. This decrease in bone mass is mediated by a renal calcium excretion [22]. In this regard,
given an approximate intake of 450 mg of sodium in the diet, the kidney is capable of removing
in parallel up to 10 mg of calcium. Accordingly, the recommendations established for calcium
intake in adolescents, they must not exceed a daily sodium intake greater than 2000 mg or what
is just 5 grams of salt [22].
Intake of vitamin D and K and its importance in the process of bone mineralization
Vitamin D belongs to the group of so-called fat-soluble vitamins. Their presence in food
is by way of cholecalciferol  (D3) and ergocalciferol.  Usually has its  origin in cholesterol
or ergosterol derivative which is converted to ergocalciferol (D2) the effect of ultraviolet
radiation.  However,  the active form of  this  vitamin is  called calcitriol  [23].  Its  synthesis
is closely associated with sun exposure, that is,  with a daily sun exposure is insufficient
to  meet  the  physiological  needs  of  the  vitamin  in  our  body  [24].  Their  presence  facili‐
tates the absorption of calcitriol in the intestine. In this regard, serum levels of this vita‐
min  have  been  correlated  with  bone  density  in  certain  locations  such  as  the  lumbar
spine and femoral neck. Another vitamin involved in the process of bone mineralization
during childhood and adolescence is vitamin K. Participates in the process of carboxyla‐
tion  of  osteocalcin  and thereby cause  a  deficit  decreased and carboxylation  of  osteocal‐
cin  synthesis  [25].  Fluorine  Within  the  elementary  ions,  fluoride  in  nature  and chemical
behavior  is  the  most  active  of  all  elementary  ions.  Its  concentration  is  high  in  mineral
water, fish, tea and certain meals [26].  Fluoride ingested through the diet,  is rapidly ab‐
sorbed from the gastrointestinal  tract  to blood from which will  be distributed to tissues
and organs by simple diffusion. Among its benefits to bone level highlights its ability to
stimulate osteoblast activity, increasing the mainly trabecular bone. In this regard, it  has
been demonstrated that administration of 25 mg/day slow-release fluoride supplied for 4
years reduces the incidence of vertebral fractures [26]. Consumption of carbonated drinks
The increased consumption of carbonated beverages is associated with a progressive decrease
in milk intake, has led to high consumption of phosphoric acid associated with calcium defi‐
ciency [27]. This eating pattern will have consequences for bone health, because when a diet
is high in phosphorus and low in calcium, bone resorption increases to recover the serum levels
of this mineral. There are epidemiological studies that linked the consumption of carbonated
beverages to an increased risk of fracture in children and young girls. However, there is some
controversy about this relationship [28]. Many authors, conclude that the major effect of car‐
bonated beverages is mainly due to displacement of milk in the diet, especially among young
people.
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Alcohol consumption, snuff and caffeine
Excessive alcohol consumption, is an important risk factor for osteoporosis, especially among
young males. Ingestion, causes a decrease in bone mass through an alteration of the formation
and bone remodeling [29]. During adolescence, a high intake of alcohol reduces bone mass
peak. This circumstance enables the development of osteopenia or osteoporosis at an early age
[30]. In addition, alcohol intake is associated with dietary disorders, which adversely affect the
bone metabolism. Thus, their intake is related to a deficiency of vitamin D and parathyroid
hormone (PTH), hypoproteinemia, liver, hypomagnesemia, deficit B vitamins and folic acid,
iron overload and decreased testosterone [31].
Regarding the consumption of snuff in adolescents, it has been associated with a significant
reduction in bone mineral density (BMD). It has been shown that adolescent smokers, espe‐
cially girls, have a lower bone mineral density and increased rate of bone loss that girls do not
smoke. This has been demonstrated also among male adolescents [32].
Regarding caffeine intake, it increases urinary calcium excretion during the first 3 hours after
ingestion. It has been found that a daily intake of two or more cups of coffee, is correlated with
lower bone mineral density in these subjects.
4. In conclusion
Among all the factors involved in the mineralization of bone mass, maintaining a balanced
diet is a key factor. A balanced and varied diet will be the best procedure to ensure proper
bone development among young people. Therefore, an adequate energy and protein intake,
coupled with a contribution provided essential nutrients such as calcium, phosphorus or flu‐
orine and certain vitamins such as D and K Assume the basic nutritional elements to ensure
adequate bone mass during the later stages early in life. Given that bone development achieved
during childhood and adolescence will influence the health status and bone mass in adulthood
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iron overload and decreased testosterone [31].
Regarding the consumption of snuff in adolescents, it has been associated with a significant
reduction in bone mineral density (BMD). It has been shown that adolescent smokers, espe‐
cially girls, have a lower bone mineral density and increased rate of bone loss that girls do not
smoke. This has been demonstrated also among male adolescents [32].
Regarding caffeine intake, it increases urinary calcium excretion during the first 3 hours after
ingestion. It has been found that a daily intake of two or more cups of coffee, is correlated with
lower bone mineral density in these subjects.
4. In conclusion
Among all the factors involved in the mineralization of bone mass, maintaining a balanced
diet is a key factor. A balanced and varied diet will be the best procedure to ensure proper
bone development among young people. Therefore, an adequate energy and protein intake,
coupled with a contribution provided essential nutrients such as calcium, phosphorus or flu‐
orine and certain vitamins such as D and K Assume the basic nutritional elements to ensure
adequate bone mass during the later stages early in life. Given that bone development achieved
during childhood and adolescence will influence the health status and bone mass in adulthood




Address all correspondence to: emigoji@ugr.es
Department of Nursing. Faculty of Nursing (Campus of Melilla), University of Granada,
Melilla, Spain




[1] Jones, G. Early life nutrition and bone development in children. Nestle Nutr Workshop
Ser Pediatr Program (2011). , 68, 227-33.
[2] Tristán Fernández JMRuiz Santiago F, Pérez de la Cruz A, Lobo Tañer G, Aguilar Cor‐
dero MJ, Collado Torreblanca F. Influencia de la nutrición y del entorno social en la
maduración ósea del niño. Nutr Hosp (2007). , 22, 417-24.
[3] Quesada Gómez JMSosa Henríquez M. Nutrición y osteoporosis. Calcio y vitamina D.
Rev Osteoporos Metab Miner (2011). , 4, 165-82.
[4] Adami, S, Isaia, G, Luisetto, G, Minisola, S, Sinigaglia, L, Silvestri, S, et al. ICARO Study
Group. Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
Osteoporos Int (2008). , 19, 1219-23.
[5] Bechtold-Dalla Pozza SBone density measurements on growing skeletons and the clin‐
ical consequences. Z Rheumatol (2011). , 70(10), 844-52.
[6] Cashman, K. D. Diet, Nutrition, and Bone Health. J Nutr (2007). S, 2507-12.
[7] Hirota, T, & Hirota, K. Nutrition in bone growth and development. Clin Calcium
(2011). , 21(9), 1329-33.
[8] Qiu, Z. Y, Li, G, Zhang, Y. Q, Liu, J, Hu, W, Ma, J, & Zhang, S. M. Fine structure analysis
and sintering properties of Si-doped hydroxyapatite. Biomed Mater (2012).
[9] Mora, S, & Gilsanz, V. Establishment of peak bone mass. Endocrinol Metab Clin N Am
(2003). , 32, 39-63.
[10] Zofková, I. Soft tissues, hormones and the skeleton. Vnitr Lek (2012). , 58(2), 135-39.
[11] Krall, E. A, & Dawson-hughes, B. Osteoporosis: En: Shils ME, Olson JA, Ross AC, ed‐
itores. Nutrición en Salud y Enfermedad. México, Interamericana, (2002).
[12] Zatonski, T, Temporale, H, & Krecicki, T. Hearing and balance in metabolic bone dis‐
eases. Pol Merkur Lekarski (2012). , 32(189), 198-201.
[13] Zagarins, S. E, Ronnenberg, A. G, Gehlbach, S. H, Lin, R, & Bertone-johnson, E. R. Are
existing measures of overall diet quality associated with peak bone mass in young
premenopausal women? J Hum Nutr Diet (2012). , 25(2), 172-79.
[14] Bonjour, J. P. Protein intake and bone health. Int J Vitam Nutr Res (2011).
[15] Caroli, A, Poli, A, Ricotta, D, Banfi, G, & Cocchi, D. Invited review: Dairy intake and
bone health: a viewpoint from the state of the art. J Dairy Sci (2011). , 94(11), 5249-62.
[16] Food and Nutritional BoardDietary Reference Intakes (DRI) for calcium, phosphorus,
magnesium, vitamin D and fluoride. Washington: National Academy of Sciences. Na‐
tional Academy Press; (1997).
[17] Bonjour, J. P. Bone mineral adquisition in adolescente. En: Markus R, Felman D, Kesley
J, editores. Osteoporosis. San Diego: Academic Press; (1996). , 465-476.
[18] Loui, A, Raab, A, Obladen, M, & Brätter, P. Calcium, phosphorus and magnesium bal‐
ance: FM 85 fortification of human milk does not meet mineral needs of extremely low
birthweight infants. Eur J Clin Nutr (2002). , 56(3), 228-35.
Topics in Osteoporosis212
[19] Basabe, B, Mena, M. C, Faci, M, Aparicio, A, López-sobaler, A. M, & Ortega, R. M.
Influencia de la ingesta de calcio y fósforo sobre la densidad mineral ósea en mujeres
jóvenes. Arch Latinoam Nutr (2004). , 54, 203-8.
[20] Jackson, R. D. LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium
plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006). , 354,
669-83.
[21] Johsnton, C. C, Miller, J. Z, Siemenda, C. W, Reister, T. K, Hui, S, & Christian, J. C.
Calcium supplementation and increases in bone mineral in children. N Engl J Med
(1992). , 82-87.
[22] Chan, R, Woo, J, Lau, W, Leung, J, Xu, L, Zhao, X, Yu, W, Lau, E, & Pocock, N. Effects
of lifestyle and diet on bone health in young adult Chinese women living in Hong Kong
and Beijing. Food Nutr Bull (2009). , 30(4), 370-78.
[23] Holick, M. F, & Chen, T. C. Vitamin D deficiency: A world wide problem with health
consequences. Am J Clin Nutr (2008). , 87, 1080-86.
[24] Holick, M. F. Vitamin D deficiency. N Engl J Med (2007). , 357, 266-81.
[25] Ahmadieh, H, & Arabi, A. Vitamins and bone health: beyond calcium and vitamin D.
Nutr Rev (2011). , 69(10), 584-98.
[26] Grajeta, H. Nutrition in prevention and treatment of osteoporosis. Przegl Lek (2003). ,
60(10), 649-53.
[27] Ma, D, & Jones, G. Soft drink and milk consumption, physical activity, bone mass, and
upper limb fractures in children: a population-based case-control study. Calcif Tissue
Int (2004). , 75(4), 286-91.
[28] Wyshak, G. Teenaged girls, carbonated beverage consumption, and bone fractures.
Arch Pediatr Adolesc Med (2000). , 154(6), 610-13.
[29] Chakkalakal, D. A. Alcohol-induced bone loss and deficiente bone repair. Alcohol Clin
Exp Res (2005). , 29, 2077-90.
[30] Turner, R. T. Skeletal response to alcohol. Alcohol Clin Exp Res (2000). , 24, 1693-701.
[31] Kim, M. J, Shim, M. S, Kim, M. K, Lee, Y, Shing, Y. G, Churg, C. H, et al. Effect of chronic
alcohol ingestión on bone mineral density in males without liver cirrosis. Korean J
Intern Med (2003). , 18, 174-80.
[32] Vogt, M. T, Hanscom, B, Lauerman, W. C, & Kang, I. D. Influence of smoking on the
health patients. The National Spine network data base. Spine (2002). , 27, 313-19.




[1] Jones, G. Early life nutrition and bone development in children. Nestle Nutr Workshop
Ser Pediatr Program (2011). , 68, 227-33.
[2] Tristán Fernández JMRuiz Santiago F, Pérez de la Cruz A, Lobo Tañer G, Aguilar Cor‐
dero MJ, Collado Torreblanca F. Influencia de la nutrición y del entorno social en la
maduración ósea del niño. Nutr Hosp (2007). , 22, 417-24.
[3] Quesada Gómez JMSosa Henríquez M. Nutrición y osteoporosis. Calcio y vitamina D.
Rev Osteoporos Metab Miner (2011). , 4, 165-82.
[4] Adami, S, Isaia, G, Luisetto, G, Minisola, S, Sinigaglia, L, Silvestri, S, et al. ICARO Study
Group. Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
Osteoporos Int (2008). , 19, 1219-23.
[5] Bechtold-Dalla Pozza SBone density measurements on growing skeletons and the clin‐
ical consequences. Z Rheumatol (2011). , 70(10), 844-52.
[6] Cashman, K. D. Diet, Nutrition, and Bone Health. J Nutr (2007). S, 2507-12.
[7] Hirota, T, & Hirota, K. Nutrition in bone growth and development. Clin Calcium
(2011). , 21(9), 1329-33.
[8] Qiu, Z. Y, Li, G, Zhang, Y. Q, Liu, J, Hu, W, Ma, J, & Zhang, S. M. Fine structure analysis
and sintering properties of Si-doped hydroxyapatite. Biomed Mater (2012).
[9] Mora, S, & Gilsanz, V. Establishment of peak bone mass. Endocrinol Metab Clin N Am
(2003). , 32, 39-63.
[10] Zofková, I. Soft tissues, hormones and the skeleton. Vnitr Lek (2012). , 58(2), 135-39.
[11] Krall, E. A, & Dawson-hughes, B. Osteoporosis: En: Shils ME, Olson JA, Ross AC, ed‐
itores. Nutrición en Salud y Enfermedad. México, Interamericana, (2002).
[12] Zatonski, T, Temporale, H, & Krecicki, T. Hearing and balance in metabolic bone dis‐
eases. Pol Merkur Lekarski (2012). , 32(189), 198-201.
[13] Zagarins, S. E, Ronnenberg, A. G, Gehlbach, S. H, Lin, R, & Bertone-johnson, E. R. Are
existing measures of overall diet quality associated with peak bone mass in young
premenopausal women? J Hum Nutr Diet (2012). , 25(2), 172-79.
[14] Bonjour, J. P. Protein intake and bone health. Int J Vitam Nutr Res (2011).
[15] Caroli, A, Poli, A, Ricotta, D, Banfi, G, & Cocchi, D. Invited review: Dairy intake and
bone health: a viewpoint from the state of the art. J Dairy Sci (2011). , 94(11), 5249-62.
[16] Food and Nutritional BoardDietary Reference Intakes (DRI) for calcium, phosphorus,
magnesium, vitamin D and fluoride. Washington: National Academy of Sciences. Na‐
tional Academy Press; (1997).
[17] Bonjour, J. P. Bone mineral adquisition in adolescente. En: Markus R, Felman D, Kesley
J, editores. Osteoporosis. San Diego: Academic Press; (1996). , 465-476.
[18] Loui, A, Raab, A, Obladen, M, & Brätter, P. Calcium, phosphorus and magnesium bal‐
ance: FM 85 fortification of human milk does not meet mineral needs of extremely low
birthweight infants. Eur J Clin Nutr (2002). , 56(3), 228-35.
Topics in Osteoporosis212
[19] Basabe, B, Mena, M. C, Faci, M, Aparicio, A, López-sobaler, A. M, & Ortega, R. M.
Influencia de la ingesta de calcio y fósforo sobre la densidad mineral ósea en mujeres
jóvenes. Arch Latinoam Nutr (2004). , 54, 203-8.
[20] Jackson, R. D. LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium
plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006). , 354,
669-83.
[21] Johsnton, C. C, Miller, J. Z, Siemenda, C. W, Reister, T. K, Hui, S, & Christian, J. C.
Calcium supplementation and increases in bone mineral in children. N Engl J Med
(1992). , 82-87.
[22] Chan, R, Woo, J, Lau, W, Leung, J, Xu, L, Zhao, X, Yu, W, Lau, E, & Pocock, N. Effects
of lifestyle and diet on bone health in young adult Chinese women living in Hong Kong
and Beijing. Food Nutr Bull (2009). , 30(4), 370-78.
[23] Holick, M. F, & Chen, T. C. Vitamin D deficiency: A world wide problem with health
consequences. Am J Clin Nutr (2008). , 87, 1080-86.
[24] Holick, M. F. Vitamin D deficiency. N Engl J Med (2007). , 357, 266-81.
[25] Ahmadieh, H, & Arabi, A. Vitamins and bone health: beyond calcium and vitamin D.
Nutr Rev (2011). , 69(10), 584-98.
[26] Grajeta, H. Nutrition in prevention and treatment of osteoporosis. Przegl Lek (2003). ,
60(10), 649-53.
[27] Ma, D, & Jones, G. Soft drink and milk consumption, physical activity, bone mass, and
upper limb fractures in children: a population-based case-control study. Calcif Tissue
Int (2004). , 75(4), 286-91.
[28] Wyshak, G. Teenaged girls, carbonated beverage consumption, and bone fractures.
Arch Pediatr Adolesc Med (2000). , 154(6), 610-13.
[29] Chakkalakal, D. A. Alcohol-induced bone loss and deficiente bone repair. Alcohol Clin
Exp Res (2005). , 29, 2077-90.
[30] Turner, R. T. Skeletal response to alcohol. Alcohol Clin Exp Res (2000). , 24, 1693-701.
[31] Kim, M. J, Shim, M. S, Kim, M. K, Lee, Y, Shing, Y. G, Churg, C. H, et al. Effect of chronic
alcohol ingestión on bone mineral density in males without liver cirrosis. Korean J
Intern Med (2003). , 18, 174-80.
[32] Vogt, M. T, Hanscom, B, Lauerman, W. C, & Kang, I. D. Influence of smoking on the
health patients. The National Spine network data base. Spine (2002). , 27, 313-19.




The Effectiveness of Progressive Load Training
Associated to the Proprioceptive Training for Prevention
of Falls in Women with Osteoporosis
Lucas Teixeira, Stella Peccin, Kelson Silva,
Tiago Teixeira, Aline Mizusaki Imoto,
Joelma Magalhães and Virgínia Trevisani
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54554
1. Introduction
In most of the cases, osteoporosis is a related condition to aging. It can be seen in both genders,
but it especially manifests in women after menopause due to estrogen production rate fall.
For understanding what happens, it is necessary to bear in mind that the bones are com‐
pounded of a matrix in which mineral complexes such as calcium are laid up. Another
important feature is that they are in constant renewal process, since they are formed by cells
called osteoclasts which are responsible for reabsorbing the aged areas and others, the
osteoblasts, which is responsible for producing new bones. This permanent and constant
process makes possible the bone reconstitution when fractures happen and it explains why
around every ten years the human skeleton is entirely renewed. Along the time, however, the
old cells absorption increases and the bone new cells formation decreases. The outcome is that
the bones become more porous, losing resistance. Bone mass lighter loss features osteopenia.
Greater losses are in the osteoporosis area.
If it is not early prevented, or if it is not treated, the bone mass loss is progressively increasing,
in an asymptomatic fashion, without any manifestation, until a fracture occurrence. What
features the osteoporotic fractures, is when they take place with a minimum trauma, what
would not cause fractures in a normal bone. Therefore, they are also called fragility fractures.
The incidence of osteoporotic fractures is strictly related to the individual bone mass that
depends on the speed of loss throughout life as well as the amount of bone tissue in the end
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of puberty and beginning of adulthood. The great variation in bone mass peak is explained
not only by hereditary factors but also by gender, race, eating habits, several hormone
influence, body composition of lean mass and body fat, intercurrent diseases, chronic use of
medications and physical activity (Brandão & Vieira, 1999).
Like any other chronic disease, the ethiology of osteoporosis is multifactorial. Genetic factors
contribute approximately with 46% to 62% of bone mineral density (BMD) whereas other
causes include lifestyle, diet and physical exercise (Neto et al., 2002).
Osteoporosis clinical symptoms do not usually occur before a fracture occurrence. Osteopo‐
rosis is considered an asymptomatic disease. Indeed, during the disease progression, the bones
become progressively more fragile without affecting the individuals. This characteristic of
being a silent disease exposes the population to even a greater risk of suffering a fracture.
Osteoporosis is considered a “silent disease” until a fracture occurs. Approximately 1.5 million
fractures per year are attributable to this disease. Only in the USA, these fractures result in
500.000 hospitalizations, 800.000 emergency room visits, 2.6 million physician visits. The
treatment cost is high. In 2002, 12 billion dollars to 18 billion dollars were spent (Gass & Huges,
2006). In 1998, cost management of osteoporosis fractures in the UK recorded 942 million
pounds per year (Szejnfeld et al., 2007). Osteoporosis has become one of the major public health
problems. Nowadays, the impact of osteoporosis is compared to the impact caused by most
important health problems, such as cardiovascular diseases and cancer (Froes et al., 2002).
It exposes the fallers to a high risk of fractures (Johnell et al., 2005; Siris et al., 2006). The first
hip fracture is associated to 2.5-fold increased risk of subsequent fracture (Cólon-Emeric et al.,
2003) with a high level of morbidity and mortality (Cathleen et al., 2006).
It is believed that about 25% of menopausal women in the USA will exhibit some kind of
fracture as a consequence of osteoporosis. The most severe fractures are the fractures of femur
and they are associated with higher medical expenses than all other osteoporotic fractures
together (Moreira & Xaxier, 2001). The incidence of these fractures has doubled in the last 25
years and it is estimated that six million people in the world will suffer fracture of the proximal
femur in 2050. Fractures resulted from the decrease of bone mineral loss are considered an
orthopedic epidemic leading to an increase in costs for several countries and consequently
representing a big social and economic problem (Ramalho et al., 2001).
There have been a significant number of evidences showing that the decrease in bone quality,
from generation to generation, is caused by a change in life style, having as a main determinant
the lack of physical activity. This evidence varies with the biology of the basic bone. However,
epidemiological studies indicate that physical activity is the most important factor to maintain
bone mass and prevent fractures (Mosekilde, 1995).
Almost all hip fractures (more than 90%) occur as a result of a fall and these fractures are related
not only to the decreased bone mass, but also to other factors such as reduction of balance,
muscle strength and power in the lower extremities (American College of Sports Medicine
[ACSM], 1995; Parkkari et al. 1999). Therefore, aging and alterations in balance and muscle
strength, as well as sensorial changes, predispose patients with osteoporosis to a higher risk
of having fractures due to falls.
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Falls are multifactorial (Cathleen et al., 2006), (Tinetti et al., 1989) and their intrinsic causes
include altered balance, gait, muscle strength, visual acuity, cognition and the presence of
chronic diseases (van Schoor et al., 2002).
The participation of environmental risk factors might reach up to 50% of the falls in elderly
that live in the community. These factors include poor lighting, slippery surfaces, loose or
folded rugs, high or narrow stairs, obstacles in the way (low furniture, small objects, wires),
lack of rails in halls and bathrooms, extremely low or high shelves, inadequate shoes and
clothes, poorly maintained streets with holes or irregularities and inappropriate orthosis.
A reduction of approximately 30% in the strength is found in individual ages ranging from 50
to 70. These changes are more common in women than in men, more prevalent in lower limbs
than in upper limbs and a great amount of this reduction in strength is caused by a selective
atrophy of Type IIB fibers (American College of Sports Medicine Position, 1998).
Evidences have shown that specific exercises might reduce the risk factors for falls and the
number of falls in the elderly.
The purpose of our study was to evaluate the efficacy of the resistance training associated to
a proprioceptive training in the prevention of falls and reduction of the respective risk factors
in postmenopausal women with osteoporosis.
2. Physical exercise to prevent falls
Prevention in individuals older than 60 years has an important role in avoiding adverse
consequences resulting from falls (Weatherall, 2004).
The work to prevent fractures related to osteoporosis should focus the prevention or increase
of material and structural properties of the bone, the prevention of falls and improvement of
total mass of lean tissue (American College of Sports Medicine, 1995).
The American College of Sports Medicine recommends that:
1. physical activity of transporting weight is essential to the normal development and
maintenance of a health skeleton. Activities that focus the increase of muscle strength
might also be beneficial, particularly for bones that do not support weight;
2. a sedentary woman might progressively increase her bone mass by becoming active, but
the primary benefit of increasing the activity is to prevent a future bone reduction that
resulting from the lack of activity;
3. exercise should not be recommended as a replacement to medications treatment;
4. the optimal program for an older woman might include activities that improve the
strength, flexibility and coordination which might indirectly, but effectively decrease the
incidence of osteoporotic fractures by reducing the probability of falls. Therefore, the
treatment of osteoporosis should aim the prevention of falls and fractures and preserva‐
tion or improvement of bone mineral density.
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2.1. Exercises for postural control
Postural control is a result of the combination of several types of sensorial information, such
as visual, vestibular and somatosensorial information, and passive and active properties of the
nervous system and skeletomuscle system that composes the human postural control system
(Figure 2), (Shumway-Cook et al., 2000).
The postural control system use three functions that are required to maintain balance: support,
stabilization and balance. The body should contract the adequate muscles to sustain the body
against gravity; the articular segments should be stabilized and the body should be stabilized
in the body’s support base (Rothwell, 1994). This way the treatment program which aims at
falls prevention should contain strength and resistance increasing components for promoting
the articular coaptation and to face the gravity, it also should prevent the posture reorganiza‐
tion aligning the body gravity center.
Currently, proprioception is defined as a set of afferent information provided by joints,
muscles, tendons and other tissues that reaches the Central Nervous System (CNS) where it is
processed, having an influence on reflex responses and voluntary motor control. Propriocep‐
tion contributes to postural control, joint stability and several conscious sensations (Lephart
& Fu, 2000).
Therefore the sensorial-motor training becomes indispensable for an appropriate falls pre‐
vention program, since it potentializes the propriocetive information captation and transmis‐
sion providing to SNC information regarding the contraction speed, movement speed,
articular position and angle, which are fundamental for a good motor control.
It is extremely important to understand that proprioception is only limited to the acquisition
of the mechanical stimulus and its transduction in neural stimuli, not having any influence on
the CNS processing and its motor response (Lephart & Fu, 2000).
Proprioception is part of a system denominated somatosensorial system. This includes all
mechanical information provided by the mechanoreceptors. The feeling of pain is provid‐
ed by the nociceptors and the thermal information provided by thermoreceptors (Guyton
& Hall, 2006).
All propriocetive information are originated at the muscular and tendon receptors called
muscular fusion and Golgi tendon organ and receptors located in ligaments, articular capsule,
meniscus and cutaneous tissues (Guyton & Hall, 2006).
Four elements should be focused to reestablish the sensorimotor deficits:  proprioception,
stabilization,  reactive  neuromuscular  control  and  functional  motor  patterns  (Lephart  &
Henry, 1995).
The proprioceptive mechanism comprises both conscious and unconscious pathways.
Therefore, the prescribed exercises need to include conscious exercises to stimulate the
cognition as well as sudden and unexpected alterations of joint position that initiate reflex
muscle contraction. These exercises should involve balance in an unstable surface while the
individual perform functional activities. The purpose of the dynamic stabilization training is
to improve the co-activation between the antagonist muscles (Hurd et al., 2006)
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Exercises to stimulate proprioception and dynamic stabilization should be performed in
closed-chain activities and with small movements, since the compression stimulates the
articular receptors and the changes in the curve length-tension stimulate the muscle receptors.
Limbs repositioning exercises should also be performed to stimulate the sense of joint position
and neuromuscular control (Lephart & Henry, 1995).
The improvement of dynamic stiffness is another important aspect. It is suggested that muscle
receptors increase its sensitivity through the increase of dynamic stiffness (Adler et al., 2008).
Exercises  that  involve  eccentric  training,  like  going  down  the  stairs  and  landing  after
jumps, are the most efficient to increase anticipatory and reactive muscular stiffness (Bas‐
tian et al., 2006).
The reactive neuromuscular control is reached through exercises that create unexpected
situations, such as perturbations in unstable surfaces in unipodal support and during gait.
Apparently, this kind of training improves the preparatory and reactive muscle activation
(Swanik et al., 2002).
The training protocol might include:
1. 5 – 10 minutes of warm-up, with stretching movements for upper and lower limbs, 03
repetitions for each movement being kept for 30 seconds, with 30-second intervals among
the series. After stretching, movements of fast gait as previous warm-up were performed
and in the end of the session, slow gait movements and stretching.
2. Proprioceptive exercises followed an evolution sequence based on the use of stable
surfaces to unstable, walking straight forward progressing to changes in direction, from
gait with no obstacles to gait with obstacles, alteration in the support base (from open to
closed), exercises with eyes open to closed eyes, always respecting the functional capacity
of each patient and progressively increasing the difficulty of each exercise. To aid the
training, cones, balance boards, sticks, mats and trampolines were used. According to the
patient’s evolution, the exercises were combined creating the circuits.
2.2. Stretching
Stretching should be performed during the warm up and in the last phase. A great joint range
of motion (ROM) increases the muscle, reduces the risk of lesion and increases the cartilage
nutrition. Painful joints should not be stretched excessively to a point that will result in more
pain; all movements should be made in order to get the maximum pain-free ROM. The use of
heat before stretching reduces pain and increases the range. At least three sessions of stretching
might be performed a week. In the beginning, three to five repetitions and a gradual increase
up to 10 repetitions is the ideal. The muscle should be stretched during 10 to 30 seconds.
2.3. Muscle strengthening
Muscle strengthening should be acquired with weights or elastic bands which will give
endurance to the movement. The training protocols should include the following principles:
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surfaces to unstable, walking straight forward progressing to changes in direction, from
gait with no obstacles to gait with obstacles, alteration in the support base (from open to
closed), exercises with eyes open to closed eyes, always respecting the functional capacity
of each patient and progressively increasing the difficulty of each exercise. To aid the
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patient’s evolution, the exercises were combined creating the circuits.
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Stretching should be performed during the warm up and in the last phase. A great joint range
of motion (ROM) increases the muscle, reduces the risk of lesion and increases the cartilage
nutrition. Painful joints should not be stretched excessively to a point that will result in more
pain; all movements should be made in order to get the maximum pain-free ROM. The use of
heat before stretching reduces pain and increases the range. At least three sessions of stretching
might be performed a week. In the beginning, three to five repetitions and a gradual increase
up to 10 repetitions is the ideal. The muscle should be stretched during 10 to 30 seconds.
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endurance to the movement. The training protocols should include the following principles:
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• muscle contraction exercises should be made in a moderate speed;
• exercises should be chosen according to joint stability and degree of pain and edema;
• muscles should not be exercised to fatigue;
• exercise endurance should be submaximal;
• inflamed articular joints should be strengthen with isometric exercises and at first it should
include few repetitions;
• pain or edema in a joint after an hour of exercise indicates excessive activity.
Isometric exercises are indicated for unstable or swollen joints. On the other hand, isometric
contractions result in a low articular pressure and are well tolerated by older patients. It should
start with contractions with an intensity of approximately 30% of maximal strength, slowly
increasing to 80%. The contraction should not be kept for more than 6-10 seconds and the
repetitions should be increased from 8 to 10, if tolerated by the patient. It should be performed
twice a day during the inflammatory period and after the inflammation is over, it should be
increased from 5 to 10 times a day.
Isotonic exercises should include from 8 to 10 exercises involving the major muscle groups
(four exercises for the upper limbs and from four to six for the lower limbs). At first, patients
should use weights with 40% of the individual’s maximal load, increasing up to 80%. Gener‐
ally, a series of four to six repetitions should be made, avoiding the muscle fatigue. At first,
the frequency should be at most twice a week but in case of individuals with advanced age or
significant fragility the exercises should be made only once a week. Between the sessions, there
might be at least one full day of rest.
Changes in strength after resistance exercise training RET are assessed using a variety of
methods, including isometric, isokinetic, one-repetition maximum (1-RM), and multiplerepe‐
tition (e.g., 3-RM) maximum-effort protocols. In general, strength increases after RET in older
adults seem to be greater with measures of 1-RM or 3-RM performance compared with
isometric or isokinetic measures. Older adults can substantially increase their strength after
RET—with reported increases ranging from less than 25% to greater than 100% (American
College of Sports Medicine, 2009).
3. Material and methods
The present research was approved by the Research Ethics Committee of the Federal Univer‐
sity of São Paulo. The clinical trial was registered in the Australian New Zealand Clinical Trials
Registry (ANZCTR).
Among the 758 bone densitometries tests made in the Image Diagnosis Service at the Ambu‐
latório de Especialidades de Interlagos, São Paulo - Brazil, 284 were found positive for
Osteoporosis, where 162 of these densitometries tests were from patients which ages were
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within the age group proposed by the present research and 80 of them were included in the
study, since they met the required inclusion criteria (Fig. 1).
Patients were from 65 to 75 years old and only individuals with a postmenopausal osteopo‐
rosis, according to the OMS, with a bone mineral density (BMD) T-score of −2.5 standard
deviation (SD), in the lumbar spine, femoral neck or total femur region (Lewiecki et al., 2004)
were included.
The following women were excluded: those with secondary osteoporosis, visual deficiency
with no possibilities of previous corrections; severe auditive deficiency; with vestibular
alteration of important clinical status; as well as women who used assisted walking devices
(orthesis or prosthesis); those who planned to be out of town for two consecutive weeks during
the 18-week study and also women who presented absolute contraindications for physical
exercise, according to the American College of Sports Medicine.
All patients selected according to the inclusion and exclusion criteria signed an informed
consent (IC). The randomization was performed by a technical assistant not involved in the
research using a computer program and the sequential numbers were kept in opaque, not
translucent and sealed envelope being given to one of the two groups based on the Consort
recommendations.
The volunteers were included in two groups: the first group (G1) comprised 40 patients who
underwent 18-week proprioceptive and progressive muscular strength training associated to
a drug treatment of Osteoporosis; and the second called G2 also included 40 patients that only
underwent a conventional drug treatment.
3.1. Evaluation
The registration of patients was made during the medical evaluation in order to include or
exclude the individuals in the research and their personal and clinical data were also registered.
All patients were evaluated by a physical therapist who was blinded to the group to which the
patient belonged. The quality of life, functional skills and the risk and number of falls were
evaluated.
The quality of life was evaluated using the Short Form Health Survey (SF-36), a questionnaire
displayed in a scale from 0 to 100, where 0 means the worst quality of life and 100 points
corresponds to the best quality of life, according to what is proposed by the survey (Ciconelli
et al., 1999).
The Berg Balance Scale, a test where the maximum score that can be achieved is 56 and where
each item has an ordinal scale of five alternatives which varied from 0 to 4 points, was used to
evaluate the balance (Berg et al., 1996), Miyamoto et al., 2004).
The functional mobility was evaluated by the Timed “Up & Go” Test which measures the time
an individual takes to get up of a chair, walks to a line on the floor 3 meters away as fast and
safe as possible, turn around, walk back to the chair and sits down again allowing the buttocks
and lumbar region to touch the seat surface (Podsiadlo et al., 1991, Shumway-Cook et al.,
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1997). The TUG was performed along with other balance and functional mobility tests
(Bohannon et al., 2006) since it is a sensitive and specific measurement of the fall probability
among elderly adults (Large et al., 2006, Kristensen et al., 2007).
The dynamic strength of the quadriceps muscle was evaluated by the One Repetition Maxi‐
mum (1 RM) Test that measures the maximum weight a subject can lift with one repetition
when making a standard weight lifting exercise. Three attempts were made to reach the plateau
in the 1-RM score with 3-minute intervals between each attempt (Weier 1997, Hortobagyi et
al., 1998).
The number of falls was evaluated by monitoring the immediate report of falls from patients
of both groups during 24 weeks. The patients were also questioned if they experienced falls
six months preceding the study.
3.2. Treatment protocol of Teixeira & Silva et al., 2010
The protocol consisted of a routine where: 1) the patients participated in a 5-10 minutes warm-
up in a treadmill, static stretching exercises (global and segmentary) for the upper and lower
limbs, lumbar, cervical and thoracic region with 3 repetitions for each muscle or muscular
group, maintaining the stretching for 30 seconds between the 2 series of exercises. 2) The
functional exercises (proprioception and balance) were performed in a routine that follows a
progressive order beginning with stable surface and changing to unstable surfaces, gait
training without obstacles and then performance of gait training with obstacles, exercises first
with eyes opened and then eyes closed, first low speed exercises and according to the patient
performance high speed exercises, bipedal training and then unipedal, also using resources
such as balance, trampoline and proprioceptive boards always using the same progressive
order (table 1). 3) Strengthening exercises included leg extensions with a load up to 80% of 1-
RM, following a protocol of two weeks of adjustment wearing 1 to 2 kilos ankle weight,
progressing for 50%, 60%, 70% up to 80% of 1-RM (American College of Sports Medicine, 2002).
Examples of exercises: ten repetitions with one-minute intervals for antero-posterior and
latero-lateral gait; gait with obstacles (20 cm high); gait over mattress; going up and down the
stairs; change in direction according to the sound stimulus; balance exercises lasting 30 seconds
and with one-minute interval for unipodal and bipodal support on the floor with eyes open
and/or closed; change in floor for a more unstable surface such as a trampoline and balance
board; exercises with dissociation of waist and use of a stick (Table 1).
3.3. Data analysis
After evaluating 758 patients, 80 were randomized and only 65 concluded the study, being 33
patients from G1 and 32 from G2. Three patients included in the G1 group did not complete
the study because they did not have appropriate means of transportation, two others due to
financial conditions, another one moved to a different city and the last one abandoned the
study due to personal reasons. Two patients from G2 group did not complete the study for
personal reasons, three started exercising regularly in another place, one quit due to illness of
a family member and two others because we could not contact them by phone in order to
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schedule their re-evaluations, as illustrated in the chart based on the Consort recommendations
(Moher et al., 2001) (Fig. 1).
Options of Exercises Evolution of Exercises Time or # of repetitions
Balance exercises (balance board, mini-trampoline.
Dyna disc)
Eyes open or closed / stable or unstable 10 rep / 30s
Stability exercises
Unipodal or bipodal support / open or
close base
10 rep / 30s
Anteroposterior and latero-lateral gait
With or without obstacle and Variation
in speed
10 rep (3 m)
Mat exercises Go up/down: 1 to 3 mats 10 rep / 3 series
Exercises on the stairs Variation in speed 10 rep / 3 series
Exercises with sticks With or without arm movements 10 rep / 3 series
Table 1. Examples of exercises
Anteroposterior and latero-lateral gait With or without obstacle and Variation in speed 10 rep (3 m) 
Mat exercises Go up/down: 1 to 3 mats 10 rep / 3 series 
Exercises on the stairs Variation in speed  10 rep / 3 series 
Exercises with sticks With or without arm movements 10 rep / 3 series 
Table 1. Examples of exercises 
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758 bone densitometries 
tests evaluated 
40 allocated into the control 
group 
40 allocated into the 
exercise group 
33 analysed  32 analysed 
80 randomized 
 658 were excluded 
374 didn’t have 
osteoporosis 
122 weren’t in the age 
group 
162 didn’t meet the 
7 didn’t complete the study 
3 no means of transportation 
2 due to financial conditions 
1 moved to a different city 
1 for personal reasons 
8 didn’t complete the study 
3 started exercising in another 
center  
2 for personal reasons 
2 due to loss of telephone 
contact 
1 due to illness of a family 
member 
Figure 1. Organizational chart (based on Consort recommendations) including the inclusion and exclusion analysis,
randomization, group allocation, losses and patients who concluded the study.
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In order to verify the presumed normality in the data distribution, the Shapiro-Wilk test was
used, as well as the Q-Q plot. Since the studied variable distribution could not be rounded up
by the normal distribution the median and quartile 1 and 3 were calculated to describe the
variables in the study.
The chi-square test was employed to evaluate the epidemiological data in the baseline.
The significance of the influence of the time the treatment was performed (pre and post-
intervention) and influence of the groups (control and experimental) was evaluated by using
the nonparametric hypothesis test (Robertson et al., 2005).
The statistical  significance was set  at  P ≤ 0.05.  All  the statistical  process was performed
with  the  statistical  language  R  (version,  2.6.2;  R  Foundation  for  Statistical  Computing,
Vienna, Austria).
3.5. Results
The basal characteristics of the patients of both groups were similar in relation to age, bone
mineral density, history of fractures, osteoporosis treatment, use of diuretics, hypnotics, and
antidepressants, other rheumatic diseases and number of individuals that fell 6 months prior
to the study.
According to data described in Table 2, it is possible to conclude that the scores for SF-36 in
the intervention group were better in all eight sub-scales after the rehabilitation period
compared to the admission time, as well as the control group. These changes were statistically
(p ≤ 0.007) and clinically significant (a change of at least 13.5 points in each sub-scale of the
SF-36) for all sub-scales.
According to what was described in Table 3, there was a significant difference in the results
of the Timed Up & Go Test in the pre and post- training (p < 0.001) for the experimental group.
Furthermore, the post-training values for the experimental group were significantly greater
than the ones shown by the control group (p < 0.001). In terms of maximum dynamic load, a
significant increase between pre and post-training in the experimental group (p < 0.001) was
observed. Besides that, the post-training values in the experimental group were significantly
greater than the ones of the control group (p < 0.001).
Variables such as physical activity, rotational component and decreased base showed a
significant increase when compared to the admission data and the control group (p ≤ 0.003).
The general score of the Berg Scale (TABLE 4) showed a significant increase in the experimental
group (p < 0.001), where the post-training values were significantly greater in the experimental
group compared to the control (p < 0.001). No significant differences were found in the items
Transference and Static Tests. Although the changes in numbers are not huge they are
consistent. A lot of people in the experimental group showed increased scores; therefore the
possibility of a small score may not be great. No statistical reduction in the number of falls per
patient was observed.
Topics in Osteoporosis224
Variables Moment Control (N=32) Intervention (N=33) ∆ (intervention-control) p-value
Functional skills
t0 54,4(26,42) 63,95(22,56) — —
t18 50,6(29,45) 82,44(17,3) 25,11[17,7;32,52] < 0.0001
Physical aspects
t0 44,05(33,95) 36,05(34,63) — —
t18 43,57(37,42) 92,44(17,71) 51,62[39,97;63,28] < 0.0001
Pain
t0 38,88(20,63) 38,21(19,94) — —
t18 44,93(21,51) 65,58(23,2) 20,98[12,29;29,68] < 0.0001
General Health Status
t0 52(22,38) 51,09(17,72) — —
t18 55,88(23,81) 73,67(17,54) 18,38[11,29;25,47] < 0.0001
Vitality
t0 50,71(22,4) 58,26(20,26) — —
t18 54,05(23,51) 74,88(15,49) 16,55[9,61;23,48] < 0.0001
Social aspects
t0 63,62(29,4) 69,4(26,69) — —
t18 68,05(28,51) 93,12(13,68) 23,06[14,32;31,81] < 0.0001
Emotional aspects
t0 52,4(44,29) 55,79(40,38) — —
t18 61,12(44,15) 85,28(28,49) 22,7[8,69;36,7] < 0.0018
Mental health
t0 48,29(21,08) 64,3(20,52) — —
t18 52,86(21,05) 78,84(17,41) 15,26[9,03;21,48] < 0.0001
The data were expressed as the mean (standard deviation) or average [95% confidence interval].
Table 2. Pre and post-training values for SF-36 scores
Variables Moment Control (N=32) Intervention (N=33) ∆(intervention-control) p-value
Maximum load (kg) t0 7.6(2.27) 8.02(1.81) — —
Maximum load (kg) t18 8.1(2.81) 14.81(3.14) 3.65[2.74;4.57] < 0.0001
Time up and go (s) t0 11.35(2.88) 10.74(2.23) — —
Time up and go (s) t18 11.15(2.55) 6.9(1.11) -3.96[-4.63;-3.29] < 0.0001
The data were expressed as the mean (standard deviation) or average [95% confidence interval].
Table 3. Pre and Post-Training Values for the Time Up and Go Test (s), maximum load (Kg) and Berg Balance Scale
(scores).
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Functional skills
t0 54,4(26,42) 63,95(22,56) — —
t18 50,6(29,45) 82,44(17,3) 25,11[17,7;32,52] < 0.0001
Physical aspects
t0 44,05(33,95) 36,05(34,63) — —
t18 43,57(37,42) 92,44(17,71) 51,62[39,97;63,28] < 0.0001
Pain
t0 38,88(20,63) 38,21(19,94) — —
t18 44,93(21,51) 65,58(23,2) 20,98[12,29;29,68] < 0.0001
General Health Status
t0 52(22,38) 51,09(17,72) — —
t18 55,88(23,81) 73,67(17,54) 18,38[11,29;25,47] < 0.0001
Vitality
t0 50,71(22,4) 58,26(20,26) — —
t18 54,05(23,51) 74,88(15,49) 16,55[9,61;23,48] < 0.0001
Social aspects
t0 63,62(29,4) 69,4(26,69) — —
t18 68,05(28,51) 93,12(13,68) 23,06[14,32;31,81] < 0.0001
Emotional aspects
t0 52,4(44,29) 55,79(40,38) — —
t18 61,12(44,15) 85,28(28,49) 22,7[8,69;36,7] < 0.0018
Mental health
t0 48,29(21,08) 64,3(20,52) — —
t18 52,86(21,05) 78,84(17,41) 15,26[9,03;21,48] < 0.0001
The data were expressed as the mean (standard deviation) or average [95% confidence interval].
Table 2. Pre and post-training values for SF-36 scores
Variables Moment Control (N=32) Intervention (N=33) ∆(intervention-control) p-value
Maximum load (kg) t0 7.6(2.27) 8.02(1.81) — —
Maximum load (kg) t18 8.1(2.81) 14.81(3.14) 3.65[2.74;4.57] < 0.0001
Time up and go (s) t0 11.35(2.88) 10.74(2.23) — —
Time up and go (s) t18 11.15(2.55) 6.9(1.11) -3.96[-4.63;-3.29] < 0.0001
The data were expressed as the mean (standard deviation) or average [95% confidence interval].
Table 3. Pre and Post-Training Values for the Time Up and Go Test (s), maximum load (Kg) and Berg Balance Scale
(scores).
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Variables Moment Control (N=32) Intervention (N=33) ∆(intervention-control) p-value
Decreased base t0 9.98(2.31) 10.05(1.4) — —
t18 9.67(2.2) 11.28(1.44) 1.56[1.04;2.08] < 0.0001
Static Tests t0 11.88(0.33) 11.95(0.21) — —
t18 11.71(0.99) 12(0) 0.19[-0.07;0.45] 0.1537
Rotational component t0 11.21(1.14) 11.37(1.75) — —
t18 11.17(099) 11.91(0.37) 0.7[0.43;0.97] < 0.0001
Transference t0 11.24(1.16) 11.53(1.05) — —
t18 11.26(1.21) 11.81(0.93) 0.35[0.01;0.69] 0.0533
General score t0 51.71(4.1) 52.07(3.63) — —
t18 51.26(4.66) 55.12(1.73) 3.58[2.75;4.42] < 0.0001
The data were expressed as the mean (standard deviation) or average [95% confidence interval].
Table 4. Table 4. Pre and Post-Training Values for the Berg Balance Scale (scores).
Based on the positive results of the protocol used for the physical status, an expressive
reduction in the number of total falls (Figure 2) was observed. We could also observe a
significant reduction between the pre and post-training in the experimental group (p < 0.001).
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possibility of a small score may not be great. No statistical reduction in the number of falls per patient was observed. 
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Figure 2. Number of falls 24 weeks preceding the treatment (Before) and 24 weeks after the treatment (After), in the Intervention (G1) and Control 
Groups (G2) 
Besides that, the post-training values in the experimental group were significantly lower than the ones shown by the control group 
(p < 0.001), confirmed by the odds ratio (TABLE 5). 
 Control (n=32) Intervention (n=33) 
T0 0,5625 (18/32) 0,6060 (20/33) 
T18 0,6250 (20/32) 0,1515 (5/33) 
Razão T18/T0 1,111 0,25 
Table 5. Comparison of odds ratio falling between the control and intervention groups. 
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Control (n=32) Intervention (n=33)
T0 0,5625 (18/32) 0,6060 (20/33)
T18 0,6250 (20/32) 0,1515 (5/33)
Razão T18/T0 1,111 0,25
The data were expressed as ratio and odds ratio.
Table 5. Comparison of odds ratio falling between the control and intervention groups.
4. Discussion
Evidences have shown that specific exercises might reduce the risk factors for falls and number
of falls in older people (Table 6, 7).
Muscle Strength Training and Balance Training




balance, strength and agility in
elderly people and thus may
prevent falls. However, specific
exercise programs that might be
widely used in the community
and that might be “prescribed”
by physicians, especially for
patients with osteoporosis, have
not been evaluated. We
conducted a randomized
controlled trial of such a
program designed specifically
for women with osteoporosis.
We identified women 65 to 75
years of age in whom
osteoporosis had been
diagnosed by dual-energy X-ray
absorptiometry in our hospital
between 1996 and 2000 and
who were not engaged in
regular weekly programs of
moderate or hard exercise.
Women who agreed to
participate were randomly
assigned to participate in a
twice-weekly exercise class or to
not participate in the class. We
measured baseline data and, 20
weeks later, changes in static
balance (by dynamic
posturography), dynamic
balance (by a timed figure-eight
run) and knee extension
strength (by dynamometry).
Of 93 women who began the
trial, 80 completed it. Before
adjustment for covariates, the
intervention group tended to
have greater, although
nonsignificant, improvements
in static balance (mean
difference 4.8%, 95%
confidence interval [CI] –1.3%
to 11.0%), dynamic balance
(mean difference 3.3%, 95%
CI –1.7% to 8.4%) and knee
extension strength (mean




The purpose of this study was to
investigate the effect of a 12-
month Balance Training
Sixty-six consecutive elderly
women were selected from the
Osteometabolic Disease
Sixty women completed the
study and were analyzed. The
BBS difference was significant
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Variables Moment Control (N=32) Intervention (N=33) ∆(intervention-control) p-value
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Muscle Strength Training and Balance Training
Autor Objective Desing Results
Program on balance, mobility
and falling frequency in women
with osteoporosis
Outpatient Clinic and
randomized into 2 groups: the
‘Intervention’, submitted for
balance training; and the
‘Control’, without intervention.
Balance, mobility and falling
frequency were evaluated
before and at the end of the
trial, using the Berg Balance
Scale (BBS), the Clinical Test
Sensory Interaction Balance
(CTSIB) and the Timed “Up & Go”
Test (TUGT). Intervention used
techniques to improve balance
consisting of a 1-hour session
each week and a home-based
exercise program.
higher in the Intervention
group compared to Control
(5.5±5.67 vs differences
between the TUGT were
reduced in the Intervention
group compared to Control
(−3.65±3.61 vs 2.27±7.18
seconds, p< 0.001). Notably,
this improvement was
paralleled by a reduction in
the number of falls/patient in
the Intervention group
compared to Control (−0.77 ±
1.76 vs 0.33 ± 0.96, p=0.018).
Chyu, et al,
2010
To evaluate the effects of tai chi
exercise on risk factors for falls in
postmenopausal women with
osteopaenia through
measurements of balance, gait,
physical function and quality of
life.
Sixty-one independently living
elderly females aged 65 years
and older with low bone.
Subjects were recruited and
randomly assigned to 24 weeks
of tai chi (60 minutes/session,
three sessions/week, n = 30) or a
control group (n = 31).
Computerized dynamic
posturography, gait, 'timed up
and go', five-chair sit-to-stand
and quality of life assessed at
baseline, 12 and 24 weeks.
After 24 weeks, subjects in the
tai chi group demonstrated an
increase in stride width (P =
0.05) and improvement in
general health (P = 0.008),
vitality (P = 0.02) and bodily
pain (P = 0.03) compared with
those in the control group.
Table 6. Studies that used different methods of muscle strength training and balance training
Muscle Strength Training and Balance Training
Autor Objective Desing Results
Smulders E et
al; 2010
To evaluate the efficacy of the
Nijmegen Falls Prevention
Program (NFPP) for persons
with osteoporosis and a fall
Persons with osteoporosis and a fall
history (N=96; mean ± SD age,
71.0±4.7y; 90 women). Randomized
in two groups. Primary outcome
The fall rate in the exercise
group was 39% lower than for
the control group (.72 vs 1.18
falls/person-year; risk ratio, .
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Muscle Strength Training and Balance Training
Autor Objective Desing Results
history in a randomized
controlled trial.
measure was fall rate, measured by
using monthly fall calendars for 1
year. Secondary outcomes were
balance confidence (Activity-specific
Balance Confidence Scale), quality
of life (QOL), and activity level
(LASA), assessed posttreatment
subsequent to the program and
after 1 year of follow-up.
61; 95% confidence interval, .
40-.94). Balance confidence in
the exercise group increased
by 13.9% (P=.001). No group
differences were observed in
QOL and activity levels.
Burke TN et
al; 2010
To assess the efficacy of an
exercise program aiming to
improve balance and
muscular strength, for
postural control and muscular
strength of women with
osteoporosis.
Sample consisted of 33 women with
osteoporosis, randomized into one
of two groups: intervention group,
in which exercises for balance and
improvement of muscular strength
of the inferior members were
performed for 8 wks (n = 17, age
72.8 +/- 3.6 yrs); control group,
which was women not practicing
exercises (n = 16, age 74.4 +/- 3.7
yrs).At baseline and after 8 wks of
treatment, postural control was
assessed using a force plate
(Balance Master, Neurocom), and
muscular strength during ankle
dorsiflexion, knee extension, and
flexion was assessed by
dynamometry.
When compared with the
control group, individuals in
the intervention group
significantly improved the
center of pressure velocity (P =
0.02) in the modified clinical
test of sensory interaction for
balance test, center of pressure
velocity (P < 0.01), and
directional control (P < 0.01) in
limits of stability test, isometric
force during ankle dorsiflexion
(P = 0.01), knee extension (P <




To evaluate the effect of a
progressive muscular strength
and proprioception training
program on the muscle
strength of the quadriceps,
balance, quality of life and





osteoporosis, ages ranging from 55
to 75, were randomized into two
groups: the intervention group
comprised of 50 patients who
underwent a 18-week of
progressive load training for the
quadriceps and proprioception
training and the control group that




the research. The program
promoted a significant
difference among the groups
for SF-36 in the eight sub-
scales (p ≤ 0.007), Timed Up &
Go Test (p < 0.001), 1-RM test
(p < 0.001), Berg Balance Scale
(p < 0.001) and also a decrease
in the total number of falls in
the intervention group
compared to control (p <
0.001).
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Muscle Strength Training and Balance Training
Autor Objective Desing Results
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Muscle Strength Training and Balance Training
Autor Objective Desing Results
mobility, quality of life were
evaluated in the beginning and end
of the research. The number of falls




Tai Chi (TC) is a mind-body
exercise that shows potential
as an effective and safe
intervention for preventing
fall-related fractures in the
elderly.
In a pragmatic randomized trial, 86
post-menopausal osteopenic
women, aged 45-70, were
recruited. Primary outcomes were
changes between baseline and nine
months of bone mineral density
(BMD) of the proximal femur and
lumbar spine (dual-energy X-ray
absorptiometry) and serum markers
of bone resorption and formation.
Secondary outcomes included
quality of life.
Changes in sway parameters
were significantly improved by
TC vs. UC (average sway
velocity, P = 0.027; anterior-
posterior sway range, P =
0.014). Clinical measures of
balance and function showed
non-significant trends in favor
of TC.
Table 7. Studies that used different methods of muscle strength training and balance training
Because of the strong interaction between osteoporosis and falls, the selection of participants
in protocols for the prevention of fractures should be based on factors related to bones and
falls (Pfeifer et al., 2004).
The German Society of Sport Medicine and the American College of Sport Medicine also
recommend that the ideal program for women with osteoporosis should include activities that
improve strength, flexibility and coordination that might indirectly and more effectively
decrease the incidence of osteoporotic fractures by the reduction in the probability of falls
(Lange et al., 2005).
Few studies take into consideration the importance of the proprioceptive training as a
fundamental and unseparable part of a muscular strengthening program. Mechanoreceptors
located in the joints, tendons, muscles and neighbor tissue provide information to the Nervous
System about the position and articular movements and about the forces generated in the
muscles (Huntlei, 2003) (van der Esch, 2007).
The knee proprioception is essential for the modulation and accurate activation of the muscle
contraction, once the functional skill and muscular balance are strongly affected by the
proprioceptive inaccuracy and muscle weakness (van der Esch, 2007). Studies including
patients with knee ligament lesions show that the proprioceptive training promotes additional
sensorial information that contributes to the improvement in postural control (Bonfin, 2008).
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This relationship becomes even more important when the muscle strengthening program aims
to improve the functional balance and prevention of falls.
Despite the knowledge on muscular strength power and the proprioception for a good motor
control, and consequently a lower unbalance and fall risk, previous studies to this one ignore
the association importance of sensorial-motor training to strength training.
The significant results found in the present research might be explained by the concern in
following the ACSM recommendations when prescribing exercises, respecting the basic
concepts of prescription exercises.
Additionally, one should take into consideration that the skill to develop muscle strength
decreases with aging (Hakkinen et al, 1998) explaining the importance of the gradual progres‐
sion (Adams et al, 1999). With sedentary elderly people, a period of adaptation and low
working load for two weeks should be applied for further implementation of a loading
progression protocol (American College of Sports Medicine, 2002).
Data combined from three studies conducted by Gillespie et al., 2006 (Cochrane Library
review) with a total of 556 women aged 80 years or older, who underwent to the same
progressive muscular strengthening program, balance training and gait training indicate that
this intervention decreased the number of individuals that fell during a year, having also
reduced the number of injurious falls. Although the studies had methodological limitations,
there is a determined consistency as for the decrease of falls in multiple interventions exercises
(Gillespie et al., 2009). As for the physical exercise, we only know that it improves balance
without a direct association with the decrease in the number of falls (Howe Tracey et al., 2009)
and that although the decline in muscle strength is a risk factor for falls, the muscle strength
training could not be associated to the reduced number of falls (Sherrington et al, 2009),
(Gillespie, et al., 2009).
During strength training elderly people respond positively presenting exponential gains in
muscular strength, on explosion as well in muscular resistance. This is explained due to
muscular mass decreases in approximately 50% between twenty and ninety years old and the
number of muscular fibers in an elder person is around 20% less than in an adult person, being
clear the latent capability for recovery of a strength pattern nearly to an adult.
In this study, after a 18-week training, an average increase of 89.5% in the maximum dynamic
strength of the quadriceps muscle (1RM) in the intervention group was observed, being within
the values described by Humphries et al., 2000 which shows increases of 20 to 200% in the
dynamic muscle strength of the quadriceps depending on the initial values and duration of
the training. This increase in the knee extension force is significantly important because this
force is an independent risk factor for falls and fractures caused by osteoporosis (Nguyen et
al., 1993). The increase in the force occurs as a result of neural changes and muscle adjustments
(Resende et al, 2006).
The body balance depends on information appropriate receiving through sensorial, cognitive
components from the nervous system and from the musculoskeletal system in an integrated
manner by the proprioception. The association of muscle strengthening and proprioceptive
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Autor Objective Desing Results
mobility, quality of life were
evaluated in the beginning and end
of the research. The number of falls




Tai Chi (TC) is a mind-body
exercise that shows potential
as an effective and safe
intervention for preventing
fall-related fractures in the
elderly.
In a pragmatic randomized trial, 86
post-menopausal osteopenic
women, aged 45-70, were
recruited. Primary outcomes were
changes between baseline and nine
months of bone mineral density
(BMD) of the proximal femur and
lumbar spine (dual-energy X-ray
absorptiometry) and serum markers
of bone resorption and formation.
Secondary outcomes included
quality of life.
Changes in sway parameters
were significantly improved by
TC vs. UC (average sway
velocity, P = 0.027; anterior-
posterior sway range, P =
0.014). Clinical measures of
balance and function showed
non-significant trends in favor
of TC.
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training was fundamental to the increase of functional mobility and skills, which can be related
to the reduction of 36% in the time spent to the performance of the TUG. In this case, the lower
the time spent to make the exercise, the better the balance (Resende et al, 2006).
Although the changes in the numbers were small, the improvement in the balance evaluated
by the BBS was consistent, and they are in agreement with the results found by Madureira et
al, 2007.
Bemben (2000) compared the effects of high and low-intensity training in 25 postmenopausal
women (41 to 60 years old) using a high repetition (40% 1-RM, 16 repetitions) and high load
(80 % 1-RM, 8 repetitions) protocols for six months showing increases from 30 to 40%,
respectively in the dynamic strength in quadriceps.
In a randomized controlled trial of 10 weeks of strength, balance and stretching training in 53
postmenopausal women with osteoporosis, Malmros and colleagues (1998) showed that
strength and muscle mass and also the static balance improved significantly.
In another randomized clinical trial, physiotherapy-directed exercise in 30 patients with
osteoporosis significantly improved static balance measured by functional reach and increased
quadriceps dynamic strength (Mitchell et al, 1998).
These two studies indicate that the exercises programs improved the profile of fall risk but
showed limitations because of the small number of samples and short time of the interventions.
Hartard et al. (1996) studied the effects of muscle strength training in 16 postmenopausal
women with osteopenia, where fifteen belonged to the control group. Although they used a
small group, a proper load protocol for 6 months, twice a week at 70% 1RM was applied
demonstrating a considerable increase in muscle strength ranging from 44 to 76%, with results
similar to the ones found in the present investigation.
Kemmler et. al (2002) evaluated the dynamic force (1RM tests) in 137 postmenopausal women
with osteopenia divided in two groups and observed a significant increase of 43% in the leg
press in the intervention group training at 70% of 1-RM for fourteen months.
Carter et al. (2002) in a program that trains instructors to work with the community selected
93 postmenopausal women with osteoporosis who were randomized and underwent physical
exercises of balance and muscle strength for twenty weeks. No improvement in the quality of
life was found, which might be explained by the high quality of life at baseline. Researchers
observed an improvement of 6.3% in the dynamic balance and an increase of 12.8% in the
muscular strength.
On the other hand, this study contradicts other researches since it shows a significant im‐
provement in the quality of life evaluated by the SF-36, where the values for the physical
aspects and mental aspects were considerably higher than the ones found in the control group
and the values in the baseline. These outcomes might be related to the systemic physiologic
benefits provided by the exercises, which improves the capability of performing daily
activities. The results can also be explained by the psychological effects the physical exercise
provides, the socialization with other patients and the low levels of quality of life the patients
had in the beginning of this study.
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Madureira et. al (2006) conducted a randomized clinical trial that included 66 postmenopausal
women with osteoporosis assigned to two groups. One of the groups underwent a 12-month
of balance training once a week combined with oriented training at home showing significant
results concerning balance, mobility and decrease in the number of falls.
Swanenburg et. al (2007) studied 24 women (65 years old or older) with osteoporosis or
osteopeny who underwent three months of strength, balance and coordination training. After
twelve months, they observed a reduction in the risk of fall (Berg Scale) and increase in the
muscle strength of lower limbs. They also found a decrease in the number of falls in the
intervention group (89%), showing a significant number although it was a pilot study.
Our figures concerning the reduction of number of falls are similar to the ones found in other
studies, although an average of 40% (Barnett et al., 2003) is still not well-substantiated, which
can be explained by the differences in the population and mainly in the interventions used in
the different researches.
The programmed answers execution by the central nervous system is performed by the
musculoskeletal system and the reflex answers, voluntary motor control, postural control and
articular stability influence it, fundamental components for falls risk decrease. Therefore the
proposed and performed program in this study took in consideration the effector system
optimization importance and the neural components, thus, by associating the strength training
to sensorial-motor training we obtained effective outcomes and even more vigorous than those
that only use muscular strength or balance without taking in consideration the integrated
action among the central nervous system, peripheral nervous system (through proprioceptors)
and the effecting organs.
As we could observe, several studies have shown to be effective to increase the strength,
balance and functional skills, decreasing the risk of falls. Only the research conducted by
Madureira et al. 2007 and Swanenburg et al. 2007 direct related these outcomes with the
number of falls. However, it is difficult to compare the studies because the training programs
and the evaluation methods are different.
The possible limitations of the present study include the tests and functional scales used, that
are validated but are not so accurate as the lab tests considered the gold pattern. On the other
side, we used the BBS, TUG and 1-RM Test which are highly reproducible in the daily clinic
practice, where the access to lab tests is not very often.
A high adherence rate to the exercises, the thorough evaluation made by a blinded physical
therapist, the size of the sample and also the strict methodology used when prescribing the
exercises might have contributed to the outcomes in this present study.
The purpose of this study was to implement a muscle and proprioceptive training program
that would follow the recommendations stated by ACSM, promoting a program that would
be strictly followed and prescribed, but easy to use and reproduce.
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The association of progressive strength training for the quadriceps and the proprioceptive
training is effective for the prevention of falls, increasing the muscle power, the static and
dynamic balance and increasing the speed of the motor responses, therefore improving the
performance of daily activities.
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1. Introduction
Osteoporosis is a systemic skeletal disease characterized by low bone mineral density
(BMD), microarchitectural deterioration of bone tissue, and an increase in fracture risk [1].
Several drugs have been developed to treat osteoporosis: most of these are inhibitors of bone
resorption. Effective treatment of osteoporosis requires not only resorption inhibitors, but al‐
so stimulators of bone formation especially in patients who already have lost a significant
degree of bone. Although therapeutic alternatives are available for inhibiting bone resorp‐
tion, options of bone anabolic agents are much more limited with regard to the bone resorp‐
tion inhibitors.
Although patients included in randomised controlled trials have osteoporosis defined ac‐
cording to the WHO criteria, i.e. a T score below -2.5 SD and/or prevalent fragility fractures,
a large proportion of fractures occurs at T-scores above -2.5 SD and in patients without prior
fractures [1]. Therefore, therapies with proven fracture risk reduction efficacy in patients
with osteopenia and/or clinical risk factors may contribute to earlier and more effective in‐
tervention against fractures.
The past decade has witnessed major advances in the diagnosis and treatment of osteoporo‐
sis. It would appear that anabolic drugs challenge prevailing paradigm by stimulating bone
formation, therefore enhancing bone turnover. There is a great need to anabolic agents for
reverse of osteoporosis. In this review, we summarize current informations about the ana‐
bolic agents.
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2. Parathormon
Parathyroid hormon (PTH) is released from the parathyroid glands and is an important reg‐
ulator in the bloodstream’s levels of calcium phosphorus. It stimulates both bone formation
and resorption [2,3]. Its intermittent low-dose using increases bone formation more than
bone resorption, leading to increased bone mass. Intermittent PTH administration increases
the number and activity of osteoblasts, enhances the mean wall thickness and trabecular
bone volume, and improves bone microarchitecture by establishing trabecular connectivity
and increasing cortical thickness [2,4].
Continuous infusions, which result in a persistent elevation of the serum parathyroid hor‐
mone concentration, lead to greater bone resorption than do daily injections, which cause
only transient increases in the serum parathyroid hormone concentration [5,6]. The anabolic
effects of PTH on bone formation are through the medium of PTH receptor-dependent
mechanisms. Teriparatide (PTH 1-34 ) is the biological active, a recombinant form of PTH [7].
Patients with fractures of postmenopausal osteoporosis administered teriparatide 20 and 40
μg/d in FPT (Fracture Prevention Trial) [8]. After 18 months teriparatide 20 μg/d reduces the
risk of spine fracture by %65 and non-spine fracture risk by %53. Over a median of 18
months spine fracture risk reduced by %69 and non-spine fracture risk reduced by %54 with
the 40 μg/d regimen [8].
Subbiah et al. reported the second patient to develop osteosarcoma [9]. Although teripara‐
tide reduces osteoporosis related fractures in select patient populations, important contrain‐
dications, such as prior radiation exposure, Paget’s disease of bone, unexplained elevations
of serum alkaline phosphate, open epiphysis should be considered before use.
It has been suggested teriparatide could be useful for treatment of severe and resistant
forms of osteoporosis to other medications [10].
In summary, we think that the clinical benefits of parathyroid hormone reflect its ability to
stimulate bone formation and thereby increase bone mass and strength. This hormone ap‐
pears to be effective in preventing fractures in postmenopausal women. Hovewer, it should
be used attention because of its important contraindications.
3. Stontium ranelate
Strontium ranelate is composed of an organic molecule (ranelic acid) and of two atoms of
stable non-radioactive strontium [11]. Strontium naturally present in trace amounts in hu‐
man body and has close similarities with calcium; act as calcium agonist in most of physio‐
logic process [12].
Strontium is similar to calcium in its absorption in the gastrointestinal track takes place in
two ways: passive diffusion and carrier mediated absorption. Both calcium and strontium
share the same carrier system, which tents to be greater affinity to calcium. High dietary in‐
take of calcium has been shown to reduce concurrent absorption of strontium [11].
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Ingested strontium is distributed in the body in three compartments: plasma extracellular
fluid; soft tissue and superficial zone of bone tissue; and bone itself, the greatest portion
is  the  calcified  tissues  [13].  In  bones,  total  amount  of  strontium  relatively  lower  than
amount  of  calcium.  After  its  absorption,  both  strontium  and  calcium  exhibit  the  same
characteristics [12].
The strontium levels in bone vary according to the anatomical  site.  However,  strontium
levels at different skeletal sites are strongly correlated [14]. The strontium levels in bone
also vary according to the bone structure and higher amounts of strontium are found in
cancellous bone than in cortical bone. Strontium is mainly incorporated by exchange on‐
to the crystal surface. In new bone, only a few strontium atoms may be incorporated in‐
to the crystal  by ionic substitution of  calcium [12,  14].  Bone strontium content is  highly
correlated  with  plasma  strontium  levels.  Mechanism  of  action  of  strontium  ranelate  is
shown in figure 1.
Figure 1. Mechanism of action of strontium ranelate in bone [13]
Strontium ranelate decreases osteoclast differentiation and activity [15]. Also able to increase
pre-osteoblast replication, collagen type I synthesis [16]. Therefore strontium ranelate has a
dual affect on bone remodeling, being able to stimulate bone formation by osteoblasts, a
property shared with bone-forming agents, and to inhibit bone resorption by osteoclasts, as
do anti-resorptive agents [17,18].
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dual affect on bone remodeling, being able to stimulate bone formation by osteoblasts, a
property shared with bone-forming agents, and to inhibit bone resorption by osteoclasts, as
do anti-resorptive agents [17,18].
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Strontiun ranelate shows affect by binding calcium receptor in bone. Strontium has lower
affinity for calcium sensing receptor than calcium[19].
There are higher calcium ion concentrations within the bone microenvironment in case of
osteoclastic resorption. Affect of calcium receptor increases in higher extracellular calcium
concentrations. Strontium ranelate intake prevents bone loss with non-osteoporotic patients
in early post-menopausal period [19].
In the PREVOS study (PREVention Of early postmenopausal bone loss by Strontium rane‐
late) usage of strontium ranelate 1g/d for period of 2 years resulted in significantly high‐
er increase of femur BMD (bone mineral density). There was a significant increase in the
bone formation markers and concurrent increase of bone resorption markers has not been
recorded [20].
In  the  Treatment  of  Peripheral  Osteoporosis  (TROPOS)  study  strontium  ranelate  in‐
creased bone mineral density throughout the study, reaching at 3-yr 8.2% (femoral neck)
and 9.8% (total  hip).  Same study shows %36 decrease in hip fracture risk even in high-
risk subgroup over 3-yr period [21].
The Spinal Osteoporosis Therapeutic Intervention (SOTI) study investigated the safety of
strontium ranelate and its efficacy against vertebral fractures. In patients used strontium ra‐
nelate 2 g/d the risk of vertebral fractures was decreased by 41% over 3-yr [22].
In both studies strontium ranelate was well tolerated. The most common adverse events
consisted of nausea and diarrhea was disappeared after third month of treatment [21,22].
Therefore, we suggest that strontium ranelate has been proving antifracture efficacy in pa‐
tients with osteopenia and/or clinical risk factors and very old elderly. Also, it may contrib‐
ute to earlier and more effective intervention against fractures because of well- tolerated.
4. Prostaglandins
Prostaglandins  act  as  locally  acting  hormones,  developed as  new therapeutic  approach.
They  show  the  effect  and  are  metabolized  in  the  tissue  where  they  are  synthesized.
Prostaglandins are synthesized from arachidonic acid,  a  polyunsaturated fatty acid with
20-carbon chain [23].
Prostaglandins are produced from bone cells by mediated cyclooxygenase. Prostaglandin
production is regulated by mechanical stress, cytokines, growth factor and systemic hor‐
mones. Furthermore, prostaglandins are able to regulate their own production [24]. Prosta‐
glandins have both inhibitory and stimulatory effects on bone structuring. The most
prominent effect of prostaglandin E2 (PGE2) is to stimulate bone resorption and formation
[24]. PGE2 exerts its action through the cell surface receptors. Four subtypes of prostaglan‐
din E receptors (EP1, EP2, EP3 and EP4) [25,26] have been identified. PGE2 stimulates bone
formation by EP4 receptor mediation [26]. The importance and impact of prostaglandins in
bone metabolism is summarized in figure 2
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Figure 2. The mechanism of action and place of prostaglandins in bone metabolism [24]
It has been reported in certain studies that prostaglandins have anabolic effect on the bone
formation, therefore can be used in osteoporosis treatment [27].
It  has  been  demonstrated  that  systemic  PGE2  administration  stimulates  proliferation  of
osteoblast precursors or differentiation of osteoprogenitor cells in bone marrow and 4.7%
increase  in  bone  mass  eventually  was  found  in  the  same  study  [27].  Increase  of  total
bone  surface  by  means  of  osteoblast  stimulation  with  PGE2  administration  to  rats  has
been reported [28].
Misoprostol is a methylene analogue of prostaglandin E1 (PGE1) has been administered to
oophorectomized rats. Misoprostol is being used for treatment of gastric ulcer due to its cy‐
toprotective effect by inhibiting gastric acid and pepcin secretion [23]. Rats receiving miso‐
prostol had significantly reduced oophorectomy related bone loss at site of lumber spine.
Thus, it has been proposed that misoprostol is choice for treatment of post-menopausal os‐
teoporosis prophylaxis [29,30].
Misoprostol 800 μg/d had been administered for 6 moths to post-menopausal osteoporotic
patients. At the end of the treatment increase by 8.1% in femur bone mineral density, by 5%
increase in lumber spine bone mineral density and by 3.6% increase in Ward’s triangle bone
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mineral density have been found. It has been reported that misoprostol can be an alternative
on treatment of osteoporosis [31].
We think that misoprostol may be an alternative therapy for patients with osteopenia and
osteoporosis who are not suitable for hormone replacement therapy.
5. Sesamin
Sesamin is  a major lignan compound in sesame seeds.  Its  activity on bone cell  function
is  unclear.  Recently,  it  has  been  reported  that  sesamin  has  direct  effects  on  osteoblasts
by stimulating the expression of  essential  genes and key enzymes of  the bone minerali‐
zation process [32,33].
Wanachewin et al suggested that sesamin had the ability to trigger osteoblast differantiation
by activation of the p38 and ERK/MAPK (mitogen-activated protein kinase) signaling path‐
way and possibility indirectly regulate osteoclast development via the expression of OPG
and RANKL in osteoblasts [32].
The MAPK/ERK pathway is a chain of proteins in the cell that transmits a signal from a re‐
ceptor on the surface of the cell to the DNA in the nucleus of the cell. MAPKs play impor‐
tant roles in cellular response to growth factors, cytokines, or environmental stress.
They are  classified into  four  classes:  extracellular  signal-regulated kinases  (ERKs),  c-Jun
N-terminal  kinase  or  stress-activated protein  kinase,  p38  MAPKs,  and ERK5 [34].  ERKs
are  involved in  cell  proliferation/transformation and survival.  p38  MAPKs are  involved
in  many  cellular  processes,  such  as  inflammatory  responses,  osteoblast  differentiation,
apoptosis [35,36].
We think that sesamin which is a phytochemical agent, may be effective addition to osteo‐
porotic therapy. Future studies are needed.
6. Statins
Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase.
Usually,  it  has  been  known  that  they  have  efficacy  and  credibility  on  coronary  artery
diseases  and  hyperlipidemia  [37,38].  First,  Mundy et  al  showed that  statins  lead  to  in‐
crease  90  %  in  the  trabecular  bone  volume  by  stimulating  bone  formation  invitro  and
therefore it was started to studies investigating the place of statins for osteoporosis treat‐
ment [39]. Hamelin et al suggested that statins decrease the bone destruction by supress‐
ing the formation of  the mevalonate  that  it  is  an important  precursor  on the control  of
osteoclastic activity as bisphosphonates [40].
It was reported that statins have efficacy on the bone metabolism, by increasing bone mor‐
phogenetic protein 2 (BMP2) activation stimulated osteoblastic cell proliferation and matu‐
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ration [41]. Maeda et al showed that hydrophobic statins such as simvastatin, atorvastatin,
and cerivastatin stimulated VEGF expression by osteoblasts via reduced protein prenylation
and the phosphatidylinositide-3 kinase pathway, promoting osteoblastic differentiation [42].
In 2009 Pault et al revealed a dose-dependent effect and improved fracture healing under
local application of simvastatin [43].
Fukui et al reported that the effect of the systemic administration of statins was limited due
to its metabolism in the liver and high-dose administration may cause adverse side effects.
They locally applied with gelatin hydrogel to fracture sites at a dose similar to that used in
clinical settings and shown to induced fracture union in a rat unhealing bone fracture model
via its effect on both angiogenesis and osteogenesis [44].
We suggest that the results of studies also point to the need for more information in order to
particularly gelatin hydrogel form.
7. Growth hormone and IGF-I
It is known that growth hormone (GH) is important in the regulation of longitudinal bone
growth [45]. Several in vivo and in vitro studies have demonstrated that GH is important in
the regulation of both bone formation and bone resorption. In Figure 3 a model for the cellu‐
lar effects of GH in the regulation of bone remodeling is showed [45].
Figure 3. The mechanism of action at the cellular level for GH in regulation of bone remodeling. The left part of the
figure represents osteoclast-mediated bone resorption. The right part represents osteoblast-mediated bone forma‐
tion. ? indicates that both stimulatory and inhibitory effects have been shown [45]
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GH increases bone formation in two ways [46]:
1. via a direct interaction with GHRs on osteoblasts
2. via an induction of endocrine and autocrine/paracrine IGF-I (Insulin like Growth Fac‐
tor-1).
rhGH (recombinant human Growth Hormone) increases bone turnover in normal subjects
and improves bone mineral metabolism in postmenopausal females [45]. GH treatment also
results in increased bone resorption. It is still unknown whether osteoclasts express func‐
tional GHRs, but recent in vitro studies indicate that GH regulates osteoclast formation in
bone marrow cultures [45, 46]. Possible modulations of the GH/IGF (Insulin like Growth
Factor) axis by glucocorticoids and estrogens are also included in Fig. 3 [45].
Bone is the second richest source of IGF-I in the body. Locally this peptide promotes osteo‐
blast differentiation and growth [48]. Recently, studies show that low levels of IGF-I are as‐
sociated with a greater risk of hip and spine fractures [49–51]. Hence, there is a strong
opinion for considering human GH or IGF-I as potential anabolic agents for the treatment of
osteoporosis. There are potential advantages for using rhIGF-I (recombinant human Insulin
like Growth Factor-1) compared with rhGH in the treatment of osteoporosis. These include
1. more direct stimulation of bone formation,
2. bypass of skeletal GH resistance that can be present, and
3. a reduction in GH-induced side-effects such as carpal tunnel and diabetes mellitus. [47]
It was reported that low doses of rhIGF-I may directly increase osteoblastic function with
only a minimal increase in bone resorption [52]. In 2008, it was suggested a potential role for
IGF-1 in the early identification of women at risk for low bone mass and osteoporosis. They
suggested measuring the serum level of IGF-1 in women around 40 years old. When its val‐
ue is 1.5 SD below the peak, BMD measurement by DXA could be considered [53]
There are limited number studies using rhIGF-I than rhGH. Therefore, these advantages
have not been validated yet.
8. Sodium fluoride
Sodium fluoride is the first anabolic agentsto be used in the treatment of postmenopausal
osteoporosis. Side-effects, consisting of upper gastrointestinal symptoms and a lower ex‐
tremity pain syndrome, are common.
Using slow release formulation of sodium fluoride, it was showed a 50% reduction in verte‐
bral fracture incidence with impressive increases in bone mass [54-56]. More recently, it has
been suggested that a different formulation of fluoride, monofluorophosphate when is used
in lower dosages and more favorable formulations, gastrointestinal side-effects are reduced
[57-59]. However, consensus about its clinical utility has still not been reached.
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9. Other potential agents for anabolic treatment of osteoporosis
Bortezomib: There are multiple potential alternative agents for increasing bone formation.
A potential treatment is to target the osteoblast proteasome. It was reported that the protea‐
some inhibitor bortezomib (Bzb) had bone forming effects in patients with multiple mye‐
lome [60]. The mechanism for Bzb’s effects on osteoblastic differentiation has not been
clearly defined.
It  was showed that Bzb with lenalidomide or thalidomide may increase bone formation
by stimulating osteoblast activity and inhibiting osteoclastic bone destruction, respective‐
ly Figure 4.
Figure 4. Bzb’s action on bone formation in the patients with multiple myeloma [60]
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9. Other potential agents for anabolic treatment of osteoporosis
Bortezomib: There are multiple potential alternative agents for increasing bone formation.
A potential treatment is to target the osteoblast proteasome. It was reported that the protea‐
some inhibitor bortezomib (Bzb) had bone forming effects in patients with multiple mye‐
lome [60]. The mechanism for Bzb’s effects on osteoblastic differentiation has not been
clearly defined.
It  was showed that Bzb with lenalidomide or thalidomide may increase bone formation
by stimulating osteoblast activity and inhibiting osteoclastic bone destruction, respective‐
ly Figure 4.
Figure 4. Bzb’s action on bone formation in the patients with multiple myeloma [60]
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Oxytocin: An other approach is oxytocin (OT) that increases osteoblastic bone formation. It
has been reported that OT may regulate maternal skeletal homeostasis during pregnancy
and lactation. The fetal skeleton is unlikely to be mineralized effectively in the absence of
calcium mobilized from the maternal skeleton [61]. It has been suggested that elevated OT
levels during pregnancy and lactation not only enhance bone resorption by increasing the
number of osteoclasts to make maternal calcium existing to the fetus, but also prevent unre‐
stricted bone removal by inhibiting the activity of mature osteoclasts. Therefore, it was re‐
ported that recombinant OT or its analogs because of its skeletal anabolic action, might have
potential utility in therapy for human osteoporosis [61].
Beta-blocker: Wiens et al found that beta-blocker use was associated with a significant de‐
crease in fracture risk [62]. However, in 2008, Reid determinated that there was no any evi‐
dence to support the hypothesis that beta‚-blockers reduce fracture numbers [63]. In 2012,
Yang et al reported that beta-blockers are associated with reduced risk of fracture in older
adults, but the effect size is likely to be modes [64]t. In summary, there was no an adequate
evidence to support using beta-blockers in the treatment of osteoporosis.
Lithium: The mean (+/-SD) bone density in lithium treated patients was reported that 4.5%
higher at the spine (P<0.05), 5.3% higher at the femoral neck (P<0.05) and 7.5% higher at the
trochanter (P<0.05). In addition, lithium treated patients had lower serum total ALP
(P<0.005), lower serum osteocalcin (P<0.005) and lower serum CTX (P<0.05) but the totalcal‐
cium, PTH and urinary calcium excretion did not differ significantly between patients and
controls. In conclusion, it was suggested that therapy with lithium carbonate may preserve
or enhance bone mass [65].
Figure 5. Modulation of Wnt signaling by sclerostin [73]
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Anti-sclerostin monoclonal antibody: Sclerostin is a protein encoded by the SOST gene in
osteocytes. It inhibits osteoblastic bone formation [66,67]. The binding of Wnt proteins to the
LRP5/6-Frizzled co-receptor on the cell membrane of osteoblasts leads to stabilization of in‐
tracellular beta-catenin and regulation of gene transcription that promotes osteoblastic bone
formation. Sclerostin is a modulator of osteoblast function. It antagonizes Wnt signaling and
inhibits osteoblastic bone formation [68]. Recent studies reported that anti-sclerostin therapy
enhances fracture healing and bone repair.[69-71]. AMG 785 is a humanized sclerostin mon‐
oclonal antibody, was first studied in humans. It enhances Wnt signaling and increase osteo‐
blastic bone formation [72]. Figure 5
Treatment with AMG 785 has been well tolerated. In postmenopausal women with low
bone mineral density (BMD) after 12 months of AMG 785 administration, increase in BMD is
determined. Although there is no evidence that AMG 785 increases the risk of osteosarcoma,
new studies are needed to modify this risk.
10. Conclusion
Aging is associated with impaired bone formation which is a principal pathogenetic cause
mediating bone fragility in osteoporosis. Ideally, patients at high risk of fracture should be
identified early and treated by a combination of lifestyle changes, correction of secondary
causes of osteoporosis, and specific treatments to improve bone density and decrease frac‐
ture risk. By now, there were a limited number of therapeutic agent for activating bone for‐
mation and increasing bone mass and strength. More effective and better tolerated therapies
will become available soon. We think that new treatments will be able to contribute to in‐
crease the currently low treatment rate of even severe osteoporosis by allowing approaches
aimed at minimising fracture risk at the individual patient level.
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1. Introduction
1.1. Renal stones during spaceflight
No major medical diffifulties were experienced during spaceflight in the era of Russian Vostok/
Voshot or spaceflight programs of Mercury and Gemini, however, when prolonged stays in
space stations began in the 1980’s, astronauts or Russian cosmonauts had an increased risk of
suffering from renal stones, and resultant bone loss. The detailed mechanism behind this
phenomenon is still unknown, but one explanation is that unloading of the skeleton that would
normally bear the bodyweight led to calcium (Ca) leaving the bones for the bloodstream. The
Ca entered the kidneys, filtered into the urine, causing hypercalciuria, and increased the risk
of kidney stone formation. Such stones formed in the kidney break down and travel into the
ureter, causing flank pain. Thus astronauts continually subjected to risks of bone and Ca loss
while in microgravity [Buckey, 2006].
Factors that seem to affect the bone and Ca loss while in microgravity are as follows; low light
levels, high environmental CO2 levels, and minimal skeletal loading. It is reported that urinary
Ca excretion increases by 60-70 % within a few days of entering the microgravity. Data from
the Skylab program in 1973-74, when nine astronauts stayed in the space station for 28 to 84
days, showed that the estimated rate of Ca loss from the bone per month was 0.3% of the total
body Ca [Whedon et al. 1974].Data from the Mir program indicated that the bone losing the
most Ca losing bone is the coxal bone estimated to lose 1.5% of the total body Ca per month
[Le Blanc et al. 2000]. Skylab was a space station launched and operated by NASA (National
Aeronautics and Space Administration of the USA) and was the America’s first space station,
which orbited the Earth from 1973 to 79, and included a workshop, a solar observatory, and
other systems with the weight of 77 tons. Mir (мир, peace/world) was a space station that
operated in low Earth orbit from 1986 to 2001, at first by Soviet Union and then by Russia.
Assembled in orbit from 1986 to 96, Mir was the first modular space station and had a greater
© 2013 Iwase et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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mass than that of any previous spacecraft until its deorbit on March 21, 2001. Many experiments
including biomedical sciences.
In spite of rapid bone loss under conditions of weightlessness, a slow recovery rate is reported.
Data from the Mir program showed that approximately 12% of bone was lost during 4.5
months in space while only 6% recovered in a year on the Earth [Linenger 2000]. Follow-up
study of the Skylab crew members after 28-84 days of the microgravity exposure suggested
that not all the bone lost on the station had been recovered [Tilton et al. 1980]. These findings
indicate the seriousness of bone loss under conditions of microgravity, which could present
significant problems, and may progress to osteoporosis, in long-duration spaceflight. Bone
loss under conditions of weightlessness should be strictly monitored and controlled.
2. Calcium metabolism during spaceflight
During spaceflight, several factors influence the Ca metabolism, including alterations in diet
intake, low lighting, increased ambient CO2, and the most important factor is unloading of the
bodyweight when considering the long duration spaceflight.
The recommended Ca2+ intake is 1,000 mg/day, and nutritionists prepare the space food to
satisfy this criterion.
In spacecraft, where no sunlight or ultraviolet light exposure is occurs, vitamin D deficiency
may develop without sufficient Ca intake, which causes poor mineralization of bone, dimin‐
ished intestinal Ca absorption, decreased serum Ca2+ levels. These situations may cause an
increase in parathormone, but actually, sufficient Ca intake protects the bone loss, and serum
Ca2+ level has been proved to be increased, and parathormone level is suppressed..
Compared with the low CO2 level on the Earth, which is 0.03% of the atmosphere, confined
and isolated circumstances such as in spacecraft or a space station have increased CO2 levels
of 0.7-1%, which affects the acid-base balance, and consequently the bone metabolism.
Increased CO2 levels in inhaled air cause acidosis, and carbonates and phosphates in the bone
play important roles in neutralizing the acidosis, which leads to bone resorption [Bushinsky
et al., 1997]. Although CO2 levels >1% were reported to have some effects on urinary bone
absorption markers [Drummer et al. 1998], respiratory acidosis may decrease the urinary pH,
and increase the risk of kidney stone formation [Coe et al. 1992].
Bone remodeling and the remodeling changes during spaceflight are profoundly dependent
on genetic factors in terms of the baseline level [Boyden et al. 2002, Judex et al. 2002]
3. Bone formation factors
3.1. Mechanical loading
The mechanism by which bone senses and responds to loading has yet to be fully clarified yet.
Frost [1987] postulated that bone has a mechanostat that senses strain and maintains bone mass
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at an appropriate level to keep the strain within an appropriate range, showing that exceeding
the setpoint of bone strain bone modeling intiates reduction of the strain back to the setpoint
had been carried out. Surveys on athletes indicated that high weight bearing, which is observed
in weightlifters and significant impact loading in gymnasts resulted in significantly high bone
mass [Nilsson & Westlin, 1971, Uusi-Rasi et al. 1971, Taaffe et al. 1997, Huddleston et al., 1980].
As for the gravity-induced high bone mass density, evidence has shown that heavy-weight
people exhibited higher bone density, and spinal injury patients with a wheelchair lose
significantly bone mass at lower extremity while not in the lumbar spine [Biering-Sorensen et
al., 1988, 1990]. The impact of contact with the ground on the bones of the coxa and the lower
extremities is an important factor to maintain the bone mass density [Kreb et al., 1998].
Not only impacts or weight bearing on the bone, but also muscular contractions also play a
role in strain bearing on the bone at 1 G [Kreb et al., 1998, Schulthesis et al., 1991]. However,
0 G conditions may influence the skeletal loading both through a loss of ground reaction forces
and through marked reduction in the forces needed to move the weightless limbs.
Adapted with permission from Flier JS: Nature 420(6916): 619, 621-622(2002)
Figure 1. Regulation of energy balance and bone mass Leptin suppresses appetite and enhances sympathetic nerve
activity through the hypothalamus elevating energy expenditure. At the same time higher activity of the sympathetic
nervous system inhibits bone formation of osteoblasts, inducing bone loss.
3.2. Hormones
Sex hormones, estrogens and androgens are associated with bone mass density; however, there
seems to be no significant changes in sex hormones during spaceflight. Growth hormone
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like growth factor (IGF-1) has also been shown to be an agent that can increase bone mass, and
in animal experiments performed during the Space Shuttle experiment, administration of
IGF-1 to rats during the 10 days of the Shuttle flight increased bone formation in the humerus.
Parathormone has a complex effect on the bone. Its ultimate goal is to increase the serum
Ca2+ level, so that without enough Ca2+ intake or vitamin D deficiency, it acts on bone resorption
and reduces the bone mass. The action sites of parathormone are the bone, the kidney, and the
intestine.
The mechanism of parathormone action on the bone is indirect since osteoclasts have no
receptor of parathormone, rather parathormone binds to osteoblasts to increase their expres‐
sion of RANKL (receptor activator of nuclear factor kappa-B ligand, osteoclast differentiation
factor) and inhibits their expression of osteoprotegrin. Osteoprotegerin binds to RANKL and
inhibits it from interacting with RANK (receptor activator of nuclear factor kappa-B, receptor
of osteoclast differentiation factor). The binding of RANKL to RANK is facilitated by the
decreased amount of osteoprotegerin, and stimulates osteoclast precursors to fuse. It resulted
to form new osteoclasts, which ultimately enhances bone resorption.
Parathormone also acts on the kidney to enhance the active reabsorption of Ca2+ and Mg2+ from
the distal tubules and the thick ascending limb, and maintains or increases the serum Ca2+
levels.
It also enhances the absorption of Ca2+ from the intestine indirectly, by increasing the produc‐
tion of activated vitamin D, which is activated in the kidney. The activated vitamin D increases
the absorption of Ca2+ by the intestine.
Calcitonin is secreted from the thyroid gland by an increase in serum Ca2+ levels, and acts to
lower the Ca2+ levels, which counteracts parathormone. Calcitonin lowers Ca2+ levels by 1)
inhibiting Ca2+ absorption by the intestines, 2) inhibiting osteoclast activity in bones, 3)
inhibiting renal tubular cell reabsorption of Ca2+ by allowing Ca2+ to be secreted in the urine.
Therefore, calcitonin protects bone from Ca2+ loss, however, it has not proved to be effective
in preventing bone loss in immobilization in either animals [Thomas et al., 1995] or humans
[Hantman et al., 1973].
3.3. Dietary factors
Ca, vitamin D, and vitamin K are the essential factors for bone formation, and their oral intake
is recommended during spaceflight.
3.4. Electric fields and vibration
Studies have shown exposure of marrow culture to low-frequency, low-intensity electric fields
inhibited the recruitment of osteoclasts [Rubin et al., 1996]. Low magnitude (0.25 G) and high
frequency (30-90 Hz) vibration has been proved to be effective in inhibiting bone loss and
increasing bone formation in humans [Bosco et al., 1999, Rubin et al. 2004]. This vibration
constitues a promising countermeasure against bone loss in spaceflight, and studies are now
being conducted to clarify the optimal magnitude and frequency.
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4. Bone resorption factors
4.1. Immobilization
The unloading of weight bearing on bone on Earth is associated with prolonged bed rest,
immobilization, or paralysis. Studies of patients with spinal cord injury have demonstrated
that approximately 30–50% of lower extremity bone mass can be lost before reaching a plateau,
which occurs an average of approximately 16 months after admission [Biering-Sorensen et al.
1990, Garland et al. 1992].
4.2. Hormones
Chronic increase in parathormone levels enhances resorption, which causes osteoporosis. This
increase in parathormone is sometimes produced by lower serum Ca2+ and vitamin D;
however, intermittent administration of parathormone with enough Ca2+ levels with vitamin
D can also be anabolic. Thyroid hormones and glucocorticoid can be a cause of osteoporosis,
but it is unlikely to occur in space.
4.3. Dietary factors
High Na+ intake enhances Na+ excretion as well as urinary Ca2+ excretion. A high level of dietary
protein also provides an acid load, which causes bone loss mediated by skeletal buffering.
Therefore, it is favorable for space food to contain low salt as well as low protein.
5. Bone loss and osteoporosis in spaceflight
Skylab missions were the first opportunity to study the Ca metabolism in space [Whendon et
al., 1974]. These included the unmanned Skylab 1, Skylab 2 with 3 crew members staying 29
days of stay, Skylab 3 also with 3 crew members staying 59 days, and Skylab 4 again with 3
crew members staying 84 days. Thereafter, various Space Shuttle Programs have been
conducted to examine the effects of space flights on Ca metabolism in humans.
Urinary excretion of Ca2+ is enhanced promptly just after microgravity exposure, and remains
elevated for several months throughout weightlessness exposure or eventually returns to
normal depending on individual. The mechanism behind individual differences has not benn
well clarified. Data from two Russian cosmonauts demonstrated no Ca2+ excretion increases
were observed after 218 days of microgravity exposure [Grigoriev et al., 1994]. The reason for
this lack of an increase in Ca2+ might be the effectiveness of countermeasure program.
5.1. Bone loss markers during spaceflight
Frozen urine samples from the Skylab mission were subsequently examined; the data showed
that N-telopeptide was increased throughout the flight [Smith et al., 1998], and C-telopeptide
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Elevation of these two markers demonstrated that the increased urinary Ca2+ was due to an
increase in bone resorption. Osteocalcin, a bone formation marker, measured during a 180-day
Mir flight showed a decrease.
5.2. Bone loss location
Bone mineral density was measured before and after flights on the Mir program. The changes
per month were as follows; +0.6% in the skull, +0.1% in the arm, −1.07% in the spine, −1.35%
in the pelvis, −1.16% in the femoral neck, −1.58% in the trochanter major, −1.25% in the tibia,
and −1.50% in the calcaneus, all per month, with comparable results obtained from the
International Space Station [Lang et al., 2004].
The bones that are most affected during spaceflight seems to be weight bearing bones, such as
the pelvis (os coxae), the trochanter major of the femur, the femoral neck, the tibia, and the
calcaneus.
5.3. Parathormone and Vitamin D
Data from the Skylab program exhibited a slight increase in serum Ca2+ levels and decrease in
parathormone. Spacelab Life Sciences 1 (9 days), and 2(14 days) flights and a 180-day Mir flight
showed decreased serum parathormone levels in crew members, and active vitamin D levels
were also decreased, which in turn reduced Ca absorption [Caillot-Augusseau et al., 1998].
5.4. Summary
In summary, bone resorption is increased, bone formation is decreased, bone loss occurs in
weight-bearing areas, and parathormone is suppressed during space flight, which are
comparable to the data from immobilization under conditions of bedrest or spinal cord injury.
6. Sympathetic modulation of bone metabolism during spaceflight
It has been reported that sympathetic neural traffic to bone inhibits the function of osteoblasts
and enhances that of osteoclasts thus facilitating bone loss. Possible roles of the sympathetic
nervous system in the mechanisms of bone loss in humans exposed to long-term space flight
will be discussed [Mano et al., 2010].
6.1. Alterations in sympathetic neural traffic under microgravity
Sympathetic neural traffic indirectly measured by plasma noradrenaline level has been
reported to increase during spaceflight compared with the pre-flight control level [Christensen
& Norsk, 1998, Ertl et al., 2002], and vagal activity estimated by power spectral analysis of heart
rate variability has been shown to be reduced after long-term spaceflight [Cooke et al., 2000,
Mano, 2005].
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Microneurographically, on the other hand, recorded neural traffic in humans is known to
reflect muscle and skin sympathetic nerve activity (MSNA and SSNA), and MSNA controls
the vasomotor function of the muscular bed, responding to blood pressure changes against
gravitational stress [Iwase et al., 1987, Mano 1990, Mano et al., 2009]. MSNA was found to be
suppressed during an exposure to short-term microgravity induced by parabolic flight [Iwase
et al., 1999], to mild lower body positive pressure (10-20 mmHg LBPP) [Fu et al., 1998], and to
thermoneutral head-out water immersion [Miwa et al., 1996] responding to the loading or
unloading of cardiopulmonary receptor stimulated by cephalad fluid shift. Contrarily, MSNA
was enhanced after an exposure to long-term microgravity in spaceflight and its simulation
induced by dry immersion (Iwase et al., 2000), and 6°head-down bed rest (Kamiya et al.,
2000), caused by various mechanisms including plasma volume loss, changes in baroreflex,
and vascular compliance after the human body has acclimated to microgravity situation..
As for the sympathetic influence on bone metabolism, sympathetic stimulation facilitated bone
resorption, while it inhibited ossification by osteoblasts mediated by hypothalamus and leptin
in mouse. Loading of weak chronic stress in mouse reduced the osteoblastic activity with
elevated noradrenaline, which was prevented by β-blocker [Kondo et al., 2005]. The beneficial
effects of β-adrenergic blocker on bone mass and metabolism were reported in mice and rats
[Minkowitz et al., 1991, Pierroz, et al., 2006]. Other studies were controversial, however, recent
studies have indicated that there are two systems that regulate bone metabolism; one through
β2 receptors in bone which facilitates osteolysis and inhibits osteogenesis, and the other that
facililtates osteogenesis through a kind of neuropeptide called CART (cocaine amphetamine
regulated transcript) [Elefteriou et al., 2005].
From human studies, there have been reports that administration of β-blockers may reduce
the risk of bone fracture as well as higher bone density (Graham et al., 2008, Levasseur et al.,
2005, Pasco et al., 2004, 2005, Reid et al., 2005a, b, Reinmark et al., 2004, 2006, Schlienger et al.,
2004, Turker et al., 2006)
6.2. Space flight-related changes in sympathetic regulation on bone metabolism
Prolonged exposure to microgravity in space for 14 days enhanced the sympathetic neural
traffic in humans as evidenced by the Neurolab mission[Cox et al., 2002, Fu et al., 2002, Levine
et al., 2002, Ertl et al., 2002], with comparable results in elevated noradrenaline spillover and
clearance in space [Ertl et al., 2002]. Corresponding results were obtained from simulated
microgravity including dry immersion [Iwase et al., 2000] or head-down bed rest [Kamiya et
al., 2000]. Elderly people generally have low bone mass and density and high sympathetic
neural traffic to muscles although response to gravitational stress becomes lowered (Iwase et
al. 1991). Our preliminary data show that changes in sympathetic neural traffic to muscles after
long-term bedrest of 20 days had a significant correlation with changes in the urinary secretion
level of deoxypyridinoline (Mano et al., 2009, Nishimura et al., 2010) (Fig.2), which a specific
marker for bone resorption (Robbins et al., 1994). On the basis of these findings, it is postulated
that an exposure to prolonged microgravity enhances the sympathetic neural traffic to bone,
which increases the noradrenaline level, inhibits osteogenesis and facilitates osteolysis through
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Adapted with permission from Nishimura N et al: Space Utiliz Res. 26: 122-124 (2010)
Figure 2. Correlation between muscle sympathetic nerve activity (MSNA) and urinary secretion of deoxypyridinoline in
healthy humans exposed to long-term bed rest. A significant correlation was found between percent changes in burst
numbers per minute of MSNA recorded microneurographically from the tibial nerve (abscissa) and percent changes in
urinary secretion of deoxypyridinoline (ordinate) in 11 young healthy male subjects (24±5 years old) exposed to long-
term head-down bed rest (20 days).
7. Countermeasures for space-related osteoporosis
The bone has difficulty regaining its density and once it is lost, as shown by the studies of bed
rest and spinal cord injury patients. Data from spaceflight suggest that this slow recovery is
also exhibited by astronauts as well [Linenger, 2000, Tilton et al., 1980]. Bone can be recovered,
but it takes a longer time to recover it than to lose it. This means that the prevention of bone
loss is a more preferable than its recovery by aggressive rehabilitation. The strategy of “less
loss to regain fast” might be an effective way to minimize the necessary amount of postflight
rehabilitation needed and to extend the time people can remain in microgravity.
7.1. Vitamin D and calcium intake
The low light levels in the spacecraft necessitate sufficient oral intake of vitamin D and Ca since
parathormone levels are suppressed during spaceflight. Oral intake of 600−800 IU/day vitamin
D is recommended in the absence of sunlight although 400 IU/day is usually adequate to
maintain bone mass density [Holick, 1996].
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The Ca intake necessary to minimize a negative Ca balance is approximately 1,000 mg of
elemental Ca (~40% of CaCO3), which is currently recommended for space station flights up
to 360 days [Weaver, 2000]. Howver, excessive oral intake of Ca is associated with a risk of
hypercalciuria due to skeletal unloading, which may lead to high risk of kidney stones.
However, kidney stones may not develop because orally administered Ca may bind to oxalate
in the intestine and reduce the oxalate absorption [Heller 1999]. Therefore, Ca intake during
spaceflight should be taken orally [Martini & Wood, 2000].
7.2. Physical factors
Exercise upon exposure to weightlessness has been incorporated into some countermeasure
programs, however, exercise alone cannot prevent the bone loss. The current exercise program
for the ISS is a combination of aerobic and resistive exercises for 2.5 hrs, 6 days/week. Data
from the space flight demonstrate that bone loss occurs mainly in the femur, tibia, calcaneus,
and vertebrae. Therefore, exercise should be concentrated on these bones, and impact loading
should primarily be provided rather than static loading [Taaffe et al., 1997].
Hip joint: Some of the larger bone losses observed in the space program have been concentrated
in the hips (os coxae mainly) [Le Blanc et al., 1999]. A study using hip joint pressure sensors
has demonstrated that peak joint forces can range from 3–4 times when walking, 5.5 times with
jogging, and as high as 8.7 times bodyweight with stumbling [Hall, 1995], which are do not
seem to be generated during the exercise in microgravity. The peak pressure in the articulatio
coxae (hip joint) during supine isometric abduction was 3.78 mPa, which was as high as those
during walking of 3.64 mPa [Strickland et al., 1992], and that during rising from a seated
position, was 7.14 mPa [Hodge et al., 1986]. These data suggest that running on a treadmill
generates an insufficient load to generate enough loads, but short periods of high loading using
abduction, adduction and squatting would be necessary to load sufficient pressures on the hip
joint.
Lumbar spine: The bodyweight is loaded on the L3 vertebra when standing under conditions
of 1 G state, but unloaded vertebrae would lose their bone mass density under microgravity.
The concern is the minimum period of standing position required to maintain the bone mass,
which has not been clarified. Moreover, the even if this duration is clarified; weight loading
under weightlessness is difficult. Whether a shorter duration of a higher load can provide the
same bone protection as a longer duration of a lower load has also yet to be solved.
Femur: The femoral neck and the trochanter major are the principal sites of weight bearing
under the condition of 1 G, and are site at which significant bone mass is lost during the
spaceflight. The femoral shaft mainly consists of cortical bone and the loss of bone mass from
the femoral shaft were −1.6% on average after 4–6 months of spaceflight [Oganov, 1996]. The
kind of exercise that be most effective to prevent bone loss from the femur is not known.
Tibia: The proximal tibia consists of trabecular and cortical bone, and its loss of bone mass was
reported to be −1.25% per month. The most effective exercise to prevent the bone loss from this
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Calcaneus: The calcaneus receives a reaction force from the ground of 2–3 times of body weight
to the foot while running under 1 G. The fact that the calcaneus of gymnasts exhibits increased
bone density suggests that not only the number of loading cycles but also peak loading is
significant in increasing bone mass density in the calcaneus [Taaffe et al., 1999].
7.3. Pharmacological factors
Since bone mass is adequate at the onset of spaceflight, the optimal strategy for pharmaco‐
therapy against bone loss is the prevention of bone loss, not the acceleration of bone formation,
when the loading is removed during spaceflight. Several drugs have been proposed for the
prevention of bone loss under microgravity.
7.3.1. Bisphosphonates
Bisphosphonates have two phosphonate (PO3) groups and have a similar structure to pyro‐
phosphate. They bind to hydroxyapatite in the bone matrix, and prevent the bone loss by
inhibiting the osteoclastic bone resorption. Bisphosphonates have been demonstrated to be
effective in preventing bone loss during bed rest studies [Grigoriev et al., 1992, Rodan &
Fleisch, 1996, Thompson et al., 1990, LeBlanc et al., 1998]. Among several kinds of bisphosph‐
onate, pamidronate has been proved to suppress bone mineral loss and to prevent the
formation of renal stones during bedrest study (Watanabe et al., 2004).
In 2010, LeBlanc and Matsumoto proposed an experiment on the effectiveness of bisphosph‐
onate as a countermeasure to spaceflight-induced bone loss. The astronauts chose either oral
administration of alendronate at 70 mg once per week or intravenous administration of
zoledronate at 4 mg before flight, and were examined their bone density by DEXA (dual energy
x-ray absorptiometry), QCT (quantitative computed tomography), and pQCT (peripheral
qualitative computed tomography), bone metabolism markers including bone formation and
resorption markers, and renal stone formation. One of the co-investigators, Ohshima reported
successful results in suppressing the space flight-induced bone loss and renal stone formation
[Ohshima, personal communication].
The disadvantages of bisphosphonates are local irritation of the upper gastrointestinal (GI)
tract, and poor absorption from the GI tract. Therefore, the oral administration of bisphosph‐
onates requires the intake with 200 mL of water and for the subject to remain upright posture
for at least 30 min, and until after consumption of the first food of the day to facilitate delivery
to the stomach. The problem is that an upright posture cannot be achieved in space under
conditions of microgravity. Another problem is the possibility of osteonecrosis of the maxilla
and the mandible occurring although the incidence of this is low [Durie et al., 2005]. Since these
osteonecroric or osteolytic phenomena are always accompanied by physiological stress
(mastication), iatrogenic trauma (tooth extraction/denture injury), or tooth infection [Ruggiero
et al. 2004, 2008], it is preferable to prevent such phenomena.
Bisphosphonates are hardly metabolized, and high concentrations of them are maintained in
the bones for long periods. Because bone formation is closely coupled to bone turnover, long-
term use of these compounds with the resultant suppression of bone turnover can compromise
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the healing of even physiological microinjuries within bone. Osteonecrosis of the maxilla and
the mandible likely results from the inability of hypodynamic and hypovascular bone to meet
an increased demand for repair and remodeling because several kinds of manipulation are
associated with this necrosis.
7.3.2. Thiazide diuretics and potassium citrate
Thiazide diuretics and potassium citrate are not usually considered drugs for bone loss
prevention, but are usually used for kidney stone prevention; they act by markedly reducing
the urinary Ca level.
7.3.3. Selective estrogen receptor modulators
Estrogen is effective for bone mass preservation in both men and women, but it has a side effect
of thrombophlebitis, which would be a very significant for bedrest subjects or astronauts in
the space.
7.3.4. Statins
There is some evidence suggesting that statins might be effective to increase bone mass, in
addition to their main role; however, no data from bedrest or immobilization studies have
shown the effectiveness of their use. Therefore it might be too early to apply it to astronauts
in spaceflight.
7.3.5. Parathormone
Parathormone has anabolic effects on bone, and also acts on the kidney to stimulate the
resorption of Ca2+ and enhance the synthesis of vitamin D. In this sense, parathormone may
stimulate the bone formation, increase vitamin D synthesis, and stimulate Ca2+ resorption.
Since the suppression of bone resorption is favorable for stimulating bone formation during
spaceflight, the administration of parathormone appears strategically unfavorable.
7.4. Artificial gravity
For human space voyages of several years duration, such as those envisioned for the explora‐
tion of Mars, astronauts would be at risk of catastrophic consequences should any of the
systems that provide adequate air, water, food, or thermal protection fail. Beyond that,
astronauts will face serious health and/or safety risks resulting from severe physiologic
deconditioning associated with prolonged weightlessness [Buckey 1999]. The principal
physiologic deconditioning risks are related to physical and functional deterioration of the loss
of regulation of several systems including blood circulation, decreased aerobic capacity,
musculo-skeletal systems, and altered sensory-motor system performance. These physiologic
effects of weightlessness are generally adaptive to spaceflight and present a hazard only
following G-transitions upon return to Earth or landing on another planet [Young 1999].
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7.4.1. Why artificial gravity?
Space biomedical researchers have been working for many years to develop “countermeas‐
ures” to reduce or eliminate the deconditioning associated with prolonged weightlessness.
Intensive and sustained aerobic exercise on a treadmill, bicycle, or rowing machine coupled
with intensive resistive exercise has been used on U.S. and Russian spacecraft to minimize
these problems. The procedures were uncomfortable and excessively time-consuming for
many astronauts, and their effectiveness for maintaining bone, muscle, and aerobic fitness has
not been demonstrated, owing, at least in part to the low reliability of the devices used to date.
Furthermore, they have had inconsistent effects on postflight orthostatic hypotension or
sensory-motor adaptive changes. With the exception of fluid loading before reentry, other
kinds of countermeasures (e.g., diet, lower body negative pressure, or wearing a “penguin
suit” to force joint extension against a resistive force) have been either marginally effective or
present an inconvenience or hazard.
To succeed in the near-term goal of a human mission to Mars during the second quarter
of this century, the human risks associated with prolonged weightlessness must be mitigated
well beyond our current capabilities. Indeed, during nearly 45 years of human spaceflight
experience,  including numerous  long-duration  missions,  research  has  not  produced any
single  countermeasure  or  combination  of  countermeasures  that  is  completely  effective.
Current operational countermeasures have not been rigorously validated and have not fully
protected  any  long-duration  (>3  months)  astronauts  in  low-Earth  orbit.  Thus,  it  seems
unlikely that they will adequately protect astronauts journeying to Mars and back over a
three-year period.
Although improvements in exercise protocols, changes in diet, or pharmaceutical treatments
of individual systems may be of value, they are unlikely to eliminate the full range of physio‐
logic deconditioning. Therefore, a complete research and development program aimed at
substituting for the missing gravitational cues and loading in space is warranted.
The urgency for exploration-class countermeasures is compounded by the limited availability
of flight resources for vallidating a large number of system-specific countermeasure ap‐
proaches. Furthermore, recent evidence of rapid degradation of pharmaceuticals flown aboard
long-duration missions, putatively because of radiation effects, raises concerns regarding the
viability of some promising countermeasure development research. Although the rotation of
a Mars-bound spacecraft will not be a panacea for all the human risks of spaceflight (artificial
gravity cannot solve the critical problems associated with radiation exposure, isolation,
confinement, and environmental homeostasis), artificial gravity does offer significant promise
as an effective, efficient, multi-system countermeasure against the physiologic deconditioning
associated with prolonged weightlessness. Virtually all of the identified risks associated with
cardiovascular deconditioning, myatrophy, bone loss, and neurovestibular disturbances,
space anemia, immune compromise, neurovegetative might be alleviated by the appropriate
application of artificial gravity.
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7.4.2. Why artificial gravity with exercise?
While short radius centrifuge has been proposed several times, only the loading of artificial
gravity has not so effective to prevent spaceflight deconditioning. Also human-powered short-
arm centrifuge is effective to load exercise to the astronaut. Considering the size of the
International Space Station, it is appropriate to employ the short-radius centrifuge
In 1999, Iwase proposed the manufacture of the facility of artificial gravity with ergomet‐
ric exercise, and it was subsequently installed at Nagoya University [Iwase 2005]. Several
studies  were  performed  using  this  short-radius  centrifuge  with  an  ergometer.  In  2002,
bedrest  study  was  carried  out  to  validate  the  effectiveness  of  artificial  gravity  with
ergometric  exercise.  In  2005,  the  facility  was  moved  to  Aichi  Medical  University,  and
bedrest  studies were performed to finalize the protocol.  In 2006,  this daily AG-EX step-
up protocol (1.4 G of artificial gravity load with 60W of ergometric exercise, and the load
was stepped up by 0.2 G and 15 W respectively) has been shown to be effective to prevent
cardiovascular, musculoskeletal, and bone metabolism deconditioning, while an alternate-
day protocol failed to prevent this. In this experiment, bone metabolism was moderately
ameliorated by this protocol, but not completely.
The authors proposed installing a short-radius centrifuge facility at the International Space
Station, and using it to prevent this spaceflight deconditioning including bone loss. This
project, Artificial GRavity with Ergometric Exercise (AGREE project) is promising for the
prevention of bone loss in spaceflight (Fig. 3).
8. Bone loss monitoring in space
Most of the space medicine studies on bone metabolism have utilized the blood/urine samples
collected before, during, and after spaceflight, and analyzed them in laboratories on Earth.
However, during prolonged spaceflight now and in the future, the astronauts or spaceflight
surgeons will necessitate to collect samples by themselves and to analyze them in the space
station or spacecraft to assess the effects of any countermeasures. Although dual X-ray
absorptiometry (DEXA) is effective to measure the bone mass, it cannot detect small changes
in bone metabolism so may not provide timely information on the effects of countermeasures..
At least, serum/urinary Ca levels and blood/urinary markers of bone resorption should be
determined and monitored, and additional information on bone mass (and/or density) and
bone formation/resorption markers in blood and urine is desirable.
Guidelines for bed rest standardization [2012] suggest the use of osteocalcin, bone-specific
alkaline phosphatase (BSAP), N-terminal propeptide of type I procollagen (P1NP) as bone
formation markers, and N-telopeptide, C-telopeptide, and deoxypyridinoline as bone resorp‐
tion markers.
Further measurements for bone loss using miniature mass spectrometers and ultrasound may
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Figure 3. Short arm centrifuge to be installed in the International Space Station.
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9. Conclusion and summary
In conclusion, it is favorable to administer bisphosphonate orally with artificial gravity with
exercise in order to prevent the osteoporosis in space. Monitoring of the blood and urine
samples in a space station or spacecraft by a simple method is necessary to assess the effec‐
tiveness of any countermeasure program against bone loss..
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Osteoporosis affects the osteo-articular system. However, there are hormonal, 
kidney related, gastrointestinal and neuromuscular factors among other, that can be 
involved in the etiopathogenesis of the disease. In the other hand, for osteoporosis 
prevention there are many lifestyle conditions that are very important, as dietary 
habits, physical activity, drugs and caffeine intake, smoking, associated diseases, etc. 
Based on the above, treatment and prevention of osteoporosis have to be addressed in 
a multidisciplinary and integral approach. The knowledge about bone metabolism and 
the related disorders represents an extensive field that is currently increasing through 
many investigations conducted in the world. The purpose of this book is to show 
several reviews and original investigations related with osteoporosis.
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